WO2019105419A1 - 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 - Google Patents
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 Download PDFInfo
- Publication number
- WO2019105419A1 WO2019105419A1 PCT/CN2018/118232 CN2018118232W WO2019105419A1 WO 2019105419 A1 WO2019105419 A1 WO 2019105419A1 CN 2018118232 W CN2018118232 W CN 2018118232W WO 2019105419 A1 WO2019105419 A1 WO 2019105419A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide
- sirna
- group
- nucleotide sequence
- seq
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 150000007523 nucleic acids Chemical class 0.000 title description 33
- 238000002360 preparation method Methods 0.000 title description 33
- 108020004707 nucleic acids Proteins 0.000 title description 20
- 102000039446 nucleic acids Human genes 0.000 title description 20
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 922
- 239000002773 nucleotide Substances 0.000 claims abstract description 773
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 513
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 242
- 108091081021 Sense strand Proteins 0.000 claims abstract description 208
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 50
- 230000014509 gene expression Effects 0.000 claims abstract description 26
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims abstract description 19
- 102100030970 Apolipoprotein C-III Human genes 0.000 claims abstract description 19
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 18
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 167
- 125000000217 alkyl group Chemical group 0.000 claims description 132
- -1 D-4-thioribose Chemical compound 0.000 claims description 107
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 85
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 68
- 229910052799 carbon Inorganic materials 0.000 claims description 57
- 230000000295 complement effect Effects 0.000 claims description 57
- 239000002777 nucleoside Substances 0.000 claims description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 49
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 48
- 230000002441 reversible effect Effects 0.000 claims description 48
- 230000008685 targeting Effects 0.000 claims description 46
- 125000001188 haloalkyl group Chemical group 0.000 claims description 39
- 150000002632 lipids Chemical class 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 239000003446 ligand Substances 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 31
- 125000005647 linker group Chemical group 0.000 claims description 25
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 25
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 22
- 150000001412 amines Chemical class 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 21
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 21
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 20
- 230000021615 conjugation Effects 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 18
- 238000012986 modification Methods 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 101150001527 APOC3 gene Proteins 0.000 claims description 15
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 15
- 210000003494 hepatocyte Anatomy 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 229910019142 PO4 Inorganic materials 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 14
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 14
- 108091028664 Ribonucleotide Proteins 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 239000010452 phosphate Substances 0.000 claims description 13
- 239000002336 ribonucleotide Substances 0.000 claims description 13
- 229910052770 Uranium Inorganic materials 0.000 claims description 12
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 10
- 125000002015 acyclic group Chemical group 0.000 claims description 10
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229930182830 galactose Natural products 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 8
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000005549 heteroarylene group Chemical group 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 125000004419 alkynylene group Chemical group 0.000 claims description 7
- 125000000732 arylene group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 5
- 229960002246 beta-d-glucopyranose Drugs 0.000 claims description 5
- 229960001031 glucose Drugs 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- CYQRQVCFUKNSLT-SVXWRWBYSA-N (4S,5S,6R)-6-(hydroxymethyl)-3-sulfonyloxane-2,4,5-triol Chemical compound S(=O)(=O)=C1C(O)O[C@@H]([C@H]([C@@H]1O)O)CO CYQRQVCFUKNSLT-SVXWRWBYSA-N 0.000 claims description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- KXTUJUVCAGXOBN-WQXQQRIOSA-N 2-methyl-N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]propanamide Chemical compound CC(C)C(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O KXTUJUVCAGXOBN-WQXQQRIOSA-N 0.000 claims description 3
- 108010002913 Asialoglycoproteins Proteins 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-DHVFOXMCSA-N L-galactose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-DHVFOXMCSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 claims description 3
- RTEOJYOKWPEKKN-HXQZNRNWSA-N N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]propanamide Chemical compound CCC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O RTEOJYOKWPEKKN-HXQZNRNWSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 claims description 3
- 150000001350 alkyl halides Chemical class 0.000 claims description 3
- AVVWPBAENSWJCB-UKFBFLRUSA-N alpha-D-glucofuranose Chemical compound OC[C@@H](O)[C@H]1O[C@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-UKFBFLRUSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- FDJKUWYYUZCUJX-VTERZIIISA-N N-glycoloyl-alpha-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-VTERZIIISA-N 0.000 claims description 2
- JZSWZDBPGBBRNA-UHFFFAOYSA-N [hydroxymethyl(methyl)amino]methanol Chemical compound OCN(C)CO JZSWZDBPGBBRNA-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- RFSUNEUAIZKAJO-ZXXMMSQZSA-N alpha-D-fructofuranose Chemical compound OC[C@H]1O[C@@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ZXXMMSQZSA-N 0.000 claims description 2
- AVVWPBAENSWJCB-QZABAPFNSA-N beta-D-glucofuranose Chemical compound OC[C@@H](O)[C@H]1O[C@@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-QZABAPFNSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- ZXNYUXIMAXVSFN-VFUOTHLCSA-N 2,2,2-trifluoro-n-[(2r,3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound OC[C@H]1O[C@@H](O)[C@H](NC(=O)C(F)(F)F)[C@@H](O)[C@H]1O ZXNYUXIMAXVSFN-VFUOTHLCSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- MSFSPUZXLOGKHJ-KTZFPWNASA-N beta-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-KTZFPWNASA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000005549 deoxyribonucleoside Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 description 363
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 215
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 143
- 238000006243 chemical reaction Methods 0.000 description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- 239000002904 solvent Substances 0.000 description 80
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 74
- 239000002585 base Substances 0.000 description 61
- 238000005859 coupling reaction Methods 0.000 description 59
- 239000003153 chemical reaction reagent Substances 0.000 description 57
- 125000000524 functional group Chemical group 0.000 description 49
- 239000000178 monomer Substances 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- 239000003960 organic solvent Substances 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 42
- 238000003786 synthesis reaction Methods 0.000 description 41
- 239000007790 solid phase Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000012071 phase Substances 0.000 description 36
- 238000010511 deprotection reaction Methods 0.000 description 35
- 239000000741 silica gel Substances 0.000 description 35
- 229910002027 silica gel Inorganic materials 0.000 description 35
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 34
- 230000008878 coupling Effects 0.000 description 34
- 238000010168 coupling process Methods 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- 230000035484 reaction time Effects 0.000 description 31
- 239000007787 solid Substances 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- 238000000746 purification Methods 0.000 description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
- 125000006239 protecting group Chemical group 0.000 description 28
- 239000012074 organic phase Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 238000010532 solid phase synthesis reaction Methods 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 24
- 238000010828 elution Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 150000008300 phosphoramidites Chemical class 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 238000007254 oxidation reaction Methods 0.000 description 20
- 238000000926 separation method Methods 0.000 description 20
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 17
- 239000003208 petroleum Substances 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000008346 aqueous phase Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 239000004593 Epoxy Substances 0.000 description 14
- 150000001768 cations Chemical class 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 12
- 229960005215 dichloroacetic acid Drugs 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000005987 sulfurization reaction Methods 0.000 description 12
- 238000004255 ion exchange chromatography Methods 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 239000012046 mixed solvent Substances 0.000 description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 9
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 8
- 235000021317 phosphate Nutrition 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000013375 chromatographic separation Methods 0.000 description 7
- 238000011033 desalting Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000003147 glycosyl group Chemical group 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000009437 off-target effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 229930192474 thiophene Natural products 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 238000004073 vulcanization Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 5
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012351 deprotecting agent Substances 0.000 description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 229940014800 succinic anhydride Drugs 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 101000887162 Gallus gallus Gallinacin-5 Proteins 0.000 description 4
- 101000887166 Gallus gallus Gallinacin-7 Proteins 0.000 description 4
- 108091093094 Glycol nucleic acid Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 101000608768 Rattus norvegicus Galectin-5 Proteins 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 4
- PIXGWQWJMXYFMU-UHFFFAOYSA-N 1-(3-chloropentan-3-yl)-2-phenylbenzene Chemical compound C1(=CC=CC=C1)C1=C(C=CC=C1)C(Cl)(CC)CC PIXGWQWJMXYFMU-UHFFFAOYSA-N 0.000 description 3
- ZAFWPRJYCRGMNS-UHFFFAOYSA-N 1-(chloromethyl)-2,3,4-triethylbenzene Chemical compound CCC1=CC=C(CCl)C(CC)=C1CC ZAFWPRJYCRGMNS-UHFFFAOYSA-N 0.000 description 3
- GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010001496 Galectin 2 Proteins 0.000 description 3
- 102100021735 Galectin-2 Human genes 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229910001413 alkali metal ion Inorganic materials 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000337 buffer salt Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 3
- 125000000532 dioxanyl group Chemical group 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000005059 halophenyl group Chemical group 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- UIZVMOZAXAMASY-UHFFFAOYSA-N hex-5-en-1-ol Chemical compound OCCCCC=C UIZVMOZAXAMASY-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- DKPVADYIAYWCGB-UHFFFAOYSA-N (1-chloro-3,3-diphenylpropyl)benzene Chemical compound C1(=CC=CC=C1)C(CC(Cl)C1=CC=CC=C1)C1=CC=CC=C1 DKPVADYIAYWCGB-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 2
- RKVHNYJPIXOHRW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanyloxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 2
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- GXGKKIPUFAHZIZ-UHFFFAOYSA-N 5-benzylsulfanyl-2h-tetrazole Chemical compound C=1C=CC=CC=1CSC=1N=NNN=1 GXGKKIPUFAHZIZ-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039558 Galectin-3 Human genes 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-Lactic acid Natural products C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 101100170604 Mus musculus Dmap1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 2
- 102000057403 human APOC3 Human genes 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 230000001743 silencing effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- KNWYARBAEIMVMZ-VFUOTHLCSA-N (2r,3r,4s,5s,6r)-6-(hydroxymethyl)thiane-2,3,4,5-tetrol Chemical compound OC[C@H]1S[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O KNWYARBAEIMVMZ-VFUOTHLCSA-N 0.000 description 1
- CYNAPIVXKRLDER-LBPRGKRZSA-N (2s)-2-benzamido-3-(4-hydroxy-3-nitrophenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C([N+]([O-])=O)=C1 CYNAPIVXKRLDER-LBPRGKRZSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PXHFLWCSJYTAFU-UHFFFAOYSA-N 1,3-oxazolidin-4-one Chemical compound O=C1COCN1 PXHFLWCSJYTAFU-UHFFFAOYSA-N 0.000 description 1
- CWRWJDAEKWYUJT-CGKXPTHNSA-N 1-(9S,13S,12-oxophytodienoyl)-2-(7Z,10Z,13Z)-hexadecatrienoyl-3-(beta-D-galactosyl)-sn-glycerol Chemical compound C([C@H](OC(=O)CCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC[C@@H]1[C@@H](C(=O)C=C1)C\C=C/CC)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O CWRWJDAEKWYUJT-CGKXPTHNSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- MZMVVHAHSRJOEO-UHFFFAOYSA-N 1-chloropropylbenzene Chemical compound CCC(Cl)C1=CC=CC=C1 MZMVVHAHSRJOEO-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- YKCJZLRVOJGDHI-UHFFFAOYSA-N 2,3-dihydropyrrol-4-one Chemical compound O=C1CCN=C1 YKCJZLRVOJGDHI-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- YRUBIFAMCRFPPC-UHFFFAOYSA-N 2-chloro-7-fluoro-1h-quinazolin-4-one Chemical compound N1C(Cl)=NC(=O)C=2C1=CC(F)=CC=2 YRUBIFAMCRFPPC-UHFFFAOYSA-N 0.000 description 1
- IKDUROKVYYYZLJ-UHFFFAOYSA-N 2-cyanatocarbonylbenzoic acid Chemical compound C1=CC=C(C(=C1)C(=O)O)C(=O)OC#N IKDUROKVYYYZLJ-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150077194 CAP1 gene Proteins 0.000 description 1
- 101150014715 CAP2 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101100342821 Haemonchus contortus GAL-1 gene Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- QOELQYIFQXVVAD-DBKUKYHUSA-N N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide hydrochloride Chemical compound Cl.C(C)(=O)N[C@H]1C(O)O[C@@H]([C@@H]([C@@H]1O)O)CO QOELQYIFQXVVAD-DBKUKYHUSA-N 0.000 description 1
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
- 101100326803 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-2 gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- DAMJCWMGELCIMI-UHFFFAOYSA-N benzyl n-(2-oxopyrrolidin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNC1=O DAMJCWMGELCIMI-UHFFFAOYSA-N 0.000 description 1
- PMMURAAUARKVCB-KAZBKCHUSA-N beta-D-ara-dHexp Natural products OC[C@H]1O[C@@H](O)C[C@@H](O)[C@@H]1O PMMURAAUARKVCB-KAZBKCHUSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
- 125000005514 but-1-yn-3-yl group Chemical group 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- VPWAVWZPVGDNMN-UHFFFAOYSA-L calcium;2,3-dihydroxypropanoate Chemical compound [Ca+2].OCC(O)C([O-])=O.OCC(O)C([O-])=O VPWAVWZPVGDNMN-UHFFFAOYSA-L 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- XDVMALRBCQSYLB-UHFFFAOYSA-N diethoxyphosphoryloxymethyl diethyl phosphate Chemical compound P(=O)(OCC)(OCC)OCOP(=O)(OCC)OCC XDVMALRBCQSYLB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- BTJRKNUKPQBLAL-UHFFFAOYSA-N hydron;4-methylmorpholine;chloride Chemical compound Cl.CN1CCOCC1 BTJRKNUKPQBLAL-UHFFFAOYSA-N 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- DEQXHPXOGUSHDX-UHFFFAOYSA-N methylaminomethanetriol;hydrochloride Chemical compound Cl.CNC(O)(O)O DEQXHPXOGUSHDX-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- ZJHUBLNWMCWUOV-UHFFFAOYSA-N oxocane-2,8-dione Chemical compound O=C1CCCCCC(=O)O1 ZJHUBLNWMCWUOV-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000005036 potential barrier Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- NRTYMEPCRDJMPZ-UHFFFAOYSA-N pyridine;2,2,2-trifluoroacetic acid Chemical compound C1=CC=NC=C1.OC(=O)C(F)(F)F NRTYMEPCRDJMPZ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Definitions
- Dyslipidemia also known as hyperlipidemia, is a systemic disease in which fat metabolism or abnormality is caused, and plasma lipids are higher than normal, which is seriously threatening the health of patients worldwide.
- the existing drugs for treating dyslipidemia mainly include statins, cholesterol absorption inhibitors, resins, probucol, fibrates, and nicotinic acid and its derivatives.
- Apolipoprotein C3 plays an important role in lipid metabolism.
- the expression of APOC3 in the blood circulation of people carrying the APOC3 mutant gene decreased by 46%, and the plasma triglyceride level decreased by 39% compared with the average person.
- the level of lipids can reduce the risk of heart disease in APOC3 mutant carriers by 35.1% compared with non-carriers. Therefore, if you can silence gene expression from the gene level and block the production of APOC3, it will undoubtedly be the most ideal treatment.
- Small interfering RNA siRNA can inhibit or block the expression of any gene of interest in a sequence-specific manner based on the mechanism of RNA interference (RNAi), thereby achieving the purpose of treating diseases.
- RNAi RNA interference
- siRNA stabilization modification and its delivery system are two key technologies in the development of small RNA drugs.
- the disclosure provides an siRNA conjugate having the structure shown in Formula (1):
- N1 is an integer selected from 1 to 3
- n3 is an integer selected from 0 to 4;
- M1, m2 and m3 are independently an integer selected from 2-10;
- R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are each independently H or selected from the group consisting of C 1 -C 10 alkyl, C 1 -C 10 haloalkane a group and a C 1 -C 10 alkoxy group;
- R 3 is a group of the structure represented by the formula A59:
- E 1 is OH, SH or BH 2 and Nu is an siRNA
- each of the nucleotides in the siRNA is independently a modified or unmodified nucleotide, the siRNA comprising a sense strand and an antisense strand, the sense strand comprising nucleotide sequence 1, the antisense strand Included in nucleotide sequence 2, the nucleotide sequence 1 and the nucleotide sequence 2 are at least partially reverse-complementary to form a double-stranded region, the nucleotide sequence 1 and the nucleus shown in SEQ ID NO:
- the nucleotide sequence is equal in length and no more than 3 nucleotide differences, and the nucleotide sequence 2 is equal in length to the nucleotide sequence shown in SEQ ID NO: 2, and is not more than 3 nucleotides. difference:
- the nucleotide sequence 1 comprises a nucleotide Z A having a position corresponding to Z
- the nucleotide sequence 2 comprises a nucleotide Z' B having a position corresponding to Z', wherein the Z' B is The first nucleotide of the 5' end of the antisense strand;
- each L 1 is independently selected from a combination of one or more of the groups of formulas A1 to A26:
- j1 is an integer from 1 to 20;
- j2 is an integer from 1 to 20;
- R' is a C 1 -C 10 alkyl group
- Ra is selected from the group consisting of the group A27-A45 or any combination thereof:
- Rb is a C 1 -C 10 alkyl group
- M 1 represents a targeting group.
- the present disclosure provides a method for preparing a conjugate comprising: under the conditions of solid phase synthesis of phosphoramidite, according to the nucleotide type and order of the siRNA sense strand and the antisense strand, respectively, according to The nucleoside monomers are sequentially linked in the direction of 'to 5', and the linkage of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization; the sense strand and the antisense strand of the siRNA are isolated and annealed Wherein each of the nucleotides in the siRNA is independently a modified or unmodified nucleotide, the siRNA comprising a sense strand and an antisense strand, the sense strand comprising nucleotide sequence 1, The antisense strand comprises a nucleotide sequence 2, and the nucleotide sequence 1 and the nucleotide sequence 2 are at least partially complementary in opposite directions to form a double-stranded
- the nucleotide sequence 1 comprises a nucleotide Z A having a position corresponding to Z
- the nucleotide sequence 2 comprises a nucleotide Z' B having a position corresponding to Z', wherein the Z' B is The first nucleotide of the 5' end of the antisense strand;
- the method further comprises contacting the compound of the formula (321) with a nucleoside monomer or a nucleotide sequence attached to the solid support in the presence of a coupling reaction condition and a coupling reagent, thereby allowing the formula ( The compound shown in 321) is linked to the nucleotide sequence by a coupling reaction.
- the compound represented by the formula (321) is also referred to as a conjugation molecule.
- Each S 1 is independently a group formed by substituting all of the active hydroxyl groups in M 1 with a YCOO- group, wherein each Y is independently selected from the group consisting of methyl, trifluoromethyl, difluoromethyl, and fluoro One of a group, a trichloromethyl group, a dichloromethyl group, a monochloromethyl group, an ethyl group, a n-propyl group, an isopropyl group, a phenyl group, a halogenated phenyl group, and an alkylphenyl group;
- n1, n3, m1, m2, m3, R 10, R 11, R 12, R 13, R 14, R 15, L 1, M 1 are each as defined and selectable range as described above.
- the disclosure provides a modified siRNA capable of inhibiting APOC3 gene expression, the siRNA comprising a sense strand and an anti-sense strand, each of the nucleotides of the sense strand and the anti-sense strand are modified a nucleotide, wherein the sense strand and the antisense strand each comprise a fluoro modified nucleotide and a non-fluoro modified nucleotide; the sense strand comprises a nucleotide sequence I, the antisense strand comprising Nucleotide sequence II, wherein the nucleotide sequence I and the nucleotide sequence II at least partially complement each other to form a double-stranded region, wherein the nucleotide sequence I comprises a nucleotide sequence A, Nucleotide sequence A is equal in length to the nucleotide sequence shown in SEQ ID NO: 1, and no more than 3 nucleotide differences, and said nucleotide sequence II contains nucleo
- the nucleotide sequence A comprises a nucleotide Z A corresponding to a position in the nucleotide sequence B, and the nucleotide sequence B contains a nucleotide Z' B corresponding to Z', wherein the Z' B is The first nucleotide of the 5' end of the antisense strand;
- the fluoro-modified nucleotide is located in nucleotide sequence A and nucleotide sequence B, in the direction from the 5' end to the 3' end, at positions 7, 8, and 9 of the nucleotide sequence A.
- the nucleotide is a fluoro-modified nucleotide; and, in the direction from the 5' end to the 3' end, the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence B are fluoro modifications Nucleotide.
- the disclosure provides for the preparation of a modified siRNA, pharmaceutical composition, and/or siRNA conjugate of the disclosure for the treatment and/or prevention of lipids caused by overexpression of apolipoprotein C3 (ApoC3) Use in abnormal drugs.
- ApoC3 apolipoprotein C3
- the disclosure provides a method of treating dyslipidemia, the method comprising administering to a subject having dyslipidemia an effective amount of a modified siRNA, pharmaceutical composition, and/or siRNA conjugate of the disclosure Compound.
- the disclosure provides a method of inhibiting hepatocyte APOC3 gene expression, the method comprising: administering an effective amount of a modified siRNA, a pharmaceutical composition, and/or an siRNA conjugate of the disclosure to the hepatocyte Make contact.
- the disclosure provides a kit comprising a modified siRNA, a pharmaceutical composition, and/or an siRNA conjugate of the disclosure.
- the siRNA provided by the present disclosure a composition comprising the siRNA, or an siRNA conjugate can have greater stability and/or higher activity in vivo.
- the siRNA, siRNA composition or siRNA conjugate provided by the present disclosure exhibits at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95 in vivo. % target gene expression inhibition rate.
- the siRNA, siRNA composition or siRNA conjugate provided by the present disclosure exhibits at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95 in vivo. % APOC3 gene expression inhibition rate.
- the siRNA, siRNA composition or siRNA conjugate provided by the present disclosure exhibits at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95 in vivo. % inhibition of APOC3 gene expression in the liver. In some embodiments, the siRNA, siRNA composition or siRNA conjugate provided by the present disclosure exhibits at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95 in vivo. Inhibition rate of intracellular APOC3 gene expression in % animal models. In some embodiments, the siRNA, siRNA composition or siRNA conjugate provided by the present disclosure exhibits at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95 in vivo.
- the siRNA provided by the present disclosure does not exhibit a significant off-target effect.
- the off-target effect can be, for example, inhibition of normal expression of a gene of a non-target gene. It is believed that the off-target effect is insignificant if the binding/inhibition of off-target gene expression is less than 50%, 40%, 30%, 20% or 10% compared to the target gene effect.
- the siRNA conjugates provided by the present disclosure exhibit superior properties for inhibiting APOC3 gene expression: inhibiting at least 88% of APOC3 gene expression in the liver of high-fat model mice at a dose of 1 mg/kg.
- the modified siRNA and siRNA conjugates provided by the present disclosure exhibit superior gene inhibition rates and low off-target effects compared to conjugates formed by conjugated molecules provided by the prior art; and, the present disclosure The provided siRNA conjugates were able to consistently exhibit excellent lipid inhibition over a period of up to 189 days at low doses and low dosing frequencies.
- siRNA, pharmaceutical compositions and siRNA conjugates provided herein are effective in reducing target cell gene expression and exhibit superior delivery potential.
- Figure 1 shows the inhibitory activity of conjugates F1-F5 in the in vitro psiCHECK system.
- Figure 2 shows the inhibition rate of APCO3 mRNA expression in liver tissue of human APOC3 transgenic mice by D14-day conjugate 1.
- Figures 3A and 3B show the inhibition of blood lipids by different doses of conjugate 1, expressed as serum total cholesterol (CHO) and triglycerides (TG).
- conjugate 1 expressed as serum total cholesterol (CHO) and triglycerides (TG).
- Figures 4A and 4B show the inhibition of blood lipids by different doses of conjugate 2 using serum total cholesterol (CHO) and triglyceride (TG) as indicators.
- CHO serum total cholesterol
- TG triglyceride
- Figures 5A, 5B, 5C, and 5D show the inhibition of blood lipids by different doses of conjugates 1-3 using total cholesterol (CHO) and triglyceride (TG) in serum.
- CHO total cholesterol
- TG triglyceride
- the APOC3 gene refers to a gene sequence such as the gene shown by Genbank Accession No. NM_000040.1.
- the target mRNA sequence is shown as NM_000040.1.
- the capital letters C, G, U, A represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide adjacent to the left side of the letter m is a methoxy group.
- Modified nucleotide indicates that one nucleotide adjacent to the left side of the letter f is a fluoro-modified nucleotide; lowercase s indicates between two nucleotides adjacent to the left and right of the letter s Connected to a phosphorothioate group; P1 indicates that one nucleotide adjacent to the right side of the P1 is a nucleotide modified by a 5'-phosphate nucleotide or a 5'-phosphate analog, and a letter combination VP indicates the letter combination VP One nucleotide adjacent to the right side is a vinyl phosphate modified nucleotide, and the letter combination Ps indicates that the nucleotide adjacent to the right side of the letter combination Ps is a phosphorothioate modified nucleotide, capital letter P indicates that one nucleotide adjacent to the right side of the letter P is a 5'-phosphate nucleotide.
- fluorinated modified nucleotide refers to a nucleotide formed by substitution of a hydroxyl group at the 2' position of a ribose group of a nucleotide with fluorine
- non-fluorinated modified nucleotide means A nucleotide or nucleotide analog formed by the substitution of a hydroxyl group at the 2' position of the ribose group of a nucleotide with a non-fluoro group.
- Nucleotide analog refers to the ability to replace a nucleotide in a nucleic acid, but differs in structure from adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uridine ribonucleotides or thymus A group of pyrimidine deoxyribonucleotides. Such as an isonucleotide, a bridged nucleic acid (BNA) or an acyclic nucleotide.
- BNA bridged nucleic acid
- methoxy-modified nucleotide refers to a nucleotide formed by substituting a 2'-hydroxyl group of a ribose group with a methoxy group.
- the terms "complementary” or “reverse complementation” are used interchangeably and have the meanings well known to those skilled in the art that in a double stranded nucleic acid molecule, the base of one strand is linked to another strand.
- the bases on are paired in a complementary manner.
- the purine base adenine (A) is always paired with the pyrimidine base thymine (T) (or uracil (U) in RNA); the purine base guanine (C) is always with the pyrimidine base.
- Cytosine (G) is paired. Each base pair includes a purine and a pyrimidine.
- mismatch in the art means that in a double-stranded nucleic acid, the bases at corresponding positions are not paired in a complementary form.
- substantially reverse complementation means that there are no more than three base mismatches between the two nucleotide sequences involved; “substantially reverse complementarity” “” means that there are no more than one base mismatch between the two nucleotide sequences; “fully complementary” means that there is no base mismatch between the two nucleotide sequences.
- nucleotide difference between one nucleotide sequence and another nucleotide sequence means that the base type of the nucleotide at the same position is changed in the former compared with the latter.
- one nucleotide base is A
- the corresponding nucleotide base at the same position in the former is U, C, G or T
- a nucleotide at the home position is replaced with an abasic nucleotide or an equivalent thereof, a nucleotide difference is also considered to occur at that position.
- the nucleoside monomer means, according to the preparation
- modified or unmodified nucleoside phosphoramidites used in solid phase synthesis of phosphoramidite (unmodified or modified RNA phosphoramidites, sometimes RNA phosphoramidites also known as Nucleoside Phosphoramidites).
- the phosphoramidite solid phase synthesis is a method used in RNA synthesis well known to those skilled in the art.
- the nucleoside monomers used in the present disclosure are commercially available.
- conjugation means that two or more chemical moieties each having a particular function are linked to each other in a covalently bonded manner; accordingly, the “conjugate” is A compound formed by covalent attachment between the various chemical moieties.
- siRNA conjugate refers to a compound formed by covalent attachment of one or more chemical moieties having a particular function to an siRNA.
- siRNA conjugate of the present disclosure is sometimes simply referred to as "conjugate”.
- An siRNA conjugate is understood to be a generic term for an siRNA conjugate, a first siRNA conjugate or a second siRNA conjugate, depending on the context.
- a "conjugated molecule” is understood to be a specific compound that can be conjugated to a siRNA by reaction, ultimately forming an siRNA conjugate of the present disclosure.
- a short cross that is not between two letters or between two symbols is the position used to indicate the attachment point of the substituent.
- -C 1 -C 10 alkyl-NH 2 is attached via a C 1 -C 10 alkyl group.
- optionally substituted alkyl includes “alkyl” and “substituted alkyl” as defined below.
- alkyl refers to straight and branched chains having the indicated number of carbon atoms, typically from 1 to 20 carbon atoms, such as from 1 to 10 carbon atoms, such as from 1 to 8 Or 1 to 6 carbon atoms.
- a C1-C6 alkyl group contains a straight chain and a branched alkyl group of 1 to 6 carbon atoms.
- alkyl residue having a specific number of carbons it is intended to cover all branched and straight-chain forms having this amount of carbon; thus, for example, "butyl” means including n-butyl, sec-butyl Base, isobutyl and tert-butyl; “propyl” includes n-propyl and isopropyl.
- An alkylene group is a subset of an alkyl group and refers to a residue that is the same as the alkyl group but has two points of attachment.
- alkenyl refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon double bond, which is derived from adjacent carbon atoms of the parent alkyl group. Obtained by removing one hydrogen molecule. The group can be in the cis or trans configuration of the double bond.
- Typical alkenyl groups include, but are not limited to, ethenyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl Base), prop-2-en-2-yl; butenyl group, for example, but-1-en-1-yl, but-1-en-2-yl, 2-methylprop-1-ene-1- Base, but-2-en-1-yl, but-2-en-2-yl, butan-1,3-dien-1-yl, butan-1,3-dien-2-yl and the like.
- an alkenyl group has 2 to 20 carbon atoms, and in other embodiments, 2 to 10, 2 to 8, or 2 to 6 carbon atoms.
- An alkenylene group is a subset of an alkenyl group and refers to a residue that is the same as an alkenyl group but has two points of attachment.
- alkynyl refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon triple bond which is derived from adjacent carbon atoms of the parent alkyl group. Obtained by removing two hydrogen molecules.
- Typical alkynyl groups include, but are not limited to, ethynyl; propynyl, such as prop-1-yn-1-yl, prop-2-yn-1-yl; butynyl, such as but-1-yne- 1-yl, but-1-yn-3-yl, but-3-yn-1-yl and the like.
- an alkynyl group has 2 to 20 carbon atoms, and in other embodiments, 2 to 10, 2 to 8, or 2 to 6 carbon atoms.
- An alkynylene group is a subset of an alkynyl group and refers to a residue that is the same as an alkynyl group but has two points of attachment.
- alkoxy refers to an alkyl group of the indicated number of carbon atoms attached through an oxygen bridge, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, Sec-butoxy, tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methyl Pentyloxy and the like.
- the alkoxy group usually has 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms attached through an oxygen bridge.
- aryl refers to a radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system formed by the removal of a hydrogen atom from a ring carbon atom.
- the aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon of 6 to 18 carbon atoms, wherein at least one of the rings is completely unsaturated, ie it comprises a ring according to the Hückel theory. Delocalized (4n+2) ⁇ -electron system.
- the aryl group includes, but is not limited to, a group such as a phenyl group, a fluorenyl group, and a naphthyl group.
- An arylene group is a subset of an aryl group and refers to a residue that is the same as the aryl group but has two points of attachment.
- cycloalkyl refers to a non-aromatic carbocyclic ring, typically having from 3 to 7 cyclic carbon atoms. The ring can be saturated or have one or more carbon-carbon double bonds.
- cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl, as well as bridged and caged ring groups such as norbornane.
- halogen substituent or “halo” refers to fluoro, chloro, bromo and iodo, and the term “halogen” includes fluoro, chloro, bromo and iodo.
- haloalkyl refers to an alkyl group as defined above, wherein a specified number of carbon atoms are replaced by one or more, up to a maximum allowable number of halogen atoms.
- haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and pentafluoroethyl.
- Heterocyclyl means a stable 3- to 18-membered non-aromatic cyclic group containing from 2 to 12 carbon atoms and from 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless otherwise stated in the specification, a heterocyclic group is a monocyclic, bicyclic, tricyclic or tetracyclic system and may include a fused ring or bridged ring system. The heteroatoms in the heterocyclic radical may optionally be oxidized. One or more nitrogen atoms, if present, are optionally quaternized. Heterocyclyl groups are partially saturated or fully saturated. A heterocyclic group can be attached to the remainder of the molecule through any atom of the ring.
- heterocyclic groups include, but are not limited to, dioxoalkyl, thienyl [1,3]disulfonyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, heterophilic Azolidinyl, morpholinyl, octahydroindenyl, octahydroisoindolyl, 2-oxapiperazinyl, 2-oxapiperidinyl, 2-oxapyrimidinyl, oxazolidinyl, piperidine Pyridyl, piperazinyl, 4-piperidinone, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trisulfonyl, tetrahydropyranyl, thiomorpholinyl, Thiomorpholinyl, 1-oxoal
- Heteroaryl refers to a radical derived from a 3- to 18-membered aromatic ring radical comprising from 2 to 17 carbon atoms and from 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- a heteroaryl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system in which at least one ring in the ring system is completely unsaturated, ie, according to Hückel theory, comprising a circular delocalization (4n) +2) ⁇ -electron system.
- Heteroaryl groups include fused ring or bridged ring systems. The heteroatoms in the heteroaryl are optionally oxidized.
- heteroaryl group is attached to the remainder of the molecule through any atom in the ring.
- heteroaryl groups include, but are not limited to, azepandinyl, acridinyl, benzimidazolyl, benzindenyl, 1,3-benzobisoxazolyl, benzofuranyl, benzene And oxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]bisoxazolyl, benzo[b][1,4]oxazolyl, 1 , 4-benzobisoxazolyl, benzonaphthofuranyl, benzodiazolyl, benzodioxanyl, benzopyranyl, benzopyranone, benzofuranyl, benzene And furanone, benzothienyl, benzothiophene [3,2-d]pyrimidin
- hydroxy protecting groups can be used in the present disclosure.
- a protecting group renders a chemical functionality insensitive to a particular reaction condition and can be added and removed in that functionality in the molecule without substantially damaging the remainder of the molecule.
- Representative hydroxy protecting groups are disclosed in Beaucage et al, Tetrahedron 1992, 48, 2223-2311, and Greeneand Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2d ed, John Wiley & Sons, New York, 1991, cited The above documents are incorporated herein in their entirety.
- the protecting group is stable under basic conditions, but can be removed under acidic conditions.
- non-exclusive examples of hydroxy protecting groups that may be used herein include dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthene-9-yl ( Pixyl) and 9-(p-methoxyphenyl)xanthene-9-yl (Mox).
- non-exclusive examples of hydroxy protecting groups that may be used herein include Tr (trityl), MMTr (4-methoxytrityl), DMTr (4,4'-dimethoxy). Trityl) and TMTr (4,4',4"-trimethoxytrityl).
- subject refers to any animal, such as a mammal or marsupial.
- Subject matter of the present disclosure includes, but is not limited to, humans, non-human primates (eg, rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cows, sheep, rats, and poultry of any kind.
- therapeutic methods As used herein, “therapeutic methods,” “treatment,” “alleviation,” or “improvement” are used interchangeably herein. These terms refer to methods of obtaining beneficial or desired results, including but not limited to therapeutic benefits. “Therapeutic benefits” means eradication or improvement of potential barriers to treatment. Moreover, the therapeutic benefit is obtained by eradicating or ameliorating one or more physiological symptoms associated with the underlying disorder, thereby observing an improvement in the subject, although the subject may still be afflicted with a potential disorder.
- the siRNA of the present disclosure contains a nucleotide group as a basic structural unit, which is well known to those skilled in the art, and the nucleotide group contains a phosphate group, a ribose group, and a base, and will not be described herein.
- the present disclosure provides a modified siRNA capable of inhibiting APOC3 gene expression, the modified siRNA comprising a sense strand and an antisense strand, each nucleotide of the sense strand and the antisense strand being a modified nucleotide
- the sense strand and the antisense strand each comprise a fluoro-modified nucleotide and a non-fluoro-modified nucleotide
- the sense strand comprises a nucleotide sequence I
- the antisense strand comprising a nucleotide Sequence II
- the nucleotide sequence I and the nucleotide sequence II are at least partially reverse-complementary to form a double-stranded region
- the nucleotide sequence I comprises a nucleotide sequence A
- the nucleotide Sequence A is the same length as the nucleotide sequence shown in SEQ ID NO: 1, and no more than 3 nucleotide differences
- the nucleotide sequence A comprises a nucleotide Z A corresponding to a position in the nucleotide sequence B, and the nucleotide sequence B contains a nucleotide Z' B corresponding to Z', wherein the Z' B is a first nucleotide at the 5' end of the antisense strand; and the fluoro modified nucleotide is located in nucleotide sequence A and nucleotide sequence B, in the direction from the 5' end to the 3' end,
- the nucleotide at positions 7, 8, and 9 of the nucleotide sequence A is a fluoro-modified nucleotide; and, in the direction from the 5' end to the 3' end, the nucleotide sequence B 2.
- the nucleotides at positions 6, 6, and 16 are fluoro-modified nucleotides.
- the nucleotide sequence A has no more than five fluoro-modified nucleotides; the nucleotide sequence B has no more than seven fluoro-modified nucleotides.
- positional correspondence means the same position in the nucleotide sequence from the same end of the nucleotide sequence.
- the first nucleotide at the 3' end of nucleotide sequence A is a nucleotide that corresponds to the 1st nucleotide of the 3' end of SEQ ID NO: 1.
- the sense strand comprises only nucleotide sequence I
- the antisense strand comprises only nucleotide sequence II.
- the nucleotide sequence A differs from the nucleotide sequence set forth in SEQ ID NO: 1 by no more than 1 nucleotide difference, and/or the nucleotide sequence B and SEQ There is no more than one nucleotide difference between the nucleotide sequences shown by ID NO:2.
- the nucleotide difference between the nucleotide sequence B and the nucleotide sequence set forth in SEQ ID NO: 2 comprises a difference at the Z' B position, and Z' B is selected from A, C or G. In some embodiments, the nucleotide difference is a difference at the Z' B position, and Z' B is selected from A, C or G. In some embodiments, Z A is a nucleotide that is complementary to Z' B. These nucleotide differences do not significantly reduce the target gene inhibition ability of the siRNA conjugate, and these siRNA conjugates containing nucleotide differences are also within the scope of the present disclosure.
- the nucleotide sequence A and the nucleotide sequence B are substantially reverse complementary, substantially reverse complementary or fully reverse complementary; the substantially reverse complement refers to two cores There are no more than 3 base mismatches between the nucleotide sequences; the substantially reverse complement means that there are no more than one base mismatch between the two nucleotide sequences; complete reverse complementation It means that there is no mismatch between the two nucleotide sequences.
- nucleotide sequence A is the nucleotide sequence set forth in SEQ ID NO: 60
- nucleotide sequence B is the nucleotide sequence set forth in SEQ ID NO: 61:
- Z' B is the first nucleotide at the 5' end of the antisense strand
- Z A is selected from A, U, G or C
- Z' B is a nucleotide complementary to Z A
- the nucleotides at positions 7, 8, and 9 of the nucleotide sequence A are fluoro-modified nucleotides in the direction from the 5' end to the 3'end; in the direction from the 5' end to the 3' end,
- the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence B are fluoro-modified nucleotides.
- the siRNA comprises a sense strand and a reverse strand comprising a nucleotide sequence I comprising a nucleotide sequence II, nucleotide sequence I and nucleotide Sequence II is reverse-complementary to form a double-stranded region, nucleotide sequence I contains the nucleotide sequence set forth in SEQ ID NO: 60, and nucleotide sequence II contains the nucleotide sequence set forth in SEQ ID NO: 61:
- Z' B is the first nucleotide at the 5' end of the antisense strand
- Z A is selected from A, U, G or C
- Z' B is a nucleotide complementary to Z A ;
- Z A is A
- Z' B is U;
- the nucleotides at positions 7, 8, and 9 of SEQ ID NO: 60 in the sense strand of the siRNA are fluoro-modified nucleotides, and the sense strand of siRNA The nucleotides in the remaining positions are non-fluoro-modified nucleotides; and, in the direction from the 5' end to the 3' end, the 2, 6, and 14 of SEQ ID NO: 61 in the antisense strand of the siRNA
- the nucleotide at position 16 is a fluoro-modified nucleotide, and the nucleotides at the rest of the antisense strand of the siRNA are non-fluoro-modified nucleotides.
- the sense strand and the antisense strand are the same or different in length, the sense strand is 19-23 nucleotides in length, and the antisense strand is 19-26 nucleotides in length.
- the length ratio of the sense strand and the antisense strand of the siRNA provided by the present disclosure may be 19/19, 19/20, 19/21, 19/22, 19/23, 19/24, 19/25, 19/26, 20/20, 20/21, 20/22, 20/23, 20/24, 20/25, 20/26, 21/20, 21/21, 21/22, 21/23, 21/24, 21/ 25, 21/26, 22/20, 22/21, 22/22, 22/23, 22/24, 22/25, 22/26, 23/20, 23/21, 23/22, 23/23, 23/24, 23/25 or 23/26.
- the length ratio of the sense strand and the antisense strand of the siRNA is 19/21, 21/23 or 23/25
- the sense strand and the antisense strand are of the same length
- the nucleotide sequence I further comprises a nucleotide sequence III
- the nucleotide sequence II further comprises a nucleotide sequence IV, a nucleotide
- the sequence III and nucleotide sequence IV lengths are each independently 1-4 nucleotides; the nucleotide sequence III is linked to the 5' end of the nucleotide sequence A, which is ligated to the nucleoside The 3' end of the acid sequence B; the nucleotide sequence III and the nucleotide sequence IV are of equal length.
- nucleotide sequence III and the nucleotide sequence IV may or may not be complementary.
- the nucleotide sequence III and the nucleotide sequence IV are at least partially complementary; in some implementations
- nucleotide sequence III and nucleotide sequence IV are more than 80% base complementary, or more than 90% base complementary; in some embodiments, nucleotide sequence III and nucleotide sequence IV are substantially Reverse complementary or fully reverse complementary; said substantially reverse complement refers to the presence of no more than one base mismatch between two nucleotide sequences; complete reverse complementation refers to two nucleotide sequences There is no mismatch between them; in some embodiments, nucleotide sequence III and nucleotide sequence IV are completely reverse complementary.
- the siRNA sense strand and the antisense strand are of equal length and have a length ratio of 20/20, 21/21, 22/22 or 23/23. In some embodiments, the length ratio of the sense strand and the antisense strand of the siRNA is 21/21 or 23/23.
- the nucleotide sequence III and the nucleotide sequence IV are each 1 nucleotide in length, the nucleotide sequence III has a base C, and the nucleotide sequence IV has a base G.
- the length ratio of the sense strand and the antisense strand is 20/20; or, the nucleotide sequences III and IV are both 2 nucleotides in length, and the nucleoside is in the direction from the 5' end to the 3' end.
- the base of the acid sequence III is sequentially C and C, and the base of the nucleotide sequence IV is G and G, respectively; in this case, the length ratio of the sense strand and the antisense strand is 21/21; or, the nucleotide sequence III And the length of IV is 3 nucleotides.
- the bases of nucleotide sequence III are U, C, and C, and the bases of nucleotide sequence IV are G.
- the length ratio of the sense strand and the antisense strand is 22/22; or, the lengths of the nucleotide sequences III and IV are 4 nucleotides, according to the 5' end to the 3' end In the orientation, the nucleotide sequence III has C, U, C, and C in turn, and the nucleotide sequence IV has G, G, A, and G in sequence; in this case, the length ratio of the sense strand and the antisense strand It is 23/23.
- the nucleotide sequence III and the nucleotide sequence IV are 2 nucleotides in length, and the nucleotide sequence III has a base C in the order of the 5' end to the 3' end.
- C the nucleotide sequence of the nucleotide sequence IV is G, G; in this case, the length ratio of the sense strand and the antisense strand is 21/21.
- nucleotide sequence III and nucleotide sequence IV are the same length and are completely reverse-complementary, thus giving the nucleotide sequence III base, and the nucleotide sequence IV base is also It is determined.
- the sense strand and the antisense strand are different in length
- the nucleotide sequence II further comprises a nucleotide sequence V
- the nucleotide sequence V is 1 to 3 nucleotides in length, and is ligated
- the 3' end of the antisense strand constitutes the 3' overhanging end of the antisense strand.
- the length ratio of the sense strand and the antisense strand of the siRNA provided by the present disclosure may be 19/20, 19/21, 19/22, 20/21, 20/22, 20/23, 21/22, 21/23. , 21/24, 22/23, 22/24, 22/25, 23/24, 23/25 or 23/26.
- the nucleotide sequence V is 2 nucleotides in length, whereby the length ratio of the siRNA sense strand and the antisense strand provided by the present disclosure may be 19/21, 21/23 or 23 /25.
- Each of the nucleotide sequences V may be any nucleotide, and the nucleotide sequence V is two consecutive thymidine deoxyribonucleotides for ease of synthesis and to save on synthesis cost ( TT) or two consecutive uracil ribonucleotides (UU); in order to increase the affinity of the siRNA antisense strand to the target mRNA, the nucleotide sequence V is complementary to the nucleotide at the corresponding position of the target mRNA.
- TT thymidine deoxyribonucleotides
- UU uracil ribonucleotides
- the sense strand comprises the nucleotide sequence set forth in SEQ ID No: 60, the antisense strand comprising the nucleotide sequence set forth in SEQ ID No: 3:
- the sense strand contains the nucleotide sequence set forth in SEQ ID No: 4
- the antisense strand contains the nucleotide sequence set forth in SEQ ID No: 5:
- Z' B is the first nucleotide at the 5' end of the antisense strand
- Z A is selected from A, U, G or C
- Z' B is a nucleotide complementary to Z A .
- the siRNA described in the disclosure is siAP1 or siAP2:
- Antisense strand 5'-UUCUUGUCCAGCUUUAUUGGG-3' (SEQ ID No: 7)
- Antisense strand 5'-UUCUUGUCCAGCUUUAUUGGGAG-3' (SEQ ID No: 9).
- the nucleotides at position 7, 8, 9 or 5, 7, 8, and 9 of the nucleotide sequence A are in the sense strand in the direction from the 5' end to the 3' end.
- the nucleotide is a fluoro-modified nucleotide, and the nucleotides at the rest of the sense strand are non-fluoro-modified nucleotides; in the antisense strand, the nucleotide sequence B is the second
- the nucleotides at positions 6, 14, 16 or 2, 6, 8, 9, 14, and 16 are fluoro-modified nucleotides, and the nucleotides at the remaining positions in the antisense strand are non-fluorinated. Nucleotide.
- the fluoro-modified nucleotide refers to a nucleotide formed by substituting a hydroxyl group at the 2'-position of a ribose group of a nucleotide with fluorine, and has a structure represented by the following formula (107).
- a non-fluorinated modified nucleotide refers to a nucleotide or nucleotide analog formed by the substitution of a hydroxyl group at the 2' position of the ribose group of a nucleotide with a non-fluoro group.
- each non-fluoro modified nucleotide is independently selected from a nucleotide or nucleotide analog formed by the substitution of a hydroxyl group at the 2' position of the ribose group of a nucleotide with a non-fluoro group.
- Nucleotides formed by substitution of a hydroxyl group at the 2' position of the ribose group with a non-fluoro group are well known to those skilled in the art, and these nucleotides may be selected from 2'-alkoxy modified nucleotides, 2'- Substituted alkoxy-modified nucleotide, 2'-alkyl modified nucleotide, 2'-substituted alkyl modified nucleotide, 2'-amino modified nucleotide, 2'- One of a substituted amino-modified nucleotide, 2'-deoxynucleotide.
- the 2'-alkoxy-modified nucleotide is a methoxy-modified nucleotide (2'-OMe) as shown in formula (108).
- the 2'-substituted alkoxy-modified nucleotide can be, for example, a 2'-O-methoxyethyl modified nucleotide (2'-MOE), such as formula (109) ) shown.
- the modified nucleotide 2'-amino (2'-NH 2) as shown in formula (110).
- the 2'-deoxynucleotide (DNA) is as shown in formula (111).
- a nucleotide analog refers to the ability to replace a nucleotide in a nucleic acid, but differs in structure from adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uridine ribonucleotides or thymine deoxygenation.
- the nucleotide analog can be an isonucleotide, a bridged nucleic acid (BNA) or an acyclic nucleotide.
- the BNA refers to a restricted or inaccessible nucleotide.
- the BNA may contain a five-membered ring, a six-membered ring, or a seven-membered ring with a bridge structure of "fixed" C3'-endo-glycans. This bridge is typically incorporated into the 2'-, 4'-position of the ribose to provide a 2',4'-BNA nucleotide.
- the BNA may be LNA, ENA, cET BNA, etc., wherein the LNA is as shown in the formula (112), the ENA is as shown in the formula (113), and the cET BNA is as shown in the formula (114).
- an acyclic nucleotide is a type of nucleotide formed by the opening of a sugar ring of a nucleotide.
- the acyclic nucleotide can be an unlocked nucleic acid (UNA) or a glycerol nucleic acid (GNA), wherein UNA is as shown in formula (115) and GNA is as shown in formula (116).
- R is selected from H, OH or alkoxy (O-alkyl).
- An isonucleotide refers to a compound formed by a change in the position of a base in a nucleotide on a ribose ring.
- an isonucleotide can be a compound formed by the base moving from the 1 '-position to the 2 '- or 3'-position of the ribose ring, as shown by formula (117) or (118).
- Base represents a base such as A, U, G, C or T; and R is selected from H, OH, F or a non-fluoro group as described above.
- the nucleotide analog is selected from the group consisting of an isonucleotide, LNA, ENA, cET, UNA, and GNA.
- each non-fluoro-modified nucleotide is a methoxy-modified nucleotide, and above and below, the methoxy-modified nucleotide refers to 2' of a ribose group. a nucleotide formed by substituting a hydroxyl group with a methoxy group.
- fluoro-modified nucleotide refers to a compound having a structure represented by formula (107) formed by substitution of a 2'-hydroxy group of a nucleotide with a fluorine;
- methoxy modified nucleotide refers to nucleoside A compound having a structure represented by the formula (108) formed by substituting a 2'-hydroxy group of an acid ribose group with a methoxy group.
- the siRNA of the present disclosure is an siRNA having a modification in the direction of the 5' end to the 3' end, in the sense strand, positions 7, 8, and 9 of the nucleotide sequence A
- the nucleotides at positions 5, 7, 8, and 9 are fluoro-modified nucleotides
- the nucleotides at the remaining positions in the sense strand are methoxy-modified nucleotides
- the nucleotides at positions 2, 6, 14, 16 or 2, 6, 8, 9, 14, 16 of the nucleotide sequence B are fluoro-modified nucleotides
- the antisense The nucleotides remaining in the chain are methoxy modified nucleotides.
- the siRNA of the present disclosure is an siRNA having a modification of the 5th, 7th, 8th, and 9th positions of the nucleotide sequence A in the sense strand of the siRNA in the direction from the 5' end to the 3' end.
- the nucleotide is a fluoro-modified nucleotide
- the nucleotide at the remaining position of the sense strand of the siRNA is a methoxy-modified nucleotide, and, in the direction from the 5' end to the 3' end, the siRNA
- the nucleotides at positions 2, 6, 8, 9, 14 and 16 of the nucleotide sequence B in the antisense strand are fluoro-modified nucleotides
- the nucleotides at the rest of the antisense strand of the siRNA are methoxy groups.
- Modified nucleotide is a fluoro-modified nucleotide
- the nucleotides at positions 7, 8 and 9 of the nucleotide sequence A in the sense strand of the siRNA are -fluoro-modified nucleotides, and the sense strand of siRNA
- the nucleotides at the remaining positions are methoxy-modified nucleotides, and, in the direction from the 5' end to the 3' end, the second, sixth, and fourth nucleotide sequences of the antisense strand of the siRNA are
- the nucleotide at position 16 is a fluoro-modified nucleotide
- the nucleotide at the rest of the antisense strand of the siRNA is a methoxy-modified nucleotide.
- the ribose group in the phosphate-sugar backbone of the siRNA has a modifying group, respectively: in the direction from the 5' end to the 3' end, the nucleotide sequence A of the siRNA is in the fifth, seventh,
- the glycosyl group at positions 8 and 9 is a 2'-fluororibosyl group, and the sugar group at the remaining position of the sense strand of the siRNA is a 2'-methoxyribosyl group, and, according to the 5' end to the 3' end
- the glycosyl group at positions 2, 6, 8, 9, 14 and 16 of the nucleotide sequence B in the antisense strand of the siRNA is a 2'-fluororibosyl group, and the nucleotides at the remaining positions of the antisense strand of the siRNA
- the glycosyl group is a 2'-methoxyribosyl group;
- the glycosyl group at positions 7, 8 and 9 of the nucleotide sequence A in the sense strand of the siRNA is 2'-fluororibosyl, in the direction from the 5' end to the 3' end, and the rest of the sense strand of the siRNA
- the glycosyl group at the position nucleotide is a 2'-methoxyribosyl group
- the second, sixth, and fourth nucleotide sequences B in the antisense strand of the siRNA are in the direction from the 5' end to the 3' end.
- the glycosyl group at position 16 is a 2'-fluororibose group
- the sugar group at the rest of the antisense strand of the siRNA is a 2'-methoxyribosyl group.
- the siRNA molecule is any one of siAP1-M1, siAP2-M1, siAP1-M2, siAP2-M2:
- Antisense strand 5'-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3' (SEQ ID NO: 11)
- the sense strand 5'-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3' (SEQ ID NO: 12)
- Antisense strand 5'-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3' (SEQ ID NO: 13)
- Antisense strand 5'-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3' (SEQ ID NO: 15)
- Antisense strand 5'-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3' (SEQ ID NO: 17)
- the phosphate groups in the phosphate-sugar backbone of at least one single strand of the sense strand and the antisense strand of the siRNA provided by the disclosure are phosphate groups having a modifying group.
- the phosphate group having a modifying group is a phosphorothioate group formed by substitution of at least one oxygen atom of a phosphodiester bond in a phosphate group with a sulfur atom; in some embodiments, The phosphate group having a modifying group is a phosphorothioate group having a structure represented by the formula (101):
- This modification stabilizes the double-stranded structure of the siRNA, maintaining high specificity and high affinity for base pairing.
- the phosphorothioate linkage is present at at least one of the group consisting of: the first and second nuclei at either end of the sense strand or the antisense strand Between the glycosides; between the second and third nucleotides at either end of the sense strand or the antisense strand; or any combination of the above.
- the phosphorothioate linkage is present at all of the above positions except for the 5' end of the sense strand.
- the phosphorothioate linkage is present at all of the above positions except for the 3' end of the sense strand.
- the phosphorothioate linkage is present at at least one of the following locations:
- the 2' end of the 3' end of the antisense strand is between the 2nd nucleotide and the 3rd nucleotide.
- the siRNA is any one of siAP1-M1S, siAP2-M1S, siAP1-M2S, siAP2-M2S:
- the sense strand 5'-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3' (SEQ ID NO: 18)
- Antisense strand 5'-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3' (SEQ ID NO: 19)
- the sense strand 5'-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3' (SEQ ID NO: 20)
- Antisense strand 5'-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3' (SEQ ID NO: 21)
- Antisense strand 5'-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3' (SEQ ID NO: 23)
- Antisense strand 5'-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3' (SEQ ID NO: 25)
- the 5' terminal nucleotide of the siRNA antisense strand is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide.
- 5'-phosphate nucleotides may have the following structure:
- R is selected from H, OH, methoxy or fluorine
- Base represents a base selected from A, U, C, G or T.
- the 5'-phosphate nucleotide is a 5'-phosphate modified nucleotide represented by formula (102), and the 5'-phosphate analog modified nucleotide comprises a vinyl phosphate ( 5'-(E)-vinylphosphonate, E-VP) modified nucleotide, as shown in formula (103), or a phosphorothioate-modified nucleotide, as shown in formula (105).
- the siRNA provided by the present disclosure may be any one of siAP1-M1P1, siAP2-M1P1, siAP1-M2P1, siAP2-M2P1, siAP1-M1SP1, siAP2-M1SP1, siAP1-M2SP1, siAP2-M2SP1:
- Antisense strand 5'-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3'SEQ ID NO:26)
- the sense strand 5'-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3' (SEQ ID NO: 12)
- Antisense strand 5'-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3' (SEQ ID NO: 27)
- Antisense strand 5'-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3' (SEQ ID NO: 28)
- Antisense strand 5'-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3' (SEQ ID NO: 29)
- the sense strand 5'-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3' (SEQ ID NO: 18)
- Antisense strand 5'-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3' (SEQ ID NO: 30)
- the sense strand 5'-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3' (SEQ ID NO: 20)
- Antisense strand 5'-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3' (SEQ ID NO: 31)
- Antisense strand 5'-P1-UmsUfsCmUmUmGfUmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3' (SEQ ID NO: 32)
- Antisense strand 5'-P1-UmsUfsCmUmUmGfUmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3' (SEQ ID NO: 33)
- the inventors of the present disclosure have found that the siRNA provided by the present disclosure not only has significantly enhanced plasma and lysosomal stability, reduces off-target effects, but also retains high gene inhibitory activity.
- the siRNA provided by the present disclosure can be obtained by a nucleic acid production method (for example, a method of solid phase synthesis and liquid phase synthesis) which is conventional in the art. Among them, solid phase synthesis already has commercial customized services.
- a method of preparing a nucleoside monomer having a corresponding modification and introducing a modified nucleotide group can be carried out by introducing a modified nucleotide group having a corresponding modified nucleoside monomer into the siRNA described in the present disclosure. Methods of siRNA are also well known to those skilled in the art.
- the present disclosure provides a pharmaceutical composition comprising a modified siRNA as described above and a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be a carrier conventionally used in the field of siRNA administration, such as, but not limited to, magnetic nanoparticles (such as Fe 3 O 4 or Fe 2 O 3 -based nanoparticles), carbon nanotubes ( Carbon nanotubes), mesoporous silicon, calcium phosphate nanoparticles, polyethylenimine (PEI), polyamidoamine (PAMAM), polylysine Acid (poly(L-lysine), PLL), chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly D Type or L-type lactic acid/glycolic acid copolymer (poly(D&L-lactic/glycolic acid) copolymer, PLGA), poly(2-aminoethyl ethylene phosphate) (PPEEA) and poly( One or more of poly(2-dimethylaminoethyl methacrylate) (PDMAEMA) and derivatives thereof.
- the pharmaceutical composition has no particular requirement for the amount of siRNA and pharmaceutically acceptable carrier.
- the weight ratio of siRNA to pharmaceutically acceptable carrier can be 1: ( 1-500), in some embodiments, the above weight ratio is 1: (1-50).
- the pharmaceutical composition may further comprise other excipients that are pharmaceutically acceptable, and the excipients may be one or more of various formulations or compounds conventionally employed in the art.
- the pharmaceutically acceptable additional excipient may include at least one of a pH buffer, a protective agent, and an osmotic pressure adjusting agent.
- the pH buffer may be a trishydroxymethylaminomethane hydrochloride buffer having a pH of 7.5-8.5 and/or a phosphate buffer having a pH of 5.5-8.5, such as a phosphate having a pH of 5.5-8.5. Buffer.
- the protective agent may be at least one of inositol, sorbitol, sucrose, trehalose, mannose, maltose, lactose, and glucose.
- the protective agent may be included in an amount of from 0.01 to 30% by weight based on the total weight of the pharmaceutical composition.
- the osmotic pressure adjusting agent may be sodium chloride and/or potassium chloride.
- the osmotic pressure adjusting agent is present in an amount such that the osmotic pressure of the pharmaceutical composition is from 200 to 700 milliosmoles per kilogram (mOsm/kg).
- the content of the osmotic pressure adjusting agent can be easily determined by those skilled in the art depending on the desired osmotic pressure.
- the pharmaceutical composition may be a liquid preparation, such as an injection solution; or a lyophilized powder injection, which is mixed with a liquid adjuvant when administered, and formulated into a liquid preparation.
- the liquid formulation can be, but is not limited to, for subcutaneous, intramuscular or intravenous administration, and can be, but is not limited to, administered to the lungs by spraying, or administered to other organ tissues (such as the liver) via the lungs by spraying.
- the pharmaceutical composition is for intravenous administration.
- the pharmaceutical composition can be in the form of a liposomal formulation.
- the pharmaceutically acceptable carrier used in the liposome formulation comprises an amine-containing transfection compound (which may also be referred to hereinafter as an organic amine), helper lipid, and/or PEGylation. Lipid.
- the organic amine, helper lipid, and pegylated lipid are each selected from the group consisting of amine-containing transfection compounds described in CN103380113A (incorporated herein by reference in its entirety) One or more of the accepted salts or derivatives, helper lipids, and pegylated lipids.
- the organic amine can be a compound of formula (201) or a pharmaceutically acceptable salt thereof as described in CN103380113A:
- X 101 and X 102 are each independently O, S, NA or CA, wherein A is hydrogen or a C1-C20 hydrocarbon chain;
- R 101 , R 102 , R 103 , R 104 , R 105 , R 106 and R 107 are each independently hydrogen, cyclic or acyclic, substituted or unsubstituted, branched or straight-chain aliphatic radical a cyclic, acyclic or acyclic, substituted or unsubstituted, branched or straight chain heteroaliphatic group, substituted or unsubstituted, branched or straight chain acyl group, substituted or not Substituted, branched or straight-chain aryl, substituted or unsubstituted, branched or straight-chain heteroaryl;
- x is an integer from 1 to 10;
- n is an integer from 1 to 3
- m is an integer from 0 to 20
- R 103 and the nitrogen in the formula (201) form a structure as shown in the formula (202) or the formula (203):
- HCC represents a hydrocarbon chain
- N represents a nitrogen atom in the formula (201).
- R 103 is a polyamine. In other embodiments, R 103 is a ketal. In some embodiments, each of R 101 and R 102 in formula (201) is independently any substituted or unsubstituted, branched or straight chain alkyl or alkenyl group, said alkane
- the base or alkenyl group has from 3 to about 20 carbon atoms, such as from 8 to about 18 carbon atoms, and from 0 to 4 double bonds, such as from 0 to 2 double bonds.
- R 103 can be any of the following formulas (204) - (213):
- g, e and f are each independently an integer of 1-6
- each "HCC” represents a hydrocarbon chain
- each * shows R 103 and is in the formula (201)
- a possible point of attachment of a nitrogen atom in which each H at any * position can be replaced to effect attachment to the nitrogen atom in formula (201).
- the compound of the formula (201) can be produced according to the description in CN103380113A.
- the organic amine is an organic amine as shown in formula (214) and/or an organic amine as shown in formula (215):
- the helper lipid is a cholesterol, an analog of cholesterol, and/or a derivative of cholesterol;
- the PEGylated lipid is 1,2-dipalmitamide-sn-glycero-3-phosphatidylethanolamine-N-[methoxy(polyethylene glycol)]-2000.
- the molar ratio between the organic amine, the helper lipid, and the PEGylated lipid is (19.7-80) in the pharmaceutical composition: (19.7-80) ): (0.3-50), for example, may be (50-70): (20-40): (3-20).
- the pharmaceutical composition particles formed from the siRNA of the present disclosure and the amine-containing transfection reagent described above have an average diameter of from about 30 nm to about 200 nm, typically from about 40 nm to about 135 nm, and more typically, the liposome
- the average diameter of the particles is from about 50 nm to about 120 nm, from about 50 nm to about 100 nm, from about 60 nm to about 90 nm, or from about 70 nm to about 90 nm, for example, the average diameter of the liposome particles is about 30, 40, 50, 60, 70. , 75, 80, 85, 90, 100, 110, 120, 130, 140, 150 or 160 nm.
- the weight of the siRNA and all lipids in a pharmaceutical composition formed from the siRNAs of the present disclosure and the amine-containing transfection reagents described above
- the ratio is from about 1:1 to about 1:50, from about 1:1 to about 1:30, from about 1:3 to about 1:20, from about 1:4 to about 1: 18.
- the weight ratio of the siRNA of the present disclosure to the total lipid is about 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1 : 11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17 or 1:18.
- the components of the pharmaceutical composition may be present separately upon sale and may be in the form of a liquid formulation when used.
- the pharmaceutical composition of the siRNA provided by the present disclosure and the above pharmaceutically acceptable carrier can be prepared according to various known methods, except that the siRNA provided by the present disclosure is substituted for the existing siRNA; In an embodiment, it can be prepared as follows:
- the organic amine, the auxiliary lipid and the PEGylated lipid are suspended in the alcohol according to the above molar ratio and mixed to obtain a lipid solution; the amount of the alcohol is such that the total mass concentration of the obtained lipid solution is 2-25 mg/mL, For example, it can be 8-18 mg/mL.
- the alcohol is selected from a pharmaceutically acceptable alcohol, such as an alcohol that is liquid near room temperature, for example, ethanol, propylene glycol, benzyl alcohol, glycerin, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400. One or more of them may be, for example, ethanol.
- the siRNA provided in the present disclosure was dissolved in a buffered saline solution to obtain an aqueous siRNA solution.
- the concentration of the buffer salt solution is 0.05-0.5M, for example, 0.1-0.2M, and the pH of the buffer salt solution is adjusted to 4.0-5.5, for example, 5.0-5.2, and the buffer solution is used in an amount such that the concentration of the siRNA does not exceed 0.6 mg. /mL, for example, may be 0.2-0.4 mg/mL.
- the buffer salt is selected from one or more of soluble acetate and soluble citrate, and may be, for example, sodium acetate and/or potassium acetate.
- the lipid solution and the siRNA aqueous solution are mixed, and the product obtained after the mixing is incubated at 40 to 60 ° C for at least 2 minutes, for example, 5 to 30 minutes, to obtain a liposome preparation after the incubation.
- the volume ratio of the lipid solution to the aqueous siRNA solution is 1: (2-5), for example, 1:4.
- the liposome preparation after the incubation is concentrated or diluted to remove impurities and sterilized, and the pharmaceutical composition provided by the present disclosure has the physical and chemical parameters of pH 6.5-8, encapsulation efficiency of not less than 80%, and particle size of 40-200nm, polydispersity index is not higher than 0.30, osmotic pressure is 250-400mOsm/kg; for example, physical and chemical parameters can be pH 7.2-7.6, encapsulation efficiency is not less than 90%, particle size is 60-100nm, more The dispersion index is not higher than 0.20, and the osmotic pressure is 300-400 mOsm/kg.
- concentration or dilution can be carried out before, after or simultaneously with the removal of impurities.
- the method of removing impurities can be carried out by various methods, for example, a phase-cut flow system, a hollow fiber column, ultrafiltration under a condition of 100 K Da, and an ultrafiltration exchange solution of phosphate buffer (PBS) having a pH of 7.4.
- the sterilization method can be carried out by various methods, for example, it can be sterilized by filtration on a 0.22 ⁇ m filter.
- the present disclosure provides an siRNA conjugate comprising the above siRNA and a conjugation group conjugated to the siRNA.
- the conjugate group comprises a pharmaceutically acceptable at least one targeting group and an optional linker, and the siRNA, the linker and the targeting group are linked in sequence.
- the targeting group is 1-6.
- the targeting group is 2-4.
- the siRNA molecule can be non-covalently or covalently conjugated to the conjugate group, for example, can be covalently conjugated to the conjugate group.
- the conjugation site of the siRNA to the conjugate group may be at the 3' or 5' end of the siRNA sense strand, or at the 5' end of the antisense strand, or in the internal sequence of the siRNA. In some embodiments, the conjugation site of the siRNA to the conjugate group is at the 3' end of the siRNA sense strand.
- the conjugate group can be attached to a phosphate group, a 2'-position hydroxy group or a base of a nucleotide.
- the conjugated group can also be attached to the 3'-position hydroxyl group, in which case the nucleotides are linked by a 2'-5' phosphodiester linkage.
- the conjugate group is attached to the end of the siRNA strand, the conjugate group is typically attached to the phosphate group of the nucleotide; when the conjugate group is attached to the internal sequence of the siRNA, the conjugate group Usually attached to a ribose sugar ring or base.
- the siRNA and the conjugate group may be linked by an acid labile or reducible chemical bond, and in the acidic environment of the cell endosomes, these chemical bonds may degrade, thereby rendering the siRNA free.
- the conjugate group can be attached to the sense strand of the siRNA to minimize the effect of conjugation on siRNA activity.
- the pharmaceutically acceptable targeting group can be a ligand conventionally used in the field of siRNA administration, such as the various ligands described in WO2009082607A2, the entire disclosure of which is incorporated herein by reference. This article.
- the pharmaceutically acceptable targeting group can be selected from one or more of the following ligands or derivatives thereof: lipophilic molecules, such as cholesterol, bile acids, Vitamins (eg vitamin E), lipid molecules of different chain lengths; polymers such as polyethylene glycol; polypeptides such as transmembrane peptides; aptamers; antibodies; quantum dots; saccharides such as lactose, polylactose, mannose Sugar, galactose, N-acetylgalactosamine (GalNAc); folate; receptor ligands expressed by hepatocytes, such as asialoglycoprotein, asialoglycohol residues, lipoproteins (eg high density) Lipoprotein, low density lipoprotein, etc., glucagon, neurotransmitters (such as adrenaline), growth factors, transferrin and the like.
- lipophilic molecules such as cholesterol, bile acids, Vitamins (eg vitamin E), lipid molecules of different chain lengths
- polymers such as poly
- each of said ligands is independently selected from a ligand capable of binding to a cell surface receptor.
- at least one of the ligands is a ligand capable of binding to a hepatocyte surface receptor.
- at least one of the ligands is a ligand capable of binding to a mammalian cell surface receptor.
- at least one of the ligands is a ligand capable of binding to a human hepatocyte surface receptor.
- at least one of the ligands is a ligand capable of binding to a hepatic surface asialoglycoprotein receptor (ASGPR).
- ASGPR hepatic surface asialoglycoprotein receptor
- the pharmaceutically acceptable targeting group can be any ligand that binds to an asialoglycoprotein receptor (ASGPR) on the surface of a mammalian liver cell.
- each ligand is independently a asialoglycoprotein, such as asialogorosomucoid (ASOR) or asialogneein (ASF).
- the ligand is a sugar or a derivative of a sugar.
- At least one of the ligands is a sugar. In some embodiments, each ligand is a sugar. In some embodiments, at least one of the ligands is a monosaccharide, a polysaccharide, a modified monosaccharide, a modified polysaccharide, or a sugar derivative. In some embodiments, at least one of the ligands can be a monosaccharide, a disaccharide or a trisaccharide. In some embodiments, at least one of the ligands is a modified sugar. In some embodiments, each ligand is a modified sugar.
- each ligand is independently selected from the group consisting of a polysaccharide, a modified polysaccharide, a monosaccharide, a modified monosaccharide, a polysaccharide derivative, or a monosaccharide derivative.
- each or at least one ligand is selected from the group consisting of glucose and its derivatives, mannan and its derivatives, galactose and its derivatives, xylose and its derivatives, ribose and its derivatives, Fucose and its derivatives, lactose and its derivatives, maltose and its derivatives, arabinose and its derivatives, fructose and its derivatives and sialic acid.
- each of the ligands may be independently selected from the group consisting of D-mannopose, L-mannopose, D-arabinose, D-nitrofuran, L-nitroxylose, D- Glucose, L-glucose, D-galactose, L-galactose, ⁇ -D-furanmannose, ⁇ -D-furanmannose, ⁇ -D-mannopose, ⁇ -D-mannopyrose, ⁇ -D-glucopyranose, ⁇ -D-glucopyranose, ⁇ -D-glucofuranose, ⁇ -D-glucofuranose, ⁇ -D-fructofuranose, ⁇ -D-pyranose, ⁇ -D-pyridyl Galactose, ⁇ -D-galactopyranoside, ⁇ -D-galactofuranoside, ⁇ -D-galactopyranosylose, glucosamine, sia
- the pharmaceutically acceptable targeting group in the first siRNA conjugate can be galactose or N-acetylgalactosamine, wherein the galactose or N-acetylgalactosamine molecule can It is one price, two price, three price, and four price.
- the monovalent, divalent, trivalent, and tetravalent terms described herein refer to the formation of siRNA conjugates of siRNA molecules and conjugated groups containing galactose or N-acetylgalactosamine molecules as targeting groups, respectively.
- the molar ratio of the siRNA molecule to the galactose or N-acetylgalactosamine molecule in the siRNA conjugate is 1:1, 1:2, 1:3 or 1:4.
- the pharmaceutically acceptable targeting group is N-acetylgalactosamine.
- the siRNA of the present disclosure when the siRNA of the present disclosure is conjugated to a conjugating group containing N-acetylgalactosamine, the N-acetylgalactosamine molecule is trivalent or tetravalent.
- the siRNA of the present disclosure is conjugated to a conjugating group containing N-acetylgalactosamine, the N-acetylgalactosamine molecule is trivalent.
- the targeting group can be linked to the siRNA molecule via a suitable linker, and one skilled in the art can select a suitable linker depending on the particular type of targeting group.
- suitable linker one skilled in the art can select a suitable linker depending on the particular type of targeting group.
- the types of these linkers, the types of targeting groups, and the manner of attachment to siRNA can be found in the disclosure of WO 2015006740 A2, the entire contents of which being incorporated herein by reference.
- a suitable linker can be a structure as shown in formula (301):
- k is an integer from 1 to 3;
- L A is a chain moiety comprising an amide bond having a structure represented by formula (302), each of said L A having an ether bond at its two ends with one of said targeting group and said L C moiety, respectively connection:
- L B is a chain moiety comprising an N-acylpyrrolidine having a structure represented by the formula (303), the chain moiety having a carbonyl group at one end thereof and being bonded to the L C moiety via an amide bond at the other end Has an oxy group and is linked to the siRNA via a phosphate linkage:
- L C is a 2-4 valent linking group based on hydroxymethylaminomethane, dimethylolaminomethane or trishydroxymethylaminomethane, and the L C is via an oxygen atom to each of the L A moieties via an ether linkage. It is linked and is linked to the L B moiety via an amide bond via a nitrogen atom.
- L C is a trimethylolaminomethane-based tetravalent linking group, linked by -(L A ) 3 trishydroxymethylaminomethane-L B - as a linker
- the first siRNA conjugate formed by the N-acetylgalactosamine molecule and the siRNA molecule has the structure shown in the following formula (304):
- the double helix structure represents siRNA.
- the conjugation site of the siRNA to the conjugated group can be at the 3' or 5' end of the siRNA sense strand, also at the 5' end of the antisense strand, and also in the internal sequence of the siRNA.
- the 3' terminus of the sense strand of the siRNA of the present disclosure is covalently linked to three N-acetylgalactosamine (GalNAc) molecules via a linker-(L A ) 3 trishydroxymethylaminomethane-L B -
- the first siRNA conjugate having a molar ratio of siRNA molecule to GalNAc molecule of 1:3 was obtained by conjugation, which may also be referred to as (GalNAc) 3 -siRNA hereinafter, and its structure is shown in the following formula (305):
- double helix structure represents the siRNA and the linker is ligated to the 3' end of the sense strand of the siRNA.
- a suitable linker can be a structure as shown in formula (306):
- l is an integer from 0-3;
- * indicates a site on the linker that is attached to the targeting group via an ether linkage
- # indicates a site on the linker that is linked to the siRNA via a phosphate bond.
- the first siRNA conjugate has a structure as shown in formula (307):
- double helix structure represents the siRNA and the linker is ligated to the 3' end of the sense strand of the siRNA.
- WO 2015006740 A2 describes in detail the preparation of various conjugates.
- the first siRNA conjugate of the present disclosure is obtained by means well known to those skilled in the art.
- the preparation method of the structure represented by the formula (305) is described in WO2014025805A1
- the preparation method of the structure represented by the formula (307) is described by Rajeev et al. in ChemBioChem 2015, 16, 903-908.
- the disclosure provides a second siRNA conjugate having the structure shown in Formula (1):
- N1 is an integer selected from 1 to 3
- n3 is an integer selected from 0 to 4;
- M1, m2 and m3 are independently an integer selected from 2-10;
- R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are each independently H or selected from the group consisting of C 1 -C 10 alkyl, C 1 -C 10 haloalkane a group and a C 1 -C 10 alkoxy group;
- R 3 is a group of the structure represented by the formula A59:
- E 1 is OH, SH or BH 2 and Nu is an siRNA
- Each nucleotide in the siRNA represented by Nu is independently a modified or unmodified nucleotide, and the siRNA represented by Nu contains a sense strand and an antisense strand, and the sense strand comprises nucleotide sequence 1, the counter The sense strand comprises a nucleotide sequence 2, and the nucleotide sequence 1 and the nucleotide sequence 2 are at least partially inversely complementary to form a double-stranded region, the nucleotide sequence 1 and SEQ ID NO: 1
- the nucleotide sequence is equal in length and no more than 3 nucleotide differences, and the nucleotide sequence 2 is equal in length to the nucleotide sequence shown in SEQ ID NO: 2, and no more than 3 nuclei Glycoside difference:
- the nucleotide sequence 1 comprises a nucleotide Z A having a position corresponding to Z
- the nucleotide sequence 2 comprises a nucleotide Z' B having a position corresponding to Z', wherein the Z' B is The first nucleotide of the 5' end of the antisense strand;
- positional correspondence means the same position in the nucleotide sequence from the same end of the nucleotide sequence.
- the first nucleotide at the 3' end of nucleotide sequence 1 is a nucleotide that corresponds to the 1st nucleotide of the 3' end of SEQ ID NO: 1.
- L 1 may be selected from the group consisting of A1-A26 groups or any combination thereof, wherein the structures and definitions of A1-A26 are as follows:
- j1 is an integer from 1 to 20;
- j2 is an integer from 1 to 20;
- R' is a C 1 -C 10 alkyl group
- Ra is selected from the group consisting of the group A27-A45 or any combination thereof:
- Rb is a C 1 -C 10 alkyl group; Represents a site where a group is attached to the rest of the molecule.
- L 1 is defined as a linear alkyl group, but it may not be a linear group or a different name, such as an amine or alkenyl group replaced the above and / or substitutions generated.
- the length of L 1 is the number of atoms in the chain connecting the two attachment points.
- a ring for example, a heterocyclylene group or a heteroarylene group obtained by substituting a carbon atom of the linear alkylene group is counted as one atom.
- each M 1 represents a targeting group whose definition and selectable range are the same as those described above.
- each M 1 is independently selected having one affinity ligand for the asialoglycoprotein receptor on the cell surface of mammalian liver.
- n1 may be an integer from 1 to 3
- n3 may be an integer from 0 to 4.
- the number of M 1 targeting groups in the conjugate is at least 2; in some embodiments, n1+n3 ⁇ 2, such that the number of M 1 targeting groups is at least 3, thereby targeting group M 1 so that the surface of the liver asialoglycoprotein receptor binding easier, thereby promoting the conjugate enters the cell by endocytosis.
- n1 is an integer of 1-2
- n3 is an integer of 0-1
- n1+n3 2-3.
- the spatial position between the plurality of M 1 targeting groups can be adapted to the M 1 targeting group and the liver surface desialic acid
- m1, m2 and m3 are each independently an integer from 2 to 5
- R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are each independently selected from H, C 1 -C 10 alkyl, C 1 -C 10 haloalkyl, and C when one kind of 1 -C 10 alkoxy, not change the nature of the present disclosure conjugates, are object of the present disclosure may be implemented.
- R 10 , R 11 , R 12 , R 13 , R 14 , and R 15 are each independently selected from the group consisting of H, methyl, and ethyl.
- R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are both H.
- R 3 is a group of the structure represented by the formula A59, wherein E 1 is OH, SH or BH 2 , and in some embodiments, E 1 is OH or SH, based on consideration of ease of preparation of the raw material.
- R 2 The choice of R 2 is to achieve a linkage to N and A59 on the nitrogen-containing backbone.
- the "nitrogen-containing skeleton” means a chain structure in which a carbon atom to which R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are bonded to each other is bonded to N.
- R 2 can be any linking group capable of attaching the A59 group to the N on the nitrogen-containing backbone in an appropriate manner.
- the R 2 group needs to contain both a linkage to the N on the nitrogen-containing backbone and to the R 3 The P-phase is connected to the attachment site.
- R 2 can be B5, B6, B5' or B6':
- a site indicating a covalent bond of a group A site indicating a covalent bond of a group.
- q 2 may range from an integer of 1-10, and in some embodiments, q 2 is an integer from 1 to 5.
- L 1 is to link the M 1 targeting group to the N on the nitrogen-containing backbone to provide a liver targeting function for the second siRNA conjugate.
- L 1 is selected from a combination of linkages of one or more of the groups of Formulas A1 to A26.
- L 1 is selected from the group consisting of a combination of one or more of A1, A4, A5, A6, A8, A10, A11, and A13.
- L 1 is selected from the group consisting of at least two of A1, A4, A8, A10, and A11.
- L 1 is selected from the group consisting of at least two of A1, A8, and A10.
- L 1 can be from 3 to 25 atoms, from 3 to 20 atoms, from 4 to 15 atoms, or from 5 to 12 atoms. In some embodiments, the length of L 1 is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60 atom.
- L 1 is defined as a linear alkyl group, but it may not be a linear group or a different name, such as an amine or alkenyl group replaced the above and / or substitutions generated.
- the length of L 1 is the number of atoms in the chain connecting the two attachment points.
- a ring for example, a heterocyclylene group or a heteroarylene group obtained by substituting a carbon atom of the linear alkylene group is counted as one atom.
- j1 is an integer from 2 to 10, and in some embodiments, j1 is an integer from 3-5.
- j2 is an integer from 2 to 10, and in some embodiments, j2 is an integer from 3-5.
- R' is a C1-C4 alkyl group, and in some embodiments, R' is one of a methyl group, an ethyl group, and an isopropyl group.
- Ra is one of A27, A28, A29, A30 and A31, and in some embodiments, Ra is A27 or A28.
- Rb is a C1-C5 alkyl group, and in some embodiments, Rb is one of a methyl group, an ethyl group, an isopropyl group, and a butyl group.
- the respective formula A1-A26 of j1, j2, R ', Ra , Rb are selected in order to achieve targeting group M 1 on the N-linked nitrogen-containing backbone with targeting and M 1 The spatial position between the groups is more suitable for binding of the M 1 targeting group to the hepatic surface asialoglycoprotein receptor.
- the conjugate has the formula (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) , (13), (14), (15), (16), (17), (18), (19), (20), (21) or (22):
- the P in the formula A59 can be linked to any possible position in the siRNA sequence represented by Nu, for example, P in the formula A59 can be linked to any one of the siRNA sense strands or the antisense strand of the siRNA represented by Nu Acid; in some embodiments, P in formula A59 can be attached to any one of the nucleotides of the sense strand of siRNA represented by Nu. In some embodiments, P in Formula A59 is joined to the end of the sense or antisense strand of siRNA represented by Nu; in some embodiments, P in Formula A59 is joined to the end of the sense strand of siRNA represented by Nu.
- the terminus of the siRNA represented by Nu refers to the first 4 nucleotides from the one end of the siRNA sense strand or the antisense strand represented by Nu.
- the P in the formula A59 is linked to the terminus of the sense or antisense strand of the siRNA represented by Nu; in some embodiments, the P in the formula A59 is linked to the 3' of the sense strand in the siRNA represented by Nu End.
- a separate siRNA antisense strand can be released to block the APOC3 mRNA translation protein. The process of inhibiting apolipoprotein C3 (ApoC3) gene expression.
- P in Formula A59 can be attached to any possible position on a nucleotide in the siRNA represented by Nu, eg, the 5' position of the nucleotide, the 2' position of the nucleotide, the nucleotide 3' position or nucleotide base.
- P in formula A59 can be linked to the 2', 3' or 5' position of the nucleotide in the siRNA represented by Nu by forming a phosphodiester bond.
- the P in the formula A59 is linked to an oxygen atom formed after dehydrogenation of the 3' hydroxyl group of the 3' terminal nucleotide of the siRNA sense strand represented by Nu, or the siRNA represented by the substitution of Nu in the formula A59 Hydrogen in the 2'-hydroxyl group of one nucleotide in the sense strand is linked to the nucleotide, or P in the formula A59 is substituted by Nu to represent the hydrogen in the 5' hydroxyl group of the 5' terminal nucleotide of the siRNA sense strand. Nucleotide linkage.
- the nucleotide sequence 1 differs from the nucleotide sequence set forth in SEQ ID NO: 1 by no more than 1 nucleotide, and/or the nucleotide sequence 2 and SEQ ID NO The nucleotide sequence shown in 2 shows no more than one nucleotide difference.
- the nucleotide difference between the nucleotide sequence 2 and the nucleotide sequence set forth in SEQ ID NO: 2 comprises a difference at the Z' B position, and Z' B is selected from A, C or G; in some embodiments, the nucleotide difference is a difference at the Z' B position, Z' B is selected from A, C or G; in some embodiments, Z A is complementary to Z' B Nucleotide.
- the nucleotide sequence 1 and the nucleotide sequence 2 are substantially reverse complementary, substantially reverse complementary or fully reverse complementary.
- the substantially reverse complementation means that there are no more than three base mismatches between the two nucleotide sequences; the substantially reverse complementation means that there is no more than between the two nucleotide sequences One base mismatch; complete reverse complementation means that there is no mismatch between the two nucleotide sequences.
- the sense strand further comprises a nucleotide sequence 3, the antisense strand further comprising a nucleotide sequence 4, the nucleotide sequence 3 and the length of the nucleotide sequence 4 are each independent
- the ground is 1-4 nucleotides, and the nucleotide sequence 3 corresponds to the position of the nucleotide sequence 4.
- nucleotide sequence 4 is at least partially complementary to a nucleotide at a corresponding position in the target mRNA, and in some embodiments, nucleotide sequence 4 is fully complementary to a nucleotide at a corresponding position in the target mRNA.
- the nucleotide sequence 3 is ligated at the 5' end of the nucleotide sequence 1 and the nucleotide sequence 4 is ligated at the 3' end of the nucleotide sequence 2.
- the nucleotide sequence 3 and the nucleotide sequence 4 are equal in length and complementary in the reverse direction.
- the sense strand and the antisense strand can be 19-23 nucleotides in length.
- the nucleotide sequence 3 and the nucleotide sequence 4 are each 1 nucleotide in length, and the nucleotide sequence 3 has a base C.
- the length of the region may be 20 nucleotides, that is, the ratio of the length of the sense strand to the antisense strand may be 20/20; or,
- the nucleotide sequence 3 and the nucleotide sequence 4 are both 2 nucleotides in length, and the bases of the nucleotide sequence 3 are sequentially C and C according to the direction from the 5' end to the 3' end.
- the length of the double-stranded region may be 21 nucleotides, that is, the ratio of the length of the sense strand to the antisense strand may be 21/21;
- the nucleotide sequence 3 and the nucleotide sequence 4 are each 3 nucleotides in length, and the base of the nucleotide sequence 3 is U in the order of the 5' end to the 3' end.
- C and C in this case, the length of the double-stranded region may be 22 nucleotides, that is, the ratio of the length of the sense strand to the antisense strand may be 22/22;
- the nucleotide sequence 3 and the nucleotide sequence 4 are each 4 nucleotides in length, and the nucleotide sequence 3 has the base C in the order of the 5' end to the 3' end.
- U, C and C in this case, the length of the double-stranded region may be 23 nucleotides, that is, the ratio of the length of the sense strand to the antisense strand may be 23/23.
- the nucleotide sequence 3 is 2 nucleotides in length, and the nucleotide sequence 3 has the bases C and C in the order of the 5' end to the 3' end.
- nucleotide sequence 3 and the nucleotide sequence 4 are the same length and complementary, and therefore, the base of the nucleotide sequence 3 is given, and the base of the nucleotide sequence 4 is also It is determined.
- the siRNA represented by Nu in the formula (1) further comprises a nucleotide sequence 5, the nucleotide sequence 5 having a length of 1 to 3 nucleotides, linked to the antisense strand The 3' end, thereby constituting the 3' overhang of the antisense strand.
- the nucleotide sequence 5 is 1 or 2 nucleotides in length.
- the ratio of the length of the sense strand and the antisense strand of the siRNA represented by Nu may be 19/20, 19/21, 20/21, 20/22, 21/22, 21/23, 22/23, 22/24. , 23/24 or 23/25.
- the nucleotide sequence 5 is 2 nucleotides in length and is in the direction of the 5' end to the 3' end, the nucleotide sequence 5 being two consecutive thymidine deoxyribose Nucleotide, two consecutive uracil ribonucleotides, or two nucleotides complementary to the target mRNA.
- the ratio of the sense strand and the antisense strand of the siRNA represented by Nu is 19/21 or 21/23, in which case the conjugate containing the siRNA has better APOC3 mRNA silencing activity. .
- the sense strand comprises the nucleotide sequence set forth in SEQ ID NO: 60, the antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 3:
- the sense strand contains the nucleotide sequence set forth in SEQ ID NO: 4
- the antisense strand contains the nucleotide sequence set forth in SEQ ID NO: 5:
- Z' B is the first nucleotide at the 5' end of the antisense strand
- Z A is selected from A, U, G or C
- Z' B is a nucleotide complementary to Z A .
- the siRNA represented by Nu is siAP1 or siAP2:
- Antisense strand 5'-UUCUUGUCCAGCUUUAUUGGG-3' (SEQ ID NO: 7);
- the sense strand 5'-CCCAAUAAAGCUGGACAAGAA-3' (SEQ ID NO: 8);
- Antisense strand 5'-UUCUUGUCCAGCUUUAUUGGGAG-3' (SEQ ID NO: 9).
- the nucleotides in the siRNA represented by Nu in the formula (1) are each independently a modified or unmodified nucleotide.
- the nucleotide in the siRNA represented by Nu is an unmodified nucleotide; in some embodiments, some or all of the nucleotides in the siRNA represented by Nu are modified nucleotides, a nucleus These modifications on the nucleoside group do not result in a significant attenuation or loss of the function of the second siRNA conjugate of the present disclosure to inhibit APOC3 gene expression.
- the siRNA in the conjugate contains at least 1 modified nucleotide.
- modified nucleotide refers to a nucleotide or nucleotide analog formed by the substitution of a ribose 2' hydroxyl group of a nucleotide with another group, or a nucleoside.
- the base on the acid is the nucleotide of the modified base.
- the modified nucleotide does not result in a significant attenuation or loss of the ability of the siRNA conjugate to inhibit gene expression.
- modified nucleotides disclosed in J. K. Watts, G. F. Deleavey, and M. J. Damha, Chemically modified siRNA: tools and applications. Drug Discov Today, 2008, 13 (19-20): 842-55 can be selected.
- At least one nucleotide of the sense strand or the antisense strand is a modified nucleotide
- at least one phosphate group is a phosphate group having a modifying group
- at least a portion of the phosphate group and/or ribose group in the phosphate chain of at least one single strand of the sense strand and the antisense strand is a phosphate group having a modifying group and/or having a modifying group.
- the sense strand and/or all of the nucleotides in the antisense strand are modified nucleotides.
- each of the sense strand and the antisense strand are independently a fluoro-modified nucleotide or a non-fluoro-modified nucleotide.
- siRNA represented by Nu in the second siRNA conjugate is the following siRNA, a high balance of plasma stability and gene silencing efficiency is obtained in animal experiments:
- the fluoro-modified nucleotide is located in nucleotide sequence 1 and nucleotide sequence 2, and, in the direction from the 5' end to the 3' end, the nucleotide sequence 1
- the nucleotides at positions 7, 8, and 9 are fluoro-modified nucleotides; the nucleus at positions 2, 6, 14, and 16 of the nucleotide sequence 2 in the direction from the 5' end to the 3' end Glycosylates are fluoro-modified nucleotides.
- the nucleotide sequence 1 has no more than 5 fluoro-modified nucleotides; in some embodiments, the nucleotide sequence 2 has fewer fluoro-modified nucleotides In seven.
- the nucleus at position 7, 8, 9 or 5, 7, 8, and 9 of nucleotide sequence 1 in the sense strand is in the direction from the 5' end to the 3' end.
- the nucleotide is a fluoro-modified nucleotide, and the nucleotides at the rest of the sense strand are non-fluoro-modified nucleotides; in the antisense strand, in the direction from the 5' end to the 3' end
- the nucleotide at position 2, 6, 14, 16 or 2, 6, 8, 9, 14, 16 of the nucleotide sequence 2 is a fluoro-modified nucleotide in the antisense strand
- the nucleotides at the remaining positions are non-fluoro modified nucleotides.
- the nucleotides at positions 5, 7, 8, and 9 of nucleotide sequence 1 in the sense strand of siRNA represented by Nu are fluoro-modified nucleosides in the direction from the 5' end to the 3' end.
- the acid, the nucleotide at the rest of the sense strand of the siRNA is a methoxy-modified nucleotide, and, in the direction from the 5' end to the 3' end, Nu represents the nucleotide sequence of the antisense strand of the siRNA
- the nucleotides at positions 2, 6, 8, 9, 14 and 16 are fluoro-modified nucleotides, and the nucleotides at the rest of the antisense strand of the siRNA are methoxy-modified nucleotides;
- the nucleotides at positions 7, 8 and 9 of the nucleotide sequence 1 in the sense strand of the siRNA represented by Nu are fluoro-modified nucleotides, and the sense strand of siRNA The nucleotides in the remaining positions are methoxy-modified nucleotides, and, in the direction from the 5' end to the 3' end, Nu represents the second, sixth, and fourth nucleotide sequences of the antisense strand of the siRNA.
- the nucleotide at position 16 is a fluoro-modified nucleotide
- the nucleotide at the rest of the antisense strand of the siRNA is a methoxy-modified nucleotide.
- the nucleotide has a phosphate group modification.
- the phosphate group is modified to a phosphorothioate modification as shown in formula (101) below, ie, the non-bridged oxygen atom in the phosphodiester bond is replaced with a sulfur atom to thereby phosphorothioate
- the diester bond replaces the phosphodiester bond. This modification stabilizes the structure of the siRNA, maintaining high specificity and high affinity for base pairing.
- the phosphorothioate group linkage is present in at least one of the group consisting of: the first and second nucleosides at either end of the sense strand or the antisense strand Between acids; between the second and third nucleotides at either end of the sense strand or the antisense strand; or any combination of the above.
- the phosphorothioate linkage is present at all of the above positions except for the 5' end of the sense strand.
- the phosphorothioate linkage is present at all of the above positions except for the 3' end of the sense strand.
- the phosphorothioate linkage is present at at least one of the following locations:
- the 2' end of the 3' end of the antisense strand is between the 2nd nucleotide and the 3rd nucleotide.
- the 5' terminal nucleotide of the antisense strand sequence of the siRNA molecule represented by Nu is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide.
- 5'-phosphate nucleotides can have the following structure:
- nucleotides modified by the 5'-phosphate analog are well known to those skilled in the art, for example, Anastasia Khvorova and Jonathan K. Watts, The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology, The following four nucleotides are disclosed in 2017, 35(3): 238-48:
- R represents a group selected from the group consisting of H, OH, F and methoxy
- Base represents a base selected from A, U, C, G or T.
- the nucleotide modified by the 5'-phosphate nucleotide or the 5'-phosphate analog is a nucleotide containing a 5'-phosphate modified group represented by formula (102), represented by formula (103) A nucleotide containing E-vinylphosphonate (E-VP) or a nucleotide containing a 5'-thiophosphate modification represented by formula (105).
- the inventors of the present disclosure have surprisingly discovered that the second siRNA conjugate of the present disclosure exhibits significantly improved plasma stability, low off-target effects, and also exhibits a significantly reduced APOC3 mRNA silencing activity, and also has Higher blood lipid inhibition.
- the siRNA represented by Nu in the second siRNA conjugate of the present disclosure may be siAP1, siAP2, siAP1-M1, siAP2-M1, siAP1-M2, siAP2-M2, siAP1-M1S, siAP2 -M1S, siAP1-M2S, siAP2-M2S, siAP1-M1P1, siAP2-M1P1, siAP1-M2P1, siAP2-M2P1, siAP1-M1SP1, siAP2-M1SP1, siAP1-M2SP1, siAP2-M2SP1, as shown in Table 1 show.
- each adjacent nucleotide is linked by a phosphodiester bond or a phosphorothioate diester bond, and a non-bridging in a phosphodiester bond or a phosphorothioate diester bond
- the oxygen atom or the sulfur atom has a negative charge, which may exist in the form of a hydroxyl group or a sulfhydryl group, and the hydrogen ion in the hydroxyl group or the thiol group may also be partially or completely substituted by a cation.
- the cation may be any cation such as one of a metal cation, an ammonium ion NH 4 + , and an organic ammonium cation.
- the cation is selected from one or more of an alkali metal ion, an ammonium cation formed by a tertiary amine, and a quaternary ammonium cation.
- the alkali metal ion may be K + and/or Na +
- the cation formed by the tertiary amine may be an ammonium ion formed by triethylamine and/or an ammonium ion formed by N,N-diisopropylethylamine.
- the siRNA or the first or second siRNA conjugate of the present disclosure may exist at least partially in the form of a salt.
- the non-bridging oxygen or sulfur atom in the phosphodiester bond or the phosphorothioate diester bond is at least partially bound to the sodium ion, the siRNA or the first or second siRNA conjugate of the present disclosure. It exists in the form of a sodium salt or a partial sodium salt.
- modified nucleotide groups can be introduced into the siRNA by using nucleoside monomers having corresponding modifications. Methods of preparing nucleoside monomers having corresponding modifications and methods of introducing modified nucleotide groups into siRNA are also well known to those skilled in the art. All modified nucleoside monomers are either commercially available or can be prepared by known methods.
- the second siRNA conjugate can be prepared using any reasonable synthetic route.
- the second siRNA conjugate can be prepared by a method comprising, under the conditions of solid phase synthesis of phosphoramidite, according to the nucleotide type and order of the sense strand and the antisense strand of the siRNA, respectively.
- the nucleoside monomers are sequentially linked in the direction of 3' to 5', and the linkage of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization; the sense strand and the antisense strand of the siRNA are isolated.
- each nucleotide in the siRNA represented by Nu is independently a modified or unmodified nucleotide, and the siRNA represented by Nu contains a sense strand and an antisense strand, and the sense strand comprises a nucleotide sequence 1.
- the antisense strand comprises nucleotide sequence 2, and the nucleotide sequence 1 and the nucleotide sequence 2 are at least partially reverse-complementary to form a double-stranded region, the nucleotide sequence 1 and SEQ ID
- the nucleotide sequence shown by NO: 1 is equal in length and not more than 3 nucleotide differences
- the nucleotide sequence 2 is equal in length to the nucleotide sequence shown in SEQ ID NO:
- the nucleotide sequence 1 comprises a nucleotide Z A having a position corresponding to Z
- the nucleotide sequence 2 comprises a nucleotide Z' B having a position corresponding to Z', wherein the Z' B is The first nucleotide of the 5' end of the antisense strand;
- the method further comprises contacting the compound of the formula (321) with a nucleoside monomer or a nucleotide sequence attached to the solid support in the presence of a coupling reaction condition and a coupling reagent, thereby allowing the formula ( The compound shown in 321) is linked to the nucleotide sequence by a coupling reaction.
- the compound represented by the formula (321) is also referred to as a conjugation molecule.
- R 4 is a moiety capable of binding to the siRNA represented by Nu. In some embodiments, R 4 is a moiety capable of binding to a siRNA represented by Nu by a covalent bond. In some embodiments, R 4 is a moiety capable of being reacted to conjugate to any functional group of the siRNA represented by Nu by a phosphodiester bond;
- Each S 1 is independently a group formed by substituting all of the active hydroxyl groups in M 1 with a YCOO- group, wherein each Y is independently selected from the group consisting of methyl, trifluoromethyl, difluoromethyl, and fluoro One of a group, trichloromethyl, dichloromethyl, monochloromethyl, ethyl, n-propyl, isopropyl, phenyl, halophenyl, and alkylphenyl; in some embodiments , Y is a methyl group.
- n1, n3, m1, m2, m3, R 10, R 11, R 12, R 13, R 14, R 15, L 1, M 1 are each as defined and selectable range as described above.
- R 4 is selected to N in order to achieve a nitrogen-containing backbone connection, and to provide suitable reaction sites for the synthesis of a second siRNA conjugate.
- R 4 includes an R 2 linking group or a protected R 2 linking group, and a functional group capable of forming a structure represented by A59 with a siRNA by a reaction.
- R 4 comprises a first functional group capable of forming a phosphite with a group represented by Nu or an nucleoside monomer, and a second functional group reactive with a hydroxyl group or an amino group to form a covalent bond or containing The covalently bonded solid phase carrier.
- the first functional group is a phosphoramidite, a hydroxyl group, or a protected hydroxyl group.
- the second functional group is a phosphoramidite, a carboxylic acid, or a carboxylate.
- the second functional group is a solid support that is linked to other portions of the molecule via a covalent bond, the covalent bond being formed from a hydroxyl group or an amino group.
- the solid support is linked via a phosphate bond, a carboxylate bond, or an amide bond.
- the solid support is a resin.
- the first functional group contains a hydroxyl group, -OR k or a group represented by formula (C3); and the second functional group contains formulas (C1), (C2), (C3), (C1' ) or the structure shown in (C3'):
- q 1 is an integer from 1 to 4
- X is O or NH
- M + is a cation
- R k is a hydroxy protecting group
- SPS is a solid phase carrier. Represents a site where a group is attached to the rest of the molecule.
- the first functional group contains a phosphoramidite group, as shown in formula (C3), and the phosphoramidite group may be a hydroxyl group at any position on the nucleotide, such as a 2' hydroxyl group or The 3' hydroxyl group undergoes a coupling reaction to form a phosphite, and is oxidized or sulfided to form a phosphodiester bond or a phosphorothioate bond represented by the formula A59, and the conjugation molecule is conjugated to the siRNA.
- the compound of the formula (321) can be conjugated to the nucleotide without affecting the acquisition of the second siRNA conjugate.
- the compound of the formula (321) is reacted with a hydroxyl group at the terminal nucleotide in the nucleotide sequence, and A phosphodiester bond or a phosphorothioate linkage is formed during oxidation or vulcanization, and the compound of formula (321) is conjugated to the siRNA.
- the first functional group contains a protected hydroxyl group.
- the second functional group comprises a group reactive with a solid support, the reaction providing a conjugation molecule comprising a solid support.
- the second functional group contains a carboxyl group, a carboxylate or a phosphoramidite, as represented by formula (C1), (C2) or (C3), when the second functional group comprises a carboxyl group or a carboxylate.
- the compound of the formula (321) is subjected to an esterification reaction or amidation reaction with a solid phase carrier such as a hydroxyl group or an amino group on the resin to form a conjugated molecule comprising a solid phase carrier linked via a carboxylate bond.
- the compound of the formula (321) is coupled with a general-purpose solid phase carrier, for example, a hydroxyl group on a resin, and is oxidized to form a phosphodiester-linked solid phase carrier. Conjugated molecules. Subsequently, the nucleoside monomer is sequentially linked according to the phosphoramidite solid phase synthesis method, and the sense strand or the antisense strand of the siRNA to which the conjugated group is attached is obtained starting from the product after the above-mentioned solid phase carrier is attached. During the solid phase synthesis of phosphoramidite, the first functional group undergoes deprotection and subsequent coupling with a phosphoramidite group on the nucleoside monomer under coupling reaction conditions.
- a general-purpose solid phase carrier for example, a hydroxyl group on a resin
- the first functional group contains a hydroxyl group or a protected hydroxyl group
- the second functional group contains a solid phase carrier linked by a carboxylate bond or a solid phase carrier linked by an amide bond, or a phosphate bond.
- the attached solid support is as shown in formula (C1') or (C3').
- the nucleoside monomer is sequentially linked according to the phosphoramidite solid phase synthesis method to obtain a sense strand or an antisense strand of the siRNA to which the conjugated group is attached.
- the carboxylate can be represented as -COO - M + , wherein M + is a cation, such as one selected from the group consisting of a metal cation, an ammonium cation NH 4 + , and an organoammonium cation.
- M + is a cation, such as one selected from the group consisting of a metal cation, an ammonium cation NH 4 + , and an organoammonium cation.
- the metal ion is selected from one of the alkali metal ions, such as K + or Na + .
- the organic ammonium ion is an ammonium cation or a quaternary ammonium cation formed by a tertiary amine, such as an ammonium ion formed by triethylamine or N, N-di Ammonium ion formed by isopropylethylamine.
- the carboxylate is a triethylamine carboxylate or an N,N-diisopropylethylamine carboxylate.
- R 4 comprises a structure of formula (B9), (B10), (B9'), (B10'), (B11), (B12), (B11'), or (B12'):
- q 1 is an integer from 1 to 4
- q 2 is an integer from 1 to 10
- X is O or NH
- M + is a cation
- R k is a hydroxy protecting group
- SPS is a solid phase carrier. Represents a site where a group is attached to the rest of the molecule.
- q 1 is 1 or 2.
- q 2 is an integer from 1 to 5.
- R 4 contains a structure represented by formula (B9) or (B10).
- R 4 contains a structure represented by formula (B11) or (B12).
- R k is Tr (trityl), MMTr (4-methoxytrityl), DMTr (4,4'-bismethoxytrityl), TMTr (4 One or more of 4', 4'-trimethoxybenzyl.
- R k may be DMTr, i.e. methoxytrityl, 4,4'-bis (4,4'-dimethoxytrityl).
- L 1 The definition of L 1 is as described above.
- L 1 M 1 are used to connect the targeting group to the N atom a nitrogen-containing backbone to provide a liver function as a second targeting siRNA conjugate.
- L 1 comprises any one of A1-A26 or a combination thereof.
- the conjugated molecule can be linked by the above first functional group and optionally the second functional group as compared to the phosphoramidite solid phase synthesis method well known in the art.
- a second siRNA conjugate to any possible position of the nucleotide sequence for example, the conjugate molecule is attached to the end of the nucleotide sequence and the conjugate molecule is ligated to the end of the nucleotide sequence.
- each S 1 is independently M 1 . In some embodiments, each S 1 is independently a group formed by the protection of at least one reactive hydroxyl group of M 1 by a hydroxy protecting group. In some embodiments, each S 1 is independently a group formed by any of the active hydroxyl groups present in M 1 being protected by a hydroxy protecting group. In some embodiments, any known to those skilled hydroxy protecting groups may be used to protect the reactive hydroxyl groups of M 1.
- the protected hydroxy group can be represented by the formula YCOO-, wherein each Y is independently selected from the group consisting of a C 1 -C 10 alkyl group and a C 6 -C 10 aryl group, the C The 1- C 10 alkyl group and the C 6 -C 10 aryl group are optionally substituted by one or more substituents selected from the group consisting of halogen and C 1 -C6 alkyl groups.
- each Y is independently selected from the group consisting of methyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl , monochloromethyl, ethyl, n-propyl, isopropyl, phenyl, halophenyl, and C 1 -C 6 alkylphenyl.
- each S 1 is independently selected from the group consisting of Formulas A46-A54:
- S 1 is Formula A49 or A50.
- each Y is independently selected from the group consisting of methyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, ethyl, and One of propyl, isopropyl, phenyl, halophenyl, and alkylphenyl; in some embodiments, Y is methyl.
- the preparation method of the second siRNA conjugate further comprises the steps of synthesizing another strand of the siRNA (for example, when the above step synthesizes the siRNA sense strand to which the conjugated group is attached, The phase synthesis method synthesizes the antisense strand of siRNA, and vice versa), separates the sense strand and the antisense strand, and anneals.
- the solid phase carrier linked to the nucleotide sequence and/or the conjugated molecule is cleaved while the necessary protecting group is removed (in this case, each S in the compound of the formula (321) 1 group is converted to the corresponding M 1 targeting group), the siRNA sense strand (or antisense strand) linked to the conjugated group and the corresponding antisense strand (or sense strand), sense strand and antisense strand are obtained.
- Annealing forms a double-stranded RNA structure to obtain a second siRNA conjugate.
- the method of preparing a second siRNA conjugate comprises the steps of: formulating a compound of formula (321) with a sense strand or an antisense strand in the presence of coupling reaction conditions and a coupling reagent
- the first nucleoside monomer of the 'end is contacted, such that the compound of the formula (321) is attached to the first nucleotide in the sequence, and under the conditions of solid phase synthesis of the phosphoramidite, according to the desired sense strand or antisense
- the nucleotide sequence and sequence, the nucleoside monomers are sequentially linked in the direction of 3' to 5' to synthesize the sense strand or the antisense strand of the siRNA; wherein the (321) compound contains the first functional group and the first functional group in R 4 a bifunctional group, the first functional group containing a protected hydroxyl group, and the second functional group having a compound represented by formula (321) having a structure represented by formula (C1') or (C3'), before being
- the method of making a second siRNA conjugate comprises the steps of: nucleating the 3' to 5' direction according to the nucleotide species and sequence of the sense strand or the antisense strand of the double stranded siRNA
- the glycosides are sequentially linked to synthesize the sense strand and the antisense strand.
- the linkage of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization to obtain a sense strand and linkage attached to the solid support.
- An antisense strand on a solid support; in the presence of coupling reaction conditions and a coupling reagent, the compound of formula (321) is coupled to a sense strand attached to a solid support or to a solid support.
- the compound of the formula (321) is a compound of the formula (321) wherein the compound of the formula (321) is a first functional group in R 4 and the first functional group is a phosphoramidite group.
- the protecting group is removed and cleaved with the solid phase vector, and isolated and purified separately to obtain a sense strand or an antisense strand of the siRNA, which is annealed, wherein a conjugate group is attached to the sense strand or the antisense strand of the siRNA represented by Nu.
- the P in the formula A59 is linked to the 3' end of the sense strand in the siRNA, and the preparation method of the second siRNA conjugate comprises:
- a compound of the formula (321) is removed (wherein the compound of the formula (321) contains a first functional group and a second functional group in R 4 , the first functional group contains a protected hydroxyl group OR k , and the second functional group has a formula (C1) a hydroxy protecting group R k in the compound of the structure shown by ') or (C3'); contacting the product obtained by deprotection with a nucleoside monomer in the presence of a coupling reaction condition and a coupling reagent to obtain a conjugate a nucleoside monomer that is linked to a solid support;
- step (1) the method of removing the formula (321) R k protecting group in the compound comprising the deprotection conditions, the formula (321) contacting the compound with a deprotecting agent.
- Deprotection conditions include a temperature of 0-50 ° C, in some embodiments 15-35 ° C, a reaction time of 30-300 seconds, in some embodiments 50-150 seconds, and a deprotection reagent may be selected from trifluoroacetic acid One or more of trichloroacetic acid, dichloroacetic acid, monochloroacetic acid, in some embodiments dichloroacetic acid.
- the molar ratio of the deprotecting agent to the compound of formula (321) is from 10:1 to 1000:1, and in some embodiments from 50:1 to 500:1.
- the coupling reaction conditions and the coupling reagent may use any conditions and reagents suitable for the above coupling reaction. In some embodiments, the same conditions and reagents as for the coupling reaction in the solid phase synthesis method employed can be used.
- the conditions of the coupling reaction comprise a reaction temperature of 0-50 °C, and in some embodiments, 15-35 °C.
- the molar ratio of the compound of the formula (321) to the nucleoside monomer is from 1:1 to 1:50, in some embodiments from 1:2 to 1:5; the molar ratio of the compound of the formula (321) to the coupling reagent may be 1:1-1:50, in some embodiments 1:3-1:10, reaction time 200-3000 seconds, and in some embodiments 500-1500 seconds.
- the coupling reagent is selected from one or more of 1H-tetrazole, 5-ethylthio 1H-tetrazole, 5-benzylthio 1H-tetrazole, and in some embodiments 5-ethion Base 1H-tetrazole.
- the coupling reaction can be carried out in an organic solvent selected from one or more of anhydrous acetonitrile, anhydrous DMF, anhydrous dichloromethane, and in some embodiments anhydrous acetonitrile.
- the organic solvent is used in an amount of from 3 to 50 L/mol, and in some embodiments from 5 to 20 L/mol, relative to the compound of the formula (321).
- step (2) the method of solid phase synthesis of phosphoramidite nucleic acid is used to synthesize the nucleoside monomer which is ligated to the solid phase carrier by the conjugation molecule, and is synthesized in the direction of 3'-5'.
- the conjugate group is attached to the 3' end of the resulting sense strand.
- conditions for solid phase synthesis described in steps (2) and (3) include nucleoside monomer deprotection conditions, type and amount of deprotection reagent, coupling reaction conditions, type and amount of coupling reagent, cap reaction
- the conditions, the type and amount of the capping reagent, the oxidation reaction conditions, the type and amount of the oxidizing reagent, the vulcanization reaction conditions, the vulcanization reagent and the amount are various reagents, amounts and conditions conventionally used in the art.
- the solid phase synthesis described in steps (2) and (3) can use the following conditions:
- Nucleoside monomer deprotection conditions include a temperature of 0-50 ° C, in some embodiments 15-35 ° C, a reaction time of 30-300 seconds, in some embodiments 50-150 seconds, a deprotection reagent can be selected One or more of trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, monochloroacetic acid, in some embodiments, dichloroacetic acid.
- the molar ratio of the deprotecting agent to the 4,4'-dimethoxytrityl protecting group on the solid support can be from 2:1 to 100:1, and in some embodiments from 3:1 to 50:1. .
- the coupling reaction conditions include a temperature of 0-50 ° C, in some embodiments 15-35 ° C, the molar ratio of the nucleic acid sequence attached to the nucleoside monomer on the solid phase support may be 1:1 to 1:50, In some embodiments: 1:5-1:15; the molar ratio of the nucleic acid sequence and the coupling reagent attached to the solid support is from 1:1 to 1:100, and in some embodiments from 1:50 to 1:80.
- the reaction time and the choice of the coupling reagent are the same as described above.
- the cap reaction conditions include a temperature of 0-50 ° C, in some embodiments 15-35 ° C, a reaction time of 5-500 seconds, in some embodiments 10-100 seconds, and the capping agent is selected in the same manner as previously described.
- the molar ratio of the total amount of capping reagent to the nucleic acid sequence attached to the solid support is from 1:100 to 100:1, and in some embodiments from 1:10 to 10:1.
- the cap reagent uses an equimolar amount of acetic anhydride and N-methylimidazole
- the molar ratio of the nucleic acid sequence attached to the acetic anhydride, the N-methylimidazole, and the solid phase carrier is 1:1:10-10:10. :1, in some embodiments 1:1:2-2:2:1.
- the oxidation reaction conditions include a temperature of 0-50 ° C, in some embodiments 15-35 ° C, a reaction time of 1-100 seconds, in some embodiments 5-50 seconds, and an oxidizing agent, in some embodiments, iodine. (In some embodiments, provided in the form of iodine water).
- the molar ratio of the oxidizing reagent to the nucleic acid sequence attached to the solid support in the coupling step can range from 1:1 to 100:1, and in some embodiments from 5:1 to 50:1.
- the vulcanization reaction conditions include a temperature of 0-50 ° C, in some embodiments 15-35 ° C, a reaction time of 50-2000 seconds, in some embodiments 100-1000 seconds, and a vulcanization reagent in some embodiments is hydrogenation. Xanthogen.
- the molar ratio of the sulfurizing reagent to the nucleic acid sequence attached to the solid support in the coupling step is from 10:1 to 1000:1, and in some embodiments from 10:1 to 500:1.
- the method further comprises isolating the sense and antisense strands of the siRNA.
- Methods for isolation are well known to those skilled in the art and generally involve cleavage of the resulting nucleotide sequence from a solid support, removal of protecting groups on bases, phosphates and ligands, purification and desalting. .
- the cleavage of the synthesized nucleotide sequence from the solid phase support and removal of the protecting group on the base, on the phosphate group and on the ligand can be carried out according to conventional cleavage and deprotection methods in siRNA synthesis.
- the obtained nucleotide sequence linked to the solid phase carrier is contacted with concentrated aqueous ammonia; during deprotection, the protecting group YCOO- of the A46-A54 group is converted into a hydroxyl group, and the S 1 group is converted into a corresponding one.
- the M 1 group produces a conjugate of the formula (1).
- the concentrated ammonia water may be 25-30% by weight of ammonia water, and the amount of concentrated ammonia water may be 0.2 ml/ ⁇ mol-0.8 ml/ ⁇ mol compared with the target siRNA sequence.
- the method further comprises contacting the nucleotide sequence of the solid phase removal medium with triethylamine trihydrofluoride to remove the 2'-TBDMS protection.
- the obtained target siRNA sequence has a corresponding nucleoside having a free 2'-hydroxy group.
- the amount of pure triethylamine trihydrofluoride may be from 0.4 ml/ ⁇ mol to 1.0 ml/ ⁇ mol compared to the target siRNA sequence. This gives a second siRNA conjugate.
- the preparative ion chromatography purification column can be used to purify the nucleic acid by gradient elution with NaBr or NaCl; after product collection and combination, the reverse phase chromatography purification column can be used for desalting.
- a non-bridging oxygen atom or a sulfur atom in a phosphodiester bond or a phosphorothioate diester bond between nucleotides substantially binds to a sodium ion
- a second siRNA is conjugated.
- the substance is basically present in the form of a sodium salt.
- Other forms of the second siRNA conjugate can be obtained by replacing the sodium ion with a hydrogen ion and/or other cation using well known ion exchange methods. The cation is as previously described.
- the purity and molecular weight of the nucleic acid sequence can be detected at any time during the synthesis to better control the quality of the synthesis. Such methods of detection are well known to those skilled in the art. For example, nucleic acid purity can be detected by ion exchange chromatography and molecular weight can be determined by LC-MS chromatography.
- the synthesized sense strand (S chain) and the antisense strand (AS chain) can be simply mixed in an equimolar ratio in water for injection to 70-95 ° C, followed by cooling at room temperature to form a double bond through hydrogen bonding. Chain structure. This gives a second siRNA conjugate.
- the synthesized second siRNA conjugate can also be characterized by molecular weight detection or the like using methods such as LC/MS chromatography to determine the synthesized
- the siRNA conjugate is a second siRNA conjugate designed for the target, and the sequence of the synthesized siRNA is the sequence of the desired siRNA, for example, one of the sequences listed in Table 1.
- the compound of the formula (321) can be obtained by a production method comprising: a compound represented by the formula (313) and a cyclic group in an organic solvent under an esterification reaction condition and in the presence of a base and an ester-forming catalyst.
- the acid anhydride is contacted, ion exchanged, and the compound represented by the formula (321) is obtained:
- n1, n3, m1, m2, m3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , L 1 , S 1 are as defined above;
- R 6 is a group which provides R 4 in the formula (321). In some embodiments, R 6 has the structure shown by formula (A61):
- R i is possible to achieve the N-linked nitrogen-containing backbone, and R k O connection has a connection to any free hydroxyl group, R k is a hydroxy protecting group.
- R 4 contains a first functional group and a second functional group as a hydroxy protecting group, and the second functional group contains a compound of the formula (321) having a structure represented by the formula (C1) or (C2).
- the esterification reaction conditions include a reaction temperature of 0-100 ° C, and a reaction time of 8-48 hours. In some embodiments, the esterification reaction conditions are a reaction temperature of 10-40 ° C, and a reaction time of 20-30. hour.
- the organic solvent comprises an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropylethylamine.
- the epoxy solvent is dioxane and/or tetrahydrofuran
- the ether solvent is diethyl ether and/or methyl tert-butyl ether
- the halogenated alkane solvent is dichloromethane, three One or more of methyl chloride and 1,2-dichloroethane.
- the organic solvent is dichloromethane.
- the organic solvent is used in an amount of from 3 to 50 L/mol, and in some embodiments from 5 to 20 L/mol, relative to the compound of the formula (313).
- the cyclic anhydride is one of succinic anhydride, glutaric anhydride, adipic anhydride, or pimelic anhydride, and in some embodiments is succinic anhydride.
- the molar ratio of the cyclic anhydride to the compound of formula (313) is from 1:1 to 10:1, and in some embodiments from 2:1 to 5:1.
- the ester-forming catalyst may be any catalyst that catalyzes the esterification reaction, for example, the catalyst may be 4-dimethylaminopyridine.
- the molar ratio of the catalyst to the compound of formula (313) is from 1:1 to 10:1, and in some embodiments from 2:1 to 5:1.
- the base can be any inorganic base, organic base, or a combination thereof.
- the base may be, for example, a tertiary amine organic base.
- the tertiary amine organic base is triethylamine or N,N-diisopropylethylamine.
- the molar ratio of the tertiary amine organic base to the compound of formula (313) is from 1:1 to 20:1, and in some embodiments from 3:1 to 10:1.
- the ion exchange is the conversion of a compound of formula (321) to the desired carboxylic acid or carboxylate form, and methods of ion exchange are known to those skilled in the art, and suitable ion exchange solutions and exchange conditions can be used to obtain the foregoing.
- the cation is a M + conjugation molecule and will not be described in detail herein.
- the ion exchange reaction is carried out using a triethylamine phosphate solution having a concentration of 0.2-0.8 M.
- the triethylamine phosphate solution The concentration is from 0.4 to 0.6 M, and the triethylamine phosphate solution is used in an amount of from 3 to 6 L/mol, and in a further embodiment from 4 to 5 L/mol, relative to the compound of the formula (313).
- the compound of formula (321) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed directly to provide a crude product of the compound of formula (321), which can be used directly in the subsequent reaction.
- the method for preparing the compound of the formula (321) further comprises the product obtained by the above ion exchange reaction in the presence of a condensing agent and a tertiary amine organic base in an organic solvent under condensation reaction conditions. Further contacting with a solid phase carrier containing an amino group or a hydroxyl group.
- a compound of the formula (321) in which R 4 contains a first functional group and a second functional group, a first functional group contains a hydroxy protecting group, and a second functional group contains a structure represented by the formula (C1′) is obtained.
- the solid phase support is one of the vectors used in solid phase synthesis of siRNA, some of which are well known to those skilled in the art.
- the solid support may be selected from a solid support containing reactive hydroxyl or amino functional groups, and in some embodiments, the solid support is an amino resin or a hydroxy resin.
- the amino or hydroxy resin has the following parameters: particle size 100-400 mesh, surface amino or hydroxyl loading of 0.2-0.5 mmol/g.
- the ratio of the compound represented by the formula (321) to the solid phase carrier is from 10 to 400 ⁇ mol of the compound per gram of the solid phase carrier ( ⁇ mol/g). In some embodiments, the ratio of the compound represented by the formula (321) to the solid phase carrier is from 50 to 200 ⁇ mol/g.
- the organic solvent may be any suitable solvent or mixed solvent known to those skilled in the art.
- the organic solvent is acetonitrile, an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropyl One or more of ethylamine.
- the epoxy solvent is dioxane and/or tetrahydrofuran
- the ether solvent is diethyl ether and/or methyl tert-butyl ether
- the halogenated alkane solvent is dichloromethane, three One or more of methyl chloride and 1,2-dichloroethane.
- the organic solvent is acetonitrile.
- the organic solvent is used in an amount of from 20 to 200 L/mol, and in some embodiments from 50 to 100 L/mol, relative to the compound of the formula (321).
- the condensing agent may be benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate, 3-diethoxyphosphoryl-1,2,3-benzoazole 4 (3H)-keto and/or O-benzotriazole-tetramethylurea hexafluorophosphate, in some embodiments, the condensing agent is O-benzotriazole-tetramethylurea hexafluoro Phosphate ester.
- the molar ratio of the condensing agent to the compound of the formula (321) is from 1:1 to 20:1, and in further embodiments from 1:1 to 5:1.
- the tertiary amine organic base is triethylamine and/or N,N-diisopropylethylamine, in some embodiments N,N-diisopropylethylamine;
- the molar ratio of the tertiary amine organic base to the compound of the formula (321) is from 1:1 to 20:1, and in some embodiments from 1:1 to 5:1.
- the method for preparing the compound of the formula (321) may further comprise contacting the obtained condensation product with a capping reagent and an acylation catalyst in an organic solvent under a cap reaction condition, and separating the compound represented by the formula (321). Compound.
- the capping reaction serves to remove any reactive functional groups that have not been fully reacted to avoid the formation of unnecessary by-products in subsequent reactions.
- the conditions for the cap reaction include a reaction temperature of 0-50 ° C, in some embodiments 15-35 ° C, a reaction time of 1-10 h, and in some embodiments 3-6 h.
- the capping reagent can use a capping reagent used in siRNA solid phase synthesis, and capping reagents used in siRNA solid phase synthesis are well known to those skilled in the art.
- the cap reagent consists of cap reagent 1 (cap1) and cap reagent 2 (cap2), wherein cap reagent 1 is N-methylimidazole, in some embodiments N-methylimidazole Provided as a mixed solution of pyridine/acetonitrile, wherein the volume ratio of pyridine to acetonitrile is 1:10-1:1, in some embodiments 1:3-1:1, the total volume of pyridine and acetonitrile and N-A The volume of the imidazole is from 1:1 to 10:1, and in some embodiments from 3:1 to 7:1.
- the cap reagent 2 is acetic anhydride.
- the capping reagent 2 is provided as an acetonitrile solution of acetic anhydride, wherein the volume of acetic anhydride and acetonitrile is from 1:1 to 1:10, and in a further embodiment: 1:2-1: 6.
- the ratio of the volume of the pyridine/acetonitrile mixed solution of the N-methylimidazole to the mass of the compound of the formula (321) is 5 ml/g to 50 ml/g, and in some embodiments, 15 ml/g- 30ml/g.
- the ratio of the volume of the acetic anhydride in acetonitrile solution to the mass of the compound of formula (321) is from 0.5 ml/g to 10 ml/g, and in some embodiments from 1 ml/g to 5 ml/g.
- the capping reagent uses an equimolar amount of acetic anhydride and N-methylimidazole.
- the organic solvent is acetonitrile, an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropyl One or more of ethylamine.
- the organic solvent is acetonitrile.
- the organic solvent is used in an amount of 10 to 50 L/mol, and in some embodiments, 5 to 30 L/mol, relative to the compound of the formula (321).
- the acylation catalyst can be selected from any catalyst that can be used to form an ester condensation or an amide condensation, such as a basic heterocyclic compound.
- the acylation catalyst is 4-dimethylaminopyridine.
- the mass ratio of the catalyst to the compound of the formula (321) is from 0.001:1 to 1:1, and in some embodiments from 0.01:1 to 0.1:1.
- the compound of formula (321) can be isolated from the reaction mixture using any suitable separation method.
- the compound of formula (321) which is selected from the group consisting of acetonitrile, dichloromethane, can be obtained by extensive washing with an organic solvent and filtration to remove unreacted reactants, excess capping reagents, and other impurities.
- Methanol in some embodiments acetonitrile.
- the method for preparing the conjugated molecule of formula (321) comprises reacting the compound of formula (313) with phosphorousous acid in an organic solvent under coupling reaction conditions and in the presence of a coupling reagent.
- the acyl diamine is contacted to obtain a compound of the formula (321).
- a compound of the formula (321) in which R 4 contains a first functional group and a second functional group, a first functional group contains a hydroxy protecting group, and a second functional group contains a structure represented by the formula (C3) is obtained.
- the coupling reaction conditions include a temperature of 0 to 50 ° C, for example, 15 to 35 ° C, and a molar ratio of the compound of the formula (313) to the phosphorous diamine may be 1:1 to 1:50.
- a molar ratio of the compound of the formula (313) to the phosphorous diamine may be 1:1 to 1:50.
- it is 1:5-1:15
- the molar ratio of the compound of the formula (313) to the coupling reagent may be 1:1 to 1:100, for example, 1:50 to 1:80
- the reaction time may be 200 to 3000 seconds. , for example, 500-1500 seconds.
- the phosphoramidide for example, bis(diisopropylamino)(2-cyanoethoxy)phosphine, which is commercially available or can be obtained by a method known in the art, can be used.
- the coupling reagent is selected from one or more of 1H-tetrazole, 5-ethylthio 1H-tetrazole, 5-benzylthio 1H-tetrazole, for example, 5-ethylthio 1H-tetra Azole.
- the coupling reaction can be carried out in an organic solvent selected from one or more of anhydrous acetonitrile, anhydrous DMF, anhydrous dichloromethane, such as anhydrous acetonitrile.
- the organic solvent is used in an amount of from 3 to 50 L/mol, for example, from 5 to 20 L/mol, relative to the compound of the formula (313).
- a hydroxyl group in the compound of the formula (313) is reacted with a phosphorous diamine to form a phosphoramidite group.
- the solvent can be removed directly to provide a crude product of the compound of formula (321), which can be used directly in the subsequent reaction.
- the method of preparing the compound of the formula (321) further comprises the steps of further separating the isolated product from the hydroxyl group-containing product under coupling reaction conditions, in an organic solvent, and in the presence of a coupling reagent.
- the solid support is contacted.
- the compound of the formula (321) is isolated by a cap reaction and an oxidation reaction.
- a compound of the formula (321) having a first functional group and a second functional group in R 4 , a hydroxy protecting group in the first functional group, and a second functional group having a structure represented by the formula (C3′) is obtained.
- the solid phase support is a solid phase support known in the art and useful for solid phase synthesis of nucleic acids, for example, may be a commercially available universal solid phase support after deprotection ( UnyLinker TM 300 Oligonucleotide Synthesis Support, Kinovate Life Sciences, structure as shown in Equation B80):
- the deprotection conditions include a temperature of 0-50 ° C, such as 15-35 ° C; a reaction time of 30-300 seconds, such as 50-150 seconds.
- the deprotecting agent can be selected from one or more of trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, monochloroacetic acid, and in some embodiments, the deprotecting reagent is dichloroacetic acid.
- the molar ratio of the deprotecting agent to the -DMTr(4,4'-dimethoxytrityl) protecting group on the stationary phase is from 2:1 to 100:1, for example from 3:1 to 50:1.
- the coupling reaction conditions and the choice of coupling reagent can be as described above.
- the free hydroxyl group formed in the deprotection reaction reacts with the phosphoramidite group to form a phosphite linkage.
- the cap reaction conditions comprise a temperature of 0-50 ° C, such as 15-35 ° C, a reaction time of 5-500 seconds, such as 10-100 seconds, and the cap reaction is carried out in the presence of a capping agent.
- the selection and amount of cap reagent can be as described above.
- the oxidation reaction conditions include a temperature of 0 to 50 ° C, for example, 15 to 35 ° C, a reaction time of 1 to 100 seconds, for example, 5 to 50 seconds, and an oxidizing agent such as iodine (in some embodiments, iodine) Provided in the form of water).
- an oxidizing agent such as iodine (in some embodiments, iodine) Provided in the form of water).
- the molar ratio of oxidizing agent to phosphite groups is from 1:1 to 100:1, such as from 5:1 to 50:1.
- R 6 is one of the groups of formula B7 or B8,
- the compound of the formula (313) can be obtained by the following production method: in an organic solvent, under the conditions of an amide formation reaction, and in the presence of an amide reaction condensing agent and a tertiary amine organic base, the formula (314) The compound shown is contacted with a compound of formula (A-1) or a compound of formula (A-2), followed by separation:
- n1, n3, m1, m2, m3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , L 1 , S 1 , q 2 and R k are each defined and selected as As mentioned before.
- the amide forming reaction conditions may include a reaction temperature of 0-100 ° C and a reaction time of 1-48 hours. In some embodiments, the amide forming reaction conditions are a reaction temperature of 10-40 ° C and a reaction time of 2 16 hours.
- the organic solvent is an alcohol solvent, an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diiso One or more of propyl ethylamine.
- the alcohol solvent is, in some embodiments, one or more of methanol, ethanol, propanol, and in some embodiments, ethanol.
- the epoxy-based solvent is, in some embodiments, dioxane and/or tetrahydrofuran.
- the ether solvent is, in some embodiments, diethyl ether and/or methyl tert-butyl ether.
- the halogenated alkane solvent is, in some embodiments, one or more of dichloromethane, chloroform, and 1,2-dichloroethane.
- the organic solvent is dichloromethane.
- the organic solvent is used in an amount of from 3 to 50 L/mol, and in a further embodiment from 3 to 20 L/mol, relative to the compound of the formula (314).
- the amide-forming condensing agent is benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate, 3-diethoxyphosphoryl-1,2,3-benzene Azole 4(3H)-one, 4-(4,6-dimethoxytriazin-2-yl)-4-methylmorpholine hydrochloride, 2-ethoxy-1-ethoxycarbonyl- 1,2-Dihydroquinoline (EEDQ) or O-benzotriazole-tetramethylurea hexafluorophosphate, in a further embodiment 3-diethoxyphosphoryl-1,2,3 - benzoxazole 4(3H)-one.
- the molar ratio of the amide-forming condensing agent to the compound of formula (314) may range from 1:1 to 10:1, and in some embodiments from 2.5:1 to 5:1.
- the tertiary amine organic base is triethylamine or N,N-diisopropylethylamine, and in a further embodiment is N,N-diisopropylethylamine.
- the molar ratio of the tertiary amine organic base to the compound of formula (314) is from 3:1 to 20:1, and in some embodiments from 5:1 to 10:1.
- the compounds of formula (A-1) and formula (A-2) can be prepared by any suitable means.
- R k is a DMTr group
- a compound of formula (A-1) can be prepared by reacting calcium glycerate with DMTrCl; similarly, 3-amino-1,2-propanediol can be first contacted with a cyclic anhydride, followed by The compound of formula (A-2) is then prepared by reaction with DMTrCl, which may be a cyclic anhydride having from 4 to 13, in some embodiments from 4 to 8.
- the compound of formula (313) can also be prepared by reacting a compound of formula (314) with the cyclic anhydride, 3-amino-1,2-propanediol, and DMTrCl in that order.
- a compound of formula (314) with the cyclic anhydride, 3-amino-1,2-propanediol, and DMTrCl in that order.
- the compound of formula (313) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed directly to provide a crude product of the compound of formula (313) which can be used directly in the subsequent reaction.
- the compound of formula (314) can be obtained by the following preparation method: the method comprises contacting a compound of formula (315) with a haloacetic acid in an organic solvent under deprotection reaction conditions, followed by Separate:
- R 7 is selected from the group represented by formula (330), (331), (332) or (333), and in some embodiments, the structure of R 7 is as shown in formula (330):
- the haloacetic acid is selected from one or more of the group consisting of dichloroacetic acid, trichloroacetic acid, monochloroacetic acid, and trifluoroacetic acid, and in some embodiments is dichloroacetic acid.
- the deprotection reaction conditions include a reaction temperature of 0-100 ° C, a reaction time of 0.1-24 hours, in some embodiments a reaction temperature of 10-40 ° C, and a reaction time of 0.5-16 hours.
- the organic solvent is an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropylethylamine.
- the epoxy-based solvent is, in some embodiments, dioxane and/or tetrahydrofuran, and in some embodiments is diethyl ether and/or methyl tert-butyl ether
- the halogenated alkane solvent is in some
- the organic solvent is dichloromethane.
- the organic solvent is used in an amount of from 3 to 50 L/mol, and in a further embodiment from 5 to 20 L/mol, relative to the compound of the formula (315).
- the molar ratio of the haloacetic acid to the compound of formula (315) is from 5:1 to 100:1, and in some embodiments from 10:1 to 50:1.
- the compound of formula (314) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed directly to provide a crude product of the compound of formula (314) which can be used directly in the subsequent reaction.
- the compound of the formula (315) can be obtained by the following production method: the method comprises: in the presence of an amide reaction condensing agent and a tertiary amine organic base in an organic solvent, under the condensation reaction conditions, the formula (317) The compound is contacted with a compound of formula (316) and subsequently isolated:
- n1, n3, m1, m2, m3, R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , L 1 , S 1 are as defined above .
- the compound of the formula (316) can be, for example, a compound disclosed in J. Am. Chem. Soc. 2014, 136, 16958-16961, or the compound of the formula (316) can be produced by a person skilled in the art by various methods, for example, Certain compounds of formula (316) are prepared by reference to the methods disclosed in Example 1, U.S. Patent No. 8,106,022, the entire disclosure of which is incorporated herein in its entirety by reference.
- the condensation reaction conditions comprise a reaction temperature of 0-100 ° C, a reaction time of 0.1-24 hours, in some embodiments a reaction temperature of 10-40 ° C, and a reaction time of 0.5-16 hours.
- the molar ratio of the compound of the formula (316) to the compound of the formula (317) may be from 2:1 to 10:1, and in some embodiments from 2.5:1 to 5:1.
- the organic solvent is acetonitrile, an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropyl
- ethylamines which in some embodiments are dioxane and/or tetrahydrofuran, and in some embodiments are diethyl ether and/or methyl tert-butyl.
- the alkyl ether which in some embodiments is one or more of dichloromethane, chloroform, and 1,2-dichloroethane, in some embodiments, the organic solvent is acetonitrile .
- the organic solvent is used in an amount of from 3 to 50 L/mol, and in some embodiments from 5 to 20 L/mol, relative to the compound of the formula (317).
- the amide-forming condensing agent is benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate, 3-diethoxyphosphoryl-1,2,3-benzene Oxazol 4(3H)-one (DEPBT), O-benzotriazole-tetramethylurea hexafluorophosphate or 4-(4,6-dimethoxytriazin-2-yl)-4-methyl
- the morpholine hydrochloride in a further embodiment, is 4-(4,6-dimethoxytriazin-2-yl)-4-methylmorpholine hydrochloride.
- the molar ratio of the amide-forming condensing agent to the compound of formula (317) may range from 2:1 to 10:1, and in some embodiments from 2.5:1 to 5:1.
- the tertiary amine organic base may be N-methylmorpholine, triethylamine or N,N-diisopropylethylamine, in some embodiments N-methylmorpholine; the tertiary amine
- the molar ratio of the organoorganic base to the compound of formula (317) may range from 3:1 to 20:1, and in some embodiments from 5:1 to 10:1.
- the compound of formula (315) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed by evaporation, followed by chromatographic separation of the compound of formula (315).
- the solvent can be removed directly to provide a crude product of formula (315) which can be used directly in the subsequent reaction.
- a compound of formula (317) is reacted in a single reaction with a sufficient amount of a compound of formula (316) to form the desired compound of formula (315), in which case the individual S 1 -L 1 moieties are identical to each other.
- the formula (317) with a different batch of the compound of formula (316) compound i.e. compound L 1 and / or S 1 different from formula (316) reacts so that the resulting formula (315)
- the compound contains two or more kinds of S 1 and/or L 1 .
- a compound of formula (317) may be first contacted with 2 eq of the first compound of formula (316), and the first S 1 -L may be attached to the two terminal primary amine groups of the compound of formula (317). Part 1 , followed by contacting it with a compound of the second formula (316) of (n3+n1-1) eq (the definitions and ranges of values for n3 and n1 are as described above), in the compound of formula (317) The second S 1 -L 1 moiety is attached to the (n3+n1-1) secondary amine group.
- the compound of formula (317) can be obtained by a process comprising: contacting a compound of formula (318) with an aqueous solution of methylamine in the presence of an organic solvent under deprotection conditions, Subsequent separation:
- n1, n3, m1, m2 , m3, R 7, R 10, R 11, R 12, R 13, R 14, R 15 are each as defined and selectable range as described above.
- the deprotection reaction conditions include a reaction temperature of 0 to 150 ° C, a reaction time of 5 to 72 hours, and in some embodiments, a reaction temperature of 20 to 80 ° C and a reaction time of 10 to 30 hours.
- the organic solvent may be selected from the group consisting of alcohols, in some embodiments one of methanol, ethanol, and isopropanol, and in some embodiments, methanol; relative to the compound of formula (318), the organic solvent is used in an amount of 1-20 L/mol, in some embodiments 1.5-10 L/mol.
- the concentration of the aqueous methylamine solution may be 30-40% by mass, and the molar ratio of methylamine to the compound of the formula (318) may be 10:1 to 500:1, and in some embodiments, 50:1-200: 1.
- the compound of formula (317) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed by evaporation, followed by chromatographic separation of the compound of formula (317).
- the solvent can be removed directly to provide a crude product of the compound of formula (317), which can be used directly in the subsequent reaction.
- the compound of formula (318) can be obtained by the following preparation method: the method comprises the compound of formula (319) and triphenylchloromethane (in the presence of an organic solvent under the substitution reaction conditions). TrCl), diphenylethylphenylchloromethane, phenyldiethylphenylchloromethane or triethylphenylchloromethane, in some embodiments triphenylchloromethane (TrCl) contact, followed by separation:
- n1, n3, m1, m2 , m3, R 10, R 11, R 12, R 13, R 14, R 15 are each as defined and selectable range as described above.
- the substitution reaction conditions may include a reaction temperature of 0-100 ° C and a reaction time of 5 to 72 hours. In some embodiments, the reaction conditions include a reaction temperature of 10 to 40 ° C and a reaction time of 10 to 30 hours.
- Triphenylchloromethane (TrCl), diphenylethylphenylchloromethane, phenyldiethylphenylchloromethane or triethylphenylchloromethane are commercially available, triphenylchloromethane (TrCl), diphenyl
- the molar ratio of ethylphenylchloromethane, phenyldiethylphenylchloromethane or triethylphenylchloromethane to the compound of formula (319) may range from 1:1 to 10:1, and in some embodiments is 1: 1-3:1.
- the organic solvent may be one of an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropylethylamine or A variety.
- the epoxy-based solvent may be dioxane and/or tetrahydrofuran in some embodiments, and in some embodiments may be diethyl ether and/or methyl tert-butyl ether, the halogenated alkane solvent. In some embodiments, it can be one or more of dichloromethane, chloroform, and 1,2-dichloroethane; in some embodiments, the organic solvent is dichloromethane.
- the organic solvent may be used in an amount of from 3 to 50 L/mol, and in some embodiments from 5 to 20 L/mol, relative to the compound of the formula (319).
- the compound of formula (318) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed by evaporation, followed by chromatographic separation of the compound of formula (318).
- the compound of formula (319) can be obtained by the following preparation method: the method comprises contacting a compound of the formula (320) with ethyl trifluoroacetate under an alternative reaction condition in an organic solvent. Subsequent separation:
- n1, n3, m1, m2 , m3, R 10, R 11, R 12, R 13, R 14, R 15 are each as defined and selectable range as described above.
- the organic solvent is acetonitrile, an epoxy solvent, an ether solvent, a halogenated alkane solvent, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-diisopropyl One or more of ethylamine.
- the epoxy-based solvent is dioxane and/or tetrahydrofuran
- the ether solvent is diethyl ether and/or methyl tert-butyl ether
- the halogenated alkane solvent is one or more of dichloromethane, chloroform and 1,2-dichloroethane, and in some embodiments, the organic solvent is acetonitrile.
- the organic solvent may be used in an amount of from 1 to 50 L/mol, and in some embodiments from 1 to 20 L/mol, relative to the compound of the formula (320).
- the substitution reaction conditions may include a reaction temperature of 0-100 ° C and a reaction time of 5 to 72 hours. In some embodiments, the substitution reaction conditions include a reaction temperature of 10 to 40 ° C and a reaction time of 10 to 30 hours. .
- the molar ratio of the ethyl trifluoroacetate to the compound of formula (320) is from 2:1 to 10:1, and in some embodiments from 3:1 to 5:1.
- the compound of formula (319) can be isolated from the reaction mixture using any suitable separation method.
- the solvent can be removed by evaporation, followed by chromatographic separation of the compound of formula (319).
- the first or second siRNA conjugate of the present disclosure may also be combined with other pharmaceutically acceptable excipients, which may be one or more of various formulations or compounds conventionally employed in the art, for details. See above for a description of the pharmaceutical compositions of the present disclosure.
- the disclosure provides a modified siRNA, a pharmaceutical composition, a first siRNA conjugate, and/or a second siRNA conjugate prepared for treatment and/or prevention by the apolipoprotein Use of a drug for dyslipidemia caused by overexpression of C3 (ApoC3).
- the present disclosure provides a method of treating dyslipidemia caused by overexpression of apolipoprotein C3 (ApoC3), the method comprising administering to a subject an effective amount of a modified siRNA, a pharmaceutical combination of the present disclosure The first siRNA conjugate and/or the second siRNA conjugate.
- ApoC3 apolipoprotein C3
- the purpose of treating dyslipidemia can be achieved by a mechanism of RNA interference.
- the modified siRNA, pharmaceutical composition, first siRNA conjugate, and/or second siRNA conjugate of the present disclosure can be used to prevent and/or treat dyslipidemia, or for preparation for prevention and/or A drug that treats dyslipidemia.
- the dyslipidemia refers to dyslipidemia caused by overexpression of the APOC3 gene in hepatocytes, and is usually manifested by an increase in the level of any or all of lipids and/or lipoproteins such as triglycerides and cholesterol in the blood, and high levels of blood lipids. Highly associated with hypertension, cardiovascular disease, diabetes, and other pathological conditions. Hypertriglyceridemia is associated with atherosclerosis and can also cause pancreatitis. Dyslipidemia as described in the present disclosure includes, but is not limited to, hypercholesterolemia, hypertriglyceridemia, or atherosclerosis.
- administering/administering refers to by arranging, at least in part, the modified siRNA, pharmaceutical composition, first siRNA conjugate and/or second siRNA conjugate of the present disclosure to a desired
- the modified siRNA, pharmaceutical composition, first siRNA conjugate, and/or second siRNA conjugate of the present disclosure are placed into a subject in a manner or pathway that produces the desired effect.
- Routes of administration suitable for the methods of the present disclosure include topical administration and systemic administration. In general, topical administration results in delivery of more of the disclosed modified siRNA, pharmaceutical composition, first siRNA conjugate, and/or second siRNA conjugate to a particular body than the subject's entire body.
- the present disclosure is directed to providing a means of preventing and/or treating dyslipidemia, in some embodiments, a mode of administration capable of delivering a drug to the liver.
- Administration can be administered to a subject by any suitable route known in the art including, but not limited to, oral or parenteral routes such as intravenous, intramuscular, subcutaneous, transdermal.
- Drug can be administered to a subject by any suitable route known in the art including, but not limited to, oral or parenteral routes such as intravenous, intramuscular, subcutaneous, transdermal.
- Drug airway administration (aerosol), pulmonary administration, nasal administration, rectal administration, and topical administration (including buccal administration and sublingual administration).
- the frequency of administration can be one or more times per day, every week, every two weeks, every three weeks, every month or every year.
- the dosage of the siRNA, the pharmaceutical composition, the first siRNA conjugate and/or the second siRNA conjugate of the present disclosure may be a dosage conventional in the art, which may be based on various parameters, especially The age, weight and sex of the subjects were determined. Toxicity and efficacy can be determined by standard pharmaceutical procedures in cell culture or laboratory animals, such as determining LD50 (a dose that kills 50% of the population) and ED50 (in a quantitative response, a dose that causes 50% of the maximum response intensity, in a qualitative response) The middle finger causes a dose of 50% of the subjects to have a positive reaction).
- the range of human doses can be derived based on data obtained from cell culture assays and animal studies.
- siRNA When administering an siRNA, a pharmaceutical composition, a first siRNA conjugate, and/or a second siRNA conjugate as described herein, for example, for males or females, 6-12 weeks of age, and body weights of 18-25 g C57BL/6J or 30-45 g of ob/ob mice, based on the amount of siRNA: (i) for the first siRNA conjugate and/or the second siRNA conjugate, the siRNA can be used in an amount of 0.001-100 mg.
- the amount of siRNA may range from 0.001 to 50 mg/kg body weight, and in further embodiments from 0.01 to 10 mg/kg body weight, in still further embodiments 0.05-5 mg/kg body weight, in still further embodiments, 0.1-3 mg/kg body weight.
- the disclosure provides a method of inhibiting apolipoprotein C3 (ApoC3) gene expression in hepatocytes, the method comprising administering an effective amount of a modified siRNA of the disclosure, a pharmaceutical composition, a first siRNA The conjugate and/or the second siRNA conjugate are contacted with the hepatocytes.
- the modified siRNA, the pharmaceutical composition, the first siRNA conjugate and/or the second siRNA conjugate of the present disclosure are introduced into hepatocytes, and the purpose of inhibiting the expression of the APOC3 gene in hepatocytes is achieved by an RNA interference mechanism.
- the hepatocytes may be selected from hepatoma cell lines such as Hep3B, HepG2, Huh7 or isolated hepatic primary cells. In some embodiments, the cell is a Huh7 liver cancer cell.
- the expression of the APOC3 gene in a cell is inhibited by the method provided by the present disclosure, and the amount of siRNA in the modified siRNA, the pharmaceutical composition, the first siRNA conjugate, and/or the second siRNA conjugate provided is generally such Amount: It is sufficient to reduce the expression of a target gene and result in an extracellular concentration of 1 pM to 1 ⁇ M, or 0.01 nM to 100 nM, or 0.05 nM to 50 nM or to about 5 nM at the surface of the target cell. The amount required to achieve this local concentration will vary with a variety of factors including the method of delivery, the site of delivery, the number of cell layers between the delivery site and the target cell or tissue, whether the delivery is local or systemic, and the like. The concentration at the delivery site can be significantly higher than the concentration at the surface of the target cell or tissue.
- the present disclosure provides a kit comprising an effective amount of at least one of a modified siRNA of the present disclosure, a pharmaceutical composition, a first siRNA conjugate, and a second siRNA conjugate.
- kits described herein can provide modified siRNA in one container.
- the kits described herein can comprise a container that provides a pharmaceutically acceptable excipient.
- other components such as stabilizers or preservatives and the like may also be included in the kit.
- the kits described herein can comprise at least one additional therapeutic agent in a container other than a container that provides the modified siRNA described herein.
- the kit can include instructions for mixing the modified siRNA with a pharmaceutically acceptable carrier and/or adjuvant or other ingredients, if any.
- the modified siRNA and a pharmaceutically acceptable carrier and/or adjuvant and the modified siRNA, pharmaceutical composition, first siRNA conjugate, and/or second siRNA conjugate may be provided in any form, such as a liquid form, a dry form, or a lyophilized form.
- the modified siRNA and the pharmaceutically acceptable carrier and/or adjuvant and the pharmaceutical composition and/or conjugate and optionally the pharmaceutically acceptable excipient are substantially pure and/or Sterile.
- sterile water can be provided in a kit of the present disclosure.
- HEK293A cells were provided by the Nucleic Acid Technology Laboratory of the Institute of Molecular Medicine, Peking University, containing 20% fetal bovine serum (FBS, Hyclone) and 0.2% by volume of scleromycin double antibody (Penicillin-Streptomycin, Gibco, Invitrogen) The cells were cultured in DMEM complete medium (Hyclone) and cultured at 37 ° C in an incubator containing 5% CO 2 /95% air.
- FBS fetal bovine serum
- scleromycin double antibody Penicillin-Streptomycin, Gibco, Invitrogen
- Huh7 cells were purchased from the stem cell bank of the Chinese Academy of Sciences. Cells were cultured in DMEM complete medium (Hyclone) containing 10% fetal bovine serum (FBS, Hyclone) and 1% non-essential amino acids (NEAA, Corning) at 37 °C. Incubate in an incubator containing 5% CO 2 /95% air.
- DMEM complete medium Hyclone
- FBS fetal bovine serum
- NEAA non-essential amino acids
- the animal models used are as follows:
- Human APOC3 transgenic mouse B6; CBA-Tg (APOC3) 3707Bres/J, purchased from Jackson Laboratory, USA;
- Cynomolgus monkey provided by Suzhou Huazhen Biotechnology Co., Ltd.
- conjugates 1-3 (hereinafter, also referred to as L10-siAP1M2SVP conjugate, L10-siAP1M2SP conjugate and L10-siAP1M2SPs conjugate, respectively).
- the conjugate is a conjugate formed by conjugation of L-9 conjugated molecules to siRNAs numbered siAP1M2SVP, siAP1M2SP or siAP1M2SPs, respectively. See Table 3 for the sequence of the siRNA conjugated in this conjugate.
- the L-10 compound was synthesized as follows:
- GAL-1 N-acetyl-D-galactosamine hydrochloride, CAS No.: 1772-03-8, purchased from Ningbo Hongxiang Biochemical Co., Ltd., 463.8 mmol
- acetic anhydride purchased from Enox Corporation, 5565.6 mmol
- GAL-2 (35.1 g, 90.0 mmol) obtained in the step (1-1-1a) was dissolved in 213 ml of anhydrous 1,2-dichloroethane, and 24.0 g of TMSOTf was added in an ice water bath under nitrogen atmosphere. (CAS No.: 27607-77-8, purchased from Macleans, 108.0 mmol), reacted overnight at room temperature.
- the reaction solution was diluted with 400 ml of dichloromethane, and filtered with celite, and then 1 L of saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred, and the organic phase was separated.
- the aqueous phase was extracted twice with dichloroethane, 300 ml each time.
- the organic phase was washed with 300 ml of a saturated aqueous sodium hydrogen carbonate solution and 300 ml of brine, and the organic phase was evaporated, dried over anhydrous sodium sulfate, and evaporated.
- GAL-3 (26.9 g, 81.7 mmol) obtained in the step (1-1-1b) was dissolved in 136 ml of anhydrous 1,2-dichloroethane, and dried. 30 g of molecular sieve powder, and then added 9.0 g of 5-hexen-1-ol (CAS No.: 821-41-0, available from Adamas-beta, 89.9 mmol), stirred at room temperature for 30 minutes, added under ice bath and nitrogen protection. 9.08 g of TMSOTf (40.9 mmol) was stirred at room temperature overnight.
- GAL-4 (14.9 g, 34.7 mmol) obtained according to the method described in the step (1-1-1c) was dissolved in a mixed solvent of 77 ml of dichloromethane and 77 ml of acetonitrile, respectively, and 103 ml of deionized water and 29.7 g were added.
- Sodium periodate (CAS No.: 7790-28-5, purchased from Aladdin, 138.8 mmol), stirred for 10 minutes in an ice water bath, and added with antimony trichloride (CAS No.: 14988-67-0, purchased from An Nai Kyrgyzstan, 238 mg, 1.145 mmol), reacted overnight at room temperature.
- the reaction solution was diluted with 300 ml of water and stirred, and adjusted to pH 7.5 with saturated sodium hydrogencarbonate.
- the organic phase was separated and discarded, and the aqueous phase was extracted three times with dichloromethane (200 ml), and the organic phase was discarded.
- the aqueous phase was adjusted to pH 3 with citric acid solids, and extracted twice with dichloromethane (200 ml).
- the organic phase was combined and dried over anhydrous sodium sulfate. .
- the crude M-11-T3-Tr obtained in the step (1-1-3) (7.763 g, 10 mmol) was dissolved in 100 ml of methanol, and then 100 ml of aqueous methylamine solution (40% by mass) was added, and the reaction was stirred at 50 ° C for 23 h. The insoluble granules were removed by filtration, and the solvent was evaporated to dryness.
- the solvent was evaporated to drynessjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj
- the reaction mixture was diluted with 200 ml of dichloromethane, and the organic phase was washed with 100 ml of saturated sodium hydrogen carbonate, and the organic phase was washed with anhydrous sodium sulfate.
- Purification of 200-300 mesh normal phase silica gel column, petroleum ether packed column, neutralization of silica gel with 1% by weight of triethylamine, elution with dichloromethane: methanol 100:5-100:7 gradient, product eluent It was evaporated to dryness under reduced pressure to give the crude product L-5-Tr 7.49 g.
- the L-5-Tr (5.94 g, 3.456 mmol) obtained in the step (1-1-5) was dissolved in 69 ml of dichloromethane, then dichloroacetic acid (13.367 g, 103.67 mmol) was added, and reacted at room temperature for 2 h, added
- DMTrCl (4,4'-bismethoxytrityl chloride, 38.12 g, 112.5 mmol) was dissolved in 450 ml of anhydrous pyridine, and DL-calcium glycerate hydrate (12.88 g, 45.0 mmol) was added at 45 After reacting for 22 h at ° C, the reaction solution was filtered, and the filter cake was rinsed with 200 ml of DCM, and the filtrate was concentrated to dryness under reduced pressure.
- an L-10 compound was prepared by attaching an L-9 conjugating molecule to a solid support.
- the L-9 conjugated molecule obtained in the step (1-1-8) (0.233 g, 0.1126 mmol), O-benzotriazole-tetramethylurea hexafluorophosphate (HBTU, 0.064 g, 0.1689 mmol)
- HBTU O-benzotriazole-tetramethylurea hexafluorophosphate
- DIEA diisopropylethylamine
- CapA and CapB are capping reagent solutions
- CapA is a pyridine/acetonitrile mixed solution of 20% by volume of N-methylimidazole, and the volume ratio of pyridine to acetonitrile is 3:5
- CapB is a solution of 20% by volume of acetic anhydride in acetonitrile.
- the sense strand sequences of conjugates 1-3 are the same, so the preparation method is also the same.
- the nucleoside monomer was ligated one by one from the 3'-5' direction by the solid phase phosphoramidite method using the L-10 compound prepared by the above procedure.
- Each nucleoside monomer is linked to a four-step reaction of deprotection, coupling, capping, oxidation or sulfurization.
- a phosphate linkage is used between two nucleotides
- a nucleoside monomer is attached, a four-step reaction including deprotection, coupling, capping, and oxidation is included.
- a phosphorothioate is used between two nucleotides, when a nucleoside monomer is attached, a four-step reaction of protection, coupling, capping, and sulfurization is included.
- the synthesis conditions are given as follows:
- the nucleoside monomer is provided in a 0.1 M acetonitrile solution.
- the deprotection reaction conditions are the same for each step, that is, the temperature is 25 ° C, the reaction time is 70 seconds, and the deprotecting reagent is dichloroacetic acid in dichloromethane (3%). v/v), the molar ratio of dichloroacetic acid to the 4,4'-dimethoxytrityl protecting group on the solid support is 5:1.
- the coupling reaction conditions are the same in each step, including the temperature of 25 ° C, the molar ratio of the nucleic acid sequence and the nucleoside monomer attached to the solid phase carrier is 1:10, and the nucleic acid sequence and the coupling reagent molar on the solid phase carrier.
- the ratio was 1:65, the reaction time was 600 seconds, and the coupling reagent was a solution of 5-ethylthio-1H-tetrazole in 0.5 M acetonitrile.
- the cap conditions were the same for each step, including a temperature of 25 ° C and a reaction time of 15 seconds.
- the oxidation reaction conditions were the same for each step, including a temperature of 25 ° C, a reaction time of 15 seconds, and an oxidizing reagent of iodine water having a concentration of 0.05 M.
- the molar ratio of iodine to the nucleic acid sequence attached to the solid support in the coupling step was 30:1.
- the conditions of the sulfurization reaction were the same for each step, including a temperature of 25 ° C and a reaction time of 300 seconds, and the sulfurizing reagent was hydrogenated xanthogen.
- the molar ratio of the sulfurizing reagent to the nucleic acid sequence attached to the solid support in the coupling step is 120:1.
- the cleavage and deprotection conditions were as follows: The synthesized nucleotide sequence linked to the carrier was added to a concentration of 25% by weight aqueous ammonia, and the amount of ammonia water was 0.5 ml/ ⁇ mol, which was reacted at 55 ° C for 16 hours, the liquid was removed, and concentrated to dryness in vacuo.
- the product eluate was collected and combined, and subjected to desalting using a reverse phase chromatography purification column.
- the specific conditions include desalination using a Sephadex column, and the filler was a glucan gel G25, which was eluted with deionized water.
- Detection Purity was measured using ion exchange chromatography (IEX-HPLC), and molecular weight was analyzed using liquid chromatography-mass spectrometry (LC-MS). The theoretical value of the molecular weight of the sense strand is 7649.55, the measured value for the sense strand of conjugate 1 is 7649.1; for the sense strand of conjugates 2 and 3, the measured value is 7648.8. The measured values are in agreement with the theoretical values, indicating that the sense strand S is conjugated to the L-9 conjugated molecule at the 3' end.
- Universal solid phase support (UnyLinkerTM loaded ) by solid phase phosphoramidite method Solid Supports, Kinovate Life Sciences, Inc.) initiated the cycle to synthesize the antisense strand AS of conjugate 1.
- Conditions for deprotection, coupling, capping, oxidation or sulfurization in solid phase synthesis, cleavage and deprotection, purification and desalting conditions are identical to synthetic sense chains.
- Detection Purity was determined by ion exchange chromatography (IEX-HPLC); molecular weight was analyzed by LC-MS. The theoretical value is 6994.46, and the measured value is 6991.0. The measured values are in agreement with the theoretical values, indicating that the antisense strand AS having the target sequence is synthesized.
- VP-Um vinyl phosphate modified 2'-methoxy modified uridine monomer
- the VP-U-2 molecule was synthesized as follows:
- the aqueous phase was extracted with dichloromethane (DCM) three times, 300 ml each time, and the organic phase was combined and washed with 5% oxalic acid to pH. ⁇ 5.
- DCM dichloromethane
- the crude VP-U-1 was obtained after evaporation of the solvent to dryness and used directly for the subsequent synthesis of VP-U-2.
- the crude VP-U-1 was dissolved in 100 ml of dichloromethane, and then stirred in an ice bath for 10 minutes, and then 450 ml of 2% p-toluenesulfonic acid solution (solvent as a solvent of 3:7 by volume) which was previously stored in a refrigerator at 4 ° C was added. - dichloromethane mixed solvent), reacted for 10 minutes. The reaction was quenched by the addition of EtOAc (EtOAc) (EtOAc) The combined aqueous phases were extracted twice with dichloromethane (200 ml), and the organic phase was combined and washed twice with 200 ml of brine and evaporated to dryness.
- EtOAc EtOAc
- VP-U-2 (19.84 g, 40.0 mmol), dicyclohexylcarbodiimide (DCC, 16.48 g, 80.0 mmol), pyridine (4.20 g, 53.2 mmol), trifluoroacetic acid (6.61 g, 53.2 mmol)
- DMSO dimethyl sulfoxide
- tetraethyl methylene diphosphate 21.44 g, 74.4 mmol
- t-BuOK 11.36 g, 101.2 mmol
- the reaction was quenched with water and the aqueous phase was extracted with dichloromethane three times, 200 ml each time.
- VP-U-5 (391 mg, 1.0 mmol), trifluoroacetic acid pyridinium salt (0.232 g, 1.2 mmol), N-methylimidazole (0.099 g, 1.2) was added to 10 ml of anhydrous dichloromethane under argon.
- Methyl) bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.452 g, 1.5 mmol) was stirred at room temperature for 5 h.
- the antisense strand of conjugate 2 differs from the antisense strand of conjugate 1 only in that the first nucleotide modification at the 5'-end is different.
- the last nucleoside monomer is a 2'-methoxy modified uridine monomer (Um), which is then deprotected, coupled, capped, and oxidized.
- the step reaction ligated the CPR-I monomer (Suzhou Jima, Cat. No. 13#-2601-XX) to the 5' end of the antisense strand to form a 5'-phosphate modification.
- the universal solid phase carrier used deprotection, coupling, capping, oxidation or sulfurization reaction conditions, cutting and deprotection, purification and desalting conditions are the same as the synthetic sense strand.
- the purity was determined by ion exchange chromatography (IEX-HPLC); the molecular weight was analyzed by liquid chromatography-mass spectrometry (LC-MS), the theoretical value was 6945.47, and the measured value was 6994.8. The measured values are in agreement with the theoretical values, indicating that the antisense strand AS having the target sequence is synthesized.
- the purity was determined by ion exchange chromatography (IEX-HPLC); the molecular weight was analyzed by liquid chromatography-mass spectrometry (LC-MS), the theoretical value was 7011.53, and the measured value was 7010.9. The measured values are in agreement with the theoretical values, indicating that the antisense strand AS having the target sequence is synthesized.
- conjugate 1 the S chain and the AS chain were respectively dissolved in water for injection to obtain a solution of 40 mg/mL, mixed in an equimolar ratio, heated at 50 ° C for 15 min, and cooled at room temperature to form a double-stranded structure by hydrogen bonding. .
- the conjugate was diluted to a concentration of 0.2 mg/mL using ultrapure water (manufactured by Milli-Q ultrapure water meter, resistivity 18.2 M ⁇ *cm (25 ° C)), using a LC-MS, LC-MS, Liquid Chromatography-Mass Spectrometry, purchased from Waters, Model: LCT Premier) for molecular weight testing.
- the measured values are in agreement with the theoretical values, indicating that the synthesized conjugate 1 is a double-stranded nucleic acid sequence with a L-9-conjugated molecule of interest.
- conjugate 2-3 the molecular weight was prepared and tested in the same manner, and the measured values were in agreement with the theoretical values, indicating that the synthesized conjugate was the target designed double-stranded nucleic acid sequence with L-9 conjugated molecule.
- the structure of the conjugates 1-4 is as shown in the formula (3).
- Comparative conjugates 1-2 were synthesized in the same manner as in Preparation 1, and it is expected that conjugates 4-21 can be obtained, except that: 1) the siRNAs are respectively shown in Table 3 corresponding to the comparison.
- the product was dissolved with 0.4 ml/ ⁇ mol of N-methylpyrrolidone, followed by the addition of 0.3 ml/ ⁇ mol of triethylamine and 0.6 ml/ ⁇ mol of triethylamine trihydrofluoride to remove 2'-TBDMS protection on the ribose.
- the P-10 compound was synthesized as follows:
- the organic phase was washed with 10 ml of saturated sodium bicarbonate, and the aqueous phase was extracted with dichloromethane (3 ml), 10 ml each time, and the organic phase was washed with 10 ml of brine, and the aqueous phase was extracted twice with 10 ml each time, and the organic phase was combined.
- P-10 was prepared by the same method as the step (1-1-9) in Preparation Example 1. The difference is that the P-9 conjugated molecule is substituted for the L-9 conjugated molecule to obtain a P-9 conjugated molecule attached to the solid support.
- the conjugate 22 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the P-10 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that a P10-siAP1M2SVP conjugate can be obtained, which has the structure shown in the formula (4).
- the R-5 compound was synthesized as follows:
- GAL-3 (26.4 g, 80.2 mmol) obtained according to the method described in the step (1-1-1b) was dissolved in 134 ml of anhydrous 1,2-dichloroethane, and added. 60 g of molecular sieve powder, further adding 7-octene-1-ol (11.3 g, 88.2 mmol), stirring for 10 minutes at room temperature, adding trimethylsilyl trifluoromethanesulfonate (8.9 g) under ice bath and nitrogen protection. , 40.1 mmol), and the reaction was stirred at room temperature for 24 hours.
- GAL-C7-1 (33.3 g, 72.8 mmol) obtained in the step (4-1-1) was dissolved in a mixed solvent of 160 ml of dichloromethane and 160 ml of acetonitrile, and 216 ml of water and sodium periodate solid were respectively added ( 62.3 g, 291.2 mmol), stirred for 10 minutes in an ice water bath, and the catalyst was added to ruthenium trichloride (498 mg, 2.4 mmol). The reaction solution was diluted with 200 ml of water and stirred, and saturated sodium hydrogencarbonate was added to adjust the pH to 7.5.
- R-2 (2.391 g, 1.532 mmol) and A-1 (2.342 g, 4.596 mmol) were mixed and dissolved in 16 ml of dichloromethane, and 3-diethoxyphosphoryl-1,2,3-oxazole 4 was added.
- 3H)-ketone (DEPBT) (1.375 g, 4.596 mmol)
- diisopropylethylamine (1.188 g, 9.191 mmol) was added, and the reaction was stirred at 25 ° C for 2 h.
- R-3 (795 mg, 0.4074 mmol), succinic anhydride (82 mg, 0.8148 mmol) and 4-dimethylaminopyridine (DMAP, 100 mg, 0.8148 mmol) were mixed and dissolved in 4 ml of dichloromethane, then diisopropyl B was added.
- the amine (DIEA, 100 mg, 0.8148 mmol) was stirred at 25 ° C for 18 h.
- R-5 was prepared by the same method as the step (1-1-9) in Preparation Example 1. The difference is that the R-4 conjugated molecule replaces the L-9 conjugated molecule to give an R-4 conjugated molecule attached to a solid support.
- the conjugate 23 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the R-5 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that the R5-siAP1M2SVP conjugate can be obtained, and its structure is as shown in the formula (7).
- LA-5 compound can be synthesized:
- the conjugate 24 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the LA-5 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that the LA5-siAP1M2SVP conjugate can be obtained, and its structure is as shown in the formula (12).
- the LB-5 compound was synthesized as follows:
- LB-3 (822 mg, 0.415 mmol), succinic anhydride (83 g, 0.83 mmol) and 4-dimethylaminopyridine (DMAP, 102 mg, 0.83 mmol) were dissolved in 4 ml of dichloromethane, then DIEA (270 mg, 2.075) Methyl), the reaction was stirred at 25 ° C overnight. The reaction solution was washed three times with 0.5 M triethylamine phosphate, and the aqueous phase was extracted three times with dichloromethane (2 ml).
- DMAP 4-dimethylaminopyridine
- LB-5 was prepared by the same method as the step (1-1-9) in Preparation Example 1. The difference is that the LB-4 conjugated molecule replaces the L-9 conjugated molecule to obtain an LB-4 conjugated molecule linked to a solid support.
- the conjugate 25 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the LB-5 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that LB5-siAP1M2SVP can be obtained, and its structure is as shown in the formula (13).
- the conjugate 26 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the V-8 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that V8-siAP1M2SVP can be obtained, and its structure is as shown in the formula (14).
- the W-8 compound was synthesized as follows:
- W-3 (0.675 g, 1.517 mmol) was mixed with GAL-C7-2 (2.60 g, 5.46 mmol) in 47 ml of acetonitrile, then diisopropylethylamine (1.57 g, 12.14 mmol), and finally 3- Diethoxyphosphoryl-1,2,3-oxazolyl 4(3H)-one (DEPBT, 1.816 g, 6.04 mmol) was stirred at room temperature for 2.5 h.
- DEPBT 3- Diethoxyphosphoryl-1,2,3-oxazolyl 4(3H)-one
- the reaction mixture was diluted with 100 ml of methylene chloride, and the organic phase was washed with 80 ml of saturated sodium hydrogen carbonate solution, and the organic phase was washed with 80 ml of brine, and the organic phase was combined and dried over anhydrous sodium sulfate.
- Purification of 300 mesh normal phase silica gel column, petroleum ether packed column, neutralization of silica gel with 1% by weight of triethylamine, elution with dichloromethane: methanol 100:5-100:7 gradient, collecting product eluate, minus It was evaporated to dryness to give pure product W-4 1.610 g.
- W-8 was prepared by the same method as the step (1-1-9) in Preparation Example 1. The difference is that the W-9 conjugated molecule replaces the L-9 conjugated molecule to obtain a W-7 conjugated molecule attached to a solid support.
- the conjugate 27 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the W-8 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that W8-siAP1M2SVP can be obtained, and its structure is as shown in the formula (15).
- the conjugate 28 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the X-8 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that X8-siAP1M2SVP can be obtained, and its structure is as shown in the formula (21).
- the Z-5 compound was synthesized as follows:
- the reaction mixture was diluted with 100 ml of methylene chloride, and the organic phase was washed with 80 ml of saturated sodium hydrogen carbonate solution, and the organic phase was washed with 80 ml of brine, and the organic phase was combined and dried over anhydrous sodium sulfate.
- Purification of 300 mesh normal phase silica gel column, petroleum ether packed column, neutralization of silica gel with 1% by weight of triethylamine, elution with dichloromethane: methanol 30:1-15:1 gradient, collecting product eluent, minus It was evaporated to dryness to give a pure product, Z-1, 3.97 g.
- Z-5 was prepared by the same method as the step (1-1-9) in Preparation Example 1. The difference is that the Z-4 conjugated molecule replaces the L-9 conjugated molecule to obtain a Z-4 conjugated molecule attached to a solid support.
- the conjugate 29 was prepared by the same method as the steps (1-2), (1-3A), (1-4) in Preparation Example 1, except that the Z-5 compound was substituted for the L-10 compound to initiate justice. Chain synthesis. It is expected that a Z5-siAP1M2SVP conjugate can be obtained, which has the structure shown in formula (22).
- This preparation synthesizes the conjugates F1-F5 (hereinafter also referred to as FIN-siAP1M1SVP, FIN-siAP1M1S, FIN-siAP2M1SVP, FIN-siAP2M1S and FIN-siAP2M2S conjugate, respectively). See Table 3 for the sequence of the siRNA conjugated in this conjugate.
- the FIN-2 conjugated molecule was synthesized according to the preparation method described in Rajeev et al., ChemBioChem 2015, 16, 903-908 according to the following route:
- PRO-6 L-hydroxyproline, CAS No.: 51-35-4, available from Ange, 22.4 mmol
- 1,4-dioxane 1,4-dioxane
- reaction solution was poured into 150 ml of ice water, extracted with methyl t-butyl ether three times, 100 ml each time, the organic phase was discarded, the aqueous phase was adjusted to pH ⁇ 5 with concentrated HCl, and extracted twice with 100 ml of ethyl acetate. The organic layer was dried over anhydrous sodium sulfate (MgSO4).
- the silica gel column was basified with pyridine and then dissolved in DCM to dissolve the crude product, first containing 1% (v) /v) dimethyl pyridine was eluted with EtOAc (EtOAc) eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted eluted
- EtOAc EtOAc
- GAL-5 (4.5 g, 10 mmol) obtained according to the method described in (1-1-1) was dissolved in 40 ml of DMF, and 3.9 g of DIEA (N,N-diisopropylethylamine, CAS number: 7087-68-5, purchased from Aladdin, 30mmol) and 3.8g HBTU (benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, CAS No.:94790-37 -2, commercially available from Aladdin, 11 mmol), stirred at room temperature for 10 minutes, and PRO-10 (4.2 g, 10 mmol) obtained in the step (11-1-1d) was dissolved in 40 ml of DMF, and then added to the above reaction.
- DIEA N,N-diisopropylethylamine, CAS number: 7087-68-5, purchased from Aladdin, 30mmol
- HBTU benzotriazole-N,N
- FIN-1 (3.0 g, 3.53 mmol) obtained in the step (11-1-2) was azeotropically dehydrated with acetonitrile, dried under reduced pressure, dissolved in 10 ml of DMF, and 2.
- Isopropylamino)(2-cyanoethoxy)phosphine available from Adamas Company, trade number 11356B, 7.06 mmol
- 346 mg tetrazolium (CAS number: 288-94-8, purchased from Aladdin, 4.94 mmol)
- the reaction was stirred at room temperature, and 10 ml of DMF was added thereto, and the reaction was further stirred for 1 hour.
- the solvent was evaporated under reduced pressure and purified by silica gel column chromatography.
- the FIN-2 conjugated molecule obtained in the step (11-1-3) is connected to the universal solid phase carrier (UnyLinkerTM loaded ) through three cycles. Solid Supports) to achieve attachment of the conjugate group (FIN_FIN_FIN) to the 3' end of the RNA sense strand.
- the above-described ligation is carried out according to the preparation method described in Rajeev et al., ChemBioChem 2015, 16, 903-908. Specifically, first, starting from the above-mentioned universal solid phase carrier, the hydroxyl protecting group on the solid phase carrier is removed, and the coupling reaction is carried out. The conditions are coupled with the FIN-2 conjugated molecule in the presence of a coupling reagent, and after the cap reaction and the oxidation reaction, a FIN conjugated molecule attached to the solid support is obtained; and the FIN conjugate attached to the solid support is removed.
- a hydroxy protecting group DMTr on the molecule which is coupled to the FIN-2 conjugated molecule, undergoes a cap reaction and an oxidation reaction, and repeats the above-described deprotection-coupling-cap-oxidation step to connect the third FIN -2 Conjugation of the molecule to obtain a conjugation group (FIN_FIN_FIN) attached to the solid support.
- the title conjugate was prepared by the same method as the steps (1-2), (1-3), (1-4) in Preparation Example 1, except that: 1) obtained by the step (11-2) The compound initially synthesizes the sense strand; 2) the conjugated siRNA has the sequence corresponding to the conjugates F1-F5 shown in Table 3.
- Comparative Preparation 3 was synthesized in this preparation example, and the sequence of the siRNA conjugated in the conjugate is shown in Table 3. This conjugate is identical in structure to the compound AD-69535 of U.S. Application 15/597,225.
- Compound 30 was synthesized according to the preparation method described in WO2014025805A1, ie, the linker-(L A ) 3 trishydroxymethylaminomethane-L B - as described above and the N-acetylgalactosamine molecule as a targeting group (wherein each L A can be linked to an N-acetylgalactosamine molecule, such that a linker can link three N-acetylgalactosamine molecules) a conjugating molecule, also known as a (GalNAc) 3 conjugating molecule,
- the structure of compound 30 is as follows:
- Comparative Conjugate 1 was prepared by the same method as Steps (1-2), (1-3), (1-4) in Preparation Example 1, except that: 1) obtained by the step (12-2) The compound initiates sense strand synthesis; 2) the conjugated siRNA has the sequence shown in Table 3, numbered (GalNAc) 3 -69535.
- the preparation of the conjugate of the present disclosure described above is completed, it is lyophilized as a solid powder for storage by standard means. In use, it can be used, for example, by reconstituting it with water for injection to a solution of the desired concentration.
- modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect.
- Nucleic Acids Research, 2008.36 (7 a method described in 2136-2151, constructing a detection plasmid, co-transfected with the siRNA conjugate to be evaluated into HEK293A cells, and reacting the expression level of the double luciferase reporter gene to reflect the target of the siRNA conjugate active.
- plasmid constructs in the target plasmid comprising a target sequence, all 21 nucleotides of the sequence of the antisense strand of the target sequence with a test conjugate is fully complementary.
- the target sequence is cloned into plasmid psiCHECK TM -2 Xho I / Not I site.
- NC is a universal negative control B01001 with no homology between the gene and the gene sequence of the gene.
- the dual luciferase reporter gene assay kit (Promega, cat. E2940) was used to lyse HEK293A cells according to the instructions for use to detect the double luciferase reporter gene.
- the Renilla luciferase protein level was normalized to the firefly luciferase protein level. The result is shown in Figure 1.
- Example This experiment investigated the conjugate psiCHECK 1 IC 50 in an in vitro system.
- the target plasmid of conjugate 1 was constructed in the same manner as in Experimental Example 1-1, and the final concentration of conjugate 1 (calculated as the concentration of siRNA) was started from 1 nM, and diluted by 11 concentrations to 0.001 nM.
- the dose-response curve was fitted using the Graphpad 5.0 software log (inhibitor) vs. response-Variable slope function according to the activity results measured with different conjugate concentrations, and the IC 50 of conjugate 1 was calculated from the dose-response curve. value.
- Y is the expression level of residual mRNA
- X is the logarithm of the concentration of transfected siRNA
- Bot is the Y value at the bottom of the steady state period.
- Top is the Y value at the top of the steady state period.
- LogIC 50 is the X value when Y is halfway between the bottom and the top, and HillSlope is the slope of the curve.
- IC 50 is 0.0174nM
- siRNA conjugate has a higher activity in vitro.
- This experimental example examined the inhibition efficiency of conjugate 2 on the expression level of APOC3 mRNA in Huh7 cells in vitro.
- Lipofectamine TM 2000 conjugate 2 was transfected into the human hepatoma cell line Huh7, the final concentration of siRNA conjugate (in terms of the amount of siRNA) was diluted 3nM starting from 7 concentrations, three times, to 0.004nM. 2 duplicate wells per concentration.
- the expression level of APOC3 mRNA in Huh7 cells transfected with each concentration of conjugate 2 was detected by real-time fluorescent quantitative PCR (Quantitative Real-Time PCR).
- the specific steps are: after culturing the transfected cells for 24 hours, extract the total RNA from the cells using Trizol (Thermo Fisher) according to the standard procedure of total RNA extraction; take 1 ⁇ g of total RNA, respectively, using the reverse transcription kit (Promega) , Item No. A3500)
- the cDNA was reverse transcribed according to the method of its instructions.
- the cDNA was used as a template to detect the APOC3 mRNA expression level according to the procedure of the manual.
- PCR primers for amplifying APOC3 and ⁇ -actin as an internal reference gene are shown in Table 4.
- APOC3 mRNA expression [(test group APOC3 mRNA expression / test group ⁇ -Actin mRNA expression) / (control group APOC3 mRNA expression level / control group ⁇ -Actin The expression level of mRNA was) ⁇ 100%.
- inhibition rate (1-APOC3 mRNA expression amount) ⁇ 100%.
- each test group was Huh7 cells treated with each concentration of conjugate 2, and the control group was Huh7 cells not treated with conjugate 2.
- Experimental Example 2-1 This experimental example investigates the inhibition rate of conjugate 1 in the expression of APOC3 mRNA in liver tissue in human APOC3 transgenic mice.
- mice Human APOC3 transgenic mice (B6; CBA-Tg (APOC3) 3707 Bres/J) were randomly divided into groups according to the triglyceride content of more than 2 mmol/L, and 5 rats in each group were given conjugate 1 and contrast conjugates to each group of mice.
- RNA was extracted from liver tissue.
- APOC3 mRNA in liver tissue was measured by the same real-time fluorescent quantitative PCR method as Experimental Example 1-3.
- ⁇ -actin ( ⁇ -actin) gene was used as an internal reference gene, and primers for APOC3 and primers for ⁇ -actin were used to detect the expression levels of APOC3 and ⁇ -actin, respectively. .
- the expression level of APOC3 mRNA in the liver and the inhibition rate of the conjugate to APOC3 mRNA were calculated as in Experimental Example 1-3.
- the control group was a control group of mice administered with physiological saline in the experiment, and each test group was a group of mice administered with different siRNA conjugates. The results are shown in Figure 2.
- conjugate 1 had a significant inhibitory effect on the human APOC3 gene in transgenic mice.
- Experimental Example 2-2 This experiment investigated the inhibition rate of conjugate 1 in the expression of APOC3 mRNA in liver tissues in cynomolgus monkeys and the effect on blood lipid levels.
- the experimental example was commissioned by Suzhou Huazhen Biotechnology Co., Ltd. Two to four groups of 3-5 years old cynomolgus monkeys were randomly divided into two groups, one male and one female, and conjugate 1 and comparative conjugate 2 were administered, respectively. All animals were dosed according to body weight, administered in a single dose by subcutaneous injection.
- the dose of siRNA conjugate (measured as siRNA) was 3 mg/kg, and the conjugates were injected at a concentration of 3 mg/ml of sodium chloride.
- Liquid (Shandong Kelun Pharmaceutical Co., Ltd.) is available in the form of a dose of 1 mL/kg.
- the day of the first administration was defined as the first day of the test (D1), and the day before the administration was the first day (D0).
- the animals were subjected to venous blood collection before administration and on the 7th, 14th, 21st and 28th day after administration, and the serum test substances were detected at each time point.
- the test substance refers to blood lipids (total cholesterol CHO, triglyceride TG) and transaminase. (Gluteal transaminase AST, alanine aminotransferase ALT).
- liver tissue RNA was extracted in the same manner as in Experimental Example 2-1, and the expression level of APOC3 mRNA in the liver was measured. See Table 7 for the sequence of the detection primers.
- conjugate 1 also has a significant inhibitory effect on the APOC3 gene in non-human primates, and also has a significant inhibitory effect on serum TG, and no abnormal liver function is detected.
- Experimental Example 3-1 This experimental example investigates the effect of conjugate 1 on serum total cholesterol (CHO) and triglyceride (TG) levels in human APOC3 transgenic mice.
- Human APOC3 transgenic mice (B6; CBA-Tg (APOC3) 3707 Bres/J) were randomly divided into groups according to TG content > 2 mmol/L, and each group was divided into the following groups: (1) saline control group; (2) Compound 1 3 mg/kg group; (3) conjugate 1 1 mg/kg group. All animals were dosed according to body weight, administered in a single dose by subcutaneous injection, and the siRNA conjugates were each provided at a concentration of 0.6 mg/ml and 0.2 mg/ml in a 0.9% aqueous solution of sodium chloride at a dose of 5 mL/kg.
- the eyelids were boiled about 100 ⁇ L each time, and the serum was not less than 20 ⁇ L after centrifugation.
- the serum total cholesterol (CHO) and triglyceride (TG) content were further measured using a PM1P000/3 automatic serum biochemical analyzer (SABA, Italy).
- the standardized blood lipid level (the blood lipid content of the test group after administration / the blood lipid content of the test group before administration) ⁇ 100%.
- the inhibition rate of blood lipid level (1 - blood lipid content of the test group after administration / blood lipid content of the test group before administration) ⁇ 100%.
- Lipid refers to total cholesterol or triglycerides.
- conjugate 1 showed a significant effect of reducing TG and CHO in mouse serum for up to 189 days; indicating that it can be used for a long time. Stable and efficient inhibition of APOC3 gene expression.
- Experimental Example 3-2 This experiment examined the effect of conjugate 2 on serum total cholesterol (CHO) and triglyceride (TG) levels in human APOC3 transgenic mice.
- conjugate 2 was able to significantly reduce TG and CHO levels in transgenic mice over a period of up to 112 days, and there was a significant dose-dependent effect of this reduction.
- Serum total cholesterol (CHO) and total blood lipid (TG) were measured in the same manner as in Experimental Example 3-1 except that: 6 mice per group were administered with conjugates 1, 2 and 3, respectively, and compared. Conjugate 3, each conjugate was administered in two dose groups of 1 mg/kg and 3 mg/kg, the volume of administration was unchanged, and the concentration of the conjugate solution was adjusted accordingly; the test time was until the 112th day after administration. The results are shown in Figures 5A-5D.
- the conjugate provided by the present disclosure can effectively reduce the expression of APOC3 mRNA in the liver, lower the total cholesterol and triglyceride content in the blood, prevent and/or treat dyslipidemia, and has a good clinical application prospect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本公开提供了一种抑制载脂蛋白C3(ApoC3)基因表达的siRNA,含有该siRNA的药物组合物和缀合物。所述siRNA中的每个核苷酸均为修饰的核苷酸,该siRNA含有正义链和反义链,所述正义链含有核苷酸序列A,所述核苷酸序列A与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,所述反义链含有核苷酸序列B,所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异。本公开提供的siRNA及其药物组合物和缀合物,可以有效治疗和/或预防血脂异常。
Description
血脂异常,又名高脂血症,是脂肪代谢或运转异常,使血浆脂质高于正常值的一种全身性疾病,正严重威胁着全球患者的健康。现有的治疗血脂异常的药物主要有他汀类、胆固醇吸收抑制剂、树脂类、普罗步考、贝特类和烟酸及其衍生物。
载脂蛋白C3(APOC3)在脂质代谢中具有重要作用,携带有APOC3突变基因的人血液循环中APOC3的表达量下降46%,血浆内甘油三酯水平较普通人下降39%,同时较低的血脂水平可使APOC3突变基因携带者患心脏病的风险比非携带者降低35.1%。因此,若能从基因水平沉默基因表达,阻断APOC3的生成,无疑将是最为理想的治疗手段。小干扰RNA(small interfering RNA,siRNA)可基于RNA干扰(RNA interference,RNAi)这一机制,以序列特异性的方式抑制或阻断任何感兴趣的目的基因的表达,从而达到治疗疾病的目的。
siRNA稳定化修饰及其递送系统是小RNA药物开发中的两个关键技术。
发明内容
在一些实施方式中,本公开提供了一种siRNA缀合物,该缀合物具有式(1)所示的结构:
其中:
n1为选自1-3的整数,n3为选自0-4的整数;
m1、m2和m3独立地为选自2-10的整数;
R
10、R
11、R
12、R
13、R
14和R
15各自独立地为H,或选自于由以下基团所组成的组:C
1-C
10烷基、C
1-C
10卤代烷基以及C
1-C
10烷氧基;
R
3为式A59所示结构的基团:
其中,E
1为OH、SH或BH
2,Nu为siRNA;
所述siRNA中的每个核苷酸各自独立地为修饰或未修饰的核苷酸,所述siRNA含有正义链和反义链,所述正义链包含核苷酸序列1,所述反义链包含核苷酸序列2,所述核苷酸序列1和所述核苷酸序列2至少部分地反向互补形成双链区,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:
5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1);
5'-Z'UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2);
其中,Z为A,Z'为U,
所述核苷酸序列1中包含位置对应于Z的核苷酸Z
A,所述核苷酸序列2中包含位置对应于Z'的核苷酸Z'
B,所述Z'
B是所述反义链5'末端的第一个核苷酸;
R
2是长度为1-20个碳原子的直链亚烷基,其中一个或多个碳原子任选地被选自于以下基团所组成的组中的一个或多个所替换:C(O)、NH、O、S、CH=N、S(O)
2、C
2-C
10亚烯基、C
2-C
10亚炔基、C
6-C
10亚芳基、C
3-C
18亚杂环基和C
5-C
10亚杂芳基;并且其中,R
2可任选地具有由以下基团所组成的组中的任何一个或多个的取代基:C
1-C
10烷基、C
6-C
10芳基、C
5-C
10杂芳基、C
1-C
10卤代烷基、-OC
1-C
10烷基、-OC
1-C
10烷基苯基、-C
1-C
10烷基-OH、-OC
1-C
10卤代烷基、-SC
1-C
10烷基、-SC
1-C
10烷基苯基、-C
1-C
10烷基-SH、-SC
1-C
10卤代烷基、卤素取代基、-OH、-SH、-NH
2、-C
1-C
10烷基-NH
2、-N(C
1-C
10烷基)(C
1-C
10烷基)、-NH(C
1-C
10烷基)、氰基、硝基、-CO
2H、-C(O)O(C
1-C
10烷基)、-CON(C
1-C
10烷基)(C
1-C
10烷基)、-CONH(C
1-C
10烷基)、-CONH
2,-NHC(O)(C
1-C
10烷基)、-NHC(O)(苯基)、-N(C
1-C
10烷基)C(O)(C
1-C
10烷基)、-N(C
1-C
10烷基)C(O)(苯基)、-C(O)C
1-C
10烷基、-C(O)C
1-C
10烷基苯基、-C(O)C
1-C
10卤烷基、-OC(O)C
1-C
10烷基、-SO
2(C
1-C
10烷基)、-SO
2(苯基)、-SO
2(C
1-C
10卤代烷基)、-SO
2NH
2、-SO
2NH(C
1-C
10烷基)、-SO
2NH(苯基)、-NHSO
2(C
1-C
10烷基)、-NHSO
2(苯基)和-NHSO
2(C
1-C
10卤代烷基);
每个L
1是长度为1-70个碳原子的直链亚烷基,其中一个或多个碳原子任选地被选自于以下基团所组成的组中的一个或多个所替换:C(O)、NH、O、S、CH=N、S(O)
2、C
2-C
10亚烯基、C
2-C
10亚炔基、C
6-C
10亚芳基、C
3-C
18亚杂环基和C
5-C
10亚杂芳基;并且其中,L
1可任选地具有由以下基团所组成的组中的任何一个或多个的取代基:C
1-C
10烷基、C
6-C
10芳基、C
5-C
10杂芳基、C
1-C
10卤代烷基、-OC
1-C
10烷基、-OC
1-C
10烷基苯基、-C
1-C
10烷基-OH、-OC
1-C
10卤代烷基、-SC
1-C
10烷基、-SC
1-C
10烷基苯基、-C
1-C
10烷基-SH、-SC
1-C
10卤代烷基、卤素取代基、-OH、-SH、-NH
2、-C
1-C
10烷基-NH
2、-N(C
1-C
10烷基)(C
1-C
10烷基)、-NH(C
1-C
10烷基)、氰基、硝基、-CO
2H、-C(O)O(C
1-C
10烷基)、-CON(C
1-C
10烷基)(C
1-C
10烷基)、-CONH(C
1-C
10烷基)、-CONH
2,-NHC(O)(C
1-C
10烷基)、-NHC(O)(苯基)、-N(C
1-C
10烷基)C(O)(C
1-C
10烷基)、-N(C
1-C
10烷基)C(O)(苯基)、-C(O)C
1-C
10烷基、-C(O)C
1-C
10烷基苯基、-C(O)C
1-C
10卤烷基、-OC(O)C
1-C
10烷基、-SO
2(C
1-C
10烷基)、-SO
2(苯基)、-SO
2(C
1-C
10卤代烷基)、-SO
2NH
2、-SO
2NH(C
1-C
10烷基)、-SO
2NH(苯基)、-NHSO
2(C
1-C
10烷基)、-NHSO
2(苯基)和-NHSO
2(C
1-C
10卤代烷基)。
在一些实施方式中,每个L
1独立地选自式A1-A26基团中的一种或多种的连接组合:
其中,j1为1-20的整数;j2为1-20的整数;
R’为C
1-C
10的烷基;
Ra选自式A27-A45基团或其任意组合所组成的组:
Rb为C
1-C
10的烷基;
M
1表示靶向基团。
在一些实施方式中,本公开提供了一种缀合物的制备方法,包括在亚磷酰胺固相合成的条件下,分别按照siRNA正义链和反义链的核苷酸种类和顺序,按照3'到5'的方向将核苷单体依次连接,每个核苷单体的连接包括脱保护、偶联、盖帽、氧化或硫化四步反应;分离出siRNA的正义链和反义链,退火,其中,所述siRNA中的每个核苷酸各自独立地为修饰或未修饰的核苷酸,所述siRNA含有正义链和反义链,所述正义链包含核苷酸序列1,所述反义链包含核苷酸序列2,所述核苷酸序列1和所述核苷酸序列2至少部分地反向互补形成双链区,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:
5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1);
5'-Z'UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2);
其中,Z为A,Z'为U,
所述核苷酸序列1中包含位置对应于Z的核苷酸Z
A,所述核苷酸序列2中包含位置对应于Z'的核苷酸Z'
B,所述Z'
B是所述反义链5'末端的第一个核苷酸;
并且,该方法还包括在偶联反应条件和偶联试剂存在下,将式(321)所示的化合物与核苷单体或连接在固相载体上的核苷酸序列接触,从而使式(321)所示的化合物经偶联反应连接至核苷酸序列。下文中,式(321)所示的化合物也称作缀合分子。
其中:
R
4为能够结合至Nu代表的siRNA的部分。在一些实施方式中,R
4为能够通过共价键结合至Nu代表的siRNA的部分。在一些实施方式中,R
4为能够经反应而通过磷酸二酯键缀合至Nu代表的siRNA的任意官能团的部分;
每个S
1独立地是M
1中全部活性羟基被YCOO-基团取代而形成的基团,其中,每个Y独立地选自甲基、三氟甲基、二氟甲基、一氟甲基、三氯甲基、二氯甲基、一氯甲基、乙基、正丙基、异丙基、苯基、卤代苯基以及烷基苯基中的一种;
n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15、L
1、M
1各自的定义和可选择的范围如前所述。
在一些实施方式中,本公开提供了一种能够抑制APOC3基因表达的修饰的siRNA,该siRNA含有正义链和反义链,所述正义链和反义链的每一个核苷酸均为修饰的核苷酸,其中,所述正义链和反义链均包含氟代修饰的核苷酸和非氟代修饰的核苷酸;所述正义链包含核苷酸序列Ⅰ,所述反义链包含核苷酸序列Ⅱ,所述核苷酸序列Ⅰ和所述核苷酸序列Ⅱ至少部分地反向互补形成双链区,其中,所述核苷酸序列Ⅰ含有核苷酸序列A,所述核苷酸序列A与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列Ⅱ含有核苷酸序列B,所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:
5’-CAAUAAAGCUGGACAAGAZ-3’(SEQ ID NO:1);
5’-Z’UCUUGUCCAGCUUUAUUG-3’(SEQ ID NO:2),
其中,Z为A,Z'为U,
所述核苷酸序列A中包含位置对应于Z的核苷酸Z
A,所述核苷酸序列B中包含位置对应于Z'的核苷酸Z'
B,所述Z'
B是所述反义链5'末端的第一个核苷酸;
所述氟代修饰的核苷酸位于核苷酸序列A和核苷酸序列B中,按照5'末端到3'末端的方向,所述核苷酸序列A的第7、8、9位的核苷酸为氟代修饰的核苷酸;并且,按照5'末端到3'末端的方向,所述核苷酸序列B的第2、6、14、16位的核苷酸为氟代修饰的核苷酸。
在一些实施方式中,本公开提供了本公开的修饰的siRNA、药物组合物和/或siRNA缀合物在制备用于治疗和/或预防由载脂蛋白C3(ApoC3)的过量表达引起的血脂异常的药物中的用途。
在一些实施方式中,本公开提供了一种治疗血脂异常的方法,所述方法包括向患有血脂异常的受试者给予有效量的本公开的修饰的siRNA、药物组合物和/或siRNA缀合物。
在一些实施方式中,本公开提供了一种抑制肝细胞APOC3基因表达的方法,该方法包括将有效量的本公开的修饰的siRNA、药物组合物和/或siRNA缀合物与所述肝细胞进行接触。
在一些实施方式中,本公开提供了一种试剂盒,所述试剂盒包含本公开的修饰的siRNA、药物组合物和/或siRNA缀合物。
以引用的方式并入
本说明书中提及的所有出版物、专利以及专利申请均以引用的方式并入本文,其程度与每一单独的出版物、专利以及专利申请均专门并且单独地以引用的方式并入本文的程度相同。
在一些实施方式中,本公开提供的siRNA、含该siRNA的组合物或siRNA缀合物可在体内具有更高的稳定性和/或更高的活性。在一些实施方式中,本公开提供的siRNA、siRNA组合物或siRNA缀合物在体内显示出至少20%,30%,40%,50%,60%,70%,80%,90%或95%的靶基因表达抑制率。在一些实施方式中,本公开提供的siRNA、siRNA组合物或siRNA缀合物在体内显示出至少20%,30%,40%,50%,60%,70%,80%,90%或95%的APOC3基因表达抑制率。在一些实施方式中,本公开提供的siRNA、siRNA组合物或siRNA缀合物在体内显示出至少20%,30%,40%,50%,60%,70%,80%,90%或95%的肝内APOC3基因表达抑制率。在一些实施方式中,本公开提供的siRNA、siRNA组合物或siRNA缀合物在体内显示出至少20%,30%,40%,50%,60%,70%,80%,90%或95%的动物模型中肝内APOC3基因表达抑制率。在一些实施方式中,本公开提供的siRNA、siRNA组合物或siRNA缀合物在体内显示出至少20%,30%,40%,50%,60%,70%,80%,90%或95%的人类受试者中肝内APOC3基因表达抑制率。在一些实施方式中,本公开提供的siRNA、含该siRNA的组合物或siRNA缀合物未显示出明显脱靶效应。脱靶效应可以是例如抑制非靶基因的基因正常表达。据认为,如果脱靶基因表达的结合/抑制与在靶基因效果相比低于50%、40%、30%、20%或10%时,该脱靶效应就是不显著的。
在一些实施方式中,本公开提供的siRNA缀合物表现出优异的抑制APOC3基因表达的特性:在1mg/kg的剂量下抑制高脂模型小鼠肝脏中至少88%的APOC3基因表达。特别地,与现有技术提供的缀合分子形成的缀合物相比,本公开提供的修饰的siRNA和siRNA缀合物显示出优异的基因抑制率,及低的脱靶效应;并且,本公开提供的siRNA缀合物能够在低给药剂量、低给药频率的情况下,在长达189天的实验时间内持续显示出优异的血脂抑制作用。
上述情况表明,本文提供的siRNA、药物组合物和siRNA缀合物能够有效降低靶细胞基因表达,并且显示出优异的递送潜力。
本公开的其他特征和优点将在随后的具体实施方式部分予以详细说明。
为了更清楚地说明本发明实施例和现有技术的技术方案,下面对实施例和现有技术中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1显示了缀合物F1-F5在体外psiCHECK系统中的抑制活性。
图2显示了D14天缀合物1在人APOC3转基因小鼠肝组织中对APCO3 mRNA表 达量的抑制率。
图3A和3B显示不同剂量缀合物1对血脂的抑制率,以血清总胆固醇(CHO)和甘油三酯(TG)表示。
图4A和4B显示以血清总胆固醇(CHO)和甘油三酯(TG)为指标,不同剂量的缀合物2对血脂的抑制率。
图5A、5B、5C和5D显示了以血清中的总胆固醇(CHO)和甘油三酯(TG)为指标,不同剂量的缀合物1-3对血脂的抑制率。
以下对本公开的具体实施方式进行详细说明。应当理解的是,此处所描述的具体实施方式仅用于说明和解释本公开,并不用于限制本公开。
在本公开中,APOC3基因是指mRNA序列如Genbank注册号NM_000040.1所示的基因。所述靶mRNA序列如NM_000040.1所示。
定义
在上文及下文中,如无特别说明,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸;小写字母s表示与该字母s左右相邻的两个核苷酸之间为硫代磷酸酯基连接;P1表示该P1右侧相邻的一个核苷酸为5'-磷酸核苷酸或5'-磷酸类似物修饰的核苷酸,字母组合VP表示该字母组合VP右侧相邻的一个核苷酸为乙烯基磷酸酯修饰的核苷酸,字母组合Ps表示该字母组合Ps右侧相邻的一个核苷酸为硫代磷酸酯修饰的核苷酸,大写字母P表示该字母P右侧相邻的一个核苷酸为5'-磷酸核苷酸。
在上文及下文中,所述“氟代修饰的核苷酸”指核苷酸的核糖基2'位的羟基被氟取代形成的核苷酸,“非氟代修饰的核苷酸”指核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸或核苷酸类似物。“核苷酸类似物”指能够在核酸中代替核苷酸,但结构不同于腺嘌呤核糖核苷酸、鸟嘌呤核糖核苷酸、胞嘧啶核糖核苷酸、尿嘧啶核糖核苷酸或胸腺嘧啶脱氧核糖核苷酸的基团。如异核苷酸、桥联的核苷酸(bridged nucleic acid,简称BNA)或无环核苷酸。所述“甲氧基修饰的核苷酸”指核糖基的2'-羟基被甲氧基取代而形成的核苷酸。
在本文的上下文中,“互补”或“反向互补”一词可互相替代使用,并具有本领域技术人员周知的含义,即,在双链核酸分子中,一条链的碱基与另一条链上的碱基以互补的方式相配对。在DNA中,嘌呤碱基腺嘌呤(A)始终与嘧啶碱基胸腺嘧啶(T)(或者在RNA中为尿嘧啶(U))相配对;嘌呤碱基鸟嘌呤(C)始终与嘧啶碱基胞嘧啶(G)相配对。每个碱基对都包括一个嘌呤和一个嘧啶。当一条链上的腺嘌呤始终与另一条链上的胸腺嘧啶(或尿嘧啶)配对,以及鸟嘌呤始终与胞嘧啶配对时,两条链被认为是彼此相互补的,以及从其互补链的序列中可以推断出该链的序列。与此相应地,“错配”在本领域中意指在双链核酸中,对应位置上的碱基并未以互补的形式配对存在。
在上文及下文中,如无特别说明,“基本上反向互补”是指所涉及的两段核苷酸序列 之间存在不多于3个的碱基错配;“实质上反向互补”是指两段核苷酸序列之间存在不多于1个的碱基错配;“完全互补”是指两段核苷酸序列之间不存在碱基错配。
在上文及下文中,一个核苷酸序列与另外一个核苷酸序列存在“核苷酸差异”,是指前者与后者相比,相同位置的核苷酸的碱基种类发生了改变,例如,在后者中一个核苷酸碱基为A时,在前者的相同位置处的对应核苷酸碱基为U、C、G或者T的情况下,认定为两个核苷酸序列之间在该位置处存在核苷酸差异。在一些实施方式中,以无碱基核苷酸或其等同物代替原位置的核苷酸时,也可认为在该位置处产生了核苷酸差异。
在上文及下文中,特别是在描述本公开的siRNA、含siRNA的组合物或siRNA缀合物的制备方法时,除非特别说明,所述核苷单体(nucleoside monomer)指,根据欲制备的siRNA或siRNA缀合物中核苷酸的种类和顺序,亚磷酰胺固相合成中使用的修饰或未修饰的核苷亚磷酰胺单体(unmodified or modified RNA phosphoramidites,有时RNA phosphoramidites也称为Nucleoside phosphoramidites)。亚磷酰胺固相合成为本领域技术人员所公知的RNA合成中所用的方法。本公开所用的核苷单体均可商购得到。
在本公开的上下文中,除非另有说明,“缀合”是指两个或多个各自具有特定功能的化学部分之间以共价连接的方式彼此连接;相应地,“缀合物”是指该各个化学部分之间通过共价连接而形成的化合物。进一步地,“siRNA缀合物”表示一个或多个具有特定功能的化学部分共价连接至siRNA上而形成的化合物。在下文中,有时也将本公开的siRNA缀合物简称为“缀合物”。siRNA缀合物应根据上下文,理解为siRNA缀合物的总称、第一种siRNA缀合物或第二种siRNA缀合物。在本公开的上下文中,“缀合分子”应当理解为可通过反应缀合至siRNA,最终形成本公开的siRNA缀合物的特定化合物。
如本文所使用的,不介于两个字母之间或两个符号之间的短横(“-”)是用于指示取代基附着点的位置。例如:-C
1-C
10烷基-NH
2通过C
1-C
10烷基而附着。
如本文所使用的,“任选的”或“任选地”是指其后描述的事件或状况可以发生或不发生,并且所述描述包括事件或状况发生的情况和其中不发生的情况。例如,“任选的取代的烷基”包括下文定义的“烷基”和“取代烷基”。本领域技术人员将理解的是,对于包含一个或多个取代基的任何基团,这些基团不打算引入空间上不切实际、合成上不可行和/或内在不稳定的任何取代或取代型式。
如本文所使用的,“烷基”是指具有指定数量的碳原子的直链和支链,所述数量通常为1到20个碳原子,例如1至10个碳原子,如1至8个或1至6个碳原子。例如,C1-C6烷基包含1至6个碳原子的直链和支链烷基。当对具有特定数量的碳的烷基残基进行命名时,旨在涵盖所有具有该数量的碳的支链和直链形式;因此,例如,“丁基”意味着包括正丁基、仲丁基、异丁基和叔丁基;“丙基”包括正丙基和异丙基。亚烷基是烷基的子集,指与烷基相同、但具有两个附着点的残基。
如本文所使用的,“烯基”是指具有至少一个碳-碳双键的不饱和支链或直链烷基,所述碳-碳双键是通过从母体烷基的相邻碳原子中除去一个氢分子而获得的。该基团可以处于双键的顺式或反式构型。典型的烯基基团包括但不限于:乙烯基;丙烯基,如丙-1-烯-1-基、丙-1-烯-2-基、丙-2-烯-1-基(烯丙基)、丙-2-烯-2-基;丁烯基,例如丁-1-烯-1-基、丁-1-烯-2-基、2-甲基丙-1-烯-1-基、丁-2-烯-1-基、丁-2-烯-2-基、丁-1,3-二烯-1-基、 丁-1,3-二烯-2-基等等。在某些实施方式中,烯基基团具有2到20个碳原子,而在其他实施方式中,具有2至10个、2至8个或2至6个碳原子。亚烯基是烯基的一个子集,指与烯基相同、但具有两个附着点的残基。
如本文所使用的,“炔基”是指具有至少一个碳-碳三键的不饱和支链或直链烷基,所述碳-碳三键是通过从母体烷基的相邻碳原子中除去两个氢分子而获得的。典型的炔基基团包括但不限于:乙炔基;丙炔基,如丙-1-炔-1-基,丙-2-炔-1-基;丁炔基,例如丁-1-炔-1-基,丁-1-炔-3-基,丁-3-炔-1-基等。在某些实施方式中,炔基具有2到20个碳原子,而在其他实施方式中,具有2至10、2至8或2至6个碳原子。亚炔基是炔基的一个子集,指的是与炔基相同、但有两个附着点的残基。
如本文所使用的,“烷氧基”是指通过氧桥附着的指定数量碳原子的烷基,例如,甲氧基、乙氧基、丙氧基、异丙氧基、正丁氧基、仲丁氧基、叔丁氧基、戊氧基、2-戊氧基、异戊氧基、新戊氧基、己氧基、2-己氧基、3-己氧基、3-甲基戊氧基等。烷氧基通常具有1至10个、1至8个、1至6个,或1至4个通过氧桥附着的碳原子。
如本文所使用的,“芳基”是指衍生自芳香族单环或多环烃环系统、通过从环碳原子中除去氢原子而形成的基团。所述芳香族单环或多环烃环系统仅含有氢和6至18个碳原子的碳,其中所述环系统中的至少一个环是完全不饱和的,即,其根据Hückel理论包含环状、离域的(4n+2)π-电子系统。芳基包括但不限于苯基、芴基和萘基等基团。亚芳基是芳基的一个子集,指与芳基相同、但具有两个附着点的残基。
如本文所使用的,“环烷基”是指非芳香碳环,通常具有3至7个环状碳原子。环可以是饱和的,或具有一个或多个碳-碳双键。环烷基的实例包括环丙基、环丁基、环戊基、环戊烯基、环己基和环己烯基,以及桥联和笼状环基团,如降冰片烷(norbornane)。
如本文所使用的,“卤素取代基”或“卤”指氟代、氯代、溴代和碘代,术语“卤素”包括氟、氯、溴和碘。
如本文所使用的,“卤代烷基”是指指定数量的碳原子被一个或多个、直至最大允许数量的卤素原子取代的如上述所定义的烷基。卤代烷基的实例包括但不限于三氟甲基、二氟甲基、2-氟乙基和五氟乙基。
“杂环基”是指一个稳定的3-到18-元非芳香环基,包含2-12个碳原子和1-6个杂原子,所述杂原子选自氮、氧和硫。除非说明书中另有说明,杂环基是单环、双环、三环或四环系统,可包括稠环或桥环系统。杂环自由基中的杂原子可以任选地被氧化。一个或多个氮原子(如果存在的话)任选地被季铵化。杂环基是部分饱和或完全饱和的。杂环基可以通过环的任何原子附着至分子的其余部分。此类杂环基的实例包括但不限于:二噁烷基、噻吩基[1,3]二硫酰基、十氢异喹啉基、咪唑啉基、咪唑烷基、异噻唑烷基、异恶唑烷基、吗啉基、八氢吲哚基、八氢异吲哚基、2-氧杂哌嗪基、2-氧杂哌啶基、2-氧杂嘧啶基、恶唑烷基、哌啶基、哌嗪基、4-哌啶酮基、吡咯烷基、吡唑烷基、奎宁环基、噻唑烷基、四氢呋喃基、三硫酰基、四氢吡喃基、硫吗啉基、硫杂吗啉基、1-氧杂硫吗啉基和1,1-二氧杂硫吗啉基。
“杂芳基”指由3-至18-元芳香环自由基衍生而成的基团,其包含2个至17个碳原子和选自氮、氧和硫的1至6个杂原子。如本文所使用的,杂芳基可以是单环、双环、三环 或四环系统,其中环系统中的至少一个环是完全不饱和的,即,根据Hückel理论,包含环状离域(4n+2)π-电子体系。杂芳基包括稠环或桥环系统。杂芳基中的杂原子被任选地氧化。一个或多个氮原子(如果存在的话)任选地被季铵化。杂芳基通过环中的任何原子附着至分子的其余部分。杂芳基的实例包括但不限于:氮杂环庚三烯基、吖啶基、苯并咪唑基、苯并吲哚基、1,3-苯并二恶唑基、苯并呋喃基、苯并恶唑基、苯并[d]噻唑基、苯并噻二唑基、苯并[b][1,4]二恶唑基、苯并[b][1,4]恶唑基、1,4-苯并二恶唑基、苯并萘并呋喃基、苯并二唑基、苯并二氧杂苯基、苯并吡喃基、苯并吡喃酮基、苯并呋喃基、苯并呋喃酮基、苯并噻吩基、苯并噻吩[3,2-d]嘧啶基、苯并三唑基、苯并[4,6]咪唑[1,2-a]吡啶基、咔唑基、噌啉基、环戊基[d]嘧啶基、6,7-二氢-5H-环戊基[4,5]噻吩[2,3-d]嘧啶基、5,6-二氢苯并[h]喹唑啉基、5,6-二氢苯并[h]辛诺林基、6,7-二氢-5H-苯并[6,7]环庚[1,2-c]哒嗪基、二苯并呋喃基、二苯并噻吩基、呋喃基、呋喃酮基、呋喃[3,2-c]吡啶基、5,6,7,8,9,10-六氢环庚烷[d]嘧啶基、5,6,7,8,9,10-六氢环辛酸[d]哒嗪基、5,6,7,8,9,10-六氢环辛酸[d]吡啶基、异噻唑基、吲唑基、咪唑基、吲哚基、异吲哚基、二氢吲哚基、异二氢氮茚基、异喹啉基、吲哚嗪基、异恶唑基、5,8-甲基-5,6,7,8-四氢喹唑啉基、萘啶酮基、1,6-萘啶酮基、恶二唑基、2-氧氮杂庚基、恶唑基、恶草酰基、5,6,6a,7,8,9,10,10a-八氢苯并[H]喹唑啉基、1-苯基-1H-吡咯基、吩嗪基、吩噻嗪基、吩恶嗪基、邻苯二甲酰基、蝶啶基、嘌呤基、吡咯基、吡唑基、吡唑并[3,4-d]嘧啶基、吡啶基、吡啶并[3,2-d]嘧啶基、吡啶并[3,4-d]嘧啶基、吡嗪基、嘧啶基、哒嗪基、吡咯基、喹唑啉基、喹喔啉基、喹啉基、异喹啉基、四氢喹啉基、5,6,7,8-四氢喹唑啉基、5,6,7,8-四氢苯并[4,5]噻吩[2,3-d]嘧啶基、6,7,8,9四氢-5H-环庚烷[4,5]噻吩[2,3-d]嘧啶基、5,6,7,8-四氢吡啶并[4,5-c]哒嗪基、噻唑基、噻二唑基、三唑基、四唑基、三嗪基、噻吩[2,3-d]嘧啶基、噻吩[3,2-d]嘧啶基、噻吩[2,3-c]普萘基和噻吩基。
在本公开中可以使用各种羟基保护基团。一般来说,保护基团使化学官能度对特定的反应条件不敏感,并且可以在分子中的该官能度上附加以及去除,而不实质上损害分子的其余部分。代表性的羟基保护基团公开于Beaucage等人,Tetrahedron 1992,48,2223-2311,以及Greeneand Wuts,Protective Groups in Organic Synthesis,Chapter 2,2d ed,John Wiley&Sons,New York,1991中,以引用的方式将上述文献整体并入本文。在一些实施方式中,保护基团在碱性条件下稳定,但可以在酸性条件下脱除。在一些实施方式中,本文可使用的羟基保护基的非排他性实例包括二甲氧基三苯甲基(DMT)、单甲氧基三苯甲基、9-苯基黄嘌呤-9-基(Pixyl)和9-(对甲氧基苯基)黄嘌呤-9-基(Mox)。在一些实施方式中,本文可使用的羟基保护基的非排他性实例包括Tr(三苯甲基)、MMTr(4-甲氧基三苯甲基)、DMTr(4,4’-二甲氧基三苯甲基)和TMTr(4,4’,4”-三甲氧基三苯甲基)。
“受试者”一词,如本文所使用的,指任何动物,例如哺乳动物或有袋动物。本公开的主题包括但不限于人类、非人灵长类(例如,恒河猴或其他类型的猕猴)、小鼠、猪、马、驴、牛、绵羊、大鼠和任何种类的家禽。
如本文所使用的,“治疗方法”、“治疗”、“减轻”、或“改善”可在此处互换使用。这些术语指的是获得有益的或期望的结果的方法,包括但不限于治疗益处。“治疗 益处”意味着根除或改善被治疗的潜在障碍。此外,治疗益处通过根除或改善与潜在障碍相关的一个或多个生理症状,从而在受试者中观察到改善而获得,尽管受试者可能仍然受到潜在障碍的折磨。
如本文所使用的,“防止”和“预防”可互换使用。这些术语指获得有益或期望的结果的方法,包括但不限于预防性益处。为了获得“预防性益处”,可将缀合物或组合物给予有罹患特定疾病风险的受试者,或给予报告疾病的一种或多种病理症状的受试者,即便可能该疾病的诊断尚未作出。
修饰的siRNA
本公开的siRNA含有核苷酸基团作为基本结构单元,本领域技术人员公知,所述核苷酸基团含有磷酸基团、核糖基团和碱基,在此不再赘述。
本公开提供了一种能够抑制APOC3基因表达的修饰的siRNA,所述修饰的siRNA含有正义链和反义链,所述正义链和反义链的每一个核苷酸均为修饰的核苷酸,其中,所述正义链和反义链均包含氟代修饰的核苷酸和非氟代修饰的核苷酸;所述正义链包含核苷酸序列Ⅰ,所述反义链包含核苷酸序列Ⅱ,所述核苷酸序列Ⅰ和所述核苷酸序列Ⅱ至少部分地反向互补形成双链区,其中,所述核苷酸序列Ⅰ含有核苷酸序列A,所述核苷酸序列A与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列Ⅱ含有核苷酸序列B,所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:
5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1);
5'-Z’UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2),
其中,Z为A,Z'为U,
所述核苷酸序列A中包含位置对应于Z的核苷酸Z
A,所述核苷酸序列B中包含位置对应于Z'的核苷酸Z'
B,所述Z'
B是所述反义链5'末端的第一个核苷酸;并且,所述氟代修饰的核苷酸位于核苷酸序列A和核苷酸序列B中,按照5'末端到3'末端的方向,所述核苷酸序列A的第7、8、9位的核苷酸为氟代修饰的核苷酸;并且,按照5'末端到3'末端的方向,所述核苷酸序列B的第2、6、14、16位的核苷酸为氟代修饰的核苷酸。在一些实施方式中,所述核苷酸序列A中氟代修饰的核苷酸不多于5个;所述核苷酸序列B中氟代修饰的核苷酸不多于7个。
在上文与下文中,“位置对应”是指从核苷酸序列相同端起算,处于核苷酸序列中相同的位置。例如,核苷酸序列A的3'端第1个核苷酸是位置对应于SEQ ID NO:1的3'端第1个核苷酸的核苷酸。
在一些实施方式中,所述正义链仅包含核苷酸序列Ⅰ,所述反义链仅包含核苷酸序列Ⅱ。
在一些实施方式中,所述核苷酸序列A与SEQ ID NO:1所示的核苷酸序列之间不多于1个核苷酸差异,和/或所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列之间不多于1个核苷酸差异。
在一些实施方式中,所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列之间的核 苷酸差异包括Z'
B位置处的差异,且Z'
B选自A、C或G。在一些实施方式中,所述核苷酸差异为Z'
B位置处的差异,Z'
B选自A、C或G。在一些实施方式中,Z
A是与Z'
B互补的核苷酸。这些核苷酸差异并不会显著降低siRNA缀合物的靶基因抑制能力,而这些包含核苷酸差异的siRNA缀合物也在本公开的保护范围之内。
在一些实施方式中,所述核苷酸序列A和所述核苷酸序列B基本上反向互补、实质上反向互补或完全反向互补;所述基本上反向互补是指两个核苷酸序列之间存在不多于3个的碱基错配;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配。
在一些实施方式中,所述核苷酸序列A是SEQ ID NO:60所示的核苷酸序列,核苷酸序列B是SEQ ID NO:61所示的核苷酸序列:
5'-CAAUAAAGCUGGACAAGAZ
A-3'(SEQ ID NO:60);
5'-Z’
BUCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:61),
其中,所述Z'
B是反义链5'末端的第一个核苷酸,Z
A选自A、U、G或C,并且Z'
B是与Z
A互补的核苷酸;并且,按照5'末端到3'末端的方向,所述核苷酸序列A的第7、8、9位的核苷酸为氟代修饰的核苷酸;按照5'末端到3'末端的方向,所述核苷酸序列B的第2、6、14、16位的核苷酸为氟代修饰的核苷酸。
在一些实施方式中,该siRNA含有正义链和反义链,所述正义链含有一段核苷酸序列I,所述反义链含有一段核苷酸序列II,核苷酸序列I和核苷酸序列II反向互补形成双链区,核苷酸序列I含有如SEQ ID NO:60所示的核苷酸序列,核苷酸序列II含有如SEQ ID NO:61所示的核苷酸序列:
5'-CAAUAAAGCUGGACAAGAZ
A-3'(SEQ ID NO:60);
5'-Z'
BUCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:61),
其中,所述Z'
B是反义链5'末端的第一个核苷酸,Z
A选自A、U、G或C,并且Z'
B是与Z
A互补的核苷酸;在一些实施方式中,Z
A为A,Z'
B为U;
并且,按照5'末端到3'末端的方向,所述siRNA的正义链中SEQ ID NO:60的第7、8、9位的核苷酸为氟代修饰的核苷酸,siRNA的正义链中其余位置的核苷酸为非氟代修饰的核苷酸;并且,按照5'末端到3'末端的方向,所述siRNA的反义链中SEQ ID NO:61的第2、6、14、16位的核苷酸为氟代修饰的核苷酸,siRNA的反义链中其余位置的核苷酸为非氟代修饰的核苷酸。
所述正义链和反义链长度相同或不同,所述正义链的长度为19-23个核苷酸,反义链的长度为19-26个核苷酸。这样,本公开提供的siRNA正义链和反义链的长度比可以是19/19、19/20、19/21、19/22、19/23、19/24、19/25、19/26、20/20、20/21、20/22、20/23、20/24、20/25、20/26、21/20、21/21、21/22、21/23、21/24、21/25、21/26、22/20、22/21、22/22、22/23、22/24、22/25、22/26、23/20、23/21、23/22、23/23、23/24、23/25或23/26。在一些实施方式中,所述siRNA正义链和反义链的长度比为19/21、21/23或23/25。
在一些实施方式中,所述正义链和反义链长度相同,所述核苷酸序列I还含有核苷酸序列III,所述核苷酸序列II还含有核苷酸序列IV,核苷酸序列III和核苷酸序列IV长度 各自独立地为1-4个核苷酸;所述核苷酸序列III连接核苷酸序列A的5’末端,所述核苷酸序列IV连接在核苷酸序列B的3’末端;所述核苷酸序列Ⅲ和所述核苷酸序列Ⅳ长度相等。
所述核苷酸序列III和核苷酸序列IV可以互补或不互补,为了增加siRNA的稳定性,在一些实施方式中,核苷酸序列III和核苷酸序列IV至少部分互补;在一些实施方式中,核苷酸序列III和核苷酸序列IV 80%以上的碱基互补,或者90%以上的碱基互补;在一些实施方式中,核苷酸序列III和核苷酸序列IV实质上反向互补或完全反向互补;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配;在一些实施方式中,核苷酸序列III和核苷酸序列IV完全反向互补。由此,所述siRNA正义链和反义链等长,其长度比为20/20、21/21、22/22或23/23。在一些实施方式中,所述siRNA正义链和反义链的长度比为21/21或23/23。
在一些实施方式中,所述核苷酸序列III和核苷酸序列IV的长度均为1个核苷酸,核苷酸序列III的碱基为C,核苷酸序列IV的碱基为G;此时,正义链和反义链的长度比为20/20;或者,核苷酸序列III和IV的长度均为2个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为C、C,核苷酸序列IV的碱基依次为G、G;此时,正义链和反义链的长度比为21/21;或者,核苷酸序列III和IV的长度均为3个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为U、C、C,核苷酸序列IV的碱基依次为G、G、A;此时,正义链和反义链的长度比为22/22;或者,核苷酸序列III和IV的长度均为4个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为C、U、C、C,核苷酸序列IV的碱基依次为G、G、A、G;此时,正义链和反义链的长度比为23/23。在一些实施方式中,所述核苷酸序列III和核苷酸序列IV的长度为2个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为C、C,核苷酸序列IV的碱基依次为G、G;此时,正义链和反义链的长度比为21/21。
在一些实施方式中,核苷酸序列III和核苷酸序列IV的长度相同,并且完全反向互补,因此,给出了核苷酸序列III的碱基,核苷酸序列IV的碱基也就确定了。
在一些实施方式中,所述正义链和反义链长度不同,所述核苷酸序列II还含有核苷酸序列V,核苷酸序列V的长度为1至3个核苷酸,连接在反义链的3’末端,构成反义链的3’悬垂末端。由此,本公开提供的siRNA正义链和反义链的长度比可以是19/20、19/21、19/22、20/21、20/22、20/23、21/22、21/23、21/24、22/23、22/24、22/25、23/24、23/25或23/26。在一些实施方式中,所述核苷酸序列V的长度为2个核苷酸,由此,本公开提供的siRNA正义链和反义链的长度比可以是19/21、21/23或23/25。
所述核苷酸序列V中的每一个核苷酸可以是任意的核苷酸,为了便于合成并节约合成成本,所述核苷酸序列V为连续的2个胸腺嘧啶脱氧核糖核苷酸(TT)或连续的2个尿嘧啶核糖核苷酸(UU);为了提高siRNA反义链与靶mRNA的亲和力,核苷酸序列V与靶mRNA的相应位置的核苷酸互补。
在一些实施方式中,所述正义链含有如SEQ ID No:60所示的核苷酸序列,所述反义链含有如SEQ ID No:3所示的核苷酸序列:
5’-CAAUAAAGCUGGACAAGAZ
A-3’(SEQ ID No:60)
5’-Z'
BUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID No:3)
或者所述正义链含有如SEQ ID No:4所示的核苷酸序列,所述反义链含有如SEQ ID No:5所示的核苷酸序列:
5’-CCCAAUAAAGCUGGACAAGAZ
A-3’(SEQ ID No:4)
5’-Z'
BUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID No:5)。
其中,所述Z'
B是反义链5'末端的第一个核苷酸,Z
A选自A、U、G或C,并且Z'
B是与Z
A互补的核苷酸。
在一些实施方式中,本公开所述的siRNA为siAP1或siAP2:
siAP1
正义链:5’-CAAUAAAGCUGGACAAGAA-3’(SEQ ID No:6)
反义链:5’-UUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID No:7)
siAP2
正义链:5’-CCCAAUAAAGCUGGACAAGAA-3’(SEQ ID No:8)
反义链:5’-UUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID No:9)。
在一些实施方式中,按照5'末端到3'末端的方向,在所述正义链中,所述核苷酸序列A的第7、8、9位或者5、7、8、9位的核苷酸为氟代修饰的核苷酸,所述正义链中其余位置的核苷酸为非氟代修饰的核苷酸;在所述反义链中,所述核苷酸序列B的第2、6、14、16位或者2、6、8、9、14、16位的核苷酸为氟代修饰的核苷酸,所述反义链中其余位置的核苷酸为非氟代修饰的核苷酸。
氟代修饰的核苷酸指核苷酸的核糖基2'位的羟基被氟取代形成的核苷酸,其具有以下式(107)所示的结构。非氟代修饰的核苷酸指核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸或核苷酸类似物。在一些实施方式中,每一个非氟代修饰的核苷酸独立地选自核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸或核苷酸类似物中的一种。
这些核糖基2'位的羟基被非氟基团取代形成的核苷酸是本领域技术人员所公知的,这些核苷酸可以选自2'-烷氧基修饰的核苷酸、2'-经取代的烷氧基修饰的核苷酸、2'-烷基修饰的核苷酸、2'-经取代的烷基修饰的核苷酸、2'-氨基修饰的核苷酸、2'-经取代的氨基修饰的核苷酸、2'-脱氧核苷酸中的一种。
在一些实施方式中,2'-烷氧基修饰的核苷酸为甲氧基修饰的核苷酸(2'-OMe),如式(108)所示。在一些实施方式中,2'-经取代的烷氧基修饰的核苷酸,例如可以是2'-O-甲氧基乙基修饰的核苷酸(2'-MOE),如式(109)所示。在一些实施方式中,2'-氨基修饰的核苷酸(2'-NH
2)如式(110)所示。在一些实施方式中,2'-脱氧核苷酸(DNA)如式(111)所示。
核苷酸类似物指能够在核酸中代替核苷酸,但结构不同于腺嘌呤核糖核苷酸、鸟嘌呤 核糖核苷酸、胞嘧啶核糖核苷酸、尿嘧啶核糖核苷酸或胸腺嘧啶脱氧核糖核苷酸的基团。在一些实施方式中,核苷酸类似物可以是异核苷酸、桥联的核苷酸(bridged nucleic acid,简称BNA)或无环核苷酸。
BNA是指受约束的或不能接近的核苷酸。BNA可以含有五元环、六元环、或七元环的具有“固定的”C3'-内切糖缩拢的桥联结构。通常将该桥掺入到该核糖的2'-、4'-位处以提供一个2',4'-BNA核苷酸。在一些实施方式中,BNA可以是LNA、ENA、cET BNA等,其中,LNA如式(112)所示,ENA如式(113)所示,cET BNA如式(114)所示。
无环核苷酸是核苷酸的糖环被打开形成的一类核苷酸。在一些实施方式中,无环核苷酸可以是解锁核酸(UNA)或甘油核酸(GNA),其中,UNA如式(115)所示,GNA如式(116)所示。
上述式(115)和式(116)中,R选自H、OH或烷氧基(O-烷基)。
异核苷酸是指核苷酸中碱基在核糖环上的位置发生改变而形成的化合物。在一些实施方式中,异核苷酸可以是碱基从核糖环的1'-位移动至2'-位或3'-位而形成的化合物,如式(117)或(118)所示。
上述式(117)-式(118)化合物中,Base表示碱基,例如A、U、G、C或T;R选自H、OH、F或者如上所述的非氟基团。
在一些实施方式中,核苷酸类似物选自异核苷酸、LNA、ENA、cET、UNA和GNA中的一种。在一些实施方式中,每一个非氟代修饰的核苷酸均为甲氧基修饰的核苷酸,在上文和下文中,所述甲氧基修饰的核苷酸指核糖基的2'-羟基被甲氧基取代而形成的核苷 酸。
在上文及下文中,“氟代修饰的核苷酸”、“2'-氟修饰的核苷酸”、“核糖基团的2'-羟基被氟取代的核苷酸”和“2'-氟代核糖基”意义相同,均指核苷酸的2'-羟基被氟取代,而形成的具有如式(107)所示结构的化合物;“甲氧基修饰的核苷酸”、“2'-甲氧基修饰的核苷酸”、“核糖基团的2'-羟基被甲氧基取代的核苷酸”和“2'-甲氧基核糖基”意义相同,均指核苷酸核糖基团的2'-羟基被甲氧基取代而形成的具有如式(108)所示结构的化合物。
在一些实施方式中,本公开的siRNA是具有以下修饰的siRNA:按照5'末端到3'末端的方向,在所述正义链中,所述核苷酸序列A的第7、8、9位或者第5、7、8、9位的核苷酸为氟代修饰的核苷酸,所述正义链中其余位置的核苷酸为甲氧基修饰的核苷酸;在所述反义链中,所述核苷酸序列B的第2、6、14、16位或者第2、6、8、9、14、16位的核苷酸为氟代修饰的核苷酸,所述反义链中其余位置的核苷酸为甲氧基修饰的核苷酸。
在一些实施方式中,本公开的siRNA是具有以下修饰的siRNA:按照5’末端到3’末端的方向,所述siRNA的正义链中核苷酸序列A的第5、7、8和9位的核苷酸为氟代修饰的核苷酸,siRNA的正义链的其余位置的核苷酸为甲氧基修饰的核苷酸,并且,按照5’末端到3’末端的方向,所述siRNA的反义链中核苷酸序列B的第2、6、8、9、14和16位的核苷酸为氟代修饰的核苷酸,siRNA的反义链其余位置的核苷酸为甲氧基修饰的核苷酸;
或者,按照5’末端到3’末端的方向,所述siRNA的正义链中核苷酸序列A的第7、8和9位的核苷酸为-氟代修饰的核苷酸,siRNA的正义链的其余位置的核苷酸为甲氧基修饰的核苷酸,并且,按照5’末端到3’末端的方向,所述siRNA的反义链中核苷酸序列B的第2、6、14和16位的核苷酸为氟代修饰的核苷酸,siRNA的反义链其余位置的核苷酸为甲氧基修饰的核苷酸。
换句话说,该siRNA的磷酸-糖骨架中的核糖基分别具有如下修饰基团:按照5’末端到3’末端的方向,所述siRNA的正义链中核苷酸序列A的第5、7、8和9位的糖基为2’-氟代核糖基,siRNA的正义链的其余位置核苷酸的糖基为2’-甲氧基核糖基,并且,按照5’末端到3’末端的方向,所述siRNA的反义链中核苷酸序列B的第2、6、8、9、14和16位的糖基为2’-氟代核糖基,siRNA的反义链其余位置核苷酸的糖基为2’-甲氧基核糖基;
或者,按照5’末端到3’末端的方向,所述siRNA的正义链中核苷酸序列A的第7、8和9位的糖基为2’-氟代核糖基,siRNA的正义链的其余位置核苷酸的糖基为2’-甲氧基核糖基,并且,按照5’末端到3’末端的方向,所述siRNA的反义链中核苷酸序列B的第2、6、14和16位的糖基为2’-氟代核糖基,siRNA的反义链其余位置核苷酸的糖基为2’-甲氧基核糖基。
在一些实施方式中,所述siRNA分子为siAP1-M1、siAP2-M1、siAP1-M2、siAP2-M2中的任意一种:
siAP1-M1
正义链:5’-CmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:10)
反义链:5’-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:11)
siAP2-M1
正义链:5’-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:12)
反义链:5’-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:13)
siAP1-M2
正义链:5’-CmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:14)
反义链:5’-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:15)
siAP2-M2
正义链:5’-CmCmCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:16)
反义链:5’-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:17)
在一些实施方式中,本公开提供的siRNA的正义链和反义链中至少一条单链的磷酸-糖骨架中的磷酸酯基中的至少一部分为具有修饰基团的磷酸酯基。在一些实施方式中,具有修饰基团的磷酸酯基为磷酸酯基中的磷酸二酯键中的至少一个氧原子被硫原子取代而形成的硫代磷酸酯基;在一些实施方式中,所述具有修饰基团的磷酸酯基为具有如式(101)所示结构的硫代磷酸酯基:
这种修饰能稳定siRNA的双链结构,保持碱基配对的高特异性和高亲和力。
在一些实施方式中,本公开提供的siRNA中,硫代磷酸酯基连接存在于由以下位置组成的组中的至少一处:正义链或反义链任意一端的第一个和第二个核苷酸之间;正义链或反义链任意一端的第二个和第三个核苷酸之间;或上述的任意组合。在一些实施方式中,硫代磷酸酯基连接存在于除正义链5'末端以外的全部上述位置处。在一些实施方式中,硫代磷酸酯基连接存在于除正义链3'末端以外的全部上述位置处。在一些实施方式中,硫代磷酸酯基连接存在于以下位置中的至少一处:
所述正义链的5'末端端部第1个核苷酸和第2个核苷酸之间;
所述正义链的5'末端端部第2个核苷酸和第3个核苷酸之间;
所述正义链的3'末端端部第1个核苷酸和第2个核苷酸之间;
所述正义链的3'末端端部第2个核苷酸和第3个核苷酸之间;
所述反义链的5'末端端部第1个核苷酸和第2个核苷酸之间;
所述反义链的5'末端端部第2个核苷酸和第3个核苷酸之间;
所述反义链的3'末端端部第1个核苷酸和第2个核苷酸之间;以及
所述反义链的3'末端端部第2个核苷酸和第3个核苷酸之间。
在一些实施方式中,所述siRNA为siAP1-M1S、siAP2-M1S、siAP1-M2S、siAP2-M2S中的任意一种:
siAP1-M1S
正义链:5’-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:18)
反义链:5’-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:19)
siAP2-M1S
正义链:5’-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:20)
反义链:5’-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:21)
siAP1-M2S
正义链:5’-CmsAmsAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:22)
反义链:5’-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:23)
siAP2-M2S
正义链:5’-CmsCmsCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:24)
反义链:5’-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:25)
在一些实施方式中,所述siRNA反义链的5’末端核苷酸为5’-磷酸核苷酸或5’-磷酸类似物修饰的核苷酸。
常用的所述5’-磷酸核苷酸或5’-磷酸类似物修饰的核苷酸是本领域技术人员所公知的,如5'-磷酸核苷酸可具有如下结构:
再如,Anastasia Khvorova and Jonathan K.Watts,The chemical evolution of oligonucleotide therapies of clinical utility.Nature Biotechnology,2017,35(3):238-48中公开了如下4种5’-磷酸类似物修饰的核苷酸:
其中,R选自H、OH、甲氧基或氟;Base表示碱基,选自A、U、C、G或T。
在一些实施方式中,5'-磷酸核苷酸为式(102)所示的含有5'-磷酸修饰的核苷酸,5’-磷酸类似物修饰的核苷酸为含有乙烯基磷酸酯(5’-(E)-vinylphosphonate,E-VP)修饰的核苷酸,如式(103)所示,或者为硫代磷酸酯修饰的核苷酸,如式(105)所示。
在一些实施方式中,本公开提供的siRNA可以为siAP1-M1P1、siAP2-M1P1、siAP1-M2P1、siAP2-M2P1、siAP1-M1SP1、siAP2-M1SP1、siAP1-M2SP1、siAP2-M2SP1中的任意一种:
siAP1-M1P1
正义链:5’-CmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:10)
反义链:5’-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3’SEQ ID NO:26)
siAP2-M1P1
正义链:5’-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:12)
反义链:5’-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:27)
siAP1-M2P1
正义链:5’-CmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:14)
反义链:5’-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:28)
siAP2-M2P1
正义链:5’-CmCmCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:16)
反义链:5’-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:29)
siAP1-M1SP1
正义链:5’-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:18)
反义链:5’-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:30)
siAP2-M1SP1
正义链:5’-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:20)
反义链:5’-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:31)
siAP1-M2SP1
正义链:5’-CmsAmsAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:22)
反义链:5’-P1-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:32)
siAP2-M2SP1
正义链:5’-CmsCmsCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:24)
反义链:5’-P1-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:33)
本公开的发明人发现,本公开提供的siRNA不仅具有显著增强的血浆和溶酶体稳定性,减少了脱靶效应,还保留很高的基因抑制活性。
本公开提供的siRNA可以通过本领域常规的核酸制备方法(例如固相合成和液相合成的方法)得到。其中,固相合成已经有商业化订制服务。可以通过使用具有相应修饰的核苷单体来将修饰的核苷酸基团引入本公开所述的siRNA中,制备具有相应修饰的核苷单体的方法及将修饰的核苷酸基团引入siRNA的方法也是本领域技术人员所熟知的。
药物组合物
本公开提供了一种药物组合物,该药物组合物含有如上所述的修饰的siRNA和药学上可接受的载体。
所述药学上可接受的载体可以是siRNA给药领域常规使用的载体,例如但不限于磁性纳米粒(magnetic nanoparticles,如基于Fe
3O
4或Fe
2O
3的纳米粒)、碳纳米管(carbon nanotubes)、介孔硅(mesoporous silicon)、磷酸钙纳米粒(calcium phosphate nanoparticles)、聚乙烯亚胺(polyethylenimine,PEI)、聚酰胺型树形高分子(polyamidoamine(PAMAM)dendrimer)、聚赖氨酸(poly(L-lysine),PLL)、壳聚糖(chitosan)、1,2-二油酰基-3-三甲铵丙烷(1,2-dioleoyl-3-trimethylammonium-propane,DOTAP)、聚D型或L型乳酸/羟基乙酸共聚物(poly(D&L-lactic/glycolic acid)copolymer,PLGA)、聚(氨乙基乙撑磷酸酯)(poly(2-aminoethyl ethylene phosphate),PPEEA)和聚(甲基丙烯酸-N,N-二甲氨基乙酯)(poly(2-dimethylaminoethyl methacrylate),PDMAEMA)以及它们的衍生物中的一种或多种。
在一些实施方式中,所述药物组合物中,对siRNA和药学上可接受的载体的含量没有特别要求,在一些实施方式中,siRNA与药学上可接受的载体的重量比可以为1:(1-500),在一些的实施方式中,上述重量比为为1:(1-50)。
在一些实施方式中,所述药物组合物中,还可以包含药学上可接受的其它辅料,该辅料可以为本领域常规采用的各种制剂或化合物的一种或多种。例如,所述药学上可接受的其它辅料可以包括pH缓冲液、保护剂和渗透压调节剂中的至少一种。
所述pH缓冲液可以为pH值7.5-8.5的三羟甲基胺基甲烷盐酸盐缓冲液和/或pH值5.5-8.5的磷酸盐缓冲液,例如可以为pH值5.5-8.5的磷酸盐缓冲液。
所述保护剂可以为肌醇、山梨醇、蔗糖、海藻糖、甘露糖、麦芽糖、乳糖和葡萄糖中的至少一种。以所述药物组合物的总重量为基准,所述保护剂的含量可以为0.01-30重量%。
所述渗透压调节剂可以为氯化钠和/或氯化钾。所述渗透压调节剂的含量使所述药物组合物的渗透压为200-700毫渗摩尔/千克(mOsm/kg)。根据所需渗透压,本领域技术人员可以容易地确定所述渗透压调节剂的含量。
在一些实施方式中,所述药物组合物可以为液体制剂,例如注射液;也可以为冻干粉针剂,实施给药时与液体辅料混合,配制成液体制剂。所述液体制剂可以但不限于用于皮下、肌肉或静脉注射给药,也可以但不限于通过喷雾给药到肺脏、或通过喷雾经肺脏给药到其它脏器组织(如肝脏)。在一些实施方式中,所述药物组合物用于静脉注射给药。
在一些实施方式中,所述药物组合物可以为脂质体制剂的形式。在一些实施方式中,所述脂质体制剂中使用的药学上可接受的载体包含含胺的转染化合物(下文也可将其称为有机胺)、辅助脂质和/或聚乙二醇化脂质。其中,所述有机胺、辅助脂质和聚乙二醇化脂质可分别选自于CN103380113A(通过引用的方式将其整体并入本文)中所描述的含胺的转染化合物或其药学上可接受的盐或衍生物、辅助脂质和聚乙二醇化脂质中的一种或多种。
在一些实施方式中,所述有机胺可为CN103380113A中描述的如式(201)所示的化合物或其药学上可接受的盐:
其中:
X
101和X
102各自独立地是O、S、N-A或C-A,其中A是氢或C1-C20烃链;
Y和Z各自独立地是C=O、C=S、S=O、CH-OH或SO
2;
R
101、R
102、R
103、R
104、R
105、R
106和R
107各自独立地是氢,环状或无环的、被取代的或未被取代的、支链或直链脂族基团,环状或无环的、被取代的或未被取代的、支链或直链杂脂族基团,被取代的或未被取代的、支链或直链酰基,被取代的或未被取代的、支链或直链芳基,被取代的或未被取代的、支链或直链杂芳基;
x是1-10的整数;
n是1-3的整数,m是0-20的整数,p是0或1;其中,如果m=p=0,则R
102是氢;
并且,如果n或m中的至少一个是2,那么R
103和在式(201)中的氮形成如式(202)或式(203)所示的结构:
其中,g、e和f各自独立地是1-6的整数,“HCC”代表烃链,且每个*N表示在式(201)中的氮原子。
在一些实施方式中,R
103是多胺。在其它实施方式中,R
103是缩酮。在一些实施方式中,在式(201)中的R
101和R
102中的每一个独立地是任意的被取代的或未被取代的、支链或直链烷基或烯基,所述烷基或烯基具有3至约20个碳原子,诸如8至约18个碳原子,和0至4个双键,诸如0至2个双键。
在一些实施方式中,如果n和m中的每一个独立地具有1或3的值,那么R
103可以是下述式(204)-式(213)中的任一个:
其中,式(204)-式(213)中,g、e和f各自独立地是1-6的整数,每个“HCC”代表烃链,且每个*显示R
103与在式(201)中的氮原子的可能连接点,其中在任意*位置上的每个H可以被替换以实现与在式(201)中的氮原子的连接。
其中,式(201)所示化合物可以根据CN103380113A中的描述制备。
在一些实施方式中,所述有机胺为如式(214)所示的有机胺和/或如式(215)所示的有机胺:
所述辅助脂质为胆固醇、胆固醇的类似物和/或胆固醇的衍生物;
所述聚乙二醇化脂质为1,2-二棕榈酰胺-sn-甘油-3-磷脂酰乙醇胺-N-[甲氧基(聚乙二醇)]-2000。
在一些实施方式中,所述药物组合物中,所述有机胺、所述辅助脂质和所述聚乙二醇化脂质三者之间的摩尔比为(19.7-80):(19.7-80):(0.3-50),例如可以为(50-70):(20-40):(3-20)。
在一些实施方式中,由本公开的siRNA与上述含胺的转染试剂形成的药物组合物颗粒具有约30nm至约200nm的平均直径,通常为约40nm至约135nm,更通常地,该脂质体颗粒的平均直径是约50nm至约120nm、约50nm至约100nm、约60nm至约90nm或约70nm至约90nm,例如,该脂质体颗粒的平均直径是约30、40、50、60、70、75、80、85、90、100、110、120、130、140、150或160nm。
在一些实施方式中,由本公开的siRNA与上述含胺的转染试剂形成的药物组合物中,siRNA与全部脂质(例如有机胺、辅助脂质和/或聚乙二醇化脂质)的重量比(重量/重量比)在从约1:1至约1:50、从约1:1至约1:30、从约1:3至约1:20、从约1:4至约1:18、从约1:5至约1:17、从约1:5至约1:15、从约1:5至约1:12、从约1:6至约1:12或从约1:6至约1:10的范围内,例如,本公开的siRNA与全部脂质的重量比为约1:5、1:6、1:7、1:8、1:9、1:10、1:11、1:12、1:13、1:14、1:15、1:16、1:17或1:18。
在一些实施方式中,所述药物组合物在销售时各组分可以独立存在,在使用时可以液体制剂的形式存在。在一些实施方式中,本公开提供的siRNA与上述药学上可接受的载体形成的药物组合物可以按照已知的各种方法制备,只是用本公开提供的siRNA替代现有siRNA即可;在一些实施方式中,可以按照如下方法制备:
将有机胺、辅助脂质和聚乙二醇化脂质按照上述摩尔比悬浮于醇中并混匀得到脂质溶液;醇的用量使得到的脂质溶液的总质量浓度为2-25mg/mL,例如可以为8-18mg/mL。所述醇选自药学上可接受的醇,诸如在室温附近为液体的醇,例如,乙醇、丙二醇、苯甲醇、甘油、聚乙二醇200,聚乙二醇300,聚乙二醇400中的一种或多种,例如可以为乙醇。
将本公开提供的siRNA溶解于缓冲盐溶液中,得到siRNA水溶液。缓冲盐溶液的浓度为0.05-0.5M,例如可以为0.1-0.2M,调节缓冲盐溶液的pH至4.0-5.5,例如可以为5.0-5.2,缓冲盐溶液的用量使siRNA的浓度不超过0.6mg/mL,例如可以为0.2-0.4mg/mL。所述缓冲盐选自可溶性醋酸盐、可溶性柠檬酸盐中的一种或多种,例如可以为醋酸钠和/或醋酸钾。
将脂质溶液和siRNA水溶液混合,将混合后得到的产物在40-60℃孵育至少2分钟,例如可以为5-30分钟,得到孵育后的脂质体制剂。脂质溶液和siRNA水溶液的体积比为1:(2-5),例如可以为1:4。
将孵育后的脂质体制剂浓缩或稀释,去除杂质,除菌,得到本公开提供的药物组合物,其理化参数为pH值为6.5-8,包封率不低于80%,粒径为40-200nm,多分散指数不高于0.30,渗透压为250-400mOsm/kg;例如理化参数可以为pH值为7.2-7.6,包封率不低于90%,粒径为60-100nm,多分散指数不高于0.20,渗透压为300-400mOsm/kg。
其中,浓缩或稀释可以在去除杂质之前、之后或同时进行。去除杂质的方法可以采用现有各种方法,例如可以使用切相流系统、中空纤维柱,在100K Da条件下超滤,超滤交换溶液为pH7.4的磷酸盐缓冲液(PBS)。除菌的方法可以采用现有各种方法,例如可以在0.22μm滤器上过滤除菌。
第一种siRNA缀合物
本公开提供了一种siRNA缀合物,所述第一种siRNA缀合物含有上述siRNA以及缀合连接至该siRNA的缀合基团。
一般来说,所述缀合基团包含药学上可接受的至少一个靶向基团和任选的接头(linker),并且,所述siRNA、所述接头和所述靶向基团依次连接。在一些实施方式中,所述靶向基团为1-6个。在一些实施方式中,所述靶向基团为2-4个。所述siRNA分子可以非共价或共价缀合至所述缀合基团,例如可以共价缀合至所述缀合基团。siRNA与缀合基团的缀合位点可以在siRNA正义链的3’端或5’端,也可在反义链的5’端,还可以在siRNA的内部序列中。在一些实施方式中,所述siRNA与缀合基团的缀合位点在siRNA正义链的3’末端。
在一些实施方式中,所述缀合基团可以连接在核苷酸的磷酸基团、2’-位羟基或者碱基上。在一些实施方式中,所述缀合基团还可以连接在3’-位羟基上,此时核苷酸之间采 用2’-5’磷酸二酯键连接。当缀合基团连接在siRNA链的末端时,所述缀合基团通常连接在核苷酸的磷酸基团上;当缀合基团连接在siRNA的内部序列时,所述缀合基团通常连接在核糖糖环或者碱基上。各种连接方式可以参考Muthiah Manoharan et.al.siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.ACS Chemical biology,2015,10(5):1181-7。
在一些实施方式中,所述siRNA与缀合基团间可以通过酸不稳定的、或可还原的化学键相连,在细胞内涵体的酸性环境下,这些化学键可降解,从而使siRNA成为自由状态。对于不可降解的缀合方式,缀合基团可连接在siRNA的正义链,从而尽量降低缀合对siRNA活性的影响。
在一些实施方式中,所述药学上可接受的靶向基团可以是siRNA给药领域常规使用的配体,例如WO2009082607A2中描述的各种配体,以引用的方式将其全部公开内容并入本文。
在一些实施方式中,所述药学上可接受的靶向基团可以选自以下靶向分子或其衍生物形成的配体中的一种或多种:亲脂分子,例如胆固醇、胆汁酸、维生素(例如维生素E)、不同链长的脂质分子;聚合物,例如聚乙二醇;多肽,例如透膜肽;适配体;抗体;量子点;糖类,例如乳糖、聚乳糖、甘露糖、半乳糖、N-乙酰半乳糖胺(GalNAc);叶酸(folate);肝实质细胞表达的受体配体,例如去唾液酸糖蛋白、去唾液酸糖残基、脂蛋白(如高密度脂蛋白、低密度脂蛋白等)、胰高血糖素、神经递质(如肾上腺素)、生长因子、转铁蛋白等。
在一些实施方式中,所述的每个配体独立地选自一个能够与细胞表面受体结合的配体。在一些实施方式中,至少一个配体是能够与肝细胞表面受体结合的配体。在一些实施方式中,至少一个配体是能够与哺乳动物细胞表面受体结合的配体。在一些实施方式中,至少一个配体是能够与人肝细胞表面受体结合的配体。在一些实施方式中,至少一个配体是能够与肝表面去唾液酸糖蛋白受体(ASGPR)结合的配体。这些配体的种类为本领域技术人员所公知,其作用一般是与靶细胞表面的特异性受体相结合,介导与配体连接的siRNA递送至靶细胞。
在一些实施方式中,所述药学上可接受的靶向基团可以是与哺乳动物肝细胞表面上的去唾液酸糖蛋白受体(ASGPR)结合的任意一种配体。在一些实施方式中,每个配体独立地为去唾液酸糖蛋白,例如去唾液酸血清类粘蛋白(asialoorosomucoid,ASOR)或去唾液酸胎球蛋白(asialofetuin,ASF)。在一些实施方式中,所述配体为糖或糖的衍生物。
在一些实施方式中,至少一个配体是糖。在一些实施方式中,每个配体均是糖。在一些实施方式中,至少一个配体是单糖、多糖、修饰的单糖、修饰的多糖或糖衍生物。在一些实施方式中,至少一个所述配体可以是单糖,双糖或三糖。在一些实施方式中,至少有一个配体是修饰的糖。在一些实施方式中,每一个配体均为修饰的糖。在一些实施方式中,每个配体均独立地选自多糖、修饰的多糖、单糖、修饰的单糖、多糖衍生物或单糖衍生物。在一些实施方式中,每一个或至少一个配体选自由葡萄糖及其衍生物组、甘露聚糖及其衍生物、半乳糖及其衍生物、木糖及其衍生物、核糖及其衍生物、岩 藻糖及其衍生物、乳糖及其衍生物、麦芽糖及其衍生物,阿拉伯糖及其衍生物、果糖及其衍生物和唾液酸组成的组中。
在一些实施方式中,每个所述配体可独立地选自D-吡喃甘露糖、L-吡喃甘露糖、D-阿拉伯糖、D-呋喃木糖、L-呋喃木糖、D-葡萄糖、L-葡萄糖、D-半乳糖、L-半乳糖、α-D-呋喃甘露糖、β-D-呋喃甘露糖、α-D-吡喃甘露糖、β-D-吡喃甘露糖、α-D-吡喃葡萄糖、β-D-吡喃葡萄糖、α-D-呋喃葡萄糖、β-D-呋喃葡萄糖、α-D-呋喃果糖、α-D-吡喃果糖、α-D-吡喃半乳糖、β-D-吡喃半乳糖、α-D-呋喃半乳糖、β-D-呋喃半乳糖、葡糖胺、唾液酸、半乳糖胺、N-乙酰半乳糖胺、N-三氟乙酰基半乳糖胺、N-丙酰基半乳糖胺、N-正丁酰基半乳糖胺、N-异丁酰基半乳糖胺、2-氨基-3-O-[(R)-1-羧乙基]-2-脱氧-β-D-吡喃葡萄糖、2-脱氧-2-甲基氨基-L-吡喃葡萄糖、4,6-二脱氧-4-甲酰胺基-2,3-二-O-甲基-D-吡喃甘露糖、2-脱氧-2-磺氨基-D-吡喃葡萄糖、N-乙醇酰基-α-神经氨酸、5-硫代-β-D-吡喃葡萄糖、2,3,4-三-O-乙酰基-1-硫代-6-O-三苯甲基-α-D-吡喃葡萄糖苷甲酯、4-硫代-β-D-吡喃半乳糖、3,4,6,7-四-O-乙酰基-2-脱氧-1,5-二硫代-α-D-吡喃葡庚糖苷乙酯、2,5-脱水-D-阿洛糖腈、核糖、D-核糖、D-4-硫代核糖、L-核糖或L-4-硫代核糖。所述配体的其它选择可参见例如CN105378082A的记载,以引用的方式将其全部公开内容并入本文。
在一些实施方式中,所述第一种siRNA缀合物中药学上可接受的靶向基团可以是半乳糖或N-乙酰半乳糖胺,其中,半乳糖或N-乙酰半乳糖胺分子可以是一价、二价、三价、四价。应当理解的是,这里所述的一价、二价、三价、四价分别指siRNA分子与含有作为靶向基团的半乳糖或N-乙酰半乳糖胺分子的缀合基团形成siRNA缀合物后,该siRNA缀合物中siRNA分子与半乳糖或N-乙酰半乳糖胺分子的摩尔比为1:1、1:2、1:3或1:4。在一些实施方式中,所述药学上可接受的靶向基团是N-乙酰半乳糖胺。在一些实施方式中,当本公开所述的siRNA与含有N-乙酰半乳糖胺的缀合基团缀合时,N-乙酰半乳糖胺分子是三价或四价。在一些实施方式中,当本公开所述的siRNA与含有N-乙酰半乳糖胺的缀合基团缀合时,N-乙酰半乳糖胺分子是三价。
靶向基团可经由合适的接头与siRNA分子相连,本领域技术人员可以根据靶向基团的具体类型选择合适的接头。这些接头、靶向基团的种类以及与siRNA的连接方式,可参见WO2015006740A2的公开内容,通过引用的方式将其整体内容并入本文。
在一些实施方式中,当所述靶向基团为N-乙酰半乳糖胺时,合适的接头可以为如式(301)所示的结构:
其中,
k为1-3的整数;
L
A为具有如式(302)所示结构的包含酰胺键的链状部分,每个所述L
A在其两端分别与一个所述靶向基团和所述L
C部分通过醚键相连接:
L
B为具有如式(303)所示结构的包含N-酰基吡咯烷的链状部分,所述链状部分在其一端具有羰基并与所述L
C部分通过酰胺键相连接,在另一端具有氧基并与所述siRNA通过磷酸酯键相连接:
L
C为基于羟甲基氨基甲烷、二羟甲基氨基甲烷或三羟甲基氨基甲烷的2-4价连接基团,所述L
C经由氧原子与各个所述L
A部分通过醚键相连接,并且经由氮原子与所述L
B部分通过酰胺键相连接。
在一些实施方式中,当n=3,L
C为基于三羟甲基氨基甲烷的4价连接基团时,由作为接头的-(L
A)
3三羟甲基氨基甲烷-L
B-连接N-乙酰半乳糖胺分子和siRNA分子所形成的第一种siRNA缀合物,其结构如下式(304)所示:
式中,双螺旋结构表示siRNA。
同样,siRNA与缀合基团的缀合位点可以在siRNA正义链的3'端或5'端,也可在反义链的5'端,还可以在siRNA的内部序列中。
在一些实施方式中,本公开所述siRNA的正义链3'末端通过接头-(L
A)
3三羟甲基氨基甲烷-L
B-与三个N-乙酰半乳糖胺(GalNAc)分子共价缀合,得到siRNA分子与GalNAc分子的摩尔比为1:3的第一种siRNA缀合物,下文也可将其称为(GalNAc)
3-siRNA,其结构如下式(305)所示:
其中,双螺旋结构表示所述siRNA,并且所述接头连接至所述siRNA的正义链3'末端。
在一些实施方式中,当所述靶向基团为N-乙酰半乳糖胺时,合适的接头可以为如式(306)所示的结构:
其中,
l为0-3的整数;
*表示接头上通过醚键与靶向基团连接的位点;
#表示接头上通过磷酸酯键与siRNA连接的位点。
在一些实施方式中,当l=2时,所述第一种siRNA缀合物具有如式(307)所示的结构:
其中,双螺旋结构表示所述siRNA,并且所述接头连接至所述siRNA的正义链3'末端。
上述缀合物可以通过现有技术中已经详细描述的方法进行合成。例如,WO2015006740A2中详细描述了多种缀合物的制备方法。通过本领域技术人员熟知的方式,获得本公开的第一种siRNA缀合物。如WO2014025805A1中记载了式(305)所示结构的制备方法,Rajeev等人在ChemBioChem 2015,16,903-908中描述了式(307)所示结构的制备方法。
第二种siRNA缀合物
在一些实施方式中,本公开提供了第二种siRNA缀合物,该第二种siRNA缀合物具有如式(1)所示的结构:
其中:
n1为选自1-3的整数,n3为选自0-4的整数;
m1、m2和m3独立地为选自2-10的整数;
R
10、R
11、R
12、R
13、R
14和R
15各自独立地为H,或选自于由以下基团所组成的组:C
1-C
10烷基、C
1-C
10卤代烷基以及C
1-C
10烷氧基;
R
3为式A59所示结构的基团:
其中,E
1为OH、SH或BH
2,Nu为siRNA;
Nu代表的siRNA中的每个核苷酸各自独立地为修饰或未修饰的核苷酸,Nu代表的siRNA含有正义链和反义链,所述正义链包含核苷酸序列1,所述反义链包含核苷酸序列2,所述核苷酸序列1和所述核苷酸序列2至少部分地反向互补形成双链区,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:
5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1),
5'-Z'UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2);
其中,Z为A,Z'为U,
所述核苷酸序列1中包含位置对应于Z的核苷酸Z
A,所述核苷酸序列2中包含位置对应于Z'的核苷酸Z'
B,所述Z'
B是所述反义链5'末端的第一个核苷酸;
在上文与下文中,“位置对应”是指从核苷酸序列相同端起算,处于核苷酸序列中相同的位置。例如,核苷酸序列1的3'端第1个核苷酸是位置对应于SEQ ID NO:1的3'端第1个核苷酸的核苷酸。
R
2是长度为1-20个碳原子的直链亚烷基,其中一个或多个碳原子任选地被选自于以下基团所组成的组中的一个或多个所替换:C(O)、NH、O、S、CH=N、S(O)
2、C
2-C
10亚烯基、C
2-C
10亚炔基、C
6-C
10亚芳基、C
3-C
18亚杂环基和C
5-C
10亚杂芳基;并且其中,R
2可任选地具有由以下基团所组成的组中的任何一个或多个的取代基:C
1-C
10烷基、C
6-C
10芳基、C
5-C
10杂芳基、C
1-C
10卤代烷基、-OC
1-C
10烷基、-OC
1-C
10烷基苯基、-C
1-C
10烷基-OH、-OC
1-C
10卤代烷基、-SC
1-C
10烷基、-SC
1-C
10烷基苯基、-C
1-C
10烷基-SH、-SC
1-C
10卤代烷基、卤素取代基、-OH、-SH、-NH
2、-C
1-C
10烷基-NH
2、-N(C
1-C
10烷基)(C
1-C
10烷基)、-NH(C
1-C
10烷基)、氰基、硝基、-CO2H、-C(O)O(C
1-C
10烷基)、-CON(C
1-C
10烷基)(C
1-C
10烷基)、-CONH(C
1-C
10烷基)、-CONH
2,-NHC(O)(C
1-C
10烷基)、-NHC(O)(苯基)、-N(C
1-C
10烷基)C(O)(C
1-C
10烷基)、-N(C
1-C
10烷基)C(O)(苯基)、-C(O)C
1-C
10烷基、-C(O)C
1-C
10烷基苯基、-C(O)C
1-C
10卤烷基、-OC(O)C
1-C
10烷基、-SO
2(C
1-C
10烷基)、-SO
2(苯基)、-SO
2(C
1-C
10卤代烷基)、-SO
2NH
2、-SO
2NH(C
1-C
10烷基)、-SO
2NH(苯基)、-NHSO
2(C
1-C
10烷基)、-NHSO
2(苯基)和-NHSO
2(C
1-C
10卤代烷基)。
每个L
1是长度为1-70个碳原子的直链亚烷基,其中一个或多个碳原子任选地被选自于以下基团所组成的组中的一个或多个所替换:C(O)、NH、O、S、CH=N、S(O)
2、C
2-C
10亚烯基、C
2-C
10亚炔基、C
6-C
10亚芳基、C
3-C
18亚杂环基和C
5-C
10亚杂芳基;并且其中,L
1可任选地具有由以下基团所组成的组中的任何一个或多个的取代基:C
1-C
10烷基、C
6-C
10芳基、C
5-C
10杂芳基、C
1-C
10卤代烷基、-OC
1-C
10烷基、-OC
1-C
10烷基苯基、-C
1-C
10烷基-OH、-OC
1-C
10卤代烷基、-SC
1-C
10烷基、-SC
1-C
10烷基苯基、-C
1-C
10烷基-SH、 -SC
1-C
10卤代烷基、卤素取代基、-OH、-SH、-NH
2、-C
1-C
10烷基-NH
2、-N(C
1-C
10烷基)(C
1-C
10烷基)、-NH(C
1-C
10烷基)、氰基、硝基、-CO
2H、-C(O)O(C
1-C
10烷基)、-CON(C
1-C
10烷基)(C
1-C
10烷基)、-CONH(C
1-C
10烷基)、-CONH
2,-NHC(O)(C
1-C
10烷基)、-NHC(O)(苯基)、-N(C
1-C
10烷基)C(O)(C
1-C
10烷基)、-N(C
1-C
10烷基)C(O)(苯基)、-C(O)C
1-C
10烷基、-C(O)C
1-C
10烷基苯基、-C(O)C
1-C
10卤烷基、-OC(O)C
1-C
10烷基、-SO
2(C
1-C
10烷基)、-SO
2(苯基)、-SO
2(C
1-C
10卤代烷基)、-SO
2NH
2、-SO
2NH(C
1-C
10烷基)、-SO
2NH(苯基)、-NHSO
2(C
1-C
10烷基)、-NHSO
2(苯基)和-NHSO
2(C
1-C
10卤代烷基)。
在一些实施方式中,L
1可选自于由A1-A26基团或其任意组合所组成的组,其中A1-A26的结构和定义如下所示:
其中,j1为1-20的整数;j2为1-20的整数;
R’为C
1-C
10的烷基;
Ra选自式A27-A45基团或其任意组合所组成的组:
技术人员会理解的是,尽管为了方便起见,L
1被定义为线性烷基,但是它可能不是线性基团或者名称不同,例如由于上述替换和/或置换而产生的胺或烯基。为了本公开内容的目的,L
1的长度是连接两个附着点的链中的原子数。为此目的,将替换所述直链亚烷基的碳原子而得到的环(如亚杂环基或亚杂芳基)计为一个原子。
M
1表示靶向基团,其定义和可选择的范围与上述靶向基团相同。在一些实施方式中,每个M
1独立地选自对哺乳动物肝脏细胞表面上的去唾液酸糖蛋白受体具有亲合力的配体中的一种。
当M
1为对哺乳动物肝脏细胞表面上的去唾液酸糖蛋白受体具有亲合力的配体时,在一些实施方式中,n1可以是1-3的整数,n3可以是0-4的整数,保证所述缀合物中M
1靶向基团的个数至少为2;在一些实施方式中,n1+n3≥2,这样可以使得M
1靶向基团的个数至少为3,从而使得M
1靶向基团与肝表面去唾液酸糖蛋白受体更容易结合,进而促进所述缀合物通过内吞作用进入细胞。实验表明,当M
1靶向基团的个数大于3个时,M
1靶向基团与肝表面去唾液酸糖蛋白受体结合的容易程度增加并不明显,因此,从合成容易程度、结构/工艺成本和递送效率等多方面综合考虑,在一些实施方式中,n1为1-2的整数,n3为0-1的整数,且n1+n3=2-3。
在一些实施方式中,m1、m2和m3独立地选自2-10的整数时,可以使多个M
1靶向基团之间的空间位置适合M
1靶向基团与肝表面去唾液酸糖蛋白受体的结合,为了使本公开提供的缀合物更为简单,更容易合成和/或降低成本,在一些实施方式中,m1、m2和m3各自独立地为2-5的整数,在一些实施方式中,m1=m2=m3。
本领域技术人员可以理解,当R
10、R
11、R
12、R
13、R
14和R
15各自独立地选自H、C
1-C
10烷基、C
1-C
10卤代烷基、以及C
1-C
10烷氧基中的一种时,不会改变本公开的缀合物的性质,均可以实现本公开的目的。在一些实施方式中,R
10、R
11、R
12、R
13、R
14和R
15各自独立地选自H、甲基和乙基。在一些实施方式中,R
10、R
11、R
12、R
13、R
14和R
15均为H。
R
3为式A59所示结构的基团,其中,E
1为OH、SH或BH
2,基于制备原料易获取性 的考虑,在一些实施方式中,E
1为OH或SH。
R
2的选择是为了实现与含氮骨架上的N与A59的连接。在本公开的上下文中,“含氮骨架”是指连接有R
10、R
11、R
12、R
13、R
14和R
15的碳原子与N互相连接的链状结构。因此,R
2可以是任何能够以适当方式将A59基团连接至含氮骨架上的N的连接基团。在一些实施方式中,在通过固相合成的工艺制备第二种siRNA缀合物的情况下,R
2基团中需要同时含有与含氮骨架上的N连接的连接位点和与R
3中的P相连接的连接位点。在一些实施方式中,R
2中所述与含氮骨架上的N连接的位点与N形成酰胺键,所述与R
3上的P连接的位点与P形成磷酸酯键;在一些实施方式中,R
2可以是B5、B6、B5’或B6’:
q
2的取值范围可以是1-10的整数,在一些实施方式中,q
2为1-5的整数。
L
1的作用是将M
1靶向基团与含氮骨架上的N连接,为第二种siRNA缀合物提供肝靶向功能。在一些实施方式中,L
1选自式A1-A26基团中的一种或多种的连接组合。在一些实施方式中,L
1选自A1、A4、A5、A6、A8、A10、A11和A13中的一种或多种的连接组合。在一些实施方式中,L
1选自A1、A4、A8、A10和A11中至少2个的连接组合。在一些实施方式中,L
1选自A1、A8、A10中至少2个的连接组合。
在一些实施方式中,L
1的长度可以为3-25个原子,3-20个原子、4-15个原子或5-12个原子。在一些实施方式中,L
1的长度为3个、4个、5个、6个、7个、8个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个、20个、21个、22个、23个、24个、25个、30个、35个、40个、45个、50个、55个、60个原子。
技术人员会理解,尽管为了方便起见,L
1被定义为线性烷基,但是它可能不是线性基团或者名称不同,例如由于上述替换和/或置换而产生的胺或烯基。为了本公开内容的目的,L
1的长度是连接两个附着点的链中的原子数。为此目的,将替换所述直链亚烷基 的碳原子而得到的环(如亚杂环基或亚杂芳基)计为一个原子。
在一些实施方式中,j1为2-10的整数,在一些实施方式中,j1为3-5的整数。在一些实施方式中,j2为2-10的整数,在一些实施方式中,j2为3-5的整数。R’为C1-C4的烷基,在一些实施方式中,R’为甲基、乙基和异丙基中的一种。Ra为A27、A28、A29、A30和A31中的一种,在一些实施方式中,Ra为A27或A28。Rb为C1-C5的烷基,在一些实施方式中,Rb为甲基、乙基、异丙基和丁基中的一种。在一些实施方式中,在式A1-A26中各自对j1、j2、R’、Ra、Rb进行选择,以实现M
1靶向基团与含氮骨架上的N连接,并使M
1靶向基团之间的空间位置更适合M
1靶向基团与肝表面去唾液酸糖蛋白受体结合。
在一些实施方式中,该缀合物具有式(3)、(4)、(5)、(6)、(7)、(8)、(9)、(10)、(11)、(12)、(13)、(14)、(15)、(16)、(17)、(18)、(19)、(20)、(21)或(22)所示的结构:
在一些实施方式中,式A59中的P可以连接到Nu代表的siRNA序列中任何可能的位置,例如,式A59中的P可以连接到Nu代表的siRNA正义链或反义链的任何一个核苷酸上;在一些实施方式中,式A59中的P可以连接到Nu代表的siRNA正义链的任何一个核苷酸上。在一些实施方式中,式A59中的P连接到Nu代表的siRNA正义链或反义链的端部;在一些实施方式中,式A59中的P连接到Nu代表的siRNA正义链的端部。Nu代表的siRNA的端部指Nu代表的siRNA正义链或反义链中从其一端起算的前4个核苷酸。在一些实施方式中,式A59中的P连接到Nu代表的siRNA正义链或反义链的末端;在一些实施方式中,式A59中的P连接到Nu代表的siRNA中的正义链的3'末端。在连接至Nu代表的siRNA的正义链的上述位置的情况下,第二种siRNA缀合物进入细胞后,在解旋时,可以释放出单独的siRNA反义链,以阻断APOC3 mRNA翻译蛋白质的过程,抑制载脂蛋白C3(ApoC3)基因表达。
在一些实施方式中,式A59中的P可以连接到Nu代表的siRNA中的核苷酸上任何可能的位置,例如,核苷酸的5'位、核苷酸的2'位、核苷酸的3'位或核苷酸的碱基上。在一些实施方式中,式A59中的P可通过形成磷酸二酯键而连接至Nu代表的siRNA中的核苷 酸的2'位、3'位或5'位。在一些实施方式中,式A59中的P连接在Nu代表的siRNA正义链3'末端核苷酸的3'羟基脱氢后形成的氧原子上,或者式A59中的P通过取代Nu代表的siRNA正义链中的一个核苷酸的2'-羟基中的氢与核苷酸连接,或者式A59中的P通过取代Nu代表的siRNA正义链5'末端核苷酸的5'羟基中的氢与核苷酸连接。
在一些实施方式中,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列不多于1个核苷酸差异,和/或所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列不多于1个核苷酸差异。
在一些实施方式中,所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列之间的核苷酸差异包括Z'
B位置处的差异,且Z'
B选自A、C或G;在一些实施方式中,所述核苷酸差异为Z'
B位置处的差异,Z'
B选自A、C或G;在一些实施方式中,Z
A是与Z'
B互补的核苷酸。这些核苷酸差异并不会显著降低第二种siRNA缀合物的靶基因抑制能力,而这些包含特定核苷酸差异的第二种siRNA缀合物也在本公开的保护范围之内。
在一些实施方式中,所述核苷酸序列1和所述核苷酸序列2基本上反向互补、实质上反向互补或完全反向互补。所述基本上反向互补是指两个核苷酸序列之间存在不多于3个的碱基错配;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配。
在一些实施方式中,所述正义链还含有核苷酸序列3,所述反义链还含有核苷酸序列4,所述核苷酸序列3和所述核苷酸序列4的长度各自独立地为1-4个核苷酸,并且所述核苷酸序列3和所述核苷酸序列4的位置相对应。在一些实施方式中,核苷酸序列4与靶mRNA相应位置的核苷酸至少部分互补,在一些实施方式中,核苷酸序列4与靶mRNA相应位置的核苷酸完全互补。
在一些实施方式中,所述核苷酸序列3连接在所述核苷酸序列1的5'末端,并且所述核苷酸序列4连接在所述核苷酸序列2的3'末端。在一些实施方式中,所述核苷酸序列3和所述核苷酸序列4长度相等并且反向互补。因此,所述正义链和反义链的长度可以是19-23个核苷酸。
一些实施方式中,所述核苷酸序列3和所述核苷酸序列4的长度均为1个核苷酸,所述核苷酸序列3的碱基为C,此时,所述双链区的长度可以是20个核苷酸,即所述正义链和反义链的长度之比可以是20/20;或者,
所述核苷酸序列3和所述核苷酸序列4的长度均为2个核苷酸,按照5'末端到3'末端的方向,核苷酸序列3的碱基依次为C和C,此时,所述双链区的长度可以是21个核苷酸,即所述正义链和反义链的长度之比可以是21/21;或者,
所述核苷酸序列3和所述核苷酸序列4的长度均为3个核苷酸,按照5'末端到3'末端的方向,所述核苷酸序列3的碱基依次为U、C和C,此时,所述双链区的长度可以是22个核苷酸,即所述正义链和反义链的长度之比可以是22/22;或者,
所述核苷酸序列3和所述核苷酸序列4的长度均为4个核苷酸,按照5'末端到3'末端的方向,所述核苷酸序列3的碱基依次为C、U、C和C,此时,所述双链区的长度可以是23个核苷酸,即所述正义链和反义链的长度之比可以是23/23。
在一些实施方式中,所述核苷酸序列3的长度为2个核苷酸,并且按照5'末端到3'末 端的方向,所述核苷酸序列3的碱基依次为C和C。
应当理解的是,所述核苷酸序列3和所述核苷酸序列4的长度相同,并且互补,因此,给出了核苷酸序列3的碱基,核苷酸序列4的碱基也就确定了。
在一些实施方式中,式(1)中Nu代表的siRNA中还含有核苷酸序列5,所述核苷酸序列5的长度为1至3个核苷酸,连接在所述反义链的3'末端,从而构成所述反义链的3'突出端。在一些实施方式中,所述核苷酸序列5的长度为1或2个核苷酸。这样,Nu代表的siRNA的正义链和反义链的长度之比可以是19/20、19/21、20/21、20/22、21/22、21/23、22/23、22/24、23/24或23/25。
在一些实施方式中,所述核苷酸序列5的长度为2个核苷酸,并且按照5'末端到3'末端的方向,所述核苷酸序列5为连续的2个胸腺嘧啶脱氧核糖核苷酸、连续的2个尿嘧啶核糖核苷酸、或者与靶mRNA互补的两个核苷酸。因此,在一些实施方式中,Nu代表的siRNA的正义链和反义链的长度之比为19/21或21/23,此时,含有该siRNA的缀合物具有更好的APOC3 mRNA沉默活性。
在一些的实施方式中,所述正义链含有如SEQ ID NO:60所示的核苷酸序列,所述反义链含有如SEQ ID NO:3所示的核苷酸序列:
5’-CAAUAAAGCUGGACAAGAZ
A-3’(SEQ ID NO:60);
5’-Z'
BUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID NO:3);
或者,所述正义链含有如SEQ ID NO:4所示的核苷酸序列,所述反义链含有如SEQ ID NO:5所示的核苷酸序列:
5’-CCCAAUAAAGCUGGACAAGAZ
A-3’(SEQ ID NO:4);
5’-Z'
BUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID NO:5);
其中,所述Z'
B是反义链5'末端的第一个核苷酸,Z
A选自A、U、G或C,并且Z'
B是与Z
A互补的核苷酸。
在一些实施方式中,Nu代表的siRNA为siAP1或siAP2:
siAP1
正义链:5’-CAAUAAAGCUGGACAAGAA-3’(SEQ ID NO:6);
反义链:5’-UUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID NO:7);
siAP2
正义链:5’-CCCAAUAAAGCUGGACAAGAA-3’(SEQ ID NO:8);
反义链:5’-UUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID NO:9)。
如前所述,式(1)中Nu代表的siRNA中的核苷酸各自独立地为修饰或未修饰的核苷酸。在一些实施方式中,Nu代表的siRNA中的核苷酸为未经修饰的核苷酸;在一些实施方式中,Nu代表的siRNA中的部分或全部核苷酸为修饰的核苷酸,核苷酸基团上的这些修饰不会导致本公开的第二种siRNA缀合物抑制APOC3基因表达的功能明显削弱或丧失。
在一些实施方式中,缀合物中的siRNA至少含有1个修饰的核苷酸。在本公开的上下文中,所使用的术语“修饰的核苷酸”是指核苷酸的核糖基2'位羟基被其他基团取代形成的核苷酸或核苷酸类似物,或者核苷酸上的碱基是经修饰的碱基的核苷酸。所述修饰的核 苷酸不会导致siRNA缀合物抑制基因表达的功能明显削弱或丧失。例如,可以选择J.K.Watts,G.F.Deleavey,and M.J.Damha,Chemically modified siRNA:tools and applications.Drug Discov Today,2008,13(19-20):842-55中公开的修饰的核苷酸。
在一些实施方式中,所述正义链或所述反义链中的至少一个核苷酸为修饰的核苷酸,和/或至少一个磷酸酯基为具有修饰基团的磷酸酯基,换句话说,所述正义链和所述反义链中至少一条单链的磷酸-糖骨架中的磷酸酯基和/或核糖基的至少一部分为具有修饰基团的磷酸酯基和/或具有修饰基团的核糖基。
在一些实施方式中,所述正义链和/或所述反义链中的全部核苷酸均为修饰的核苷酸。在一些实施方式,正义链和所述反义链中的每一个核苷酸独立地为氟代修饰的核苷酸或非氟代修饰的核苷酸。
本公开的发明人惊奇地发现,当第二种siRNA缀合物中Nu代表的siRNA是如下siRNA时,在动物实验中获得了血浆中稳定性和基因沉默效率的高度平衡:
在一些实施方式中,所述氟代修饰的核苷酸位于核苷酸序列1和核苷酸序列2中,并且,按照5'末端到3'末端的方向,所述核苷酸序列1的第7、8、9位的核苷酸为氟代修饰的核苷酸;按照5'末端到3'末端的方向,所述核苷酸序列2的第2、6、14、16位的核苷酸为氟代修饰的核苷酸。
在一些实施方式中,所述核苷酸序列1中氟代修饰的核苷酸不多于5个;在一些实施方式中,所述核苷酸序列2中氟代修饰的核苷酸不多于7个。
在一些实施方式中,按照5'末端到3'末端的方向,在所述正义链中,所述核苷酸序列1的第7、8、9位或者5、7、8、9位的核苷酸为氟代修饰的核苷酸,所述正义链中其余位置的核苷酸为非氟代修饰的核苷酸;按照5'末端到3'末端的方向,在所述反义链中,所述核苷酸序列2的第2、6、14、16位或者2、6、8、9、14、16位的核苷酸为氟代修饰的核苷酸,所述反义链中其余位置的核苷酸为非氟代修饰的核苷酸。
氟代修饰的核苷酸及非氟代修饰的核苷酸各自的定义和可选择的范围如前所述。
在一些实施方式中,按照5’末端到3’末端的方向,Nu代表的siRNA的正义链中核苷酸序列1的第5、7、8和9位的核苷酸为氟代修饰的核苷酸,siRNA的正义链的其余位置的核苷酸为甲氧基修饰的核苷酸,并且,按照5’末端到3’末端的方向,Nu代表的siRNA的反义链中核苷酸序列2的第2、6、8、9、14和16位的核苷酸为氟代修饰的核苷酸,siRNA的反义链其余位置的核苷酸为甲氧基修饰的核苷酸;
或者,按照5’末端到3’末端的方向,Nu代表的siRNA的正义链中核苷酸序列1的第7、8和9位的核苷酸为氟代修饰的核苷酸,siRNA的正义链的其余位置的核苷酸为甲氧基修饰的核苷酸,并且,按照5’末端到3’末端的方向,Nu代表的siRNA的反义链中核苷酸序列2的第2、6、14和16位的核苷酸为氟代修饰的核苷酸,siRNA的反义链其余位置的核苷酸为甲氧基修饰的核苷酸。
在一些实施方式中,所述核苷酸具有磷酸基团修饰。在一些实施方式中,磷酸基团修饰为如下式(101)所示的硫代磷酸(phosphorthioate)修饰,即,用一个硫原子取代磷酸二酯键中的非桥氧原子,从而以硫代磷酸二酯键替换磷酸二酯键。该修饰能稳定siRNA的结构,保持碱基配对的高特异性和高亲和力。
在一些实施方式中,Nu代表的siRNA中,硫代磷酸酯基连接存在于由以下位置组成的组中的至少一处:正义链或反义链任意一端的第一个和第二个核苷酸之间;正义链或反义链任意一端的第二个和第三个核苷酸之间;或上述的任意组合。在一些实施方式中,硫代磷酸酯基连接存在于除正义链5'末端以外的全部上述位置处。在一些实施方式中,硫代磷酸酯基连接存在于除正义链3'末端以外的全部上述位置处。在一些实施方式中,硫代磷酸酯基连接存在于以下位置中的至少一处:
所述正义链的5'末端端部第1个核苷酸和第2个核苷酸之间;
所述正义链的5'末端端部第2个核苷酸和第3个核苷酸之间;
所述正义链的3'末端端部第1个核苷酸和第2个核苷酸之间;
所述正义链的3'末端端部第2个核苷酸和第3个核苷酸之间;
所述反义链的5'末端端部第1个核苷酸和第2个核苷酸之间;
所述反义链的5'末端端部第2个核苷酸和第3个核苷酸之间;
所述反义链的3'末端端部第1个核苷酸和第2个核苷酸之间;以及
所述反义链的3'末端端部第2个核苷酸和第3个核苷酸之间。
在一些实施方式中,Nu代表的siRNA分子的反义链序列5'末端核苷酸为5'-磷酸核苷酸或5'-磷酸类似物修饰的核苷酸。
如本领域技术人员所熟知的,5'-磷酸核苷酸可具有以下结构:
同时,常用的所述5'-磷酸类似物修饰的核苷酸的种类是本领域技术人员公知的,例如,Anastasia Khvorova and Jonathan K.Watts,The chemical evolution of oligonucleotide therapies of clinical utility.Nature Biotechnology,2017,35(3):238-48中公开的如下4种核苷酸:
其中,R表示选自于由H、OH、F和甲氧基所组成的组的基团;
Base表示选自A、U、C、G或T的碱基。
在一些实施方式中,5'-磷酸核苷酸或5'-磷酸类似物修饰的核苷酸为式(102)所示的含有5'-磷酸修饰的核苷酸、式(103)所示的含有乙烯基磷酸酯(E-vinylphosphonate,E-VP)的核苷酸或式(105)所示的含有5'-硫代磷酸修饰的核苷酸。
本公开的发明人意外发现,本公开的第二种siRNA缀合物在具有显著提高的血浆中稳定性、低脱靶效应的同时,还表现出并未明显降低的APOC3 mRNA沉默活性,而且还具有较高的血脂抑制作用。因此,在一些实施方式中,本公开的第二种siRNA缀合物中Nu代表的siRNA可以为siAP1、siAP2、siAP1-M1、siAP2-M1、siAP1-M2、siAP2-M2、siAP1-M1S、siAP2-M1S、siAP1-M2S、siAP2-M2S、siAP1-M1P1、siAP2-M1P1、siAP1-M2P1、siAP2-M2P1、siAP1-M1SP1、siAP2-M1SP1、siAP1-M2SP1、siAP2-M2SP1中的一种,如表1示出。
表1 本公开缀合物中的siRNA序列
本公开所述siRNA或siRNA缀合物中,每个相邻核苷酸之间由磷酸二酯键或硫代磷酸二酯键连接,磷酸二酯键或硫代磷酸二酯键中的非桥接氧原子或硫原子带有负电荷,它可以以羟基或巯基的形式存在,羟基或巯基中的氢离子也可以部分或全部被阳离子取代。所述阳离子可以是任意的阳离子,如金属阳离子,铵离子NH
4
+,有机铵阳离子中的一种。出于提高溶解性考虑,在一种实施方式中,所述阳离子选自碱金属离子、三级胺形成的铵阳离子和季铵阳离子中的一种或多种。碱金属离子可以是K
+和/或Na
+,三级胺形成的阳离子可以是三乙胺形成的铵离子和/或N,N-二异丙基乙胺形成的铵离子。因此,本公开所述siRNA或第一种或第二种siRNA缀合物可以至少部分以盐的形式存在。在一种方式中,磷酸二酯键或硫代磷酸二酯键中的非桥接氧原子或硫原子至少部分与钠离子结合,本公开所述siRNA或第一种或第二种siRNA缀合物以钠盐或部分钠盐的形式存在。
本领域技术人员清楚知晓的是,可以通过使用具有相应修饰的核苷单体来将修饰的核苷酸基团引入所述的siRNA中。制备具有相应修饰的核苷单体的方法及将修饰的核苷酸基团引入siRNA的方法也是本领域技术人员所熟知的。所有修饰的核苷单体均可以商购得到或者采用已知方法制备得到。
第二种siRNA缀合物的制备
可以采用任意合理的合成路线制备第二种siRNA缀合物。
在一些实施方式中,第二种siRNA缀合物可以采用如下方法制备,该方法包括在亚磷酰胺固相合成的条件下,分别按照siRNA正义链和反义链的核苷酸种类和顺序,按照3'到5'的方向将核苷单体依次连接,每个核苷单体的连接包括脱保护、偶联、盖帽、氧化或硫化四步反应;分离出siRNA的正义链和反义链,退火,其中,Nu代表的siRNA中的每个核苷酸各自独立地为修饰或未修饰的核苷酸,Nu代表的siRNA含有正义链和反义链,所述正义链包含核苷酸序列1,所述反义链包含核苷酸序列2,所述核苷酸序列1和所述核苷酸序列2至少部分地反向互补形成双链区,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:
5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1),
5'-Z'UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2);
其中,Z为A,Z'为U,
所述核苷酸序列1中包含位置对应于Z的核苷酸Z
A,所述核苷酸序列2中包含位置对应于Z'的核苷酸Z'
B,所述Z'
B是所述反义链5'末端的第一个核苷酸;
并且,该方法还包括在偶联反应条件和偶联试剂存在下,将式(321)所示的化合物与核苷单体或连接在固相载体上的核苷酸序列接触,从而使式(321)所示的化合物经偶联反应连接至核苷酸序列。下文中,式(321)所示的化合物也称作缀合分子。
其中:
R
4为能够结合至Nu代表的siRNA的部分。在一些实施方式中,R
4为能够通过共价键结合至Nu代表的siRNA的部分。在一些实施方式中,R
4为能够经反应而通过磷酸二酯键缀合至Nu代表的siRNA的任意官能团的部分;
每个S
1独立地是M
1中全部活性羟基被YCOO-基团取代而形成的基团,其中,每个Y独立地选自甲基、三氟甲基、二氟甲基、一氟甲基、三氯甲基、二氯甲基、一氯甲基、乙基、正丙基、异丙基、苯基、卤代苯基以及烷基苯基中的一种;在一些实施方式中,Y为甲基。
n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15、L
1、M
1各自的定义和可选择的范围如前所述。
R
4的选择是为了实现与含氮骨架上的N的连接,并且为合成第二种siRNA缀合物提供合适的反应位点。在一些实施方式中,R
4中包括R
2连接基团或经保护的R
2连接基团,以及可通过反应与siRNA形成A59所示结构的官能团。
在一些实施方式中,R
4包含可与Nu代表的siRNA或核苷单体上的基团形成亚磷酸酯的第1官能团以及可与羟基或氨基反应形成共价键的第2官能团或者含有由所述共价键连接的固相载体。在一些实施方式中,所述第1官能团为亚磷酰胺、羟基或被保护的羟基。在一些实施方式中,所述第2官能团为亚磷酰胺、羧酸或羧酸盐。在一些实施方式中,所述第2官能团为经由共价键连接至分子其他部分的固相载体,所述共价键由羟基或氨基形成。在一些实施方式中,所述固相载体经由磷酸酯键、羧酸酯键或酰胺键连接。在一些实施方式中,所述固相载体为树脂。
在一些实施方式中,所述第1官能团含有羟基、-OR
k或式(C3)所示的基团;所述第2官能团含有式(C1)、(C2)、(C3)、(C1’)或(C3’)所示的结构:
在一些实施方式中,所述第1官能团含有亚磷酰胺基团,如式(C3)所示,该亚磷酰胺基团可以与核苷酸上的任意位置的羟基,如2'位羟基或3'位羟基发生偶联反应形成亚磷酸酯,并经氧化或硫化形成式A59所示的磷酸二酯键或硫代磷酸酯键,将缀合分子缀合至siRNA。此时,即使所述第2官能团并不存在,式(321)化合物也能够缀合至核苷酸,不影响第二种siRNA缀合物的获得。在此情况下,在经由亚磷酰胺固相合成等方法获得siRNA的正义链或反义链后,使式(321)化合物与核苷酸序列中末端核苷酸上的羟基反应,并在后续的氧化或硫化过程中形成磷酸二酯键连接或硫代磷酸酯连接,将式(321)化合物缀合至siRNA。
在一些实施方式中,所述第1官能团含有被保护的羟基。在一些实施方式中,所述第2官能团包含可与固相载体反应的基团,所述反应提供包含固相载体的缀合分子。在一些实施方式中,所述第2官能团含有羧基、羧酸盐或亚磷酰胺,如式(C1)、(C2)或(C3)所示,当所述第2官能团包含羧基或羧酸盐时,式(321)化合物与固相载体,例如树脂上的羟基或氨基进行酯化反应或酰胺化反应,形成经羧酸酯键连接的包含固相载体的缀合分子。当所述第2官能团包含亚磷酰胺官能团时,式(321)化合物与通用固相载体,例如树脂上的羟基发生偶联反应,并经氧化形成经磷酸二酯键连接的包含固相载体的缀合分子。随后,以上述连接固相载体后的产物作为起始,按照亚磷酰胺固相合成方法依次连接核苷单体,获得连接有缀合基团的siRNA的正义链或反义链。在亚磷酰胺固相合成过程中,所述第1官能团发生脱保护,随后在偶联反应条件下与核苷单体上的亚磷酰胺基团发生偶联。
在一些实施方式中,所述第1官能团含有羟基或被保护的羟基;所述第2官能团含有经羧酸酯键连接的固相载体或经酰胺键连接的固相载体、或者经磷酸酯键连接的固相载体,如式(C1’)或(C3’)所示。此时,由式(321)化合物代替固相载体作为起始,按照亚磷酰胺固相合成方法依次连接核苷单体,获得连接有缀合基团的siRNA的正义链或反义链。
在一些实施方式中,羧酸盐可以表示为—COO
-M
+,其中,M
+是阳离子,例如选自金属阳离子,铵阳离子NH
4
+,有机铵阳离子中的一种。在一种实施方式中,所述金属离子选自碱金属离子中的一种,如K
+或Na
+。出于提高溶解性、使反应顺利进行的考虑,在一些实施方式中,有机铵离子为三级胺形成的铵阳离子或季铵阳离子,如,三乙胺形成的铵离子或N,N-二异丙基乙胺形成的铵离子。在一些实施方式中,羧酸盐是三乙胺羧酸盐或N,N-二异丙基乙胺羧酸盐。
在一些实施方式中,R
4含有式(B9)、(B10)、(B9’)、(B10’)、(B11)、(B12)、(B11’)或(B12’)所示的结构:
其中,q
1为1-4的整数,q
2为1-10的整数,X为O或NH,M
+为阳离子,R
k为羟基保护基团,SPS表示固相载体,
表示基团连接至分子其余部分的位点。在一些实施方式中,q
1为1或2。在一些实施方式中,q
2为1-5的整数。在一些实施方式中,R
4含有式(B9)或(B10)所示的结构。在一些实施方式中,R
4含有式(B11)或(B12)所示的结构。
在一些实施方式中,R
k是Tr(三苯甲基)、MMTr(4-甲氧基三苯甲基)、DMTr(4,4’-双甲氧基三苯甲基)、TMTr(4,4’,4’-三甲氧基苯甲基)中的一种或多种。在一些实施方式中,R
k可以是DMTr,即4,4’-双甲氧基三苯甲基(4,4’-dimethoxytrityl)。
L
1的定义如前所述。
在一些实施方式中,L
1被用于将M
1靶向基团连接至含氮骨架上的N原子,从而为第二种siRNA缀合物提供肝靶向功能。在一些实施方式中,L
1包含A1-A26中的任一个或其组合。
根据上述描述,本领域技术人员容易理解的是,相较于本领域公知的亚磷酰胺固相合成方法而言,可通过上述第1官能团以及任选的第2官能团,获得将缀合分子连接至核苷酸序列的任意可能的位置的第二种siRNA缀合物,例如,缀合分子连接至核苷酸序列的端部,缀合分子连接至核苷酸序列的末端。相应地,除非另有说明,以下涉及缀合制备的描述中,当提及“脱保护”、“偶联”、“盖帽”、“氧化”、“硫化”等反应时,应当理解为本领域公知的亚磷酰胺核酸固相合成方法中所涉及的反应条件和试剂也同样适用于这些反应。示例性的反应条件和试剂将在后文详细描述。
在一些实施方式中,每个S
1独立地是M
1。在一些实施方式中,每个S
1独立地是M
1中至少一个活性羟基被羟基保护基团保护而形成的基团。在一些实施方式中,每个S
1独立地是M
1中任何存在的活性羟基全部被羟基保护基团保护而形成的基团。在一些实施方式中,任何本领域技术人员已知的羟基保护基团均可被用于保护M
1中的活性羟基。在一些实施方式中,被保护的羟基可以式YCOO-表示,其中,每个Y独立地选自于由C
1-C
10烷基和C
6-C
10芳基所组成的组,所述C
1-C
10烷基和C
6-C
10芳基任选地被一个或多个取代基取代,所述取代基选自于由卤素和C
1-C6烷基所组成的组。在一些实施方式中,每个Y独立地选自于由以下基团所组成的组:甲基、三氟甲基、二氟甲基、单氟甲基、三氯甲基、二氯甲基、一氯甲基、乙基、正丙基、异丙基、苯基、卤苯基,以及C
1-C
6烷基苯基。
在一些实施方式中,每个S
1各自独立地选自于由式A46-A54所组成的组:
在一些实施方式中,S
1为式A49或A50。
在一些实施方式中,每个Y独立地选自甲基、三氟甲基、二氟甲基、一氟甲基、三氯甲基、二氯甲基、一氯甲基、乙基、正丙基、异丙基、苯基、卤代苯基以及烷基苯基中的一种;在一些实施方式中,Y为甲基。
如前所述,第二种siRNA缀合物的制备方法还包括以下步骤:合成siRNA的另一链(例如,当上述步骤合成了连接有缀合基团的siRNA正义链时,还包括按照固相合成方法合成siRNA的反义链,反之亦然),分离正义链和反义链,以及退火。具体地,在分离步骤中,连接至核苷酸序列和/或缀合分子的固相载体被切割下来,同时必要的保护基团被脱除(此时,式(321)化合物中的各S
1基团转化为对应的M
1靶向基团),获得连接有缀合基团的siRNA正义链(或反义链)以及对应的反义链(或正义链),正义链与反义链退火形成双链RNA结构,获得第二种siRNA缀合物。
在一些实施方式中,第二种siRNA缀合物的制备方法包含以下步骤:在偶联反应条件和偶联试剂存在下,将式(321)所示的化合物与正义链或反义链的3'端的第一个核苷单体接触,使式(321)所示的化合物连接上序列中第一个核苷酸,在亚磷酰胺固相合成的条件下,按照期望的正义链或反义链核苷酸种类和顺序,按照3'到5'的方向将核苷单体依次连接,合成siRNA的正义链或反义链;其中,(321)化合物为R
4中含有第1官能团和第2官能团,第1官能团含有被保护的羟基,第2官能团具有如式(C1’)或(C3’)所示结构的式(321)所示的化合物,与第一个核苷单体连接前,式(321)化合物经过脱保护;每个核苷单体的连接包括脱保护、偶联、盖帽、氧化或硫化四步反应;得到连接有缀合基团的核酸的正义链或反义链;在亚磷酰胺固相合成的条件下,按照反义链或正义链核苷酸种类和顺序,按照3'到5'的方向将核苷单体依次连接,合成核酸的反义链或正义链;每个核苷单体的连接包括脱保护、偶联、盖帽、氧化或硫化四步反应;脱除保护基并与固相载体切割,分离纯化获得核酸的正义链和反义链,退火。
在一些实施方式中,第二种siRNA缀合物的制备方法包含以下步骤:按照该双链 siRNA中正义链或反义链的核苷酸种类和顺序,按照3'到5'的方向将核苷单体依次连接,合成正义链和反义链,每个核苷单体的连接包括脱保护、偶联、盖帽、氧化或硫化四步反应,得到连接在固相载体上的正义链和连接在固相载体上的反义链;在偶联反应条件和偶联试剂存在下,将式(321)所示的化合物与连接在固相载体上的正义链或连接在固相载体上的反义链接触,将式(321)化合物连接至正义链或反义链,其中,式(321)化合物是R
4中含有第1官能团,第1官能团为亚磷酰胺基团的式(321)化合物;脱除保护基并与固相载体切割,分别分离纯化,获得siRNA的正义链或反义链,退火,其中,Nu代表的siRNA的正义链或反义链上连接有缀合基团。
在一些实施方式中,式A59中的P连接至siRNA中的正义链的3'末端,第二种siRNA缀合物的制备方法包括:
(1)脱除式(321)化合物(其中,式(321)化合物为R
4中含有第1官能团和第2官能团,第1官能团含有被保护的羟基OR
k,第2官能团具有如式(C1’)或(C3’)所示结构的化合物)中的羟基保护基团R
k;在偶联反应条件和偶联试剂存在下,将脱保护得到的产物与核苷单体接触,得到通过缀合分子连接至固相载体的核苷单体;
(2)以该通过缀合分子连接至固相载体的核苷单体起始,按照3'-5'的方向通过亚磷酰胺固相合成方法合成siRNA的正义链;
(3)通过亚磷酰胺固相合成方法,合成siRNA的反义链;
(4)分离出siRNA的正义链和反义链并退火,获得第二种siRNA缀合物。
其中,在步骤(1)中,脱除式(321)化合物中的保护基团R
k的方法包括在脱保护条件下,将式(321)化合物与脱保护试剂接触。脱保护条件包括温度为0-50℃,在一些实施方式中为15-35℃,反应时间为30-300秒,在一些实施方式中为50-150秒,脱保护试剂可以选自三氟乙酸、三氯乙酸、二氯乙酸、一氯乙酸中的一种或多种,在一些实施方式中为二氯乙酸。脱保护试剂与式(321)化合物的摩尔比为10:1-1000:1,在一些实施方式中为50:1-500:1。
所述偶联反应条件和偶联试剂可使用任何适合于上述偶联反应的条件和试剂。在一些实施方式中,可使用与所采用的固相合成方法中的偶联反应相同的条件与试剂。
在一些实施方式中,所述偶联反应的条件包括反应温度为0-50℃,在一些实施方式中为15-35℃。式(321)化合物与核苷单体的摩尔比为1:1-1:50,在一些实施方式中为1:2-1:5;式(321)化合物和偶联试剂的摩尔比可以为1:1-1:50,在一些实施方式中为1:3-1:10,反应时间为200-3000秒,在一些实施方式中为500-1500秒。偶联试剂选自1H-四氮唑、5-乙硫基1H-四氮唑、5-苄硫基1H-四氮唑中的一种或多种,在一些实施方式中为5-乙硫基1H-四氮唑。所述偶联反应可在有机溶剂中进行,所述有机溶剂选自无水乙腈、无水DMF、无水二氯甲烷中的一种或多种,在一些实施方式中为无水乙腈。相对于式(321)化合物,所述有机溶剂的用量为3-50L/mol,在一些实施方式中为5-20L/mol。
在步骤(2)中,通过亚磷酰胺核酸固相合成的方法,利用上述步骤制备的通过缀合分子连接至固相载体的核苷单体起始,按照3'-5'的方向合成第二种siRNA缀合物的正义链S。此时,缀合基团连接至所得到的正义链的3'末端。
步骤(2)和(3)中所述固相合成的其它条件,包括核苷单体脱保护条件,脱保护试 剂种类和用量,偶联反应条件,偶联试剂的种类和用量,盖帽反应的条件,盖帽试剂的种类和用量,氧化反应条件,氧化试剂种类和用量,硫化反应条件,硫化试剂和用量采用本领域中常规使用的各种试剂、用量和条件。
例如,在一些实施方式中,步骤(2)和(3)中所述固相合成可使用如下条件:
核苷单体脱保护条件包括温度为0-50℃,在一些实施方式中为15-35℃,反应时间为30-300秒,在一些实施方式中为50-150秒,脱保护试剂可以选自三氟乙酸、三氯乙酸、二氯乙酸、一氯乙酸、中的一种或多种,在一些实施方式中为二氯乙酸。脱保护试剂与固相载体上4,4'-二甲氧基三苯甲基保护基的的摩尔比可以为2:1-100:1,在一些实施方式中为3:1-50:1。
偶联反应条件包括温度为0-50℃,在一些实施方式中为15-35℃,固相载体上连接的核酸序列与核苷单体的摩尔比可以为1:1-1:50,在一些实施方式中为1:5-1:15;固相载体上连接的核酸序列和偶联试剂的摩尔比为1:1-1:100,在一些实施方式中为1:50-1:80,反应时间和偶联试剂的选择与前述相同。
盖帽反应条件包括温度为0-50℃,在一些实施方式中为15-35℃,反应时间为5-500秒,在一些实施方式中为10-100秒,盖帽试剂的选择与前述相同。盖帽试剂的总量与固相载体上连接的核酸序列的摩尔比为1:100-100:1,在一些实施方式中为1:10-10:1。在盖帽试剂使用等摩尔量的乙酸酐与N-甲基咪唑的情况下,乙酸酐、N-甲基咪唑以及固相载体上连接的核酸序列的摩尔比为1:1:10-10:10:1,在一些实施方式中为1:1:2-2:2:1。
氧化反应条件包括温度为0-50℃,在一些实施方式中为15-35℃,反应时间为1-100秒,在一些实施方式中为5-50秒,氧化试剂在一些实施方式中为碘(在一些实施方式中,以碘水的形式提供)。氧化试剂与偶联步骤中固相载体上连接的核酸序列的摩尔比可以为1:1-100:1,在一些实施方式中为5:1-50:1。在一些实施方式中,所述氧化反应在四氢呋喃:水:吡啶=3:1:1-1:1:3的混合溶剂中进行。硫化反应条件包括温度为0-50℃,在一些实施方式中为15-35℃,反应时间为50-2000秒,在一些实施方式中为100-1000秒,硫化试剂在一些实施方式中为氢化黄原素。硫化试剂与偶联步骤中固相载体上连接的核酸序列的摩尔比为10:1-1000:1,在一些实施方式中为10:1-500:1。在一些实施方式中,所述硫化反应在乙腈:吡啶=1:3-3:1的混合溶剂中进行。
在将所有核苷单体连接之后,退火之前,该方法还包括分离出siRNA的正义链和反义链。分离的方法为本领域技术人员所公知,一般包括将合成得到的核苷酸序列从固相载体上切割下来,脱除碱基上、磷酸基上和配体上的保护基团,纯化和脱盐。
将合成得到的核苷酸序列从固相载体上切割下来,并脱除碱基上、磷酸基上和配体上的保护基团可按照siRNA合成中常规的切割和脱保护方法进行。例如,将得到的连接有固相载体的核苷酸序列与浓氨水接触;在脱保护的过程中,A46-A54基团的保护基团YCOO-转化为羟基,S
1基团转化为相应的M
1基团,生成式(1)所示的缀合物。其中,所述浓氨水可以是25-30重量%的氨水,浓氨水的用量与目标siRNA序列相比可以为0.2ml/μmol-0.8ml/μmol。
在所合成的核苷酸序列上存在至少一个2'-TBDMS保护时,所述方法还包括将脱除了固相载体的核苷酸序列与三乙胺三氢氟酸盐接触,以脱除该2'-TBDMS保护。此时,所得 到的目标siRNA序列中具有游离的2'-羟基的相应核苷。三乙胺三氢氟酸盐纯品的用量与目标siRNA序列相比可以为0.4ml/μmol-1.0ml/μmol。这样即可得到第二种siRNA缀合物。
纯化和脱盐的方法是本领域技术人员熟知的。例如,可利用制备型离子色谱纯化柱,通过NaBr或NaCl的梯度洗脱,完成核酸的纯化;产品收集合并后,可采用反相色谱纯化柱进行脱盐。
这样得到的第二种siRNA缀合物中,核苷酸之间的磷酸二酯键或硫代磷酸二酯键中的非桥接氧原子或硫原子基本与钠离子结合,第二种siRNA缀合物基本以钠盐形式存在。可以采用熟知的离子交换方法,用氢离子和/或其他阳离子取代所述钠离子,得到其他形式的第二种siRNA缀合物。所述阳离子如前所述。
在合成过程中,可随时对核酸序列的纯度和分子量进行检测,更好地把控合成质量,此类检测的方法为本领域技术人员所公知。例如,可通过离子交换色谱检测核酸纯度,并通过液质联用色谱测定分子量。
退火的方法也是本领域技术人员熟知的。例如,可简单地将所合成的正义链(S链)与反义链(AS链)以等摩尔比混合在注射用水中加热至70-95℃,随后室温冷却,使其通过氢键形成双链结构。这样即可得到第二种siRNA缀合物。
在获得所述缀合物后,在一些实施方式中,还可利用例如液质联用色谱等方法,通过分子量检测等方式对所合成的第二种siRNA缀合物进行表征,确定所合成的siRNA缀合物为目标设计的第二种siRNA缀合物,且所合成的siRNA的序列为期望的siRNA的序列,例如为表1中所列的序列之一。
式(321)所示化合物可以通过以下制备方法得到:该方法包括在有机溶剂中,在酯化反应条件下,以及在碱和成酯催化剂存在下,将式(313)所示化合物与环状酸酐接触,离子交换,分离得到式(321)所示化合物:
其中,n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15、L
1、S
1各自的定义和可选择的范围如前所述;
R
6为提供式(321)中R
4的基团。在一些实施方式中,R
6具有式(A61)所示的结构:
其中,R
i为能够实现与含氮骨架上的N连接、与R
kO连接并且连接有一个游离羟基的 任意基团,R
k为羟基保护基团。此时,所获得的是R
4中含有作为羟基保护基团的第1官能团和第2官能团,所述第2官能团含有如式(C1)或(C2)所示结构的式(321)化合物。
所述酯化反应条件包括反应温度为0-100℃,反应时间为8-48小时,在一些实施方式中,所述酯化反应条件为反应温度为10-40℃,反应时间为20-30小时。
在一些实施方式中,所述有机溶剂包含环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。在一些实施方式中,所述环氧类溶剂为二氧六环和/或四氢呋喃,所述醚类溶剂为乙醚和/或甲基叔丁基醚,所述卤代烷类溶剂为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种。在一些实施方式中,所述有机溶剂为二氯甲烷。相对于所述式(313)所示化合物,所述有机溶剂的用量为3-50L/mol,在一些实施方式中为5-20L/mol。
在一些实施方式中,所述环状酸酐为丁二酸酐、戊二酸酐、己二酸酐或庚二酸酐中的一种,在一些实施方式中为丁二酸酐。所述环状酸酐与所述式(313)所示化合物的摩尔比为1:1-10:1,在一些实施方式中为2:1-5:1。
所述成酯催化剂可以是任何对该酯化反应起到催化作用的催化剂,例如该催化剂可以是4-二甲氨基吡啶。所述催化剂与式(313)所示化合物的摩尔比为1:1-10:1,在一些实施方式中为2:1-5:1。
在一些实施方式中,所述碱可以是任意的无机碱,有机碱或者它们的结合。考虑溶解性和产物稳定性,所述碱可以是例如三级胺类有机碱。在一些实施方式中,所述三级胺类有机碱为三乙胺或N,N-二异丙基乙胺。所述三级胺类有机碱与式(313)所示化合物的摩尔比为1:1-20:1,在一些实施方式中为3:1-10:1。
所述离子交换作用是将式(321)化合物转化为期望的羧酸或羧酸盐的形式,离子交换的方法为本领域技术人员所公知,可以使用合适的离子交换溶液和交换条件,得到前述阳离子为M
+的缀合分子,在此不做详述。在一些实施方式中,所述离子交换反应使用三乙胺磷酸盐溶液进行,所述三乙胺磷酸盐溶液的浓度为0.2-0.8M,在一些实施方式中,所述三乙胺磷酸盐溶液的浓度为0.4-0.6M,相对于式(313)化合物,所述三乙胺磷酸盐溶液的用量为3-6L/mol,在进一步的实施方式中为4-5L/mol。
可使用任何合适的分离方法从反应混合物中分离式(321)化合物。在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(321)化合物,例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用含1重量‰三乙胺的二氯甲烷:甲醇=100:18-100:20梯度洗脱;或者(2)反相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(321)化合物粗产品,该粗产品可以直接用于后续反应。
在一些实施方式中,式(321)化合物的制备方法还进一步包括在缩合反应条件下,在有机溶剂中,在缩合剂和三级胺类有机碱的存在下,将上述离子交换反应得到的产物进一步与含有氨基或羟基的固相载体进行接触。此时,所获得的是R
4中含有第1官能团和第2官能团,第1官能团含有羟基保护基团,第2官能团含有如式(C1’)所示结构的式 (321)化合物。
所述固相载体为固相合成siRNA中所用的载体中的一种,其中的一些为本领域技术人员所公知。例如,所述固相载体可以选自含有活性羟基或氨基官能团的固相载体,在一些实施方式中,所述固相载体为氨基树脂或羟基树脂。在一些实施方式中,所述氨基或羟基树脂具有如下参数:粒径100-400目(mesh),表面氨基或羟基载量为0.2-0.5mmol/g。所述式(321)所示化合物与固相载体的用量比为10-400μmol化合物/每克固相载体(μmol/g)。在一些实施方式中,所述式(321)所示化合物与固相载体的用量比为50-200μmol/g。
所述有机溶剂可以是本领域技术人员已知的任何合适的溶剂或混合溶剂。在一些实施方式中,所述有机溶剂为乙腈、环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。在一些实施方式中,所述环氧类溶剂为二氧六环和/或四氢呋喃,所述醚类溶剂为乙醚和/或甲基叔丁基醚,所述卤代烷类溶剂为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种。在一些实施方式中,所述有机溶剂为乙腈。相对于式(321)化合物,所述有机溶剂的用量为20-200L/mol,在一些实施方式中为50-100L/mol。
在一些实施方式中,所述缩合剂可以是六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷、3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮和/或O-苯并三氮唑-四甲基脲六氟磷酸酯,在一些实施方式中,所述缩合剂为O-苯并三氮唑-四甲基脲六氟磷酸酯。所述缩合剂与式(321)所示化合物的摩尔比为1:1-20:1,在进一步的实施方式中为1:1-5:1。
在一些实施方式中,所述三级胺类有机碱为三乙胺和/或N,N-二异丙基乙胺,在一些实施方式中为N,N-二异丙基乙胺;所述三级胺类有机碱与式(321)所示化合物的摩尔比为1:1-20:1,在一些实施方式中为1:1-5:1。
在一些实施方式中,式(321)化合物的制备方法还可以包括将得到的缩合产物在盖帽反应条件下,在有机溶剂中,与盖帽试剂和酰化催化剂接触,分离得到式(321)所示化合物。所述盖帽反应的作用在于除去任何尚未反应完全的活性反应官能团,以避免在后续反应中产生不必要的副产物。所述盖帽反应的条件包括反应温度为0-50℃,在一些实施方式中为15-35℃,反应的时间为1-10h,在一些实施方式中为3-6h。盖帽试剂可以使用siRNA固相合成中所使用的盖帽试剂,siRNA固相合成中所使用的盖帽试剂为本领域技术人员所公知。
在一些实施方式中,所述盖帽试剂由盖帽试剂1(cap1)和盖帽试剂2(cap2)组成,其中,盖帽试剂1为N-基甲基咪唑,在一些实施方式中以N-甲基咪唑的吡啶/乙腈混合溶液形式提供,其中,吡啶与乙腈的体积比为1:10-1:1,在一些实施方式中为1:3-1:1,吡啶与乙腈的总体积与N-甲基咪唑的体积为1:1-10:1,在一些实施方式中为3:1-7:1。所述盖帽试剂2为乙酸酐。在一些实施方式中,所述盖帽试剂2以乙酸酐的乙腈溶液形式提供,其中,乙酸酐和乙腈的体积为1:1-1:10,在进一步的实施方式中为1:2-1:6。
在一些实施方式中,所述N-甲基咪唑的吡啶/乙腈混合溶液的体积与式(321)化合物的质量之比为5ml/g-50ml/g,在一些实施方式中为15ml/g-30ml/g。所述乙酸酐的乙腈溶液的体积与式(321)化合物的质量之比为0.5ml/g-10ml/g,在一些实施方式中为 1ml/g-5ml/g。
在一些实施方式中,盖帽试剂使用等摩尔量的乙酸酐与N-甲基咪唑。在一些实施方式中,所述有机溶剂为乙腈、环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。在一些实施方式中,所述有机溶剂为乙腈。相对于式(321)化合物,所述有机溶剂的用量为10-50L/mol,在一些实施方式中为5-30L/mol。
在一些实施方式中,所述酰化催化剂可以选自任何可用于成酯缩合或成酰胺缩合的催化剂,例如碱性杂环化合物。在一些实施方式中,所述酰化催化剂为4-二甲氨基吡啶。所述催化剂与式(321)所示化合物的质量之比为0.001:1-1:1,在一些实施方式中为0.01:1-0.1:1。
在一些实施方式中,可使用任何合适的分离方法从反应混合物中分离式(321)化合物。在一些实施方式中,可通过以有机溶剂充分洗涤,并过滤,去除未反应的反应物、过量的盖帽试剂及其它杂质,得到式(321)化合物,所述有机溶剂选自乙腈、二氯甲烷、甲醇,在一些实施方式中为乙腈。
在一些实施方式中,式(321)所示缀合分子的制备方法包括在有机溶剂中,在偶联反应条件下,以及在偶联试剂存在下,将式(313)所示化合物与亚磷酰二胺接触,分离得到式(321)所示化合物。此时,所获得的是R
4中含有第1官能团和第2官能团,第1官能团含有羟基保护基团,第2官能团含有如式(C3)所示结构的式(321)化合物。
在一些实施方式中,偶联反应条件包括温度可以为0-50℃,例如为15-35℃,式(313)化合物与亚磷酰二胺的摩尔比可以为1:1-1:50,例如为1:5-1:15;式(313)化合物和偶联试剂的摩尔比可以为1:1-1:100,例如为1:50-1:80;反应时间可以为200-3000秒,例如为500-1500秒。所述亚磷酰二胺例如可使用双(二异丙基氨基)(2-氰基乙氧基)膦,其可商购获得或按照本领域中公知的方法合成获得。偶联试剂选自1H-四氮唑、5-乙硫基1H-四氮唑、5-苄硫基1H-四氮唑中的一种或多种,例如为5-乙硫基1H-四氮唑。所述偶联反应可在有机溶剂中进行,所述有机溶剂选自无水乙腈、无水DMF、无水二氯甲烷中的一种或多种,例如为无水乙腈。在一些实施方式中,相对于式(313)化合物,所述有机溶剂的用量为3-50L/mol,例如可以为5-20L/mol。通过进行该偶联反应,式(313)化合物中的羟基与亚磷酰二胺反应形成亚磷酰胺基团。在一些实施方式中,可以直接除去溶剂得到式(321)化合物粗产品,该粗产品可以直接用于后续反应。
在一些实施方式中,式(321)化合物的制备方法还进一步包括以下步骤:在偶联反应条件下,在有机溶剂中,以及在偶联试剂存在下,将分离得到的产物进一步与含有羟基的固相载体进行接触。随后,经盖帽反应、氧化反应,分离得到式(321)化合物。此时,所获得的是R
4中含有第1官能团和第2官能团,第1官能团含有羟基保护基团,第2官能团具有如式(C3’)所示结构的式(321)化合物。
在一些实施方式中,所述固相载体为本领域中公知的可用于核酸固相合成的固相载体,例如,可以是经脱保护反应后的市售的通用固相载体(
UnyLinker
TM 300 Oligonucleotide Synthesis Support,Kinovate Life Sciences公司,结构如式B80所示):
脱保护反应为本领域技术人员所公知。在一些实施方式中,脱保护条件包括温度为0-50℃,例如为15-35℃;反应时间为30-300秒,例如为50-150秒。脱保护试剂可以选自三氟乙酸、三氯乙酸、二氯乙酸、一氯乙酸中的一种或多种,在一些实施方式中,脱保护试剂为二氯乙酸。脱保护试剂与固定相上的-DMTr(4,4'-二甲氧基三苯甲基)保护基的摩尔比为2:1-100:1,例如为3:1-50:1。通过进行所述脱保护,在所述固相载体表面上获得具有反应活性的游离羟基,便于进行下一步的偶联反应。
偶联反应条件以及偶联试剂的选择可如上所述。通过进行该偶联反应,脱保护反应中形成的游离羟基与亚磷酰胺基团反应形成亚磷酸酯连接。
在一些实施方式中,盖帽反应条件包括温度为0-50℃,例如为15-35℃,反应时间为5-500秒,例如为10-100秒,所述盖帽反应在盖帽试剂存在下进行。盖帽试剂的选择和用量可如上所述。
氧化反应条件包括温度为0-50℃,例如可以为15-35℃,反应时间为1-100秒,例如可以为5-50秒,氧化试剂例如可以为碘(在一些实施方式中,以碘水的形式提供)。在一些实施方式中,氧化试剂与亚磷酸酯基团的摩尔比为1:1-100:1,例如可以为5:1-50:1。在一些实施方式中,所述氧化反应在四氢呋喃:水:吡啶=3:1:1-1:1:3的混合溶剂中进行。
在一些实施方式中,R
6为式B7或B8基团中的一种,
其中q
2的定义如前所述,
此时,式(313)所示化合物可以通过以下制备方法得到:在有机溶剂中,在成酰胺反应条件下,以及在成酰胺反应缩合剂和三级胺类有机碱存在下,将式(314)所示化合物与式(A-1)所示化合物或式(A-2)化合物接触,随后进行分离:
其中,n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15、L
1、S
1、q
2和R
k各自的定义和可选择的范围如前所述。
所述成酰胺反应条件可包括反应温度为0-100℃,反应时间为1-48小时,在一些实施方式中,所述成酰胺反应条件为反应温度为10-40℃,反应时间为2-16小时。
在一些实施方式中,所述有机溶剂为醇类溶剂、环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。所述醇类溶剂在一些实施方式中为甲醇、乙醇、丙醇中的一种或多种,在一些实施方式中为乙醇。所述环氧类溶剂在一些实施方式中为为二氧六环和/或四氢呋喃。所述醚类溶剂在一些实施方式中为为乙醚和/或甲基叔丁基醚。所述卤代烷类溶剂在一些实施方式中为为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种。在一些实施方式中,所述有机溶剂为二氯甲烷。相对于式(314)化合物,有机溶剂用量为3-50L/mol,在进一步的实施方式中为3-20L/mol。
在一些实施方式中,所述成酰胺反应缩合剂为六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷、3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮、4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐、2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉(EEDQ)或O-苯并三氮唑-四甲基脲六氟磷酸酯,在进一步的实施方式中为3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮。所述成酰胺反应缩合剂与式(314)所示化合物的摩尔比可以为1:1-10:1,在一些实施方式中为2.5:1-5:1。
在一些实施方式中,所述三级胺类有机碱为三乙胺或N,N-二异丙基乙胺,在进一步的实施方式中为N,N-二异丙基乙胺。所述三级胺类有机碱与式(314)所示化合物的摩尔比为3:1-20:1,在一些实施方式中为5:1-10:1。
在一些实施方式中,式(A-1)和式(A-2)化合物可通过任何适当的方式制备。例如,当R
k为DMTr基团时,可通过甘油酸钙与DMTrCl反应制备式(A-1)化合物;类似地,可先将3-氨基-1,2-丙二醇与环状酸酐接触,随后再与DMTrCl反应制备式(A-2)化合物,所述环状酸酐可以是碳原子数为4-13、在一些实施方式中为4-8的环状酸酐。本领域技术人员容易理解的是,所述环状酸酐的选择对应于(A-2)化合物中q
2的不同值,例如,当所述环状酸酐为丁二酸酐时,q
2=1,当所述环状酸酐为戊二酸酐时,q
2=2,以此类推。
在一些变型中,也可通过使式(314)所示化合物依次与所述环状酸酐、3-氨基-1,2-丙二醇和DMTrCl反应,制备式(313)化合物。本领域技术人员容易理解的是,这些变型不会影响式(313)化合物的结构与功能,并且这些变型是本领域技术人员在上述方法的基础上容易实现的。
与上述类似地,可使用任何合适的分离方法从反应混合物中分离式(313)化合物。在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(313)化合物,例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用石油醚:乙酸乙酯:二氯甲烷:N,N-二甲基甲酰胺=1:1:1:0.5-1:1:1:0.6梯度洗脱;以及(2)反 相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(313)化合物粗产品,该粗产品可以直接用于后续反应。
在一些实施方式中,式(314)所示化合物可以通过以下制备方法得到:该方法包括在有机溶剂中,在脱保护反应条件下,将式(315)所示化合物与卤代乙酸接触,随后进行分离:
其中,R
7选自式(330)、(331)、(332)或(333)所示的基团,在一些实施方式中,R
7的结构如式(330)所示:
n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15、L
1、S
1各自的定义和可选择的范围如前所述。
所述卤代乙酸选自二氯乙酸、三氯乙酸、一氯乙酸和三氟乙酸中的一种或多种,在一些实施方式中为二氯乙酸。
所述脱保护反应条件包括反应温度为0-100℃,反应时间为0.1-24小时,在一些实施方式中为反应温度为10-40℃,反应时间为0.5-16小时。
在一些实施方式中,所述有机溶剂为环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。所述环氧类溶剂在一些实施方式中为二氧六环和/或四氢呋喃,所述醚类溶剂在一些实施方式中为乙醚和/或甲基叔丁基醚,所述卤代烷类溶剂在一些实施方式中为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种,在一些实施方式中,所述有机溶剂为二氯甲烷。相对于式(315)化合物,有机溶剂用量为3-50L/mol,在进一步的实施方式中为5-20L/mol。
所述卤代乙酸与所述式(315)所示化合物的摩尔比为5:1-100:1,在一些实施方式中为10:1-50:1。
与上述类似地,可使用任何合适的分离方法从反应混合物中分离式(314)化合物。 在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(314)化合物,例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用二氯甲烷:甲醇=100:30-100:40梯度洗脱;以及(2)反相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(314)化合物粗产品,该粗产品可以直接用于后续反应。
式(315)所示化合物可以通过以下制备方法得到:该方法包括在有机溶剂中,在成酰胺反应缩合剂和三级胺类有机碱存在下,在缩合反应条件下,将式(317)所示化合物与式(316)所示化合物接触,随后进行分离:
其中,n1、n3、m1、m2、m3、R
7、R
10、R
11、R
12、R
13、R
14、R
15、L
1、S
1各自的定义和可选择的范围如前所述。
式(316)化合物可使用例如J.Am.Chem.Soc.2014,136,16958-16961中所公开的化合物,或者,式(316)化合物可由本领域技术人员通过各种方法制备,例如,可参照美国专利US 8,106,022 B2实施例1中所公开的方法制备某些式(316)化合物,以引用的方式将以上文献的全部内容整体并入本文。
在一些实施方式中,所述缩合反应条件包括反应温度为0-100℃,反应时间为0.1-24小时,在一些实施方式中为反应温度为10-40℃,反应时间为0.5-16小时。
所述式(316)所示化合物与所述式(317)所示化合物的摩尔比可以为2:1-10:1,在一些实施方式中为2.5:1-5:1。
在一些实施方式中,所述有机溶剂为乙腈、环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种,所述环氧类溶剂在一些实施方式中为二氧六环和/或四氢呋喃,所述醚类溶剂在一些实施方式中为乙醚和/或甲基叔丁基醚,所述卤代烷类溶剂在一些实施方式中为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种,在一些实施方式中,所述有机溶剂为乙腈。相对于式(317)化合物,所述有机溶剂的用量为3-50L/mol,在一些实施方式中为5-20L/mol。
在一些实施方式中,所述成酰胺反应缩合剂为六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷、3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT)、O-苯并三氮唑-四甲基脲六氟磷酸酯或4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐,在进一步的实施方式中为4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐。所述成酰胺反应缩合剂与式(317)所示化合物的摩尔比可以为2:1-10:1,在一些实施方式中为2.5:1-5:1。
所述三级胺类有机碱可以为N-甲基吗啉、三乙胺或N,N-二异丙基乙胺,在一些实施方式中为N-甲基吗啉;所述三级胺类有机碱与式(317)所示化合物的摩尔比可以为3:1-20:1,在一些实施方式中为5:1-10:1。
与上述类似地,可使用任何合适的分离方法从反应混合物中分离式(315)化合物。在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(315)化合物例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用二氯甲烷:甲醇=100:5-100:7梯度洗脱;以及(2)反相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(315)化合物粗产品,该粗产品可以直接用于后续反应。
在一些实施方式中,式(317)化合物与足量的一种式(316)化合物一次反应即生成期望的式(315)化合物,此时,各个S
1-L
1部分彼此相同。在一些实施方式中,可根据需要,通过使式(317)化合物分批与不同的式(316)化合物,即L
1和/或S
1不同的式(316)化合物发生反应,使得生成的式(315)化合物中含有两种以上的S
1和/或L
1。例如,对于1eq的式(317)化合物,可先使其与2eq的第一式(316)化合物接触,在式(317)化合物中的两个末端伯胺基团上连接第一S
1-L
1部分,随后,使其继续与(n3+n1-1)eq的第二式(316)化合物接触(n3和n1的定义和取值范围如前所述),在式(317)化合物中的(n3+n1-1)个仲胺基团上连接第二S
1-L
1部分。
在一些实施方式中,式(317)所示化合物可以通过以下制备方法得到:该方法包括在有机溶剂存在下,在脱保护反应条件下,将式(318)所示化合物与甲胺水溶液接触,随后进行分离:
其中,n1、n3、m1、m2、m3、R
7、R
10、R
11、R
12、R
13、R
14、R
15各自的定义和可选择的范围如前所述。
所述脱保护反应条件包括反应温度为0-150℃,反应时间为5-72小时,在一些实施方式中为反应温度为20-80℃,反应时间为10-30小时。
所述有机溶剂可选自醇,在一些实施方式中为甲醇、乙醇和异丙醇中的一种,在一些实施方式中为甲醇;相对于式(318)化合物,所述有机溶剂的用量为1-20L/mol,在一些实施方式中为1.5-10L/mol。
所述甲胺水溶液的浓度可以为30-40质量%,甲胺与式(318)所示化合物的摩尔比可以为10:1-500:1,在一些实施方式中为50:1-200:1。
与上述类似地,可使用任何合适的分离方法从反应混合物中分离式(317)化合物。在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(317)化合物例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用二氯 甲烷:甲醇:氨水(25重量%)=1:1:0.05-1:1:0.25梯度洗脱;以及(2)反相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(317)化合物粗产品,该粗产品可以直接用于后续反应。
在一些实施方式中,式(318)所示化合物可以通过以下制备方法得到:该方法包括在有机溶剂存在下,在取代反应条件下,将式(319)所示化合物与三苯基氯甲烷(TrCl)、二苯基乙苯基氯甲烷、苯基二乙苯基氯甲烷或三乙苯基氯甲烷,在一些实施方式中为三苯基氯甲烷(TrCl)接触,随后进行分离:
其中,n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15各自的定义和可选择的范围如前所述。
所述取代反应条件可包含反应温度为0-100℃,反应时间为5-72小时,在一些实施方式中,反应条件包含反应温度为10-40℃,反应时间为10-30小时。
三苯基氯甲烷(TrCl)、二苯基乙苯基氯甲烷、苯基二乙苯基氯甲烷或三乙苯基氯甲烷可商购得到,三苯基氯甲烷(TrCl)、二苯基乙苯基氯甲烷、苯基二乙苯基氯甲烷或三乙苯基氯甲烷与式(319)所示化合物的摩尔比可以为1:1-10:1,在一些实施方式中为1:1-3:1。
所述有机溶剂可以为环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。所述环氧类溶剂在一些实施方式中可以为二氧六环和/或四氢呋喃,所述醚类溶剂在一些实施方式中可以为乙醚和/或甲基叔丁基醚,所述卤代烷类溶剂在一些实施方式中可以为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种;在一些实施方式中,所述有机溶剂为二氯甲烷。相对于式(319)化合物,所述有机溶剂的用量可以为3-50L/mol,在一些实施方式中为5-20L/mol。
与上述类似地,可使用任何合适的分离方法从反应混合物中分离式(318)化合物。在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(318)化合物例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用甲醇:二氯甲烷=0.01:1-0.5:1梯度洗脱;或者使用甲醇:二氯甲烷:乙酸乙酯:石油醚=0.1:1:1:1-1:1:1:1梯度洗脱。以及(2)反相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(318)化合物粗产品,该粗产品可以直接用于后续反应。
在一些实施方式中,式(319)所示化合物可以通过以下制备方法得到:该方法包括在有机溶剂中,在取代反应条件下,将式(320)所示化合物与三氟乙酸乙酯接触,随后进行分离:
其中,n1、n3、m1、m2、m3、R
10、R
11、R
12、R
13、R
14、R
15各自的定义和可选择的范围如前所述。
在一些实施方式中,所述有机溶剂为乙腈、环氧类溶剂、醚类溶剂、卤代烷类溶剂、二甲基亚砜、N,N-二甲基甲酰胺和N,N-二异丙基乙胺中的一种或多种。在一些实施方式中,所述环氧类溶剂为二氧六环和/或四氢呋喃,在一些实施方式中,所述醚类溶剂为乙醚和/或甲基叔丁基醚,在一些实施方式中,所述卤代烷类溶剂为二氯甲烷、三氯甲烷和1,2-二氯乙烷中的一种或多种,在一些实施方式中,所述有机溶剂为乙腈。相对于式(320)化合物,所述有机溶剂的用量可以为1-50L/mol,在一些实施方式中为1-20L/mol。
所述取代反应条件可包括反应温度为0-100℃,反应时间为5-72小时,在一些实施方式中,所述取代反应条件包括反应温度为10-40℃,反应时间为10-30小时。
式(320)化合物可商购获得,或者由本领域技术人员使用已知的方法获得。例如,当m1=m2=m3=3,n1=1,n3=2,且R
10、R
11、R
12、R
13、R
14、R
15均为H时,式(320)化合物可自阿法埃莎公司商购获得。
所述三氟乙酸乙酯与式(320)所示化合物的摩尔比为2:1-10:1,在一些实施方式中为3:1-5:1。
与上述类似地,可使用任何合适的分离方法从反应混合物中分离式(319)化合物。在一些实施方式中,可通过蒸发除去溶剂、随后通过色谱方法分离式(319)化合物例如,可使用如下两种色谱条件进行分离:(1)正相纯化硅胶:200-300目硅胶填料,使用甲醇:二氯甲烷=0.01:1-0.5:1梯度洗脱;或者使用甲醇:二氯甲烷:乙酸乙酯:石油醚=0.1:1:1:1-1:1:1:1梯度洗脱。以及(2)反相纯化:C18、C8反相填料,使用甲醇:乙腈=0.1:1-1:0.1梯度洗脱。在一些实施方式中,可以直接除去溶剂得到式(319)化合物粗产品,该粗产品可以直接用于后续反应。
本公开的第一种或第二种siRNA缀合物也可以与药学上可接受的其它辅料联用,该辅料可以为本领域常规采用的各种制剂或化合物的一种或多种,详情可参见上文关于本公开的药物组合物的描述。
本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物以及第二种siRNA缀合
物的应用
在一些实施方式中,本公开提供了修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物在制备用于治疗和/或预防由所述载脂蛋白C3(ApoC3)的过量表达引起的血脂异常的药物中的用途。
在一些实施方式中,本公开提供了一种治疗载脂蛋白C3(ApoC3)的过量表达引起的血脂异常的方法,该方法包括向受试者给予有效量的本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物。
通过将本公开的siRNA活性成分给予有需要的受试者,可以通过RNA干扰的机制达到治疗血脂异常的目的。因此,本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物可用于预防和/或治疗血脂异常、或用于制备用于预防和/或治疗血脂异常的药物。
所述血脂异常指肝细胞中APOC3基因过度表达引起的血脂异常,通常表现为血液中甘油三酯、胆固醇等脂质和/或脂蛋白中的任一种或全部的水平提高,高水平的血脂与高血压、心血管疾病、糖尿病以及其他病理学病症高度相关。高甘油三酯血症与动脉粥样硬化相关,还会导致胰腺炎。本公开所述的血脂异常包括但不限于高胆固醇血症、高甘油三酯血症或动脉粥样硬化。
本文所使用的术语“给药/给予”是指通过使得至少部分地将本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物定位于期望的位点以产生期望效果的方法或途径,将本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物放置入受试者体内。适于本公开方法的给药途径包括局部给药和全身给药。一般而言,局部给药导致与受试者整个身体相比将更多本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物递送至特定位点;而全身给药导致将本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物递送至受试者的基本整个身体。考虑到本公开旨在提供预防和/或治疗血脂异常的手段,在一些实施方式中为能够将药物递送至肝脏的给药方式。
可通过本领域已知的任何合适途径向受试者给药,所述途径包括但不仅限于:口服或胃肠外途径,如静脉内给药、肌肉内给药、皮下给药、经皮给药、气道给药(气雾剂)、肺部给药、鼻部给药、直肠给药和局部给药(包括口腔含化给药和舌下给药)。给药频率可以是每天、每周、每两周、每三周、每个月或每年1次或多次。
本公开所述的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物的使用剂量可为本领域常规的剂量,所述剂量可以根据各种参数、尤其是受试者的年龄、体重和性别来确定。可在细胞培养或实验动物中通过标准药学程序测定毒性和疗效,例如测定LD50(使50%的群体致死的剂量)和ED50(在量反应中指能引起50%最大反应强度的剂量,在质反应中指引起50%实验对象出现阳性反应时的剂量)。可基于由细胞培养分析和动物研究得到的数据得出人用剂量的范围。
在给予本公开所述的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物时,例如,对于雄性或雌性、6-12周龄、体重18-25g的C57BL/6J或30-45g的ob/ob小鼠,以siRNA的量计:(i)对于第一种siRNA缀合物和/或第二种siRNA缀合物,其siRNA用量可以为0.001-100mg/kg体重,在进一步的实施方式中为0.01-50mg/kg体重,在更进一步的实施方式中为0.05-20mg/kg体重,在又进一步的实施方式中为0.1-10mg/kg体重;(ii)对于siRNA与药学上可接受的载体形成的药物组合物,其siRNA用量可以为0.001-50mg/kg体重,在进一步的实施方式中为0.01-10mg/kg体重,在更进一步的实施方式中为0.05-5mg/kg体重,在又进一步的实施方式中为0.1-3mg/kg体重。
在一些实施方式中,本公开提供了一种抑制肝细胞中载脂蛋白C3(ApoC3)基因表达的方法,该方法包括将有效量的本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物与所述肝细胞接触。将本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物导入肝细胞,通过RNA干扰机制达到抑制肝细胞中APOC3基因表达的目的。所述肝细胞可以选自Hep3B、HepG2、Huh7等肝癌细胞系或分离的肝原代细胞。在一些实施方式中,所述细胞为Huh7肝癌细胞。
采用本公开提供的方法抑制APOC3基因在细胞中表达,所提供的修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物中的siRNA用量一般是这样的量:其足以减少靶基因的表达,并导致在靶细胞表面处1pM至1μM、或0.01nM至100nM、或0.05nM至50nM或至约5nM的细胞外浓度。达到该局部浓度所需的量将随各种因素而变化,所述因素包括递送方法、递送部位、在递送部位和靶细胞或组织之间的细胞层的数目、递送是局部还是全身等。在递送部位处的浓度可以显著高于在靶细胞或组织的表面处的浓度。
试剂盒
本公开提供了一种试剂盒,所述试剂盒包含有效量的本公开的修饰的siRNA、药物组合物、第一种siRNA缀合物和第二种siRNA缀合物的至少一种。
在一些实施方式中,本文所述的试剂盒可在一个容器中提供修饰的siRNA。在一些实施方式中,本文所述的试剂盒可包含一个提供药学上可接受的赋形剂的容器。在一些实施方式中,所述试剂盒中还可包含其它成分,如稳定剂或防腐剂等。在一些实施方式中,本文所述的试剂盒可在不同于提供本文所述修饰的siRNA的容器以外的其它容器中包含至少一种其它治疗剂。在一些实施方式中,所述试剂盒可包含用于将修饰的siRNA与药学上可接受的载体和/或辅料或其它成分(若有的话)进行混合的说明书。
在本公开的试剂盒中,所述修饰的siRNA和药学上可接受的载体和/或辅料以及所述修饰的siRNA、药物组合物、第一种siRNA缀合物和/或第二种siRNA缀合物和/或缀合物,和/或药学上可接受的辅料可以任何形式提供,例如液体形式、干燥形式或冻干形式。在一 些实施方式中,所述修饰的siRNA和药学上可接受的载体和/或辅料以及所述药物组合物和/或缀合物和任选的药学上可接受的辅料基本上纯净和/或无菌。在一些实施方式中,可在本公开的试剂盒中提供无菌水。
下面通过制备例和实施例来进一步说明本公开,但是本公开并不因此而受任何限制。
实施例
以下将通过实施例对本公开进行详细描述。除非特别说明,以下实施例中所用到的试剂、培养基均为市售商品,所用到的核酸电泳、real-time PCR等操作均参照Molecular Cloning(Cold Spring Harbor LBboratory Press(1989))所记载的方法进行。
HEK293A细胞由北京大学分子医学研究所核酸技术实验室提供,用含有20%的胎牛血清(FBS,Hyclone公司)及0.2体积%的青链霉素双抗(Penicillin-Streptomycin,Gibco,Invitrogen公司)的DMEM完全培养基(Hyclone公司)培养细胞,于37℃在含5%CO
2/95%空气的培养箱中培养。
Huh7细胞购自中国科学院干细胞库,用含有10%的胎牛血清(FBS,Hyclone公司)、1%非必须氨基酸(NEAA,Corning公司)的DMEM完全培养基(Hyclone公司)培养细胞,于37℃在含5%CO
2/95%空气的培养箱中培养。
本公开合成的针对APOC3基因的siRNA、siRNA缀合物或作为阴性对照的siRNA、siRNA缀合物转染细胞时,使用Lipofectamine
TM2000(Invitrogen)作为转染试剂,具体操作参照制造商提供的说明书。
若无其它说明,以下提供的试剂比例均按体积比(v/v)计算。
所使用的动物模型如下:
人APOC3转基因小鼠:B6;CBA-Tg(APOC3)3707Bres/J,购于美国Jackson实验室;
食蟹猴:由苏州华测生物技术有限公司提供。
实验数据均以
表示,数据分析采用Graphpad prism5.0统计分析软件。首先对数据进行正态分布及方差齐性检验。符合正态分布(p>0.20)及方差齐(p>0.10):多组间比较采用单因素方差分析的LSD法进行多重比较,p<0.05认为有统计学意义;不符合正态分布或方差不齐:多组间比较采用非参数检验的Kruskal-Wallis H方法,如果Kruskal-wallis H检验结果显著(p<0.05),再将数据进行秩转换后,进行多组间两两比较,p<0.05认为有统计学意义。
制备例1 缀合物1-3的制备
本制备例合成了缀合物1-3(以下,也分别称为L10-siAP1M2SVP缀合物、L10-siAP1M2SP缀合物和L10-siAP1M2SPs缀合物)。所述缀合物为L-9缀合分子分别与编号为siAP1M2SVP、siAP1M2SP或siAP1M2SPs的siRNA缀合后形成的缀合物。该缀合物 中所缀合的siRNA的序列参见表3。
(1-1)L-10化合物的合成
按照以下方法,合成了L-10化合物:
(1-1-1)缀合末端段GAL-5的合成
(1-1-1a)GAL-2的合成
将100.0g GAL-1(N-乙酰-D-半乳糖胺盐酸盐,CAS号:1772-03-8,购自宁波弘翔生化公司,463.8mmol)溶于1000ml无水吡啶,冰水浴下加入540ml乙酸酐(购自Enox公司,5565.6mmol),室温搅拌反应1.5小时。将反应液倒入10L冰水中,减压抽滤,滤饼用2L冰水洗涤后,加乙腈/甲苯混合溶剂(体积比乙腈:甲苯=1:1)至完全溶解,蒸干溶剂,得到白色固体产品GAL-2 130.0g。
(1-1-1b)GAL-3的合成
将步骤(1-1-1a)中获得的GAL-2(35.1g,90.0mmol)溶解于213ml无水1,2-二氯乙烷中,在冰水浴且氮气保护条件下,加入24.0g TMSOTf(CAS号:27607-77-8,购自麦克林公司,108.0mmol),室温反应过夜。
在反应液中加入400ml二氯甲烷稀释,以硅藻土过滤,再加入1L饱和碳酸氢钠水溶液,搅拌均匀,分出有机相,水相用二氯乙烷萃取两次,每次300ml,合并有机相,分别用300ml饱和碳酸氢钠水溶液和300ml饱和食盐水洗涤,分出有机相,无水硫酸钠干燥,减压蒸干溶剂,得到浅黄色粘稠糖稀状产品GAL-3 26.9g。
(1-1-1c)GAL-4的合成
将步骤(1-1-1b)中获得的GAL-3(26.9g,81.7mmol)溶于136ml无水1,2-二氯乙烷中,加入干燥的
分子筛粉末30g,再加入9.0g 5-己烯-1-醇(CAS号:821-41-0,购自Adamas-beta公司,89.9mmol),室温下搅拌30分钟,冰浴和氮气保护下加入9.08g TMSOTf(40.9mmol),室温下搅拌反应过夜。过滤除去
分子筛粉末,滤液中加入300ml二氯甲烷稀释,以硅藻土过滤,再加入500ml饱和碳酸氢钠水溶液搅拌10分钟洗涤,分出有 机相,水相用300ml二氯乙烷萃取一次,合并有机相并分别用300ml饱和碳酸氢钠水溶液和300ml饱和食盐水洗涤,分出有机相,无水硫酸钠干燥,减压蒸干溶剂,得到黄色糖稀状产品GAL-4 41.3g,不进行纯化直接进行下一步氧化反应。
(1-1-1d)GAL-5的合成
将按照步骤(1-1-1c)中描述的方法得到的GAL-4(14.9g,34.7mmol,)溶于77ml二氯甲烷和77ml乙腈的混合溶剂中,分别加入103ml去离子水和29.7g高碘酸钠(CAS号:7790-28-5,购自阿拉丁公司,138.8mmol),冰水浴下搅拌10分钟,加入三氯化钌(CAS号:14898-67-0,购自安耐吉公司,238mg,1.145mmol),室温反应过夜。反应液加入300ml水稀释搅拌,加饱和碳酸氢钠调pH约为7.5,分出并弃去有机相,水相用二氯甲烷萃取三次,每次200ml,弃去有机相。水相用柠檬酸固体调节pH约为3,用二氯甲烷萃取三次,每次200ml,合并有机相,无水硫酸钠干燥,减压蒸干溶剂,得到白色泡沫状固体产品GAL-5 6.85g。
1H NMR(400MHz,DMSO)δ12.01(br,1H),7.83(d,J=9.2Hz,1H),5.21(d,J=3.2Hz,1H),4.96(dd,J=11.2,3.2Hz,1H),4.49(d,J=8.4Hz,1H),4.07–3.95(m,3H),3.92–3.85(m,1H),3.74–3.67(m,1H),3.48–3.39(m,1H),2.20(t,J=6.8Hz,2H),2.11(s,3H),2.00(s,3H),1.90(s,3H),1.77(s,3H),1.55–1.45(m,4H).
(1-1-2)M-11-T3的合成:
将J-0(1.883g,10mmol,商购自阿法埃莎公司)溶于25ml乙腈中,加入三乙胺(4.048g,40mmol)冰水浴冷却至0℃,加入三氟乙酸乙酯(5.683g,40mmol),室温下反应22h,减压蒸干溶剂,真空油泵发泡干燥18h,得到5.342g粗品固体M-11-T3,不经进一步纯化地直接用于后续反应。MS m/z:C
15H
22F
9N
4O
3,[M+H]
+,理论:477.35,实测:477.65。
(1-1-3)M-11-T3-Tr的合成:
将M-11-T3粗品(5.342g,10mmol)溶于50ml二氯甲烷,向反应液中加入TrCl(3.345g,12mmol)和三乙胺(1.518g,15mmol),室温下搅拌反应20h,用饱和碳酸氢钠洗涤反应 液2次,每次20ml,20ml饱和食盐水洗涤1次,有机相用无水硫酸钠干燥,过滤后减压蒸干有机溶剂,真空油泵发泡干燥过夜,得到粗品固体M-11-T3-Tr 7.763g。MS m/z:C
34H
36F
9N
4O
3,[M+Na]
+,理论:741.25,实测:741.53。粗品固体M-11-T3-Tr不经纯化地继续用于下一步M-18-Tr的合成。
(1-1-4)M-18-Tr的合成:
将步骤(1-1-3)中获得的M-11-T3-Tr粗品(7.763g,10mmol)溶于100ml甲醇,再加入100ml甲胺水溶液(40质量%),在50℃搅拌反应23h,过滤除去不溶颗粒物,减压蒸干溶剂,加入200ml体积比为1:1的二氯甲烷:甲醇混合溶剂,用50ml饱和碳酸氢钠洗涤,水相再用二氯甲烷(DCM)萃取3次,每次50ml,合并有机相,用无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜,用200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,以二氯甲烷:甲醇:氨水(25重量%)=1:1:0.05-1:1:0.25梯度洗脱,收集产物洗脱液,减压蒸干溶剂,真空油泵发泡干燥得到纯品M-18-Tr 2.887g。
1H NMR(400MHz,DMSO)δ7.47–7.39(m,6H),7.32–7.24(m,6H),7.19–7.12(m,3H),2.60–2.47(m,4H),2.46–2.19(m,13H),1.70–1.55(m,4H),1.40(p,J=6.8Hz,2H).MS m/z:C
28H
39N
4,[M+H]
+,理论:431.65,实测:432.61。
(1-1-5)L-5-Tr的合成:
将步骤(1-1-4)中获得的M-18-Tr(2.02g,4.69mmol)与步骤(1-1-1)中获得的GAL-5(6.93g,15.48mmol)混合溶于47ml乙腈,加入N-甲基吗啉(3.13g,30.96mmol)和4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐(DMTMM,4.28g,15.48mmol),室温搅拌反应2h。以200ml二氯甲烷稀释反应液,100ml饱和碳酸氢钠溶液洗涤有机相,100ml饱和食盐水洗涤有机相,有机相用无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品。200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,以二氯甲烷:甲醇=100:5-100:7 梯度洗脱,收集产物洗脱液,减压蒸干得到纯品L-5-Tr 7.49g。
1H NMR(400MHz,DMSO)δ7.83–7.10(m,4H),7.67–7.60(m,1H),7.44–7.34(m,6H),7.33–7.24(m,6H),7.20–7.15(m,3H),5.22(s,3H),4.97(d,J=11.3Hz,3H),4.49(d,J=8.4Hz,3H),4.06–3.07(m,9H),3.95–3.83(m,3H),3.77–3.64(m,3H),3.45–3.35(m,3H),3.12–2.87(m,8H),2.30–2.15(m,3H),2.11–1.98(m,22H),1.95–1.84(m,11H),1.81–1.61(m,14H),1.54–1.36(m,14H).MS m/z:C
85H
119N
7O
30,[M+H]
+,理论:1718.81,实测:1718.03。
(1-1-6)L-8的合成:
将步骤(1-1-5)中得到的L-5-Tr(5.94g,3.456mmol)溶于69ml二氯甲烷,再加入二氯乙酸(13.367g,103.67mmol),室温下反应2h,加入100ml二氯甲烷稀释反应液,再加饱和碳酸氢钠溶液洗涤调节pH=7-8之间,水相以二氯甲烷萃取6次,每次30ml,合并有机相,用无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品。纯化使用200-300目正相硅胶,以10重量%三乙胺中和硅胶酸性,1重量‰三乙胺平衡柱子,以二氯甲烷:甲醇=100:30-100:40梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品L-8 4.26g。
1H NMR(400MHz,DMSO)δ7.84(d,J=9.0Hz,3H),7.27–7.23(m,1H),7.13–7.18(m,1H),5.22(d,J=3.1Hz,3H),4.97(dd,J=11.3,3.1Hz,3H),4.48(d,J=8.4Hz,3H),4.09–3.98(m,9H),3.88(dd,J=19.3,9.3Hz,3H),3.75–3.66(m,3H),3.44–3.38(m,3H),3.17–3.30(m,4H),3.10–2.97(m,4H),2.35–2.20(m,6H),2.15–2.08(m,9H),2.07–1.98(m,13H),1.94–1.87(m,9H),1.81–1.74(m,9H),1.65–1.42(m,18H).MS m/z:C
85H
119N
7O
30,[M+H]
+,理论:1477.59,实测:1477.23。
(1-1-7a)A-1的合成
将DMTrCl(4,4'-双甲氧基三苯甲基氯,38.12g,112.5mmol)溶于450ml无水吡啶中,加入DL-甘油酸钙水合物(12.88g,45.0mmol),在45℃反应22h,将反应液过滤,滤饼用 200ml DCM淋洗,滤液减压浓缩至干,剩余物用500ml二氯甲烷重新溶解,0.5M三乙胺磷酸盐(pH=7-8)洗涤2次,每次200ml,水相以二氯甲烷萃取2次,每次200ml,合并有机相,用无水硫酸钠干燥,过滤,减压蒸干溶剂,200-300目正相硅胶柱纯化,以石油醚:乙酸乙酯:二氯甲烷:甲醇=1:1:1:0.35-1:1:1:0.55梯度洗脱,收集产物洗脱液,减压蒸干溶剂,500ml二氯甲烷重新溶解,以200ml 0.5M三乙胺磷酸盐洗涤1次,水相用二氯甲烷萃取2次,每次200ml,合并有机相,无水硫酸钠干燥,过滤,减压蒸干溶剂,真空油泵减压下过夜,得到白色固体产品A-1 20.7g。
1H NMR(400MHz,DMSO-d6)δ7.46(ddd,J=6.5,2.3,1.1Hz,1H),7.40–7.28(m,7H),6.89–6.81(m,4H),4.84(d,J=5.0Hz,1H),4.36–4.24(m,1H),4.29(s,6H),3.92(dd,J=12.4,7.0Hz,1H),3.67(dd,J=12.3,7.0Hz,1H),2.52(q,J=6.3Hz,6H),1.03(t,J=6.3Hz,9H).MS m/z:C
24H
23O
6,[M-H]
-,理论:407.15,实测:406.92。
(1-1-7b)L-7的合成:
将步骤(1-1-6)中获得的L-8(2.262g,1.532mmol)和步骤(1-1-7a)中获得的A-1(2.342g,4.596mmol)混合,溶于16ml二氯甲烷,加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT)(1.375g,4.596mmol),再加入二异丙基乙胺(1.188g,9.191mmol),25℃下搅拌反应2h,用10ml饱和碳酸氢钠洗涤有机相,水相以二氯甲烷萃取3次,每次10ml,以10ml饱和食盐水洗涤有机相,水相以二氯甲烷萃取2次,每次10ml,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜,得到粗品4.900g。柱纯化使用120g 200-300目正相硅胶,以20ml三乙胺中和硅胶酸性,以含1重量%三乙胺的石油醚平衡柱子,以石油醚:乙酸乙酯:二氯甲烷:N,N-二甲基甲酰胺=1:1:1:0.5-1:1:1:0.6梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品L-7 2.336g。
1H NMR(400MHz,DMSO)δ7.90–7.78(m,4H),7.75–7.64(m,1H),7.38–7.18(m,9H),6.91–6.83(m,4H),5.25–5.10(m,4H),4.97(dd,J=11.2,3.2Hz,3H),4.48–4.30(m,4H),4.02(s,9H),3.93–3.84(m,3H),3.76–3.66(m,9H),3.45–3.35(m,3H),3.24–2.98(m,10H),2.30–2.20(m,2H),2.11–1.88(m,31H),1.80–1.40(m,28H).MS m/z:C
90H
128N
7O
35,[M-DMTr]
+,理论:1564.65,实测:1564.88。
(1-1-8)L-9的合成:
将步骤(1-1-7b)中获得的L-7(2.300g,1.26mmol)、丁二酸酐(0.378g,3.78mmol)和4-二甲氨基吡啶(DMAP,0.462g,3.78mmol)混合溶于13ml二氯甲烷,再加入二异丙基乙胺(DIEA,0.814g,6.30mmol),25℃下搅拌24h,5ml 0.5M三乙胺磷酸盐洗涤反应液,水相以二氯甲烷萃取3次,每次5ml,合并有机相减压蒸干得到2.774g粗品。柱纯化使用60g 200-300目正相硅胶,以1重量%三乙胺中和硅胶酸性,以二氯甲烷平衡柱子,以含1重量‰三乙胺的二氯甲烷:甲醇=100:18-100:20梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品L-9缀合分子1.874g。
1H NMR(400MHz,DMSO)δ8.58(d,J=4.2Hz,1H),7.94–7.82(m,3H),7.41–7.29(m,5H),7.22(d,J=8.1Hz,5H),6.89(d,J=8.3Hz,4H),5.49–5.37(m,1H),5.21(d,J=3.0Hz,3H),4.97(d,J=11.1Hz,3H),4.49(d,J=8.2Hz,3H),4.02(s,9H),3.88(dd,J=19.4,9.4Hz,3H),3.77–3.65(m,9H),3.50–3.39(m,6H),3.11–2.90(m,5H),2.61–2.54(m,4H),2.47–2.41(m,2H),2.26–2.17(m,2H),2.15–1.95(m,22H),1.92–1.84(m,9H),1.80–1.70(m,10H),1.65–1.35(m,17H),1.31–1.19(m,4H),0.96(t,J=7.1Hz,9H).MS m/z:C
94H
132N
7O
38,[M-DMTr]
+,理论:1664.72,实测:1665.03。
(1-1-9)L-10化合物的合成:
此步骤中,通过将L-9缀合分子连接至固相载体,制备了L-10化合物。
将步骤(1-1-8)中获得的L-9缀合分子(0.233g,0.1126mmol)、O-苯并三氮唑-四甲基脲六氟磷酸酯(HBTU,0.064g,0.1689mmol)和二异丙基乙胺(DIEA,0.029g,0.2252mmol)混合,溶于19ml乙腈,室温搅拌5分钟,向反应液中加入氨甲基树脂(0.901g,100-200目,氨基载量400μmol/g,购自南开和成公司),25℃下进行摇床反应,转速220转/分钟,反应15h后过滤,滤饼以DCM淋洗2次,每次30ml,乙腈淋洗3次,每次30ml,30ml乙醚淋洗1次,真空油泵干燥2h,随后再按照表2中示出的投料配比加入原料(CapA、CapB、4-二甲氨基吡啶(DMAP)和乙腈)进行盖帽反应。25℃下置于摇床上,转速200转/分钟,反应5h,反应液过滤,滤饼用乙腈淋洗3次,每次30ml,抽滤至干,真空油泵减压下干燥过夜,得到L-10化合物(即,连接固相载体的L-9缀合分子)1.100g,载量90.8μmol/g。
表2 盖帽反应投料配比
原料 | 用量 | 规格 | 批号 | 生产厂家 |
CapA | 20ml | —— | —— | —— |
CapB | 2.3ml | —— | —— | —— |
DMAP | 0.01g | 分析纯 | I1422139 | Aladdin |
乙腈 | 2.3ml | 光谱纯 | O15161001 | 上海星可 |
其中,CapA和CapB为盖帽试剂溶液,CapA为20体积%N-甲基咪唑的吡啶/乙腈混合溶液,吡啶与乙腈的体积比为3:5;CapB为20体积%乙酸酐的乙腈溶液。
(1-2)合成缀合物1-3的正义链
缀合物1-3的正义链序列相同,故其制备方法也相同。
通过固相亚磷酰胺法,利用上述步骤制备的L-10化合物起始循环,按照正义链核苷酸排布顺序自3'-5'方向逐一连接核苷单体。每连接一个核苷单体都包括脱保护、偶联、盖帽、氧化或硫化四步反应。其中,两个核苷酸之间采用磷酸酯连接时,连接后一个核苷单体时,包括脱保护、偶联、盖帽、氧化四步反应。两个核苷酸之间采用硫代磷酸酯连接时,连接后一个核苷单体时,包括保护、偶联、盖帽、硫化四步反应。合成条件给定如下:
核苷单体以0.1M浓度的乙腈溶液提供,每一步的脱保护反应的条件相同,即温度为25℃,反应时间为70秒,脱保护试剂为二氯乙酸的二氯甲烷溶液(3%v/v),二氯乙酸与固相载体上4,4'-二甲氧基三苯甲基保护基的摩尔比为5:1。
每一步偶联反应条件均相同,包括温度为25℃,固相载体上连接的核酸序列与核苷单体的摩尔比为1:10,固相载体上连接的核酸序列和偶联试剂的摩尔比为1:65,反应时间为600秒,偶联试剂为5-乙硫基-1H-四氮唑的0.5M乙腈溶液。
每一步盖帽条件均相同,包括温度为25℃,反应时间为15秒。盖帽试剂溶液为摩尔比为1:1的CapA和CapB的混合溶液,盖帽试剂与固相载体上连接的核酸序列的摩尔比为乙酸酐:N-甲基咪唑:固相载体上连接的核酸序列=1:1:1。
每一步氧化反应条件相同,包括温度为25℃,反应时间为15秒,氧化试剂为浓度为0.05M的碘水。碘与偶联步骤中固相载体上连接的核酸序列的摩尔比为30:1。反应在四氢呋喃:水:吡啶=3:1:1的混合溶剂中进行。
每一步硫化反应的条件相同,包括温度为25℃,反应时间为300秒,硫化试剂为氢化 黄原素。硫化试剂与偶联步骤中固相载体上连接的核酸序列的摩尔比为120:1。反应在乙腈:吡啶=1:1的混合溶剂中进行。
切割和脱保护条件如下:将合成的连接有载体的核苷酸序列加入浓度为25重量%的氨水中,氨水用量为0.5ml/μmol,在55℃反应16h,除去液体,真空浓缩至干。
纯化与脱盐:利用制备型离子色谱纯化柱(Source 15Q),通过NaCl的梯度洗脱,完成核酸的纯化。具体而言为:洗脱剂A:20mM磷酸钠(pH 8.1),溶剂为水/乙腈=9:1(体积比);洗脱剂B:1.5M氯化钠,20mM磷酸钠(pH 8.1),溶剂为水/乙腈=9:1(体积比);洗脱梯度:洗脱剂A:洗脱剂B=100:0-50:50梯度洗脱。收集产品洗脱液后合并,采用反相色谱纯化柱进行脱盐,具体条件包括采用葡聚糖凝胶柱进行脱盐,填料为葡聚糖凝胶G25,以去离子水洗脱。
检测:使用离子交换色谱(IEX-HPLC)检测纯度,使用液质联用(LC-MS)分析分子量。正义链分子量的理论值为7649.55,对于缀合物1的正义链批次,实测值为7649.1;对于缀合物2和3的正义链批次,实测值为7648.8。实测值与理论值相符,表明所合成的是3'末端缀合了L-9缀合分子的正义链S。
(1-3)合成反义链
(1-3A)缀合物1反义链的制备
通过固相亚磷酰胺法,利用通用固相载体(UnyLinker
TM loaded
Solid Supports,Kinovate Life Sciences公司)起始循环,合成缀合物1的反义链AS。固相合成方法中的脱保护、偶联、盖帽、氧化或硫化反应条件,切割和脱保护,纯化与脱盐条件与合成正义链相同。
检测:纯度采用离子交换色谱(IEX-HPLC)进行检测;分子量采用液质联用(LC-MS)进行分析。理论值6991.46,实测值6991.0。实测值与理论值相符,表明所合成的是具有目标序列的反义链AS。
其中,乙烯基磷酸酯修饰的2'-甲氧基修饰尿嘧啶核苷单体(VP-Um)按照以下方法合成:
(1-3-1)VP-U-2的合成
按照以下方法,合成了VP-U-2分子:
将2'-甲氧基修饰的尿嘧啶核苷(2'-OMe-U,51.30g,91.6mmol),叔丁基二苯基氯硅烷(TBDPSCl,50.35g,183.2mmol),咪唑(12.47g,183.2mmol)混合溶于450ml N,N-二甲基甲酰胺(DMF),室温下搅拌反应20h。蒸除DMF,用600ml二氯甲烷溶解后加300ml饱和碳酸氢钠洗涤,水相再用二氯甲烷(DCM)萃取3次,每次300ml,合并有机相,用5%草酸洗涤至水相pH<5,蒸发溶剂至干后获得VP-U-1粗品直接用于随后VP-U-2的合成。
将VP-U-1粗品用100ml二氯甲烷溶解后,外加冰浴搅拌10分钟,再加入预先在4℃冰箱冷藏好的450ml 2%对甲苯磺酸溶液(溶剂为体积比3:7的甲醇-二氯甲烷混合溶剂),反应10分钟。再加入200ml饱和碳酸氢钠淬灭反应,有机相加入饱和碳酸氢钠水溶液洗涤至pH=8。合并水相,用二氯甲烷萃取2次,每次200ml,合并有机相,再用200ml饱和食盐水洗涤一次,蒸发溶剂至干。200-300目正相硅胶柱纯化,石油醚装柱,以石油醚:乙酸乙酯:二氯甲烷:甲醇=1:1:1:0.05-1:1:1:0.25梯度洗脱,收集产物洗脱液,减压蒸干溶剂,真空油泵发泡干燥得到纯品VP-U-2共40.00g。
1H NMR(400MHz,DMSO-d6)δ7.96(d,J=7.8Hz,1H),7.64(dtd,J=5.1,4.0,2.2Hz,4H),7.41–7.30(m,6H),6.79(d,J=4.7Hz,1H),5.73(d,J=7.6Hz,1H),4.94(t,J=7.0Hz,1H),4.12(td,J=4.6,3.9Hz,1H),4.05(dd,J=4.8,4.0Hz,1H),3.96(t,J=4.7Hz,1H),3.68(ddd,J=11.8,7.0,4.6Hz,1H),3.57–3.46(m,1H),3.39(s,3H),1.05(s,8H).MS m/z:C
26H
33N
2O
6Si,[M+H]
+,理论:497.21,实测:497.45。
(1-3-2)VP-U-4的合成:
将VP-U-2(19.84g,40.0mmol),二环己基碳二亚胺(DCC,16.48g,80.0mmol),吡啶(4.20g,53.2mmol),三氟乙酸(6.61g,53.2mmol)混合溶于200ml二甲基亚砜(DMSO),室温下搅拌反应20h。另取亚甲基二磷酸四乙酯(21.44g,74.4mmol)溶于120ml THF,冰浴降温,在冰浴温度下加入t-BuOK(11.36g,101.2mmol),先在冰浴温度下反应10min,再升至室温反应0.5h,然后加入至前述反应液中,约1h加完,冰浴温度下反应1h,再升至室温反应18h。加水淬灭反应,水相以二氯甲烷提取3次,每次200ml。合并有机相,用200ml饱和食盐水水洗一次后蒸发溶剂至干。用200-300目正相硅胶柱纯化,石油醚装 柱,以石油醚:乙酸乙酯=1:1-1:4梯度洗脱,收集产物洗脱液,减压蒸干溶剂,真空油泵发泡干燥得到纯品VP-U-4共14.00g。
1H NMR(400MHz,DMSO-d6)δ7.96(d,J=7.8Hz,1H),7.64(dtd,J=5.1,4.0,2.2Hz,4H),7.41–7.30(m,6H),6.82–6.71(m,2H),5.90(ddd,J=25.9,15.0,1.0Hz,1H),5.73(d,J=7.6Hz,1H),4.36–4.21(m,3H),4.18(t,J=4.9Hz,1H),4.05(ddq,J=9.7,8.5,6.9Hz,2H),3.87(t,J=4.8Hz,1H),3.39(s,3H),1.32(td,J=6.9,0.7Hz,6H),1.05(s,8H).MS m/z:C
31H
42N
2O
8PSi,[M+H]
+,理论:629.24,实测:629.51。
(1-3-3)VP-U-5的合成:
将VP-U-4(14.00g,22.29mmol)溶于100ml四氢呋喃,加入三乙胺三氢氟酸(17.96g,111.45mmol),室温搅拌20h反应完全。直接蒸发溶剂至干,再用二氯甲烷溶解随后蒸干2次,每次使用50ml二氯甲烷,得到粗品。用200-300目正相硅胶柱纯化,石油醚装柱,以石油醚:乙酸乙酯:二氯甲烷:甲醇=1:1:1:0.05-1:1:1:0.25梯度洗脱,收集产物洗脱液,减压蒸干溶剂,真空油泵发泡干燥得到纯品VP-U-5共6.70g。
1H NMR(400MHz,DMSO-d6)δ7.96(d,J=7.8Hz,1H),6.77(dd,J=15.0,6.2Hz,1H),5.99–5.82(m,2H),5.73(d,J=7.6Hz,1H),5.27(d,J=5.1Hz,1H),5.10(dd,J=5.3,4.7Hz,1H),4.29(ddq,J=9.8,8.6,7.0Hz,2H),4.17(ddd,J=6.2,5.2,1.0Hz,1H),4.12–3.98(m,3H),3.39(s,2H),1.32(td,J=6.9,0.6Hz,6H).MS m/z:C
15H
24N
2O
8P,[M+H]
+,理论:391.13,实测:391.38。
(1-3-4)VP-U-6的合成:
在氩气保护条件下向10ml无水二氯甲烷中加入VP-U-5(391mg,1.0mmol)、三氟乙酸吡啶盐(0.232g,1.2mmol)、N-甲基咪唑(0.099g,1.2mmol),双(二异丙基氨基)(2-氰基乙氧基)膦(0.452g,1.5mmol),室温搅拌反应5小时。蒸除溶剂至干,柱层析纯化(200-300目正相硅胶,二氯甲烷:乙腈(含0.5重量%三乙胺)=3:1-1:3梯度洗脱),收集产物洗脱液,浓缩除去溶剂,得到目标产物VP-U-6共508mg。
31P NMR(161MHz,DMSO-d6)δ150.34,150.29,17.07,15.50.MS m/z:C
24H
41N
4O
9P
2,[M+H]
+,理论:591.23,实测:591.55。表明VP-U-6是目标产物VP-Um,作为核苷单体参与RNA链合成。
(1-3B)缀合物2反义链的制备
缀合物2的反义链与缀合物1的反义链的区别仅在于5'-末端第一个核苷酸修饰不同。按照固相亚磷酰胺法制备反义链时,最后连接的核苷单体为2'-甲氧基修饰尿嘧啶核苷单体(Um),再经脱保护、偶联、盖帽、氧化四步反应将CPR-I单体(苏州吉玛,货号Cat#13-2601-XX)连接至反义链5'末端,形成5'-磷酸酯修饰。
合成中,使用的通用固相载体,脱保护、偶联、盖帽、氧化或硫化反应条件,切割和脱保护,纯化与脱盐条件与合成正义链相同。
采用离子交换色谱(IEX-HPLC)检测纯度;采用液质联用(LC-MS)分析分子量,理论值6995.47,实测值6994.8。实测值与理论值相符,表明所合成的是具有目标序列的反义链AS。
(1-3C)缀合物3反义链的制备
采用与缀合物2反义链相同的合成工艺,区别在于连接CPR-I单体时,以硫化反应条件代替上述氧化反应条件,制得具有5'-硫代磷酸酯修饰的缀合物3反义链。
采用离子交换色谱(IEX-HPLC)检测纯度;采用液质联用(LC-MS)分析分子量,理论值7011.53,实测值7010.9。实测值与理论值相符,表明所合成的是具有目标序列的反义链AS。
(1-4)合成缀合物1-3
对于缀合物1,将S链与AS链分别溶于注射用水中,得到40mg/mL的溶液,以等摩尔比混合,50℃加热15min,室温冷却后,使它们通过氢键形成双链结构。使用超纯水(Milli-Q超纯水仪自制,电阻率18.2MΩ*cm(25℃))将缀合物稀释至浓度为0.2mg/mL后,利用液质联用仪(LC-MS,Liquid Chromatography-Mass Spectrometry,购于Waters公司,型号:LCT Premier)进行分子量检测。实测值与理论值一致,说明所合成的缀合物1是目标设计的带有L-9缀合分子的双链核酸序列。
对于缀合物2-3,采用相同的方法制备并检测分子量,实测值与理论值一致,说明所合成的缀合物是目标设计的带有L-9缀合分子的双链核酸序列。缀合物1-4的结构如式(3)所示。
制备例2 缀合物4-21以及对比缀合物1-2的制备
采用与制备例1相同的方法,合成了对比缀合物1-2,预期能够制得缀合物4-21,不同的是:1)所述siRNA分别为表3中所示的对应于对比缀合物1-2以及缀合物4-21的序列;2)当目标序列中含有未修饰的核苷酸时,切割与脱保护条件中,在氨水处理后,相对于单链核酸的量,用0.4ml/μmol N-甲基吡咯烷酮溶解产品,随后加入0.3ml/μmol三乙胺和0.6ml/μmol三乙胺三氢氟酸盐,以脱除核糖上的2'-TBDMS保护。
表3 siRNA缀合物
制备例3 P10-siAP1M2SP缀合物(缀合物22)的制备
(3-1)P-10化合物的合成
按照以下方法,合成了P-10化合物:
(3-1-1)GAL5-C4-1的合成
向40ml N,N-二甲基甲酰胺中加入按照上述(1-1-1)中描述的方法得到的GAL-5 (13.43g,30.0mmol)、4-氨基酸叔丁酯盐酸盐(5.87g,30.0mmol)、O-苯并三氮唑-四甲基脲六氟磷酸酯(13.65g,36.0mmol)和二异丙基乙胺(11.63g,90.0mmol),溶解均一后室温搅拌反应5小时。向反应液中加入300ml饱和碳酸氢钠水溶液,用乙酸乙酯萃取3次,每次200ml,合并有机相,用200ml饱和食盐水洗涤一次,分出有机相,再用无水硫酸钠干燥,减压蒸除溶剂至干得到30.3g油状物粗品GAL5-C4-1,直接进行下一步反应。
(3-1-2)GAL5-C4-2的合成
将步骤(3-1-1)中获得的GAL5-C4-1粗品(30.3g,30mmol)溶于180ml甲酸中,室温搅拌反应16小时。蒸发溶剂至干,柱层析纯化(200-300目正相硅胶,二氯甲烷:甲醇=100:18-100:20梯度洗脱),收集反应洗脱液,浓缩除去溶剂,得到目标产物GAL5-C4-2共14.84g。
(3-1-3)P-6的合成:
将按照步骤(1-1-4)中描述的方法得到的M-18-Tr(2.02g,4.69mmol)与将步骤(3-1-2)中获得的GAL5-C4-2(8.24g,15.48mmol,由两批产物合并获得)混合溶于47ml乙腈,再加入N-甲基吗啉(3.13g,30.96mmol),最后加入4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐(DMTMM,4.28g,15.48mmol),室温搅拌反应2h。以20ml二氯甲烷稀释反应液,10ml饱和碳酸氢钠溶液洗涤有机相,10ml饱和食盐水洗涤有机相,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品,200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,以二氯甲烷:甲醇=100:5-100:7梯度洗脱,收集产物洗脱液,减压蒸干得到纯品P-6共8.27g。
(3-1-4)P-7的合成:
将按照上述(3-1-3)中得到的P-6(6.82g,3.456mmol)溶于69ml二氯甲烷,再加入二氯乙酸(13.367g,103.67mmol),室温下反应2h。加入100ml二氯甲烷稀释反应液,再加入饱和碳酸氢钠溶液洗涤调节pH=7-8之间,水相以二氯甲烷萃取6次,每次30ml,合并有机相,无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品。用200-300目正相硅胶纯化,以10重量%三乙胺中和硅胶酸性,以1重量‰三乙胺平衡柱子,二氯甲烷:甲醇=100:30-100:40梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到P-7共4.82g。MS m/z:C
78H
127N
10O
33,[M+H]
+,理论:1732.91,实测:1735.73。
(3-1-5)P-8的合成:
将P-7(2.653g,1.532mmol)和A-1(2.342g,4.596mmol)混合溶于16ml二氯甲烷,加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT)(1.375g,4.596mmol),再加入二异 丙基乙胺(1.188g,9.191mmol),25℃下搅拌反应2h。用10ml饱和碳酸氢钠洗涤有机相,水相以二氯甲烷萃取3次,每次10ml,10ml饱和食盐水洗涤有机相,水相以二氯甲烷萃取2次,每次10ml,合并有机相,用无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜得到粗品。柱纯化使用120g 200-300目正相硅胶,以20ml三乙胺中和硅胶酸性,以含1重量%三乙胺的石油醚平衡柱子,以石油醚:乙酸乙酯:二氯甲烷:N,N-二甲基甲酰胺=1:1:1:0.5-1:1:1:0.6梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品P-8共2.793g。
(3-1-6)P-9的合成:
将P-8(490mg,0.231mmol)、丁二酸酐(69mg,0.693mmol)和4-二甲氨基吡啶(DMAP,68mg,0.554mmol)混合溶于2.3ml二氯甲烷,再加入二异丙基乙胺(DIEA,149mg,1.155mmol),25℃下搅拌反应21h。50ml二氯甲烷稀释反应液,再加入100ml 0.5M三乙胺磷酸盐洗涤反应液,水相以二氯甲烷萃取3次,每次10ml,合并有机相,减压蒸干得到粗品。柱纯化使用80g 200-300目正相硅胶,以1重量%三乙胺中和硅胶酸性,以二氯甲烷平衡柱子,以含1重量‰三乙胺的二氯甲烷:甲醇=100:18-100:20梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品P-9缀合分子共200mg。MS m/z:C
106H
153N
10O
41,[M-DMTr]
+,理论:1921.05,实测:1920.97。
(3-1-7)P-10的合成:
通过与制备例1中步骤(1-1-9)相同的方法,制备P-10。不同的是以P-9缀合分子代替L-9缀合分子,得到连接固相载体的P-9缀合分子。
(3-2)合成P10-siAP1M2SVP缀合物
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物22,不同的是以P-10化合物代替L-10化合物起始正义链合成。预期可以得到P10-siAP1M2SVP缀合物,其结构如式(4)所示。
制备例4 R5-siAP1M2SVP缀合物(缀合物23)的制备
(4-1)R-5化合物的合成
按照以下方法,合成了R-5化合物:
(4-1-1)GAL-C7-1的合成
将按照步骤(1-1-1b)中描述的方法得到的GAL-3(26.4g,80.2mmol)溶于134ml无水1,2-二氯乙烷中,加入
分子筛粉末60g,再加入7-辛烯-1-醇(11.3g,88.2mmol),室温下搅拌反应10分钟,冰浴和氮气保护下加入三氟甲基磺酸三甲基硅酯(8.9g,40.1mmol),室温搅拌反应24小时。过滤除去
分子筛粉末,滤液中加入500ml饱和碳酸氢钠水溶液洗涤,分出有机相,水相用100ml二氯甲烷萃取一次,合并有机相并用250ml饱和食盐水洗涤一次,分出有机相,用无水硫酸钠干燥,减压蒸除溶剂至干得到黄色糖稀状产品GAL-C7-1 33.3g,不进行纯化直接进行下一步氧化反应。
(4-1-2)GAL-C7-2的合成
将按照步骤(4-1-1)中得到的GAL-C7-1(33.3g,72.8mmol)溶于160ml二氯甲烷和160ml乙腈的混合溶剂中,分别加入216ml水和高碘酸钠固体(62.3g,291.2mmol),冰水浴下搅拌10分钟,加入催化剂三氯化钌(498mg,2.4mmol)自然升至室温搅拌反应23小时。反应液加入200ml水稀释搅拌,加饱和碳酸氢钠调节pH值为7.5,分掉有机相,水相再用二氯甲烷萃取三次,弃去有机相,水相用柠檬酸固体调节pH约为3,用二氯甲烷萃取三次,每次200ml,合并有机相,无水硫酸钠干燥,减压蒸除溶剂后柱层析(200-300目正相硅胶,二氯甲烷:甲醇=100:18-100:20梯度洗脱)纯化得到白色泡沫状固体产品GAL-C7-2 22.4g。MS m/z:C
21H
32NO
11,[M+H]
+,理论:476.50,实测:475.94。
(4-1-3)R-1的合成:
将按照步骤(1-1-4)中描述的方法得到的M-18-Tr(2.02g,4.69mmol)与GAL-C7-2(7.36g,15.48mmol)混合溶于47ml乙腈,再加入N-甲基吗啉(3.13g,30.96mmol),最后加入4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐(DMTMM,4.28g,15.48mmol),室温搅拌反应2h。以200ml二氯甲烷稀释反应液,100ml饱和碳酸氢钠溶液洗涤有机相,100ml饱和食盐水洗涤有机相,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品,200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,二氯甲烷:甲醇=100:5-100:7梯度洗脱,收集产物洗脱液,减压蒸干得到纯品R-1 7.82g。
(4-1-4)R-2的合成:
将R-1(6.23g,3.456mmol)溶于69ml二氯甲烷,再加入二氯乙酸(13.367g,103.67mmol),室温下反应2h。加入100ml二氯甲烷稀释反应液,再加饱和碳酸氢钠溶液洗涤调节pH=7-8之间,水相以二氯甲烷萃取6次,每次30ml,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品。200-300目正相硅胶,以10重量%三乙胺中和硅胶酸性,以1重量‰三乙胺平衡柱子,二氯甲烷:甲醇=100:30-100:40梯度洗脱,减压蒸干溶剂得到纯品R-2 4.49g。
(4-1-5)R-3的合成:
将R-2(2.391g,1.532mmol)和A-1(2.342g,4.596mmol)混合溶于16ml二氯甲烷,加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT)(1.375g,4.596mmol),再加入二异 丙基乙胺(1.188g,9.191mmol),25℃下搅拌反应2h。用10ml饱和碳酸氢钠洗涤有机相,水相以二氯甲烷萃取3次,每次10ml,以10ml饱和食盐水洗涤有机相,水相以二氯甲烷萃取2次,每次10ml,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜得到粗品。柱纯化使用120g 200-300目正相硅胶,以20ml三乙胺中和硅胶酸性,以含1重量%三乙胺的石油醚平衡柱子,石油醚:乙酸乙酯:二氯甲烷:N,N-二甲基甲酰胺=1:1:1:0.5-1:1:1:0.6梯度洗脱,减压蒸干溶剂得到纯品R-3 2.642g。
(4-1-6)R-4的合成:
将R-3(795mg,0.4074mmol)、丁二酸酐(82mg,0.8148mmol)和4-二甲氨基吡啶(DMAP,100mg,0.8148mmol)混合溶于4ml二氯甲烷,再加入二异丙基乙胺(DIEA,100mg,0.8148mmol),25℃下搅拌反应18h。5ml 0.5M三乙胺磷酸盐洗涤反应液,水相以二氯甲烷萃取3次,每次5ml,合并有机相减压蒸干得到粗品。柱纯化使用30g 200-300目正相硅胶,以1重量%三乙胺中和硅胶酸性,以二氯甲烷平衡柱子,含1重量‰三乙胺的二氯甲烷:甲醇=100:18-100:20梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品R-4缀合分子505mg。
(4-1-7)R-5缀合分子的合成:
通过与制备例1中步骤(1-1-9)相同的方法,制备R-5。不同的是以R-4缀合分子代替L-9缀合分子,得到连接固相载体的R-4缀合分子。
(4-2)合成R5-siAP1M2SVP缀合物
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物23,不同的是以R-5化合物代替L-10化合物起始正义链合成。预期可以得到R5-siAP1M2SVP缀合物,其结构如式(7)所示。
制备例5 LA5-siAP1M2SVP缀合物(缀合物24)的制备
按照以下工艺路线,预期能够合成LA-5化合物:
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物24,不同的是以LA-5化合物代替L-10化合物起始正义链合成。预期可以得到LA5-siAP1M2SVP缀合 物,其结构如式(12)所示。
制备例6 LB5-siAP1M2SVP缀合物(缀合物25)的制备
(6-1)LB-5化合物的合成
按照以下方法,合成了LB-5化合物:
(6-1-1)LB-1的合成:
将按照步骤(1-1-6)中描述的方法得到的L-8(5.0g,3.386mmol)、己二酸酐(870mg,6.772mmol)和4-二甲氨基吡啶(DMAP,827mg,6.772mmol)混合溶于130ml二氯甲烷,再加入二异丙基乙胺(DIEA,2.2g,16.931mmol),25℃下搅拌反应4h。加入70ml二氯甲烷稀释反应液,以0.5M三乙胺磷酸盐洗涤反应液,水相以二氯甲烷萃取4次,每次10ml,合并有机相减压蒸干得到粗品。柱纯化使用120g 200-300目正相硅胶,以1重量%三乙胺 中和硅胶酸性,以二氯甲烷平衡柱子,石油醚:乙酸乙酯:二氯甲烷:甲醇=1:1:1:0.2-1:1:1:1梯度洗脱,减压蒸干溶剂得到纯品LB-1 4.267g。
(6-1-2)LB-2的合成:
将按照步骤(6-1-1)中描述的方法得到的LB-1(4.697g,2.753mmol,由两批次产物合并而得)、3-氨基-1,2-丙二醇(313mg,3.442mmol)、4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐(DMTMM,953mg,3.442mmol)和N-甲基吗啉(700mg,6.884mmol)先后加入30ml乙腈和3ml甲醇的混合液中,室温搅拌反应过夜。蒸发溶剂至干,柱层析(200-300目正相硅胶,二氯甲烷:甲醇=1:0.07-1:0.5梯度洗脱)纯化,收集产物洗脱液,浓缩除去溶剂,得到目标产物LB-2 3.27g。
(6-1-3)LB-3的合成:
将LB-2(2.27g,1.353mmol)用14ml无水吡啶溶解。再加入4,4'-双甲氧基三苯甲基氯(688mg,2.03mmol)室温下搅拌反应过夜。加150ml甲醇淬灭,蒸发溶剂至干。柱层析(200-300目正相硅胶,二氯甲烷:甲醇=1:0.05-1:0.2梯度洗脱)纯化,收集产物洗脱液,浓缩除去溶剂,得到目标产物LB-3 1.647g。
(6-1-4)LB-4的合成:
将LB-3(822mg,0.415mmol)、丁二酸酐(83g,0.83mmol)和4-二甲氨基吡啶(DMAP,102mg,0.83mmol)混合溶于4ml二氯甲烷,再加入DIEA(270mg,2.075mmol),25℃下搅拌反应过夜。0.5M三乙胺磷酸盐洗涤反应液3次,水相以二氯甲烷萃取3次,每次2ml,合并有机相减压蒸干得到粗品。柱纯化使用200-300目正相硅胶,以5重量%三乙胺中和硅胶酸性,以石油醚平衡柱子,用含1重量‰三乙胺的二氯甲烷:甲醇=100:5-100:20梯度洗脱,减压蒸干溶剂得到纯品LB-4缀合分子787mg。
(6-1-5)LB-5的合成:
通过与制备例1中步骤(1-1-9)相同的方法,制备LB-5。不同的是以LB-4缀合分子代替L-9缀合分子,得到连接固相载体的LB-4缀合分子。
(6-2)合成LB5-siAP1M2SVP缀合物
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物25,不同的是以LB-5化合物代替L-10化合物起始正义链合成。预期可以得到LB5-siAP1M2SVP,其结构如式(13)所示。
制备例7 V8-siAP1M2SVP缀合物(缀合物26)的合成
按照以下工艺路线,预期能够合成V-8化合物:
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物26,不同的是以V-8化合物代替L-10化合物起始正义链合成。预期可以得到V8-siAP1M2SVP,其结 构如式(14)所示。
制备例8 W8-siAP1M2SVP缀合物(缀合物27)的制备
(8-1)W-8化合物的合成
按照以下方法,合成了W-8化合物:
(8-1-1)W-1的合成:
将W-0(2.024g,10mmol)溶于25ml乙腈中,再加三乙胺(4.048g,40mmol),冰水浴冷却至0℃左右,加入三氟乙酸乙酯(5.683g,40mmol),室温下反应22h。减压蒸干溶剂,真空油泵发泡干燥18h,得到5.835g粗品固体W-1。
(8-1-2)W-2的合成:
将W-1粗品(5.835g,10mmol)溶于50ml二氯甲烷,向反应液中加入TrCl(3.345g,12mmol)和三乙胺(1.518g,15mmol),室温下搅拌反应20h。用20ml饱和碳酸氢钠洗涤反应液2次,用20ml饱和食盐水洗涤1次,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干有机溶剂,真空油泵发泡干燥过夜,得到粗品固体W-2 8.012g。不经处理,进行下一步脱保护反应。
(8-1-3)W-3的合成:
将W-2粗品(8.012g,10mmol)溶于100ml甲醇,再加入100ml甲胺水溶液(40重量%),在50℃下搅拌反应23h。过滤除去不溶颗粒物,减压蒸干溶剂,加入200ml体积比为1:1的DCM-甲醇混合溶剂,以50ml饱和碳酸氢钠洗涤有机相,水相再用二氯甲烷萃取3次,每次50ml,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜,200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,以二氯甲烷:甲醇:氨水(25重量%)=1:1:0.05-1:1:0.25梯度洗脱,收集产物洗脱液,减压蒸干溶剂,真空油泵发泡干燥得到纯品W-3 3.062g。
(8-1-4)W-4的合成:
将W-3(0.675g,1.517mmol)与GAL-C7-2(2.60g,5.46mmol)混合溶于47ml乙腈,再加二异丙基乙胺(1.57g,12.14mmol),最后加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT,1.816g,6.04mmol),室温搅拌反应2.5h。以100ml二氯甲烷稀释反应液,80ml饱和碳酸氢钠溶液洗涤有机相,80ml饱和食盐水洗涤有机相,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂得粗品,200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,以二氯甲烷:甲醇=100:5-100:7梯度洗脱,收集产物洗脱液,减压蒸干得到纯品W-4 1.610g。
(8-1-5)W-5的合成:
将W-4(1.61g,0.886mmol)溶于125ml二氯甲烷,再加入二氯乙酸(3.5ml,42.43mmol),室温下反应1h。加入150ml吡啶中和反应液,减压蒸干溶剂得粗品。200-300目正相硅胶,10重量%三乙胺中和硅胶酸性,1重量‰三乙胺平衡柱子,二氯甲烷:甲醇=100:30-100:40梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品W-5 1.26g。
(8-1-6)W-6的合成:
将W-5(1.25g,0.793mmol)和按照步骤(1-1-7a)中描述的方法得到的A-1(1.21g,2.38mmol)混合溶于12ml二氯甲烷,加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT, 0.712g,2.38mmol),再加入二异丙基乙胺(0.615g,4.76mmol),25℃下搅拌反应3h。用80ml饱和碳酸氢钠洗涤有机相,水相以二氯甲烷萃取3次,每次10ml,合并有机相并以10ml饱和食盐水洗涤,合并有机相并以无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜得到粗品。柱纯化使用185g 200-300目正相硅胶,20ml三乙胺中和硅胶酸性,以含1重量%三乙胺的石油醚平衡柱子,以石油醚:乙酸乙酯:二氯甲烷:N,N-二甲基甲酰胺=1:1:1:0.1-1:1:0.7梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品W-6 1.57g。
(8-1-7)W-7的合成:
将W-6(1.238g,0.63mmol)、丁二酸酐(0.189g,1.89mmol)和4-二甲氨基吡啶(DMAP,0.231g,1.89mmol)混合溶于7ml二氯甲烷,再加入DIEA(0.407g,3.15mmol),25℃下搅拌反应24h。以5ml 0.5M三乙胺磷酸盐洗涤反应液,水相以二氯甲烷萃取3次,每次5ml,合并有机相减压蒸干得到粗品。柱纯化使用30g 200-300目正相硅胶,以1重量%三乙胺中和硅胶酸性,二氯甲烷平衡柱子,以含1重量‰三乙胺的二氯甲烷:甲醇=100:18-100:20梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品W-7缀合分子1.033g。MS m/z:C101H146N7O38,[M-DMTr]+,理论:1763.92,实测:1763.21。
(8-1-8)W-8的合成:
通过与制备例1中步骤(1-1-9)相同的方法,制备W-8。不同的是以W-7缀合分子代替L-9缀合分子,得到连接固相载体的W-7缀合分子。
(8-2)合成W8-siAP1M2SVP缀合物
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物27,不同的是以W-8化合物代替L-10化合物起始正义链合成。预期可以得到W8-siAP1M2SVP,其结构如式(15)所示。
制备例9 X8-siAP1M2SVP缀合物(缀合物28)的制备
按照以下工艺路线,预期能够合成X-8化合物:
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物28,不同的是以X-8化合物代替L-10化合物起始正义链合成。预期可以得到X8-siAP1M2SVP,其结 构如式(21)所示。
制备例10 Z5-siAP1M2SVP缀合物(缀合物29)的制备
(10-1)Z-5化合物的合成
按照以下方法,合成了Z-5化合物:
(10-1-1)Z-1的合成:
将按照步骤(8-1-3)中描述的方法得到的W-3(1.50g,3.37mmol)与按照步骤(3-1-2)中描述的方法得到的GAL5-C4-2(7.18g,13.48mmol)混合溶于34ml二氯甲烷,再加入二异丙基乙胺(3.48g,26.96mmol),最后加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT,4.04g,13.48mmol),室温搅拌反应4.5h。以100ml二氯甲烷稀释反应液,80ml饱和碳酸氢钠溶液洗涤有机相,80ml饱和食盐水洗涤有机相,合并有机相并以无水硫酸钠 干燥,过滤后减压蒸干溶剂得粗品,200-300目正相硅胶柱纯化,石油醚装柱,以1重量%三乙胺中和硅胶酸性,以二氯甲烷:甲醇=30:1-15:1梯度洗脱,收集产物洗脱液,减压蒸干得到纯品Z-1 3.97g。MS m/z:C
98H
143N
10O
33,[M+H]
+,理论:1987.98,实测:1987.90。
(10-1-2)Z-2的合成:
将Z-1(3.97g,2.00mmol)溶于250ml二氯甲烷,再加入二氯乙酸(10.941g,84.85mmol),室温下反应1h。加入吡啶中和反应液至中性,减压蒸干溶剂得粗品。220g 200-300目正相硅胶装柱,10%吡啶中和硅胶酸性,1‰吡啶平衡柱子,二氯甲烷:甲醇=10:1-2:1梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品Z-2 3.49g。MS m/z:C
79H
129N
10O
33,[M+H]
+,理论:1746.94,实测:1746.90。
(10-1-3)Z-3的合成:
将Z-2(3.49g,2.0mmol)和按照步骤(1-1-7a)中描述的方法得到的A-1(3.06g,6.0mmol)混合溶于30ml二氯甲烷,加入3-二乙氧基磷酰基-1,2,3-苯唑4(3H)-酮(DEPBT,1.80g,6.0mmol),再加入二异丙基乙胺(1.55g,12.0mmol),25℃下搅拌反应3h。100ml二氯甲烷稀释反应液,用饱和碳酸氢钠洗涤有机相2次,每次30ml,水相以10二氯甲烷萃取,合并有机相并以50ml饱和食盐水洗涤,合并有机相无水硫酸钠干燥,过滤后减压蒸干溶剂,真空油泵发泡干燥过夜得到粗品。柱纯化使用200g 200-300目正相硅胶,20ml三乙胺中和硅胶酸性,以含1重量%三乙胺的石油醚平衡柱子,二氯甲烷:甲醇=25:1-15:1梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品Z-3 2.2g。MS m/z:C
103H
151N
10O
38,[M+H]
+,理论:2136.02,实测:2136.20。
(10-1-4)Z-4的合成:
将Z-3(2.10g,0.983mmol)溶解在含有DIEA(0.635g,4.915mmol)的14.8ml二氯甲烷中,加入4-二甲氨基吡啶(DMAP,240mg,1.966mmol)搅拌澄清后,加入丁二酸酐(197mg,1.966mmol),25℃下搅拌反应18h。加入50ml二氯甲烷稀释反应液,以80ml 0.5M三乙胺磷酸盐洗涤有机相,水相以二氯甲烷萃取2次,每次50ml,合并有机相减压蒸干得到粗品。柱纯化使用188g 200-300目正相硅胶,以1重量%三乙胺中和硅胶酸性,二氯甲烷平衡柱子,以含1重量‰三乙胺的二氯甲烷:甲醇=10:1-3:1梯度洗脱,收集产物洗脱液,减压蒸干溶剂得到纯品Z-4缀合分子1.95g。MS m/z:C
107H
155N
10O
41,[M+H]
+,理论:1935.07,实测:1935.29。
(10-1-5)Z-5的合成
通过与制备例1中步骤(1-1-9)相同的方法,制备Z-5。不同的是以Z-4缀合分子代替L-9缀合分子,得到连接固相载体的Z-4缀合分子。
(10-2)合成Z5-siAP1M2SVP缀合物
通过与制备例1中步骤(1-2)、(1-3A)、(1-4)相同的方法,制备缀合物29,不同的是以Z-5化合物代替L-10化合物起始正义链合成。预期可以得到Z5-siAP1M2SVP缀合物,其结构如式(22)所示。
制备例11 缀合物F1-F5的制备
本制备例合成了缀合物F1-F5(以下,也分别称为FIN-siAP1M1SVP、FIN-siAP1M1S、 FIN-siAP2M1SVP、FIN-siAP2M1S和FIN-siAP2M2S缀合物)。该缀合物中所缀合的siRNA的序列参见表3。
(11-1)FIN-2缀合分子的合成
参照Rajeev等人,ChemBioChem 2015,16,903-908中描述的制备方法,按照以下工艺路线,合成了FIN-2缀合分子:
(11-1-1)PRO-10的合成
(11-1-1a)PRO-7的合成
将2.93g PRO-6(L-羟基脯氨酸,CAS号:51-35-4,购自安耐吉公司,22.4mmol)溶于22.5ml 1,4-dioxane(1,4-二氧六环,CAS号:123-91-1)中,加入34ml 10%(w/w)Na
2CO
3的水溶液,呈悬浊液状态,将6.95g Fmoc-Cl(氯甲酸-9-芴基甲酯,CAS号:28920-43-6,购自安耐吉公司,26.8mmol)溶于34ml 1,4-dioxane,冰浴下加入到上述悬浊液中,自然升至室温反应过夜。将反应液倒入150ml冰水中,用甲基叔丁基醚萃取三次,每次100ml,弃去有机相,水相用浓HCl调节至pH≤5,用100ml乙酸乙酯萃取两次,合并有机相,无水硫酸钠干燥,减压蒸干溶剂得到白色泡沫状固体产品PRO-7 7.83g。
1H NMR(400MHz,DMSO-d
6)δ7.91(t,J=7.2Hz,2H),7.67(d,J=7.5Hz,2H),7.48–7.39(m,2H),7.38–7.27(m,2H),5.17(s,1H),4.27(s,2H),4.23–4.11(m,2H),3.55–3.41(m,3H),2.31–2.10(m,1H),2.08–1.88(m,1H).HRMS(ESI)m/z理论C
20H
19NO
5[M-H]
-352.1190,实测352.1033.
(11-1-1b)PRO-8的合成
将7.83g PRO-7(22.2mmol)溶于80ml THF(CAS号:109-99-9)中,油浴加热到65℃,回流状态下加入36.6ml 2mol/L的BH
3-Me
2S的THF溶液(CAS号13292-87-0,购自百灵威公司,73.2mmol),继续回流反应3小时。倒出反应液,用甲醇溶解剩余固体,搅拌下加入甲醇至反应液无气体放出并继续搅拌30分钟,减压蒸除溶剂后用石油醚提纯三次后得白色固体产物PRO-8 7.1g。
1H NMR(400MHz,DMSO-d
6)δ7.91(t,J=6.7Hz,2H),7.67 (d,J=7.2Hz,2H),7.49–7.39(m,2H),7.38–7.26(m,2H),5.18(dd,J=6.1,3.8Hz,1H),4.28(s,2H),4.23–4.13(m,2H),3.55–3.38(m,2H),2.32–2.11(m,1H),2.08–1.89(m,1H).HRMS(ESI)m/z理论C
20H
21NO
4[M+Na]
+362.1368,实测362.1012.
(11-1-1c)PRO-9的合成
将7.1g PRO-8(21mmol)溶于100ml吡啶中,加入14.2g DMTr-Cl(4,4'-双甲氧基三苯甲基氯,42mmol),室温下搅拌反应5小时。减压蒸除溶剂,粗品用乙酸乙酯溶解后过滤除去盐类杂质,减压蒸除溶剂后硅胶柱纯化,硅胶柱预先用吡啶碱化后DCM溶解粗品上样,先用含1%(v/v)吡啶的DCM洗脱DMTr-Cl,随后用乙酸乙酯洗脱产物,收集产物洗脱液,减压蒸干溶剂,得白色固体产物PRO-9 8.2g;HRMS(ESI)m/z理论C
41H
39NO
6[M+Na]
+664.2675,实测664.2348;C18 RP-HPLC(批号JJS160324-1)纯度94.20%。
(11-1-1d)PRO-10的合成
将8.2g PRO-9(12.8mmol)溶于64ml DMF(N,N-二甲基甲酰胺)中,加入40ml哌啶(384mmol),室温下搅拌反应30分钟。反应液倒入300ml冰水中,乙酸乙酯萃取三次,每次150ml,合并有机相,用200ml饱和食盐水洗涤后,有机相以无水硫酸钠干燥,减压蒸除溶剂后硅胶柱纯化,硅胶柱预先用吡啶碱化后DCM溶解粗品上样,先用含1%(v/v)吡啶的DCM洗脱Fmoc,随后用乙酸乙酯洗脱产物,收集产物洗脱液,减压蒸干溶剂,得白色固体产物PRO-10 4.65g。
1H NMR(400MHz,DMSO-d
6)δ7.40(d,J=7.2Hz,2H),7.35–7.18(m,7H),6.93–6.84(m,4H),4.56(d,J=3.9Hz,1H),4.12(s,1H),3.74(s,6H),3.46–3.37(m,1H),2.88(ddd,J=18.5,10.0,5.5Hz,2H),2.75(dd,J=8.7,5.8Hz,1H),2.62(dd,J=11.0,2.7Hz,1H),1.74–1.65(m,1H),1.40(ddd,J=12.9,8.5,5.9Hz,1H);HRMS(ESI)m/z理论C
26H
29NO
4[M+Na]
+442.1994,实测442.1999;C18 RP-HPLC(批号JJS160329-1)纯度97.07%。
(11-1-2)FIN-1的合成
将按照(1-1-1)中描述的方法得到的GAL-5(4.5g,10mmol)溶于40ml DMF中,依次加入3.9g DIEA(N,N-二异丙基乙胺,CAS号:7087-68-5,购自阿拉丁公司,30mmol)和3.8g HBTU(苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐,CAS号:94790-37-2,商购自阿拉丁公司,11mmol),室温下搅拌10分钟,将步骤(11-1-1d)中获得的PRO-10(4.2g,10mmol)溶于40mlDMF中,随后加入到上述反应液中,反应液中加入无水硫酸钠干燥,室温搅拌2小时。将反应液倒入120ml冰水中,用乙酸乙酯萃取三次,每次60ml,合并有机相,分别用20ml水、20ml饱和食盐水洗涤,分出有机相并以无水硫酸钠干燥,减压蒸除溶剂,硅胶柱纯化,硅胶柱预先用吡啶碱化后上样,用含1体积%三乙胺和1体积%甲 醇的二氯甲烷(DCM)溶液洗脱,收集产物洗脱液,减压蒸干溶剂,得到浅黄色泡沫状固体产品FIN-1 6.5g。
1H NMR(400MHz,DMSO-d
6)δ7.83(d,J=9.2Hz,1H),7.32(t,J=6.6Hz,4H),7.20(td,J=8.9,3.5Hz,5H),6.93–6.84(m,4H),5.21(d,J=3.2Hz,1H),5.04–4.90(m,2H),4.49(s,1H),4.40(d,J=4.4Hz,0.8H),4.31(d,J=5.0Hz,0.2H),4.15(s,1H),4.03(s,3H),3.93(s,1H),3.74(s,7H),3.59(dt,J=12.0,6.0Hz,1H),3.50–3.40(m,1H),3.39–3.25(m,3H),3.13(dd,J=8.9,5.2Hz,1H),3.00(dq,J=9.3,5.3,4.3Hz,1H),2.22(s,2H),2.07(s,3H),1.99(s,3H),1.90(s,4H),1.74(s,3H),1.50(s,3H),1.36(s,1H)。C18 RP-HPLC(批号LJ160422)纯度95.45%。
(11-1-3)FIN-2的合成
将步骤(11-1-2)中获得的FIN-1(3.0g,3.53mmol)与乙腈共沸除水,减压抽干,溶于10ml DMF,氮气保护下加入2.13g PA(双(二异丙基氨基)(2-氰基乙氧基)膦,购自Adamas公司,商品编号11356B,7.06mmol)、346mg四唑(CAS号:288-94-8,购自阿拉丁公司,4.94mmol),室温下搅拌反应,补加10ml DMF,继续搅拌反应1小时。减压蒸除溶剂后以硅胶柱色谱纯化,硅胶柱预先用吡啶碱化后DCM溶解粗品上样,乙酸乙酯洗脱,收集产物洗脱液,减压蒸除溶剂,得无色糖浆状粗品4.5g。粗品用50体积%乙腈水溶液溶解至完全溶解,用C-18,330g,
中压纯化柱纯化样品,柱子先用1体积%吡啶的乙腈溶液碱化,梯度洗脱收集产品峰,减压蒸除溶剂得白色粉末产品FIN-2缀合分子2.2g。
31P NMR(162MHz,CDCl
3)δ148.04,147.94,147.62,147.19,磷谱纯度92%;C18 RP-HPLC纯度90.54%。
(11-2)FIN-2缀合分子连接到固相载体
采用核酸固相合成方法,将步骤(11-1-3)中得到的FIN-2缀合分子,通过三次循环,连接到通用固相载体(UnyLinker
TM loaded
Solid Supports)上,从而实现缀合基团(FIN_FIN_FIN)连接在RNA正义链的3'末端。
参照Rajeev等人,ChemBioChem 2015,16,903-908中描述的制备方法进行上述连接,具体而言,首先,由上述通用固相载体开始,脱除固相载体上的羟基保护基团,在偶联反应条件和偶联试剂存在下与FIN-2缀合分子接触发生偶联,经盖帽反应和氧化反应后,获得连接至固相载体的FIN缀合分子;脱除该连接至固相载体的FIN缀合分子上的羟基保护基团DMTr,与FIN-2缀合分子接触发生偶联,进行盖帽反应和氧化反应,并再重复一次上述脱保护-偶联-盖帽-氧化步骤,连接第三个FIN-2缀合分子,获得连接在固相载体上的的缀合基团(FIN_FIN_FIN)。
上述反应中,所述的脱保护、偶联、盖帽、氧化的反应条件、溶剂和试剂用量与前述步骤(1-2)中描述的核酸固相合成方法相同。
(11-3)缀合物F1-F5的合成
通过与制备例1中步骤(1-2)、(1-3)、(1-4)相同的方法,制备题述缀合物,不同的是:1)以步骤(11-2)得到的化合物起始合成正义链;2)缀合的siRNA具有表3中所示的对应于缀合物F1-F5的序列。
利用液质联用仪(LC-MS,Liquid Chromatography-Mass Spectrometry,购于Waters公司,型号:LCT Premier)进行分子量检测。其结果,实测值与理论值相符,从而确定所合成的缀合物是目标设计的化合物,其结构如式(307)所示。
制备例12 对比缀合物3的制备
本制备例合成了对比缀合物3,该缀合物中所缀合的siRNA的序列参见表3。该缀合物与美国申请15/597,225中化合物AD-69535的结构相同。
(12-1)(GalNAc)
3缀合分子的合成
按照WO2014025805A1所述的制备方法合成化合物30,即,含有如上文所述的接头-(L
A)
3三羟甲基氨基甲烷-L
B-以及作为靶向基团的N-乙酰半乳糖胺分子(其中,每个L
A可连接一个N-乙酰半乳糖胺分子,因而一个接头可连接三个N-乙酰半乳糖胺分子)的缀合分子,也称(GalNAc)
3缀合分子,所述化合物30的结构如下式所示:
(12-2)(GalNAc)
3缀合分子连接到固相载体
通过与制备例1中步骤(1-1-9)相同的方法,将(GalNAc)
3缀合分子连接到固相载体,得到连接固相载体的(GalNAc)
3缀合分子。
(12-3)对比缀合物1的合成
通过与制备例1中步骤(1-2)、(1-3)、(1-4)相同的方法,制备对比缀合物1,不同的是:1)以步骤(12-2)得到的化合物起始正义链合成;2)缀合的siRNA具有表3中编号为(GalNAc)
3-69535所示的序列。
利用液质联用仪(LC-MS,Liquid Chromatography-Mass Spectrometry,购于Waters公司,型号:LCT Premier)进行分子量检测。其结果,实测值与理论值相符,从而确定所合成的缀合物是目标设计的化合物,其结构如式(305)所示。
在上述本公开的缀合物制备完成后,使用标准手段冻干为固体粉末保存备用。在使用时,可使用例如注射用水将其重新溶解为所需浓度的溶液使用。
实验例1本实验考察本公开的siRNA缀合物在体外(in vitro)的抑制活性
实验例1-1体外psiCHECK系统中的在靶活性
本实验例考察了缀合物F1-F5在体外psiCHECK系统中的在靶活性(on-target activity),即测定了缀合物F1-F5靶向完全匹配目标序列(其核苷酸序列与所述缀合物反义链的全长核苷酸序列完全互补)的活性。
根据Kumico Ui-Tei et.al.,Functional dissection of siRNA sequence by systematic DNA substitution:modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect.Nucleic Acids Research,2008.36(7),2136-2151描述的方法,构建检测质粒,与待评价的siRNA缀合物共转染至HEK293A细胞中,通过双萤光素酶报告基因的表达水平,来反应siRNA缀合物的在靶活性。
具体步骤如下:
[1]构建检测质粒
采用psiCHECK
TM-2(Promega
TM)质粒构建在靶质粒,该质粒含有一个目标序列,该目标序列与待测缀合物中的反义链的所有21个核苷酸序列完全互补。将目标序列克隆到psiCHECK
TM-2质粒的Xho I/Not I位点。
[2]转染
在96孔板中,根据Lipofectamine
TM 2000(Invitrogen公司)的使用说明,分别共转染siRNA缀合物和上述质粒,其中每孔转染质粒10ng,使用Lipofectamine
TM 2000 0.2μL,缀合物的终浓度(以siRNA的浓度计算)依次为0.5nM、0.1nM和0.02nM。各组以无缀合物处理为对照。每组3个复孔。
NC为吉玛公司与目的基因序列无同源性的通用阴性对照B01001。
[3]检测
共转染24小时后,使用双萤光素酶报告基因检测试剂盒(Dual luciferase reporter gene assay kit,Promega公司,cat.E2940),根据使用说明书裂解HEK293A细胞,检测双萤光素酶报告基因的表达水平。以海肾萤光素酶蛋白水平相对于萤火虫萤光素酶蛋白水平进行标准化。结果如图1所示。
结果表明,缀合物F1-F5都具有较好的体外抑制活性,高浓度下,各缀合物的抑制率为87%-97%。
实验例1-2体外psiCHECK系统中IC
50的测定
本实验例考察了缀合物1在体外psiCHECK系统中的IC
50。
采用与实验例1-1相同的方法构建缀合物1的在靶质粒,缀合物1的终浓度(以siRNA的浓度计算)自1nM起始,倍比稀释11个浓度,至0.001nM。根据采用不同缀合物浓度所测得的活性结果,利用Graphpad 5.0软件log(inhibitor)vs.response—Variable slope功能来拟合剂量-效应曲线,根据剂量-效应曲线计算缀合物1的IC
50值。
式中:
Y是残留mRNA的表达水平,
X为转染siRNA浓度的对数值,
Bot是稳态期底部的Y值,
Top是稳态期顶部的Y值,
LogIC
50是当Y在底部到顶部之间一半时的X值,而HillSlope则是曲线的斜率。
检测可得,缀合物1在体外psiCHECK系统中的IC
50为0.0174nM,说明本公开的siRNA缀合物在体外具有较高活性。
实验例1-3体外细胞系中IC
50的测定
本实验例考察了缀合物2在体外Huh7细胞中对APOC3 mRNA表达量的抑制效率。
使用Lipofectamine
TM 2000将缀合物2转染至人类肝癌细胞株Huh7中,siRNA缀合物终浓度(以siRNA的量计)自3nM起始,3倍稀释7个浓度,至0.004nM。每个浓度2个复孔。
通过实时荧光定量PCR(Quantitative Real-Time PCR)分别检测转染了各浓度的缀合物2的Huh7细胞中APOC3 mRNA的表达量。具体步骤为:培养转染的细胞24小时后,使用Trizol(Thermo Fisher公司)根据总RNA提取的标准操作步骤提取细胞中的总RNA;分别取1μg总RNA,使用反转录试剂盒(Promega公司,货号A3500)按其说明书的操作方法反转录得到cDNA。使用2×Ultra SYBR Mixture(with ROX)(北京康为世纪生物科技有限公司,货号CW0956)试剂盒,以cDNA为模板按照说明书的步骤进行APOC3 mRNA表达量的检测。其中,用于扩增APOC3和作为内参基因的β-actin的PCR引物如表4所示。
表4 检测引物的序列
APOC3 mRNA表达量按如下等式计算:APOC3 mRNA表达量=[(测试组APOC3 mRNA的表达量/测试组β-Actin mRNA的表达量)/(对照组APOC3 mRNA的表达量/对照组β-Actin mRNA的表达量)]×100%。
缀合物对APOC3 mRNA表达量的抑制率按如下等式计算:抑制率=(1-APOC3 mRNA表达量)×100%。其中,各测试组为分别经各浓度缀合物2处理的Huh7细胞,对照组为未经缀合物2处理的Huh7细胞。
根据采用不同浓度缀合物2所测得的对APOC3 mRNA表达量的抑制率,采用与实验例1-2相同的方法计算IC
50,可得缀合物2在体外Huh7细胞中的IC
50为0.0085nM,说明本公开的siRNA缀合物在体外具有较高活性。
实验例2本实验考察本公开的siRNA缀合物在体内(in vivo)对APOC3 mRNA表达量的抑制效率
实验例2-1本实验例考察缀合物1在人APOC3转基因小鼠体内对肝脏组织中APOC3 mRNA表达量的抑制率。
将人APOC3转基因小鼠(B6;CBA-Tg(APOC3)3707Bres/J)按照甘油三酯含量大于2mmol/L随机分组,每组5只,分别向每组小鼠给予缀合物1、对比缀合物1以及生理盐水NS。所有动物根据体重计算药量,采用皮下注射方式单次给药,siRNA缀合物给药剂量(以siRNA的量计)为1mg/kg和0.1mg/kg两个剂量组,缀合物分别以0.2mg/ml和0.02mg/ml浓度的0.9%氯化钠水溶液提供,给药体积为5mL/kg。给药后14天处死小鼠,收集肝脏,用RNA later(Sigma Aldrich公司)保存;随后用组织匀浆仪匀浆肝组织,再用Trizol(Thermo Fisher公司)根据总RNA提取的标准操作步骤提取得到肝组织总RNA。
采用与实验例1-3相同的实时荧光定量PCR方法检测肝组织中APOC3 mRNA的表达量。在该荧光定量PCR法中,以β-肌动蛋白(β-actin)基因作为内参基因,使用针对APOC3的引物和针对β-肌动蛋白的引物分别检测APOC3和β-肌动蛋白的表达量。
检测引物的序列参见表5。
表5 检测引物的序列
肝中APOC3 mRNA的表达量以及缀合物对APOC3 mRNA的抑制率计算同实验例1-3。其中,对照组为本实验中施以生理盐水的对照组小鼠,各测试组为分别施以不同siRNA缀合物的给药组小鼠。结果示于图2中。
结果显示,缀合物1对转基因鼠中的人APOC3基因具有显著的抑制作用。
实验例2-2本实验例考察缀合物1在食蟹猴体内对肝脏组织中APOC3 mRNA表达量的抑制率,以及对血脂水平的影响。
该实验例委托苏州华测生物技术有限公司进行。将2-4kg年龄为3-5岁的食蟹猴随机分为2组,每组一雄一雌,分别给予缀合物1以及对比缀合物2。所有动物根据体重计算药量,采用皮下注射方式单次给药,siRNA缀合物给药剂量(以siRNA的量计)为3mg/kg,缀合物分别以3mg/ml浓度的氯化钠注射液(山东科伦药业有限公司)的形式提供,给药 体积为1mL/kg。首次给药当天定义为试验第1天(D1)、给药前1天为第0天(D0)。
给药前与给药后第7、14、21、28天对动物进行静脉采血,在各时间点检测血清待测物含量,待测物指血脂(总胆固醇CHO、甘油三酯TG)和转氨酶(谷草转氨酶AST、谷丙转氨酶ALT)。待测物进行标准化处理,各待测物的抑制率按如下等式计算:抑制率=(1-给药后测试组待测物含量/给药前测试组待测物含量)×100%。其中,对甘油三酯的抑制率见表6。
表6 TG含量及其抑制率
通过检测给药后各检测点转氨酶含量,未发现肝功能异常。
给药后第28天处死动物,摘取肝脏。大体观察,未发现显著异常。采用与实验例2-1相同的方法提取肝组织RNA,检测肝中APOC3 mRNA的表达量。检测引物的序列参见表7。
表7 检测引物的序列
实时荧光定量PCR检测可得,相对于对比缀合物2,缀合物1对雌性动物的APOC3 mRNA的抑制率为55.3%;对雄性动物的APOC3 mRNA的抑制率为78.5%。
该实验显示,缀合物1对非人灵长类中的APOC3基因同样具有显著的抑制作用,并对血清TG也有显著的抑制作用,同时并未检测到肝功异常。
实验例3本实验考察本公开的siRNA缀合物在体内(in vivo)对血脂含量的影响
实验例3-1本实验例考察缀合物1在人APOC3转基因小鼠体内对血清中总胆固醇(CHO)和甘油三酯(TG)含量的影响。
将人APOC3转基因小鼠(B6;CBA-Tg(APOC3)3707Bres/J)按照TG含量>2mmol/L进行随机分组,每组7只,分组如下:(1)生理盐水对照组;(2)缀合物1 3mg/kg组;(3)缀合物1 1mg/kg组。所有动物根据体重计算药量,采用皮下注射方式单次给药,siRNA缀合物分别以0.6mg/ml和0.2mg/ml浓度的0.9%氯化钠水溶液提供,给药体积为5mL/kg。
分别于给药前(记为第0天),及给药后第7、14、21、28、35、42、49、63、77、91、112、133、147、154、161、175、189天对小鼠眼眶静脉丛取血,在各时间点检测血清CHO和TG水平。
眼眶取血每次约100μL,离心后血清不少于20μL,进一步使用PM1P000/3全自动血清生化仪(SABA,意大利)检测血清中总胆固醇(CHO)和甘油三酯(TG)的含量。
标准化的血脂水平=(给药后测试组血脂含量/给药前测试组血脂含量)×100%。
血脂水平的抑制率=(1-给药后测试组血脂含量/给药前测试组血脂含量)×100%。血脂指总胆固醇或甘油三酯。
检测结果示于图3A和3B中。
由图3A和3B可以看出,在给药后不同时间点,缀合物1显示出明显的降低小鼠血清中TG和CHO的效果,效果能长达189天;表明其能够在长时间内稳定高效地抑制APOC3基因的表达。
实验例3-2本实验例考察了缀合物2在人APOC3转基因小鼠体内对血清中总胆固醇(CHO)和甘油三酯(TG)含量的影响。
按照与实验例3-1相同的方法进行检测,区别在于,每组小鼠8只,所给予的缀合物为缀合物2;以0.1、0.3、1、3、9mg/kg五个剂量组分别给药,给药体积不变,相应调整缀合物溶液浓度;测试持续至给药后第112天。结果示于图4A和4B中。
由图4A和4B的结果可知,缀合物2能够在长达112天的时间内显著降低转基因小鼠中的TG和CHO水平,并且该降低效果存在明显的剂量依赖效应。
实验例3-3本实验例比较了缀合物1-3在人APOC3转基因小鼠体内对血清中总胆固醇(CHO)和甘油三酯(TG)含量的影响。
采用与实验例3-1相同的方法对小鼠血清总胆固醇(CHO)和总血脂(TG)进行测量,区别在于:每组小鼠6只,分别给予缀合物1、2和3以及对比缀合物3,每一种缀合物按1mg/kg和3mg/kg两个剂量组给药,给药体积不变,相应调整缀合物溶液浓度;测试时间直至给药后第112天。结果参见图5A-图5D。
由图5A-图5D的结果可知,在长达112天的时间内,本公开的缀合物1-3在不同剂量下均显示出对转基因小鼠中血脂的持续降低作用,该降低的持续效果总体上优于对比缀合物3。
上述结果表明,本公开提供的缀合物能够有效降低肝脏中APOC3 mRNA的表达,降低血液中总胆固醇、甘油三酯含量,可预防和/或治疗血脂异常,具有良好的临床应用前景。
以上详细描述了本公开的一些实施方式,但是,本公开并不限于上述实施方式中的具体细节,在本公开的技术构思范围内,可以对本公开的技术方案进行多种简单变型,这些简单变型均属于本公开的保护范围。
另外需要说明的是,在上述一些实施方式中所描述的各个具体技术特征,在不矛盾的情况下,可以通过任何合适的方式进行组合,为了避免不必要的重复,本公开对各种可能的组合方式不再另行说明。
此外,本公开的各种不同的实施方式之间也可以进行任意组合,只要其不违背本公开的思想,其同样应当视为本公开所公开的内容。
Claims (100)
- 一种siRNA缀合物,该缀合物具有式(1)所示的结构:其中,n1为选自1-3的整数,n3为选自0-4的整数;m1、m2和m3独立地为选自2-10的整数;R 10、R 11、R 12、R 13、R 14和R 15各自独立地为H,或选自于由以下基团所组成的组:C 1-C 10烷基、C 1-C 10卤代烷基以及C 1-C 10烷氧基;R 3为式A59所示结构的基团:其中,E 1为OH、SH或BH 2,Nu为siRNA;所述siRNA中的每个核苷酸各自独立地为修饰或未修饰的核苷酸,所述siRNA含有正义链和反义链,所述正义链包含核苷酸序列1,所述反义链包含核苷酸序列2,所述核苷酸序列1和所述核苷酸序列2至少部分地反向互补形成双链区,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1),5'-Z'UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2);其中,Z为A,Z'为U,所述核苷酸序列1中包含位置对应于Z的核苷酸Z A,所述核苷酸序列2中包含位置对应于Z'的核苷酸Z' B,所述Z' B是所述反义链5'末端的第一个核苷酸;R 2是长度为1-20个碳原子的直链亚烷基,其中一个或多个碳原子任选地被选自于以下基团所组成的组中的一个或多个所替换:C(O)、NH、O、S、CH=N、S(O) 2、C 2-C 10亚烯基、C 2-C 10亚炔基、C 6-C 10亚芳基、C 3-C 18亚杂环基和C 5-C 10亚杂芳基;并且其中R 2可任选地具有由以下基团所组成的组中的任何一个或多个的取代基:C 1-C 10烷基、C 6-C 10芳基、C 5-C 10杂芳基、C 1-C 10卤代烷基、-OC 1-C 10烷基、-OC 1-C 10烷基苯基、-C 1-C 10烷基-OH、-OC 1-C 10卤代烷基、-SC 1-C 10烷基、-SC 1-C 10烷基苯基、-C 1-C 10烷基-SH、-SC 1-C 10卤代烷基、卤素取代基、-OH、-SH、-NH 2、-C 1-C 10烷基-NH 2、 -N(C 1-C 10烷基)(C 1-C 10烷基)、-NH(C 1-C 10烷基)、氰基、硝基、-CO 2H、-C(O)O(C 1-C 10烷基)、-CON(C 1-C 10烷基)(C 1-C 10烷基)、-CONH(C 1-C 10烷基)、-CONH 2,-NHC(O)(C 1-C 10烷基)、-NHC(O)(苯基)、-N(C 1-C 10烷基)C(O)(C 1-C 10烷基)、-N(C 1-C 10烷基)C(O)(苯基)、-C(O)C 1-C 10烷基、-C(O)C 1-C 10烷基苯基、-C(O)C 1-C 10卤烷基、-OC(O)C 1-C 10烷基、-SO 2(C 1-C 10烷基)、-SO 2(苯基)、-SO 2(C 1-C 10卤代烷基)、-SO 2NH 2、-SO 2NH(C 1-C 10烷基)、-SO 2NH(苯基)、-NHSO 2(C 1-C 10烷基)、-NHSO 2(苯基)和-NHSO 2(C 1-C 10卤代烷基);每个L 1是长度为1-70个碳原子的直链亚烷基,其中一个或多个碳原子任选地被选自于以下基团所组成的组中的一个或多个所替换:C(O)、NH、O、S、CH=N、S(O) 2、C 2-C 10亚烯基、C 2-C 10亚炔基、C 6-C 10亚芳基、C 3-C 18亚杂环基和C 5-C 10亚杂芳基;并且其中,L 1可任选地具有由以下基团所组成的组中的任何一个或多个的取代基:C 1-C 10烷基、C 6-C 10芳基、C 5-C 10杂芳基、C 1-C 10卤代烷基、-OC 1-C 10烷基、-OC 1-C 10烷基苯基、-C 1-C 10烷基-OH、-OC 1-C 10卤代烷基、-SC 1-C 10烷基、-SC 1-C 10烷基苯基、-C 1-C 10烷基-SH、-SC 1-C 10卤代烷基、卤素取代基、-OH、-SH、-NH 2、-C 1-C 10烷基-NH 2、-N(C 1-C 10烷基)(C 1-C 10烷基)、-NH(C 1-C 10烷基)、氰基、硝基、-CO 2H、-C(O)O(C 1-C 10烷基)、-CON(C 1-C 10烷基)(C 1-C 10烷基)、-CONH(C 1-C 10烷基)、-CONH 2,-NHC(O)(C 1-C 10烷基)、-NHC(O)(苯基)、-N(C 1-C 10烷基)C(O)(C 1-C 10烷基)、-N(C 1-C 10烷基)C(O)(苯基)、-C(O)C 1-C 10烷基、-C(O)C 1-C 10烷基苯基、-C(O)C 1-C 10卤烷基、-OC(O)C 1-C 10烷基、-SO 2(C 1-C 10烷基)、-SO 2(苯基)、-SO 2(C 1-C 10卤代烷基)、-SO 2NH 2、-SO 2NH(C 1-C 10烷基)、-SO 2NH(苯基)、-NHSO 2(C 1-C 10烷基)、-NHSO 2(苯基)和-NHSO 2(C 1-C 10卤代烷基);M 1表示靶向基团。
- 根据权利要求2所述的siRNA缀合物,其中,L 1选自A1、A4、A5、A6、A8、A10、A11、A13中的一种或多种的连接组合。
- 根据权利要求2或3中所述的siRNA缀合物,其中,L 1选自A1、A4、A8、A10和A11中至少2个的连接组合。
- 根据权利要求2-4中任一项所述的siRNA缀合物,其中,L 1选自A1、A8、A10 中至少2个的连接组合。
- 根据权利要求1-5中任一项所述的siRNA缀合物,其中,L 1的长度为3-25个原子。
- 根据权利要求1-6中任一项所述的siRNA缀合物,其中,L 1的长度为4-15个原子。
- 根据权利要求2-7中任一项所述的siRNA缀合物,其中,j1为2-10的整数,j2为2-10的整数,R’为C 1-C 4的烷基,Ra为A27、A28、A29、A30和A31中的一种,Rb为C 1-C 5的烷基。
- 根据权利要求2-8中任一项所述的siRNA缀合物,其中,j1为3-5的整数,j2为3-5的整数,R’为甲基、乙基和异丙基中的一种,Ra为A27或A28,Rb为甲基、乙基、异丙基和丁基中的一种。
- 根据权利要求1-9中任一项所述的siRNA缀合物,其中,n1为1-2的整数,n3为0-1的整数,且n1+n3=2-3。
- 根据权利要求1-10中任一项所述的siRNA缀合物,其中,m1、m2和m3各自独立地为2-5的整数。
- 根据权利要求1-11中任一项所述的siRNA缀合物,其中,m1=m2=m3。
- 根据权利要求1-12中任一项所述的siRNA缀合物,其中,每个所述靶向基团独立地为与哺乳动物肝细胞表面的去唾液酸糖蛋白受体亲和的配体。
- 根据权利要求1-13中任一项所述的siRNA缀合物,其中,每个所述靶向基团独立地为去唾液酸糖蛋白或糖。
- 根据权利要求1-14中任一项所述的siRNA缀合物,其中,每个所述靶向基团独立地选自D-吡喃甘露糖、L-吡喃甘露糖、D-阿拉伯糖、D-呋喃木糖、L-呋喃木糖、D-葡萄糖、L-葡萄糖、D-半乳糖、L-半乳糖、α-D-呋喃甘露糖、β-D-呋喃甘露糖、α-D-吡喃甘露糖、β-D-吡喃甘露糖、α-D-吡喃葡萄糖、β-D-吡喃葡萄糖、α-D-呋喃葡萄糖、β-D-呋喃葡萄糖、α-D-呋喃果糖、α-D-吡喃果糖、α-D-吡喃半乳糖、β-D-吡喃半乳糖、α-D-呋喃半乳糖、β-D-呋喃半乳糖、葡糖胺、唾液酸、半乳糖胺、N-乙酰半乳糖胺、N-三氟乙酰基半乳糖胺、N-丙酰基半乳糖胺、N-正丁酰基半乳糖胺、N-异丁酰基半乳糖胺、2-氨基-3-O-[(R)-1-羧乙基]-2-脱氧-β-D-吡喃葡萄糖、2-脱氧-2-甲基氨基-L-吡喃葡萄糖、4,6-二脱氧-4-甲酰胺基-2,3-二-O-甲基-D-吡喃甘露糖、2-脱氧-2-磺氨基-D-吡喃葡萄糖、N-乙醇酰基-α-神经氨酸、5-硫代-β-D-吡喃葡萄糖、2,3,4-三-O-乙酰基-1-硫代-6-O-三苯甲基-α-D-吡喃葡萄糖苷甲酯、4-硫代-β-D-吡喃半乳糖、3,4,6,7-四-O-乙酰基-2-脱氧-1,5-二硫代-α-D-吡喃葡庚糖苷乙酯、2,5-脱水-D-阿洛糖腈、核糖、D-核糖、D-4-硫代核糖、L-核糖、L-4-硫代核糖中的一种。
- 根据权利要求1-15中任一项所述的siRNA缀合物,其中,至少一个或每个所述靶向基团为半乳糖或N-乙酰半乳糖胺。
- 根据权利要求1-16中任一项所述的siRNA缀合物,其中,R 10、R 11、R 12、R 13、R 14和R 15独立地为H、甲基或乙基。
- 根据权利要求1-17中任一项所述的siRNA缀合物,其中,R 2上同时含有与含氮 骨架上的N连接的位点和与R 3中的P连接的位点。
- 根据权利要求18所述的siRNA缀合物,其中,R 2上所述与含氮骨架上的N连接的位点与N形成酰胺键,所述与R 3中的P连接的位点与P形成磷酸酯键。
- 根据权利要求20所述的siRNA缀合物,其中,q 2为1-5的整数。
- 根据权利要求1-22中任一项所述的siRNA缀合物,其中,式A59中的P连接到siRNA正义链或反义链的端部,所述端部指所述正义链或反义链中从其一端起算的前4个核苷酸。
- 根据权利要求1-23中任一项所述的siRNA缀合物,其中,式A59中的P连接到所述siRNA正义链或反义链的末端。
- 根据权利要求1-24中任一项所述的siRNA缀合物,其中,式A59中的P连接到所述siRNA正义链的3'末端。
- 根据权利要求1-25中任一项所述的siRNA缀合物,其中,式A59中的P通过形成磷酸二酯键而连接至所述siRNA中的核苷酸的2'位、3'位或5'位。
- 根据权利要求1-26中任一项所述的siRNA缀合物,其中,所述核苷酸序列1与SEQ ID NO:1所示的核苷酸序列不多于1个核苷酸差异,和/或所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列不多于1个核苷酸差异。
- 根据权利要求1-27中任一项所述的siRNA缀合物,其中,所述核苷酸序列2与SEQ ID NO:2所示的核苷酸序列之间的核苷酸差异包括Z' B位置处的差异,且Z' B选自A、C或G。
- 根据权利要求1-28中任一项所述的siRNA缀合物,其中,Z A是与Z' B互补的核苷酸。
- 根据权利要求1-29所述的siRNA缀合物,其中,所述核苷酸序列1和所述核苷酸序列2基本上反向互补、实质上反向互补或完全反向互补;所述基本上反向互补是指两个核苷酸序列之间存在不多于3个的碱基错配;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配。
- 根据权利要求1-30所述的siRNA缀合物,其中,所述正义链还含有核苷酸序列3,所述反义链还含有核苷酸序列4,所述核苷酸序列3和所述核苷酸序列4的长度各自为1-4个核苷酸,所述核苷酸序列3连接在所述核苷酸序列1的5'末端,并且所述核苷酸序列4连接在所述核苷酸序列2的3'末端,所述核苷酸序列3和所述核苷酸序列4长度相等并且实质上反向互补或完全反向互补;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配。
- 根据权利要求31所述的siRNA缀合物,其中,所述核苷酸序列3和所述核苷酸序列4的长度均为1个核苷酸,所述核苷酸序列3的碱基为C;或者,所述核苷酸序列3和所述核苷酸序列4的长度均为2个核苷酸,按照5'末端到3'末端的方向,核苷酸序列3的碱基依次为C和C;或者,所述核苷酸序列3和所述核苷酸序列4的长度均为3个核苷酸,按照5'末端到3'末端的方向,所述核苷酸序列3的碱基依次为U、C和C;或者,所述核苷酸序列3和所述核苷酸序列4的长度均为4个核苷酸,按照5'末端到3'末端的方向,所述核苷酸序列3的碱基依次为C、U、C和C。
- 根据权利要求1-32中任一项所述的siRNA缀合物,其中,所述siRNA还含有核苷酸序列5,所述核苷酸序列5的长度为1至3个核苷酸,连接在所述反义链的3'末端,从而构成所述反义链的3'突出端。
- 根据权利要求33所述的siRNA缀合物,其中,所述核苷酸序列5的长度为2个核苷酸,并且按照5'末端到3'末端的方向,所述核苷酸序列5为连续的2个胸腺嘧啶脱氧核糖核苷酸、连续的2个尿嘧啶核糖核苷酸、或者与靶mRNA互补的两个核苷酸。
- 根据权利要求1-34中任一项所述的siRNA缀合物,其中,所述正义链含有如SEQ ID NO:60所示的核苷酸序列,所述反义链含有如SEQ ID NO:3所示的核苷酸序列:5’-CAAUAAAGCUGGACAAGAZ A-3’(SEQ ID NO:60);5’-Z' BUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID NO:3);或者,所述正义链含有如SEQ ID NO:4所示的核苷酸序列,所述反义链含有如SEQ ID NO:5所示的核苷酸序列:5’-CCCAAUAAAGCUGGACAAGAZ A-3’(SEQ ID NO:4);5’-Z' BUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID NO:5);其中,所述Z' B是反义链5'末端的第一个核苷酸,Z A选自A、U、G或C,并且Z' B是与Z A互补的核苷酸。
- 根据权利要求1-35中任一项所述的siRNA缀合物,其中,所述siRNA为siAP1或siAP2:siAP1正义链:5’-CAAUAAAGCUGGACAAGAA-3’(SEQ ID NO:6);反义链:5’-UUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID NO:7);siAP2正义链:5’-CCCAAUAAAGCUGGACAAGAA-3’(SEQ ID NO:8);反义链:5’-UUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID NO:9)。
- 根据权利要求1-36中任一项所述的siRNA缀合物,其中,所述正义链或所述反义链中的至少一个核苷酸为修饰的核苷酸,和/或至少一个磷酸酯基为具有修饰基团的磷酸酯基。
- 根据权利要求1-37中任一项所述的siRNA缀合物,其中,所述正义链和所述反义链中的每一个核苷酸独立地为氟代修饰的核苷酸或非氟代修饰的核苷酸,氟代修饰的核苷酸指核苷酸的核糖基2'位的羟基被氟取代形成的核苷酸,非氟代修饰的核苷酸指核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸或核苷酸类似物。
- 根据权利要求38所述的siRNA缀合物,其中,所述氟代修饰的核苷酸位于核苷酸序列1和核苷酸序列2中,并且,按照5'末端到3'末端的方向,所述核苷酸序列1的第7、8、9位的核苷酸为氟代修饰的核苷酸;按照5'末端到3'末端的方向,所述核苷酸序列2的第2、6、14、16位的核苷酸为氟代修饰的核苷酸。
- 根据权利要求1-39中任一项所述的siRNA缀合物,其中,按照5'末端到3'末端的方向,在所述正义链中,所述核苷酸序列1的第7、8、9位或者5、7、8、9位的核苷酸为氟代修饰的核苷酸,所述正义链中其余位置的核苷酸为非氟代修饰的核苷酸;在所述反义链中,所述核苷酸序列2的第2、6、14、16位或者2、6、8、9、14、16位的核苷酸为氟代修饰的核苷酸,所述反义链中其余位置的核苷酸为非氟代修饰的核苷酸。
- 根据权利要求38-40中任一项所述的siRNA缀合物,其中,每一个非氟代修饰的核苷酸独立地选自核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸或核苷酸类似物中的一种。
- 根据权利要求41所述的siRNA缀合物,其中,核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸选自2'-烷氧基修饰的核苷酸、2'-经取代的烷氧基修饰的核苷酸、2'-烷基修饰的核苷酸、2'-经取代的烷基修饰的核苷酸、2'-氨基修饰的核苷酸、2'-经取代的氨基修饰的核苷酸、2'-脱氧核苷酸中的一种;核苷酸类似物选自异核苷酸、 LNA、ENA、cET、UNA和GNA中的一种。
- 根据权利要求38-42中任一项所述的siRNA缀合物,其中,每一个非氟代修饰的核苷酸均为甲氧基修饰的核苷酸,所述甲氧基修饰的核苷酸指核糖基的2'-羟基被甲氧基取代而形成的核苷酸。
- 根据权利要求1-43中任一项所述的siRNA缀合物,其中,按照5’末端到3’末端的方向,所述siRNA的正义链中核苷酸序列1的第5、7、8和9位的核苷酸为氟代修饰的核苷酸,siRNA的正义链的其余位置的核苷酸为甲氧基修饰的核苷酸,并且,按照5’末端到3’末端的方向,所述siRNA的反义链中核苷酸序列2的第2、6、8、9、14和16位的核苷酸为-氟代修饰的核苷酸,siRNA的反义链其余位置的核苷酸为甲氧基修饰的核苷酸;或者,按照5’末端到3’末端的方向,所述siRNA的正义链中核苷酸序列1的第7、8和9位的核苷酸为氟代修饰的核苷酸,siRNA的正义链的其余位置的核苷酸为甲氧基修饰的核苷酸,并且,按照5’末端到3’末端的方向,所述siRNA的反义链中核苷酸序列2的第2、6、14和16位的核苷酸为氟代修饰的核苷酸,siRNA的反义链其余位置的核苷酸为甲氧基修饰的核苷酸。
- 根据权利要求1-44中任一项所述的siRNA缀合物,其中,所述siRNA为siAP1-M1、siAP2-M1、siAP1-M2、siAP2-M2中的任意一种:siAP1-M1正义链:5’-CmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:10)反义链:5’-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:11)siAP2-M1正义链:5’-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:12)反义链:5’-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:13)siAP1-M2正义链:5’-CmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:14)反义链:5’-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:15)siAP2-M2正义链:5’-CmCmCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:16)反义链:5’-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:17)其中,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸。
- 根据权利要求46所述的siRNA缀合物,其中,所述siRNA中,硫代磷酸酯基连接存在于由以下位置组成的组中的至少一处:所述正义链的5'末端端部第1个核苷酸和第2个核苷酸之间;所述正义链的5'末端端部第2个核苷酸和第3个核苷酸之间;所述正义链的3'末端端部第1个核苷酸和第2个核苷酸之间;所述正义链的3'末端端部第2个核苷酸和第3个核苷酸之间;所述反义链的5'末端端部第1个核苷酸和第2个核苷酸之间;所述反义链的5'末端端部第2个核苷酸和第3个核苷酸之间;所述反义链的3'末端端部第1个核苷酸和第2个核苷酸之间;以及所述反义链的3'末端端部第2个核苷酸和第3个核苷酸之间。
- 根据权利要求1-47中任一项所述的siRNA缀合物,其中,所述siRNA为siAP1-M1S、siAP2-M1S、siAP1-M2S、siAP2-M2S中的任意一种:siAP1-M1S正义链:5’-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:18)反义链:5’-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:19)siAP2-M1S正义链:5’-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:20)反义链:5’-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:21)siAP1-M2S正义链:5’-CmsAmsAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:22)反义链:5’-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:23)siAP2-M2S正义链:5’-CmsCmsCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:24)反义链:5’-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:25)其中,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸;小写字母s表示与该字母s左右相邻的两个核苷酸之间的连接为硫代磷酸酯基连接。
- 根据权利要求1-48中任一项所述的siRNA缀合物,其中,所述反义链的5'末端核苷酸为5'-磷酸核苷酸或5'-磷酸类似物修饰的核苷酸。
- 根据权利要求1-49中任一项所述的siRNA缀合物,其中,所述siRNA为 siAP1-M1P1、siAP2-M1P1、siAP1-M2P1、siAP2-M2P1、siAP1-M1SP1、siAP2-M1SP1、siAP1-M2SP1、siAP2-M2SP1中的任意一种:siAP1-M1P1正义链:5’-CmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:10)反义链:5’-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:26)siAP2-M1P1正义链:5’-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:12)反义链:5’-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:27)siAP1-M2P1正义链:5’-CmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:14)反义链:5’-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:28)siAP2-M2P1正义链:5’-CmCmCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:16)反义链:5’-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:29)siAP1-M1SP1正义链:5’-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:18)反义链:5’-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:30)siAP2-M1SP1正义链:5’-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:20)反义链:5’-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:31)siAP1-M2SP1正义链:5’-CmsAmsAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:22)反义链:5’-P1-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:32)siAP2-M2SP1正义链:5’-CmsCmsCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:24)反义链:5’-P1-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:33)其中,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸;P1表示该字母P1右侧相邻的一个核苷酸为5'-磷酸核苷酸或5'-磷酸类似物修饰的核苷酸。
- 一种修饰的siRNA,所述siRNA含有正义链和反义链,所述正义链和反义链的每一个核苷酸均为修饰的核苷酸,其中,所述正义链和反义链均包含氟代修饰的核苷酸和非氟代修饰的核苷酸;所述正义链包含核苷酸序列Ⅰ,所述反义链包含核苷酸序列Ⅱ,所述核苷酸序列Ⅰ和所述核苷酸序列Ⅱ至少部分地反向互补形成双链区,其中,所述核苷酸序列Ⅰ含有核苷酸序列A,所述核苷酸序列A与SEQ ID NO:1所示的核苷酸序列长度相等,且不多于3个核苷酸差异,且所述核苷酸序列Ⅱ含有核苷酸序列B,所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列长度相等,且不多于3个核苷酸差异:5'-CAAUAAAGCUGGACAAGAZ-3'(SEQ ID NO:1);5'-Z’UCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:2),其中,Z为A,Z'为U,所述核苷酸序列A中包含位置对应于Z的核苷酸Z A,所述核苷酸序列B中包含位置对应于Z'的核苷酸Z' B,所述Z' B是所述反义链5'末端的第一个核苷酸;所述氟代修饰的核苷酸位于核苷酸序列A和核苷酸序列B中,按照5'末端到3'末端的方向,所述核苷酸序列A的第7、8、9位的核苷酸为氟代修饰的核苷酸;并且,按照5'末端到3'末端的方向,所述核苷酸序列B的第2、6、14、16位的核苷酸为氟代修饰的核苷酸。
- 根据权利要求52所述的siRNA,其中,所述核苷酸序列A与SEQ ID NO:1所示的核苷酸序列之间不多于1个核苷酸差异,和/或所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列之间不多于1个核苷酸差异。
- 根据权利要求52或53所述的siRNA,其中,所述核苷酸序列B与SEQ ID NO:2所示的核苷酸序列之间的核苷酸差异包括Z' B位置处的差异,且Z' B选自A、C或G。
- 根据权利要求52-54中任一项所述的siRNA,其中Z A是与Z' B互补的核苷酸。
- 根据权利要求52-55中任一项所述的siRNA,其中,所述核苷酸序列A和所述核苷酸序列B基本上反向互补、实质上反向互补或完全反向互补;所述基本上反向互补是指两个核苷酸序列之间存在不多于3个的碱基错配;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配。
- 根据权利要求52-56中任一项所述的siRNA,其中,所述核苷酸序列A是SEQ ID NO:60所示的核苷酸序列,核苷酸序列B是SEQ ID NO:61所示的核苷酸序列:5'-CAAUAAAGCUGGACAAGAZ A-3'(SEQ ID NO:60);5'-Z’ BUCUUGUCCAGCUUUAUUG-3'(SEQ ID NO:61),其中,Z A选自A、U、G或C,并且Z' B是与Z A互补的核苷酸。
- 根据权利要求57所述的siRNA,其中,Z A为A,Z' B为U。
- 根据权利要求52-58中任一项所述的siRNA,其中,所述核苷酸序列I还含有核苷酸序列III,所述核苷酸序列II还含有核苷酸序列IV,所述核苷酸序列III和所述核苷酸序列IV的长度各自为1-4个核苷酸,所述核苷酸序列III连接在核苷酸序列A的5’末端,并且所述核苷酸序列IV连接在核苷酸序列B的3’末端;所述核苷酸序列Ⅲ和所述核苷酸序列Ⅳ长度相等并且实质上反向互补或完全反向互补;所述实质上反向互补是指两个核苷酸序列之间存在不多于1个的碱基错配;完全反向互补是指两个核苷酸序列之间没有错配。
- 根据权利要求59所述siRNA,其中,所述核苷酸序列III和IV的长度均为1个核苷酸,所述核苷酸序列III的碱基为C;或者,所述核苷酸序列III和IV的长度均为2个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为C、C;或者,所述核苷酸序列III和IV的长度均为3个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为U、C、C;或者,所述核苷酸序列III和IV的长度均为4个核苷酸,按照5’末端到3’末端的方向,核苷酸序列III的碱基依次为C、U、C、C。
- 根据权利要求52-60中任一项所述的siRNA,其中,所述核苷酸序列II还含有核苷酸序列V,核苷酸序列V的长度为1至3个核苷酸,连接在所述反义链的3’末端,构成反义链的3’垂悬末端。
- 根据权利要求61所述的siRNA,其中,所述核苷酸序列V的长度为2个核苷酸。
- 根据权利要求61或62所述的siRNA,其中,所述核苷酸序列V与靶mRNA相应位置的核苷酸互补,或者所述核苷酸序列V为连续的2个胸腺嘧啶脱氧核糖核苷酸或连续的两个尿嘧啶核糖核苷酸。
- 根据权利要求52-63中任一项所述的siRNA,其中,所述正义链含有如SEQ ID No:60所示的核苷酸序列,所述反义链含有如SEQ ID No:3所示的核苷酸序列:5’-CAAUAAAGCUGGACAAGAZ A-3’(SEQ ID No:60)5’-Z' BUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID No:3)或者所述正义链含有如SEQ ID No:4所示的核苷酸序列,所述反义链含有如SEQ ID No:5所示的核苷酸序列:5’-CCCAAUAAAGCUGGACAAGAZ A-3’(SEQ ID No:4)5’-Z' BUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID No:5);其中,所述Z' B是反义链5'末端的第一个核苷酸,Z A选自A、U、G或C,并且Z' B是与Z A互补的核苷酸。
- 根据权利要求52-64中任一项所述的siRNA,其中,所述siRNA为siAP1或siAP2:siAP15’-CAAUAAAGCUGGACAAGAA-3’(SEQ ID No:6)5’-UUCUUGUCCAGCUUUAUUGGG-3’(SEQ ID No:7)siAP25’-CCCAAUAAAGCUGGACAAGAA-3’(SEQ ID No:8)5’-UUCUUGUCCAGCUUUAUUGGGAG-3’(SEQ ID No:9)。
- 根据权利要求52-65中任一项所述的siRNA,其中,按照5'末端到3'末端的方向,在所述正义链中,所述核苷酸序列A的第7、8、9位或者5、7、8、9位的核苷酸为氟代修饰的核苷酸,所述正义链中其余位置的核苷酸为非氟代修饰的核苷酸;在所述反义链中,所述核苷酸序列B的第2、6、14、16位或者2、6、8、9、14、16位的核苷酸为氟代修饰的核苷酸,所述反义链中其余位置的核苷酸为非氟代修饰的核苷酸。
- 根据权利要求52-66中任一项所述的siRNA,其中,每一个非氟代修饰的核苷酸独立地选自核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸或核苷酸类似物中的一种。
- 根据权利要求67所述的siRNA,其中,核苷酸的核糖基2'位的羟基被非氟基团取代形成的核苷酸选自2'-烷氧基修饰的核苷酸、2'-经取代的烷氧基修饰的核苷酸、2'-烷基修饰的核苷酸、2'-经取代的烷基修饰的核苷酸、2'-氨基修饰的核苷酸、2'-经取代的氨基修饰的核苷酸、2'-脱氧核苷酸中的一种;核苷酸类似物选自异核苷酸、LNA、ENA、cET、UNA和GNA中的一种。
- 根据权利要求52-68中任一项所述的siRNA,其中,每一个非氟代修饰的核苷酸均为甲氧基修饰的核苷酸,所述甲氧基修饰的核苷酸指核糖基的2'-羟基被甲氧基取代而形成的核苷酸。
- 根据权利要求52-69中任一项所述的siRNA,其中,所述siRNA为siAP1-M1、siAP2-M1、siAP1-M2、siAP2-M2中的任意一种:siAP1-M1正义链:5’-CmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:10)反义链:5’-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:11)siAP2-M1正义链:5’-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:12)反义链:5’-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:13)siAP1-M2正义链:5’-CmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:14)反义链:5’-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:15)siAP2-M2正义链:5’-CmCmCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:16)反义链:5’-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:17)其中,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸。
- 根据权利要求52-70中任意一项所述的siRNA,其中,所述siRNA的正义链和反义链中至少一条单链的磷酸-糖骨架中的磷酸酯基中的至少一部分为具有修饰基团的磷酸酯基。
- 根据权利要求71所述的siRNA,其中,所述具有修饰基团的磷酸酯基为磷酸酯基中的磷酸二酯键中的至少一个氧原子被硫原子取代而形成的硫代磷酸酯基。
- 根据权利要求72或73所述的siRNA,其中,所述siRNA中,硫代磷酸酯基连接存在于由以下位置组成的组中的至少一处:所述正义链的5'末端端部第1个核苷酸和第2个核苷酸之间;所述正义链的5'末端端部第2个核苷酸和第3个核苷酸之间;所述正义链的3'末端端部第1个核苷酸和第2个核苷酸之间;所述正义链的3'末端端部第2个核苷酸和第3个核苷酸之间;所述反义链的5'末端端部第1个核苷酸和第2个核苷酸之间;所述反义链的5'末端端部第2个核苷酸和第3个核苷酸之间;所述反义链的3'末端端部第1个核苷酸和第2个核苷酸之间;以及所述反义链的3'末端端部第2个核苷酸和第3个核苷酸之间。
- 根据权利要求52-74中任一项所述的siRNA,其中,所述siRNA为siAP1-M1S、siAP2-M1S、siAP1-M2S、siAP2-M2S中的任意一种:siAP1-M1S正义链:5’-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:18)反义链:5’-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:19)siAP2-M1S正义链:5’-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:20)反义链:5’-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:21)siAP1-M2S正义链:5’-CmsAmsAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:22)反义链:5’-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:23)siAP2-M2S正义链:5’-CmsCmsCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:24)反义链:5’-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:25)其中,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸;小写字母s表示该字母左右两个核苷酸之间为硫代磷酸酯基连 接。
- 根据权利要求52-75中任意一项所述的siRNA,其中,所述反义链的5’末端核苷酸为5’-磷酸核苷酸或5’-磷酸类似物修饰的核苷酸。
- 根据权利要求52-77中任一项所述的siRNA,其中,所述siRNA为siAP1-M1P1、siAP2-M1P1、siAP1-M2P1、siAP2-M2P1、siAP1-M1SP1、siAP2-M1SP1、siAP1-M2SP1、siAP2-M2SP1中的任意一种:siAP1-M1P1正义链:5’-CmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:10)反义链:5’-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:26)siAP2-M1P1正义链:5’-CmCmCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:12)反义链:5’-P1-UmUfCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:27)siAP1-M2P1正义链:5’-CmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:14)反义链:5’-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGm-3’(SEQ ID NO:28)siAP2-M2P1正义链:5’-CmCmCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:16)反义链:5’-P1-UmUfCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmAmGm-3’(SEQ ID NO:29)siAP1-M1SP1正义链:5’-CmsAmsAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:18)反义链:5’-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:30)siAP2-M1SP1正义链:5’-CmsCmsCmAmAmUmAfAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:20)反义链:5’-P1-UmsUfsCmUmUmGfUmCfCfAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:31)siAP1-M2SP1正义链:5’-CmsAmsAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:22)反义链:5’-P1-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmsGmsGm-3’(SEQ ID NO:32)siAP2-M2SP1正义链:5’-CmsCmsCmAmAmUmAmAmAfGfCfUmGmGmAmCmAmAmGmAmAm-3’(SEQ ID NO:24)反义链:5’-P1-UmsUfsCmUmUmGfUmCmCmAmGmCmUmUfUmAfUmUmGmGmGmsAmsGm-3’(SEQ ID NO:33)其中,大写字母C、G、U、A表示核苷酸的碱基组成;小写字母m表示该字母m左侧相邻的一个核苷酸为甲氧基修饰的核苷酸;小写字母f表示该字母f左侧相邻的一个核苷酸为氟代修饰的核苷酸;小写字母s表示该字母左右两个核苷酸之间为硫代磷酸酯基连接;P1表示该字母P1右侧相邻的一个核苷酸为5’-磷酸核苷酸或5’-磷酸类似物修饰的核苷酸。
- 一种药物组合物,其特征在于,该药物组合物含有权利要求52-78中任意一项所述的siRNA和药学上可接受的载体。
- 根据权利要求79所述的药物组合物,其中,所述siRNA与药学上可接受的载体的重量比为1:(1-500)。
- 根据权利要求80所述的药物组合物,其中,所述siRNA与药学上可接受的载体的重量比为1:(1-50)。
- 根据权利要求79-81中任一项所述的药物组合物,其中,所述药学上可接受的载体含有有机胺、辅助脂质和聚乙二醇化脂质;其中,所述有机胺为如式(201)所示的化合物和/或其药学上可接受的盐:其中:X 101和X 102各自独立地是O、S、N-A或C-A,其中A是氢或C1-C20烃链;Y和Z各自独立地是C=O、C=S、S=O、CH-OH或SO 2;R 101、R 102、R 103、R 104、R 105、R 106和R 107各自独立地是氢,环状或无环的、被取代的或未被取代的、支链或直链脂族基团,环状或无环的、被取代的或未被取代的、支链或直链杂脂族基团,被取代的或未被取代的、支链或直链酰基,被取代的或未被取代的、支链或直链芳基,被取代的或未被取代的、支链或直链杂芳基;x是1-10的整数;n是1-3的整数,m是0-20的整数,p是0或1;其中,如果m=p=0,则R 102是氢;并且,如果n或m中的至少一个是2,那么R 103和在式(201)中的氮形成如式(202) 或式(203)所示的结构:其中,g、e和f各自独立地是1-6的整数,“HCC”代表烃链,且每个*N表示在式(201)中的氮原子。
- 根据权利要求82或83所述的药物组合物,其中,所述有机胺、所述辅助脂质和 所述聚乙二醇化脂质三者之间的摩尔比为(19.7-80):(19.7-80):(0.3-50)。
- 根据权利要求84所述的药物组合物,其中,所述有机胺、所述辅助脂质和所述聚乙二醇化脂质三者之间的摩尔比为(50-70):(20-40):(3-20)。
- 一种siRNA缀合物,所述siRNA缀合物含有权利要求52-78中任意一项所述的siRNA以及缀合连接至该siRNA的缀合基团。
- 根据权利要求86所述siRNA缀合物,其中,所述缀合基团包含药学上可接受的靶向基团和接头,并且,所述siRNA、所述接头和所述靶向基团依次共价或非共价连接。
- 根据权利要求87所述的siRNA缀合物,其中,所述接头具有如式(301)所示的结构:其中,k为1-3的整数;L A为具有如式(302)所示结构的包含酰胺键的链状部分,每个所述L A在其两端分别与一个所述靶向基团和所述L C部分通过醚键相连接:L B为具有如式(303)所示结构的包含N-酰基吡咯烷的链状部分,所述链状部分在其一端具有羰基并与所述L C部分通过酰胺键相连接,在另一端具有氧原子并与所述siRNA通过磷酸酯键相连接:L C为基于羟甲基氨基甲烷、二羟甲基氨基甲烷或三羟甲基氨基甲烷的2-4价连接基团,所述L C经由氧原子与各个所述L A部分通过醚键相连接,并且经由氮原子与所述L B部分通过酰胺键相连接。
- 根据权利要求87-91中任一项所述的siRNA缀合物,其中,所述接头连接至所述siRNA的正义链3’末端。
- 根据权利要求87、88、90和92中任一项所述的siRNA缀合物,其中,每个所述靶向基团独立地为与哺乳动物肝细胞表面的去唾液酸糖蛋白受体亲和的配体。
- 根据权利要求93所述的siRNA缀合物,其中,每个所述靶向基团独立地选自D-吡喃甘露糖、L-吡喃甘露糖、D-阿拉伯糖、D-呋喃木糖、L-呋喃木糖、D-葡萄糖、L-葡萄糖、D-半乳糖、L-半乳糖、α-D-呋喃甘露糖、β-D-呋喃甘露糖、α-D-吡喃甘露糖、β-D-吡喃甘露糖、α-D-吡喃葡萄糖、β-D-吡喃葡萄糖、α-D-呋喃葡萄糖、β-D-呋喃葡萄糖、α-D-呋喃果糖、α-D-吡喃果糖、α-D-吡喃半乳糖、β-D-吡喃半乳糖、α-D-呋喃半乳糖、β-D-呋喃半乳糖、葡糖胺、唾液酸、半乳糖胺、N-乙酰半乳糖胺、N-三氟乙酰基半乳糖胺、N-丙酰基半乳糖胺、N-正丁酰基半乳糖胺、N-异丁酰基半乳糖胺、2-氨基-3-O-[(R)-1-羧乙基]-2-脱氧-β-D-吡喃葡萄糖、2-脱氧-2-甲基氨基-L-吡喃葡萄糖、4,6-二脱氧-4-甲酰胺基-2,3-二-O-甲基-D-吡喃甘露糖、2-脱氧-2-磺氨基-D-吡喃葡萄糖、N-乙醇酰基-α-神经氨酸、5-硫代-β-D-吡喃葡萄糖、2,3,4-三-O-乙酰基-1-硫代-6-O-三苯甲基-α-D-吡喃葡萄糖苷甲酯、4-硫代-β-D-吡喃半乳糖、3,4,6,7-四-O-乙酰基-2-脱氧-1,5-二硫代-α-D-吡喃葡庚糖苷乙酯、2,5-脱水-D-阿洛糖腈、核糖、D-核糖、D-4-硫代核糖、L-核糖、L-4-硫代核糖中的一种。
- 根据权利要求93或94所述的siRNA缀合物,其中,至少一个或每个所述靶向基团为半乳糖或N-乙酰半乳糖胺。
- 权利要求1-51中任意一项所述的siRNA缀合物、权利要求52-78中任一项所述siRNA、权利要求79-85中任一项所述的药物组合物和/或权利要求86-95中任一项所述的siRNA缀合物在制备用于治疗和/或预防由载脂蛋白C3(ApoC3)的过量表达引起的血脂异常的药物中的用途。
- 根据权利要求96所述的用途,其中,所述血脂异常为高胆固醇血症、高甘油三酯血症或动脉粥样硬化。
- 一种治疗血脂异常的方法,其中,所述方法包括向患有血脂异常的受试者给予有效量的权利要求1-51中任意一项所述的siRNA缀合物、权利要求52-78中任一项所述siRNA、权利要求79-85中任一项所述的药物组合物和/或权利要求86-95中任一项所述的siRNA缀合物。
- 一种抑制肝细胞APOC3基因表达的方法,其中,该方法包括将有效量的权利要求1-51中任意一项所述的siRNA缀合物、权利要求52-78中任一项所述siRNA、权利要求79-85中任一项所述的药物组合物和/或权利要求86-95中任一项所述的siRNA缀合物与所述肝细胞进行接触。
- 一种试剂盒,其中,该试剂盒包含权利要求1-51中任意一项所述的siRNA缀合物、权利要求52-78中任一项所述siRNA、权利要求79-85中任一项所述的药物组合物和/或权利要求86-95中任一项所述的siRNA缀合物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020529410A JP7365052B2 (ja) | 2017-12-01 | 2018-11-29 | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
CN201880048597.3A CN110997917B (zh) | 2017-12-01 | 2018-11-29 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
EP18883982.3A EP3719127A4 (en) | 2017-12-01 | 2018-11-29 | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
CN202410311313.2A CN118291456A (zh) | 2017-12-01 | 2018-11-29 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
US16/758,532 US11660347B2 (en) | 2017-12-01 | 2018-11-29 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US18/301,845 US20230355775A1 (en) | 2017-12-01 | 2023-04-17 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711249345 | 2017-12-01 | ||
CN201711249345.0 | 2017-12-01 | ||
CN201711486999 | 2017-12-29 | ||
CN201711486999.5 | 2017-12-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/758,532 A-371-Of-International US11660347B2 (en) | 2017-12-01 | 2018-11-29 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US18/301,845 Continuation US20230355775A1 (en) | 2017-12-01 | 2023-04-17 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019105419A1 true WO2019105419A1 (zh) | 2019-06-06 |
Family
ID=66664715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/118232 WO2019105419A1 (zh) | 2017-12-01 | 2018-11-29 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11660347B2 (zh) |
EP (1) | EP3719127A4 (zh) |
JP (1) | JP7365052B2 (zh) |
CN (2) | CN118291456A (zh) |
TW (1) | TW201925471A (zh) |
WO (1) | WO2019105419A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021026150A1 (en) * | 2019-08-05 | 2021-02-11 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of apoc3-related diseases and disorders |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
WO2023098908A1 (en) * | 2021-12-03 | 2023-06-08 | Microbio (Shanghai) Co. Ltd. | Modification patterns for small interfering rna molecules with high stability and gene silencing activities |
WO2023143571A1 (zh) | 2022-01-30 | 2023-08-03 | 大睿生物医药科技(上海)有限公司 | 含有n-乙酰半乳糖胺的靶向配体 |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
US12084661B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3719126A4 (en) * | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, ASSOCIATED PREPARATION PROCESS AND USE |
WO2020135581A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
US20220062427A1 (en) * | 2018-12-28 | 2022-03-03 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
WO2022028457A1 (zh) * | 2020-08-04 | 2022-02-10 | 上海拓界生物医药科技有限公司 | 抑制凝血因子XI表达的siRNA、组合物及其医药用途 |
CN117580953A (zh) * | 2021-07-16 | 2024-02-20 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
JP2024528634A (ja) * | 2021-07-16 | 2024-07-30 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物及び複合体並びに調製方法と使用 |
EP4380623A1 (en) * | 2021-08-04 | 2024-06-12 | Hepagene Therapeutics (HK) Limited | Ligand conjugates for delivery of therapeutically active agents |
TW202334424A (zh) * | 2021-12-16 | 2023-09-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種dsrna、其製備方法及應用 |
KR20240116537A (ko) * | 2021-12-16 | 2024-07-29 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | dsRNA, 이의 제조 방법 및 응용 |
WO2023109945A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其制备方法及应用 |
WO2023138659A1 (zh) * | 2022-01-20 | 2023-07-27 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其应用及制备方法 |
WO2023246935A1 (zh) * | 2022-06-23 | 2023-12-28 | 安沛治疗有限公司 | 包含喹啉修饰的靶特异性核酸分子 |
WO2024002093A1 (zh) * | 2022-06-27 | 2024-01-04 | 大睿生物医药科技(上海)有限公司 | 抑制载脂蛋白C3表达的siRNA |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
CN103380113A (zh) | 2010-11-15 | 2013-10-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
WO2014025805A1 (en) | 2012-08-06 | 2014-02-13 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated rna agents and process for their preparation |
WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
CN105378082A (zh) | 2013-05-01 | 2016-03-02 | Isis制药公司 | 组合物和方法 |
WO2016154127A2 (en) * | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
CN106460025A (zh) * | 2014-03-25 | 2017-02-22 | 阿克丘勒斯治疗公司 | 在基因沉默中具有降低的脱靶效应的una寡聚物 |
CN107250362A (zh) * | 2014-11-17 | 2017-10-13 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
CN107854478A (zh) * | 2011-04-27 | 2018-03-30 | Ionis制药公司 | 载脂蛋白ciii(apociii)表达的调节 |
CN108239644A (zh) * | 2016-12-23 | 2018-07-03 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其用途 |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
WO2000027795A1 (en) | 1998-11-12 | 2000-05-18 | Invitrogen Corporation | Transfection reagents |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
JP4597976B2 (ja) | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 修飾iRNA剤 |
JPWO2005116204A1 (ja) | 2004-05-11 | 2008-06-19 | 株式会社アルファジェン | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
JP5192234B2 (ja) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 化学修飾オリゴヌクレオチド |
US20080096839A1 (en) | 2005-03-09 | 2008-04-24 | Mogam Biotechnology Research Institute | Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same |
AU2007249329C1 (en) | 2006-05-11 | 2011-03-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
CA2658183A1 (en) | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
AU2014208251B2 (en) | 2007-12-04 | 2016-07-14 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
BRPI0907008A2 (pt) | 2008-01-31 | 2015-07-07 | Alnylam Pharmaceuticals Inc | Métodos otimizados para liberação de dsrna alvejando o gene pcsk9 |
WO2009102427A2 (en) | 2008-02-11 | 2009-08-20 | Rxi Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
CN101603042B (zh) | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
WO2010012244A1 (zh) | 2008-08-01 | 2010-02-04 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
EP3335715A3 (en) | 2008-10-15 | 2018-08-08 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
CN102356158B (zh) | 2008-12-17 | 2014-04-02 | 联邦科学技术研究组织 | 调节禽类性别的方法 |
US9023820B2 (en) * | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
CA2753975C (en) | 2009-03-02 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
EP2419146A4 (en) | 2009-04-15 | 2013-11-27 | Isis Pharmaceuticals Inc | MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI |
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
KR20120050429A (ko) | 2009-06-15 | 2012-05-18 | 알닐람 파마슈티칼스 인코포레이티드 | Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
BR112012000421A2 (pt) | 2009-07-06 | 2019-09-24 | Alnylam Pharmaceuticals Inc | composições e métodos para intensificar a produção de um produto biológico. |
WO2011038031A1 (en) | 2009-09-22 | 2011-03-31 | Alnylam Pharmaceuticals, Inc. | Dual targeting sirna agents |
WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
CN102140461B (zh) | 2010-01-29 | 2012-12-05 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
CN102140460B (zh) | 2010-01-29 | 2012-12-12 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
CN102140458B (zh) * | 2010-01-29 | 2013-05-22 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
CN102140459B (zh) | 2010-01-29 | 2013-04-03 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其制药应用 |
DK2539451T3 (da) | 2010-02-24 | 2016-04-04 | Arrowhead Res Corp | Sammensætninger til målrettet tilførsel af siRNA |
JP2013523149A (ja) | 2010-04-09 | 2013-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規な単一化学物質およびオリゴヌクレオチドの送達方法 |
US8993738B2 (en) | 2010-04-28 | 2015-03-31 | Isis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
CN102344477B (zh) * | 2010-07-27 | 2015-04-08 | 苏州瑞博生物技术有限公司 | 一种核苷酸和/或寡核苷酸及其制备方法 |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2616543A1 (en) | 2010-09-15 | 2013-07-24 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
WO2012058693A2 (en) | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
EP2658981B1 (en) | 2010-12-29 | 2016-09-28 | F.Hoffmann-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
KR102104401B1 (ko) | 2011-03-29 | 2020-04-27 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
CN102719434A (zh) | 2011-03-31 | 2012-10-10 | 百奥迈科生物技术有限公司 | 抑制rna干扰脱靶效应的特异性修饰 |
CN102727907B (zh) | 2011-04-13 | 2015-03-11 | 苏州瑞博生物技术有限公司 | 一种小干扰rna药物的给药系统和制剂 |
EP2723758B1 (en) | 2011-06-21 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
US8809293B2 (en) | 2011-06-30 | 2014-08-19 | Arrowhead Madison Inc. | Compositions and methods for inhibiting gene expression of hepatitis B virus |
CN103073726B (zh) | 2011-10-26 | 2015-09-23 | 苏州瑞博生物技术有限公司 | 嵌段共聚物与液体组合物和核酸制剂及其制备方法和应用 |
PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
AU2012327227A1 (en) | 2011-11-07 | 2013-05-23 | Isis Pharmaceuticals, Inc. | Administration of Factor XI antisense oligonucleotides |
AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
EP2920304B1 (en) | 2012-11-15 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
FR2998748B1 (fr) | 2012-11-23 | 2015-04-10 | Commissariat Energie Atomique | Dispositif et procede de retransmission de donnees dans un commutateur reseau |
BR112015013105B1 (pt) | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
EP2951305B1 (en) | 2013-01-30 | 2018-08-15 | F.Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
EA201591707A1 (ru) | 2013-03-14 | 2016-03-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК КОМПОНЕНТА КОМПЛЕМЕНТА C5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
EP2994167B1 (en) | 2013-05-06 | 2020-05-06 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
CN104107437B (zh) | 2013-06-09 | 2015-08-26 | 厦门成坤生物技术有限公司 | 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法 |
EP3730619A1 (en) | 2013-06-21 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
WO2015006498A2 (en) | 2013-07-09 | 2015-01-15 | President And Fellows Of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US9889200B2 (en) | 2013-07-31 | 2018-02-13 | Qbi Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
WO2015031679A2 (en) | 2013-08-28 | 2015-03-05 | Isis Pharmaceuticals, Inc. | Modulation of prekallikrein (pkk) expression |
EP3066215B1 (en) | 2013-11-06 | 2019-04-24 | The United States of America, represented by the Secretary, Department of Health and Human Services | Method for subtyping lymphoma types by means of expression profiling |
CA2931510A1 (en) | 2013-12-24 | 2015-07-02 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
CA2937329C (en) | 2014-01-21 | 2022-05-31 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
JP2017505623A (ja) | 2014-01-30 | 2017-02-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 生物切断性コンジュゲートを有するポリオリゴマー化合物 |
DK3137091T3 (da) | 2014-05-01 | 2021-01-25 | Ionis Pharmaceuticals Inc | Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression |
BR122020024443B1 (pt) | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Composto e composição farmacêutica para modulação da expressão de angptl3 |
CA2950960A1 (en) | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
WO2016011123A1 (en) | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
EP3812462A1 (en) * | 2014-08-20 | 2021-04-28 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
CN104232644B (zh) | 2014-09-03 | 2016-10-12 | 浙江大学 | 一种特异抑制XOR基因表达的siRNA及其应用 |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
CA2969372C (en) | 2014-12-15 | 2023-05-16 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
US10036017B2 (en) | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
MX2017011422A (es) | 2015-03-17 | 2017-11-10 | Arrowhead Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen del factor xii. |
EP3283631A1 (en) | 2015-04-13 | 2018-02-21 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
BR112017021967A2 (pt) | 2015-05-06 | 2018-07-31 | Alnylam Pharmaceuticals Inc | composições do fator xii (fator hageman) (f12), kallikrein b, plasma (fator fletcher) 1 (klkb1), e kininogen 1 (kng1) irna e métodos de uso dos mesmos |
CN104922141B (zh) | 2015-05-28 | 2016-05-25 | 厦门成坤生物技术有限公司 | 一种用于治疗乙型病毒性肝炎的siRNA组合物 |
JP6715325B2 (ja) | 2015-06-26 | 2020-07-01 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用 |
US20170016000A1 (en) | 2015-07-17 | 2017-01-19 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
US20180216114A1 (en) | 2015-07-27 | 2018-08-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
WO2017019891A2 (en) | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
IL293355B2 (en) | 2015-08-25 | 2024-07-01 | Alnylam Pharmaceuticals Inc | Methods and preparations for the treatment of a disorder related to the PCSK9 gene |
WO2017055627A1 (en) | 2015-10-02 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Apoc3 mutations for the diagnosis and therapy of hereditary renal amyloidosis disease |
JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法 |
US10883107B2 (en) | 2016-01-08 | 2021-01-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof |
KR20180103166A (ko) | 2016-01-29 | 2018-09-18 | 교와 핫꼬 기린 가부시키가이샤 | 핵산 복합체 |
MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
WO2017189813A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
JP2019532027A (ja) | 2016-08-17 | 2019-11-07 | ソルスティス バイオロジクス,リミティッド | ポリヌクレオチド構築物 |
AU2017320582B2 (en) | 2016-09-02 | 2023-11-16 | Arrowhead Pharmaceuticals, Inc | Targeting ligands |
US20180104360A1 (en) | 2016-10-18 | 2018-04-19 | The Medicines Company | Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction |
CN108220293B (zh) | 2016-12-21 | 2021-09-24 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
CN108265052B (zh) | 2016-12-30 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
EP3573623A4 (en) | 2017-01-30 | 2020-11-25 | Arrowhead Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS OF INHIBITION OF GENE EXPRESSION OF FACTOR XII |
CN118460536A (zh) | 2017-04-11 | 2024-08-09 | 阿布特斯生物制药公司 | 靶向组合物 |
CN108929870B (zh) | 2017-05-19 | 2020-01-24 | 百奥迈科生物技术有限公司 | 抑制HBV的siRNA分子及其应用 |
WO2018223073A1 (en) * | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2019105418A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
CN110945131B (zh) | 2017-12-01 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
EP3719126A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, ASSOCIATED PREPARATION PROCESS AND USE |
JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
CN111050807B (zh) | 2017-12-01 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
AU2018394875B2 (en) | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF |
CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
WO2020093053A1 (en) | 2018-11-02 | 2020-05-07 | Arbutus Biopharma Corporation | Bivalent targeted conjugates |
WO2020135581A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
US20220062427A1 (en) * | 2018-12-28 | 2022-03-03 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
CN113330117B (zh) | 2019-01-18 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
CN111979237A (zh) | 2019-05-22 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |
CN111973617A (zh) | 2019-05-23 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
CN111973618B (zh) | 2019-05-23 | 2024-02-02 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与siRNA缀合物及制备方法和用途 |
CN111973619B (zh) | 2019-05-23 | 2024-01-30 | 苏州瑞博生物技术股份有限公司 | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |
US20220186221A1 (en) | 2019-05-24 | 2022-06-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method and use |
EP3978609A4 (en) | 2019-05-24 | 2024-02-07 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PROCESS OF PREPARATION AND USE |
-
2018
- 2018-11-29 CN CN202410311313.2A patent/CN118291456A/zh active Pending
- 2018-11-29 US US16/758,532 patent/US11660347B2/en active Active
- 2018-11-29 EP EP18883982.3A patent/EP3719127A4/en active Pending
- 2018-11-29 JP JP2020529410A patent/JP7365052B2/ja active Active
- 2018-11-29 CN CN201880048597.3A patent/CN110997917B/zh active Active
- 2018-11-29 WO PCT/CN2018/118232 patent/WO2019105419A1/zh unknown
- 2018-11-30 TW TW107143005A patent/TW201925471A/zh unknown
-
2023
- 2023-04-17 US US18/301,845 patent/US20230355775A1/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
US8106022B2 (en) | 2007-12-04 | 2012-01-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
CN103380113A (zh) | 2010-11-15 | 2013-10-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
CN107854478A (zh) * | 2011-04-27 | 2018-03-30 | Ionis制药公司 | 载脂蛋白ciii(apociii)表达的调节 |
WO2014025805A1 (en) | 2012-08-06 | 2014-02-13 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated rna agents and process for their preparation |
CN105378082A (zh) | 2013-05-01 | 2016-03-02 | Isis制药公司 | 组合物和方法 |
CN105392488A (zh) * | 2013-05-01 | 2016-03-09 | Isis制药公司 | 用于调节载脂蛋白c-iii表达的组合物和方法 |
WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
CN106460025A (zh) * | 2014-03-25 | 2017-02-22 | 阿克丘勒斯治疗公司 | 在基因沉默中具有降低的脱靶效应的una寡聚物 |
CN107250362A (zh) * | 2014-11-17 | 2017-10-13 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
WO2016154127A2 (en) * | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
CN108239644A (zh) * | 2016-12-23 | 2018-07-03 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其用途 |
Non-Patent Citations (11)
Title |
---|
"Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS |
ANASTASIA KHVOROVAJONATHAN K. WATTS: "The chemical evolution of oligonucleotide therapies of clinical utility", NATURE BIOTECHNOLOGY, vol. 35, no. 3, 2017, pages 238 - 48, XP055410409, DOI: 10.1038/nbt.3765 |
BEAUCAGE ET AL., TETRAHEDRON, vol. 48, 1992, pages 2223 - 2311 |
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 288-94-8 |
GREENEWUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS |
J. AM. CHEM. SOC., vol. 136, 2014, pages 16958 - 16961 |
KUMICO UI-TEI: "Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect", NUCLEIC ACIDS RESEARCH, vol. 36, no. 7, 2008, pages 2136 - 2151 |
MUTHIAH MANOHARAN: "siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes", ACS CHEMICAL BIOLOGY, vol. 10, no. 5, 2015, pages 1181 - 7, XP055448305, DOI: 10.1021/cb501028c |
RAJEEV ET AL., CHEM BIO CHEM, vol. 16, 2015, pages 903 - 908 |
RAJEEV ET AL., CHEMBIOCHEM, vol. 16, 2015, pages 903 - 908 |
WATTS, J.K.G. F. DELEAVEYM. J.DAMHA: "Chemically Modified siRNA: tools and applications", DRUG DISCOV TODAY, vol. 13, no. 19-20, 2008, pages 842 - 55, XP025434699, DOI: 10.1016/j.drudis.2008.05.007 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US12084661B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
WO2021026150A1 (en) * | 2019-08-05 | 2021-02-11 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of apoc3-related diseases and disorders |
WO2023098908A1 (en) * | 2021-12-03 | 2023-06-08 | Microbio (Shanghai) Co. Ltd. | Modification patterns for small interfering rna molecules with high stability and gene silencing activities |
WO2023143571A1 (zh) | 2022-01-30 | 2023-08-03 | 大睿生物医药科技(上海)有限公司 | 含有n-乙酰半乳糖胺的靶向配体 |
Also Published As
Publication number | Publication date |
---|---|
CN110997917B (zh) | 2024-04-09 |
US20200360522A1 (en) | 2020-11-19 |
CN110997917A (zh) | 2020-04-10 |
US20230355775A1 (en) | 2023-11-09 |
EP3719127A1 (en) | 2020-10-07 |
EP3719127A4 (en) | 2021-10-20 |
JP7365052B2 (ja) | 2023-10-19 |
JP2021503929A (ja) | 2021-02-15 |
TW201925471A (zh) | 2019-07-01 |
CN118291456A (zh) | 2024-07-05 |
US11660347B2 (en) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019105419A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
TWI810226B (zh) | 核酸、含有該核酸的藥物組合物、綴合物及其用途 | |
TWI791696B (zh) | 雙鏈寡核苷酸、包含其的藥物組合物與綴合物、及其用途與試劑盒 | |
TWI823879B (zh) | 核酸、含有該核酸的藥物組合物與綴合物以及製備方法、用途與試劑盒 | |
WO2019105435A9 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
CN110945131B (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
WO2020135581A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
WO2020135673A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
CN111050807B (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
CN111973618B (zh) | 核酸、药物组合物与siRNA缀合物及制备方法和用途 | |
WO2020238766A1 (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
WO2020238758A1 (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
CN111973619A (zh) | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
CN118217305A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
WO2020233651A1 (zh) | 核酸、药物组合物与缀合物及制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18883982 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020529410 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018883982 Country of ref document: EP Effective date: 20200701 |